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Abstract 
GABAA receptors, the essential functional components of the inhibitory synapses in the 
brain, have recently been demonstrated to play a structural role during synapse 
formation. The subunit composition of these receptors is known to determine their 
synaptic localization, but how different receptor subunits influence the formation of 
inhibitory synapses is currently unknown. 
The first aim of my thesis was to investigate whether these synaptogenic effects 
of GABAARs may be mediated by their large N-terminal extracellular domains. I have 
cloned, expressed and purified the N-terminal extracellular domains of the α1 and α2 
subunits of GABAA receptors using the baculovirus/Sf9 cell system. When added to the 
GABAergic medium spiny neurones over a period of 14 days in vitro, these proteins 
were able to adhere to the cell surface and promote GABAergic synapse formation. As 
I was interested to study the molecular mechanisms that could mediate such effects, I 
used proteomics and mass spectrometry to search for potential trans-synaptic 
interacting proteins of α1 or α2 subunits which could bind specifically to the N-terminal 
extracellular domains of these subunits.  
 In parallel, I have investigated how the activity of GABAA receptors influences 
the proper positioning and the assembly of inhibitory synapses in primary cultures of 
medium spiny neurones. In these experiments, GABAA receptor activity was blocked 
over the time period of 7 or 14 days in culture and cell survival, as well as the inhibitory 
synapse formation, were assessed. I have observed very specific structural changes in 
the density and distribution of α1- or α2-containing synapses under these conditions. 
My results indicate that the activity of GABAA receptors plays a central role in the 
formation and maintenance of different types of inhibitory synapses formed between 
GABAergic neurones during development. 
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Basal ganglia play an essential role in motor coordination and cognitive 
functions. The GABAergic medium spiny neurones account for ~98 % of all the 
neurones in the basal ganglia, and are mediators of essentially all functions attributed 
to this brain region (Tepper and Bolam, 2004). The loss of these neurones in 
Huntington’s disease (Pauly et al., 2012), or the loss of dopamine-dependent regulation 
of their activity in Parkinson’s disease result in motor disorders and loss of voluntary 
motor control (Obeso et al., 2008). Central to the normal functioning of the medium 
spiny neurones is integration of excitatory and inhibitory synaptic inputs: the former 
mediated by glutamatergic corticostriatal and thalamostriatal afferents, and the later 
mediated by GABAergic interneurones and medium spiny neurones axon collaterals 
(Picconi et al., 2012). Thus, changes in synaptic innervation of these neurones are key 
determinants of the inhibitory tone of their projections and the overall functional status 
of their synaptic targets outside of the basal ganglia.  
 In this study we have investigated formation, maturation and specificity of 
GABAergic synapses formed between the medium spiny neurones in vitro. Medium 
spiny neurones, cultured from the embryonic E17 striatal tissue, formed a highly 
homogenous population and displayed a number of properties that are similar to their 
in vivo counterparts (Goffin et al., 2010). Our experiments demonstrate that 
development of GABAergic synapses in this system is a highly regulated process 
which involves clustering of specific subtypes of GABAA receptors in the vicinity of 
presynaptic GABAergic terminals immunoreactive for glutamate decarboxylase (GAD)-
Abstract Presented at the BNA Conference,  
London 2013  
Formation, maturation and specificity of inhibitory synapses in primary 
cultures of striatal medium spiny neurones 
Jessica E. Arama, Karine Abitbol, Celine Fuchs, F. Anne Stephenson, Alex 
M Thomson and Jasmina N. Jovanovic 
UCL School of Pharmacy 29-39 Brunswick square WC1N 1AX London 
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65. During maturation, the two most abundant types of synapses incorporating either 
α1 or α2 subunit of GABAA receptors were found to undergo distinct changes in the 
overall density as well as the size of postsynaptic clusters. 
Using immunofluorescence and confocal imaging we have observed that from 7 to 14 
days in vitro the density of α1-containing synapses was increased in parallel with the 
size but not the overall density of postsynaptic GABAA receptor clusters. The density of 
α2-containing synapses was increased in correlation with the overall density of 
postsynaptic GABAA receptor clusters while their size was decreased. In parallel with 
these morphological changes, we detected an increase in the amplitude and frequency 
of spontaneous inhibitory postsynaptic currents recorded from voltage-clamped 
neurones in the whole-cell configuration. In addition, dual whole-cell recordings of 
synaptically connected pairs of neurones revealed that action potential-activated 
synaptic events, an indication of synapse maturity, occurred after 12-14 days in vitro. 
Finally, using Ca2+ indicator fluo-4-AM, we have demonstrated that depolarizing activity 
of GABAARs detected initially becomes a hyperpolarizing activity during the period of 
synaptic maturation.  
Thus, formation and maturation of α1- and α2-GABAAR containing synapses 
appear to be driven by different molecular mechanisms which are currently under 
investigation. 
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Abstract presented at FENS Conference,  
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 Investigating the role of GABAA Receptor α1 and α2 Subunits in Synapse 
Formation 
Jessica E Arama, Laura E. Brown, F. Anne Stephenson, Alex M. Thomson and 
Jasmina N. Jovanovic 
UCL School of Pharmacy, 29-39 Brunswick Square, WC1N 1AX London, UK 
 GABAA receptors (GABAARs), the essential functional components of the 
inhibitory synapses in the brain, have recently been demonstrated to play a structural 
role during synapse formation by promoting the adhesion of inhibitory axon terminals 
(Fuchs et al., 2013). The subunit composition of these receptors is known to determine 
their functional and pharmacological properties (Olsen and Sieghart, 2009), as well as 
their subcellular and synaptic localization (Thomson and Jovanovic, 2010, Gross et al., 
2011), but how different receptor subunits influence the formation of inhibitory 
synapses is currently unknown. 
 The first aim of my thesis was to investigate whether these synaptogenic effects 
may be mediated by the large N-terminal extracellular domains of GABAARs. We have 
cloned and expressed the N-terminal extracellular domains of the α1 and α2 subunits 
of GABAARs (α1 and α2 ECDs)  using Bac-to-Bac CT-TOPO expression system in Sf9 
cells, and established a protocol for their purification. The expressed proteins of ~26 
kDa were found to be immunoreactive with the corresponding extracellular domain-
specific antibodies and glycosylated. These proteins were added to the GABAergic 
medium spiny neurone cultures at different concentrations and time points over a 
period of 14 days in vitro. The controls included the extracts of untransfected Sf9 cell 
which were taken through the same purification protocol. Immunolabelling of the α1 
and α2 purified extracellular domains with specific antibodies revealed that these 
proteins were able to adhere to the cell surface. To analyse formation of synaptic 
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contacts, we performed immunolabelling with specific pre- and postsynaptic GABAergic 
markers. This analysis demonstrated that the addition of purified proteins, but not the 
controls, resulted in an increase in the size and the density of γ2-containing GABAAR 
clusters in association with the GAD65-positive presynaptic terminals, suggesting that 
the extracellular domains of GABAAR subunits may have synaptogenic effects in 
GABAergic synapse formation. As we were interested to know what mechanism could 
trigger such effect, we searched for a potential specific presynaptic binding partner of 
the α1 or α2 ECDs. Together with affinity chromatography and proteomics, mass 
spectrometry analysis allowed us to identify two heparin sulphate proteoglycans 
Pikachurin and Perlecan, which could potentially be involved during specific GABAergic 
synapse formation. 
 In parallel, we investigated how the activity of GABAA receptors influences the 
proper positioning and the assembly of inhibitory synapses. We have suppressed the 
GABAA receptor activity in the medium spiny neurone cultures using a competitive 
antagonist bicuculline over the time period of 7 or 14 days in culture. We have 
observed prominent cell loss at concentrations of bicuculline higher than 25 µM 
suggesting that GABAA receptor activity is necessary for the survival of these neurones 
during development. Using lower concentrations of bicuculline, we have observed very 
specific structural changes in the density and distribution of α1- or α2-containing 
synapses formed between the medium spiny neurones. This indicates that the activity 
of GABAA receptors plays a central role in the formation and maintenance of different 
types of inhibitory synapses during development. 
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1. Introduction 
The brain functioning relies on a balance between excitation and inhibition (Cline, 
2005). This is clear from many studies of diseases such as epilepsy, where a decrease 
in inhibitory inputs can lead to massive brain oscillatory activity (Ronner et al., 2009), or 
Parkinson’s disease, in which an imbalance between excitation and inhibition within 
striatal-thalamo-cortical connections leads to motor and cognitive impairments (Llinás 
et al., 1999). An imbalance of excitation and inhibition may also provoke several 
neurological diseases including autism (Mariner et al., 1986), Tourette’s syndrome 
(Singer and Minzer, 2003) and schizophrenia (Wassef et al., 2003). Inhibitory synapses 
are neuronal cell junctions specialised to mediate the fast inhibitory transmission in the 
central nervous system. Despite the crucial role played by inhibitory transmission in the 
brain, little is known about the early molecular events leading to the development of 
such synapses. 
1.1 The GABAergic Synapse 
In the vast majority of inhibitory synapses, transmission is mediated by the 
presynaptically-released neurotransmitter γ-aminobutyric acid (GABA), which binds to 
postsynaptic GABA-gated chloride/bicarbonate channels, also known as GABAA 
receptors (GABAARs). The main role of GABAergic synaptic transmission is to control 
neuronal excitability in order to generate oscillations that underlie cognitive processes 
(Ben-Ari et al., 2007). Via GABAARs, GABAergic networks affect probably every 
neuron in the central nervous system and regulate major neuro-developmental 
processes (Tyagarajan and Fritschy, 2014). The ultrastructure of GABAergic synapses 
appears symmetric which means that the pre- and postsynaptic elements appear 
equally dense as opposed to glutamatergic synapses.  GABAergic terminals mostly 
contact the dendritic compartment and the cell soma while the glutamatergic synapses 
are mostly found on the dendritic spines (Tretter and Moss, 2008).  
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1.1.1 The presynaptic GABAergic nerve terminal 
 GABA is one of the most abundant inhibitory neurotransmitter in the central 
nervous system (Mohler et al., 1995), and is the neurotransmitter operating at the 
GABAergic inhibitory synapses in the brain. These synapses are characterised by 
presynaptic nerve terminals where GABA is synthesised, and postsynaptic elements 
expressing receptors for GABA. At the vast majority of synapses, GABAA receptors are 
accumulated or clustered at the postsynaptic membrane, closely apposing the 
presynaptic nerve terminals (Tretter et al., 2008).  
1.1.1.1 Synthesis of GABA 
GABA is present in concentration of 1-10 mM in the vertebrate brain (Kuriyama et 
al., 1966). This neutral amino acid is the result of the L-decarboxylation of glutamate 
(glutamic acid) by the rate-limiting enzyme Glutamate Decarboxylase (GAD) (Collins, 
1972, Erlander et al., 1991). In the brain, separate genes encode for two isoforms of 
GAD, GAD 65 and GAD 67 (Figure 1). These two enzymes differ by their molecular 
size (65 and 67 kDa), amino-acid sequence, antigenicity, and localisation 
(Soghomonian and Martin, 1998). GAD65 is located in the nerve ending where it 
synthesises GABA for vesicular release (which represents about 30 % of total GABA). 
On the other hand, GAD 67 is in the cytosol and widely expressed along neuronal 
processes where it synthesises the remaining 70 % of the total GABA (Soghomonian 
and Martin, 1998). GABA is released from the presynaptic terminal by exocytosis of 
small synaptic vesicles filled with the neurotransmitter. There is evidence that GAD65 
and the vesicular GABA transporter VGAT (=VIAAT, vesicular inhibitory amino acid 
transporter) interact directly (Figure 1), suggesting that conversion of glutamate into 
GABA and subsequent vesicular uptake of the transmitter may be tightly coupled 
processes (Jin et al., 2003). 
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1.1.1.2 Vesicular loading of GABA 
VGAT is a ten-transmembrane helix protein initially identified in C.Elegans in 1997 
(McIntire et al., 1997). GABA uptake by VGAT into synaptic vesicles depends on a 
driving force provided by the vacuolar H+-ATPase. This pump creates an 
electrochemical protons gradient that is coupled to transport of neurotransmitter in the 
opposite direction (Edwards, 2007). Additionally, chloride gradients between vesicle 
lumen and presynaptic cytosol may contribute to the vesicular loading of GABA 
(Ahnert-Hilger and Jahn, 2011).  
1.1.1.3 GABA uptake by transporters 
The membrane-bound GABA transporters (GAT) move GABA across the cell 
membrane from the synaptic cleft back into the presynaptic element (Figure 1). The 
direction and efficacy of this Na+-coupled transport results from the driving 
electrochemical gradient and is usually directed inwardly (Roth and Draguhn, 2012). 
GABA transporters are differentially expressed throughout the brain but GAT-1 is the 
most abundant transporter in the rodent neuronal cells while GAT-3 is mostly present in 
glial cells (Minelli et al., 1996, Conti et al., 1998b). Another way of GABA enrichment is 
transmitter synthesis from glutamate. Thanks to EAAT3 which are membrane-bound 
glutamate transporter molecule found in the presynaptic terminals of inhibitory 
interneurones, GABA can be synthesised in the presynaptic element after recapture of 
glutamate (Conti et al., 1998a, Roth and Draguhn, 2012).  
1.1.1.4 Degradation of GABA 
GABA is catalysed by the GABA transaminase (GABA-T) which is present in 
mitochondria of glial cells and neurones (Jung et al., 1977). After transamination, 
GABA and α-ketoglutarate produce succinic semi-aldehyde and glutamate. It is 
estimated that more than 90 % of all GABA in the mammalian brain is degraded in this 
way and contributes to energy metabolism in the tricarbonic acid cycle (Roth and 
Draguhn, 2012).  
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Figure 1: The presynaptic element of GABAergic synapses (Roth and Draguhn, 2012). 
The axonal ending of an inhibitory interneurone (Pre) is drawn on the left, a glial cell (GLIA) on 
the right. The bottom structure indicates a postsynaptic membrane of a target cell (Post), for 
example, a pyramidal cell. Transporters are marked by flanking arrows, and synthesising or 
degrading enzymes are marked by a central arrow. Transporters are colour-matched to 
substrates: GABA is shown as blue particles, glutamate in red and glutamine in green. 
Enrichment of glutamate in excitatory neurones involves uptake by glia cells, conversion into 
glutamine, export via “system N” glutamine transporters followed by uptake into neurones by 
“system A” glutamine transporters and conversion into glutamate.  GS: glutamine synthase, Mit: 
mitochondrion, PAG: phosphate-activated glutaminase, SV: synaptic vesicle, and V-ATPase: 
vacuolar type H
+
 ATPase, GAD65/7: Glutamate Acid Decarboxylase 65/7, GABA-T: GABA 
transaminase, GAT-1: GABA transporter 1, V-GAT: Vesicular GABA transporter, EEAT-3: 
Glutamate transporter 3. 
 
1.1.2  The postsynaptic specialisations of GABAergic synapses 
 The action of GABA is mediated by two different classes of receptors, the 
metabotropic and ionotropic receptors. The metabotropic GABAB receptors are 
members of the family of G-protein-coupled receptors (GPCRs). They are composed of 
seven transmembrane domains and are coupled to Ca2+ and K+ channels via 
heterotrimeric G-proteins and second messengers (Bowery et al., 2002). These 
receptors are found postsynaptically where they modulate specific responses, but also 
presynaptically where they inhibit neurotransmitter release (Hines et al., 2011).  
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1.1.2.1 The structure of ionotropic GABA ARs 
 GABAA and GABAC receptors belong to the superfamily of nicotinic 
heteropentameric ‘Cys-loop’ ligand gated ion channels which also include the nicotinic 
acetylcholine, glycine and 5-HT3 receptors (Lüscher and Keller, 2004). They are both 
Cl-/HCO3
- channels but they have different pharmacological properties (Bowery et al., 
2002). GABAC receptors are only found in neurones of retina and are insensitive to 
bicuculline and baclofen. In addition, these receptors are composed of hetero- or 
homo-pentamers of ρ1-3 subunits (Bowery et al., 2002).  
 GABAA receptors are the major inhibitory receptors in the central nervous 
system. Deficits in GABAAR-mediated neurotransmission are at the origin of multiple 
disorders of the central nervous system such as epilepsy, anxiety and mood disorders, 
and neurodevelopmental pathologies such as autism, Fragile X, and schizophrenia 
(Ortells and Lunt, 1995). They were first identified accordingly to their pharmacological 
properties (Olsen and Sieghart, 2008). These receptors are activated by GABA and by 
selective agonists such as muscimol and isoguvacine, and blocked by bicuculline, 
picrotoxin, and others. They are also modulated by benzodiazepines, barbiturates, 
ethanol, neurosteroids and others (Macdonald and Olsen, 1994). 
 Sixteen subunits of GABAARs are encoded by different genes grouped in seven 
different classes (α1-6, β1-3, γ1-3, δ, π, ε, and θ). The structure of the receptor subunits is 
highly conserved (Unwin, 1993). They all consist of a large (about 200 amino acids) 
extracellular N-terminal hydrophilic domain, followed by four transmembrane 
hydrophobic domains (TMs) with a large cytoplasmic-loop between TM3 and TM4, and 
a small extracellular C-terminal domain (Figure 2) (Sieghart et al., 1999).  GABAA 
receptors are organised as pentamers of subunits surrounding a central pore that 
forms an ion channel (Figure 2). The first crystal structure of a GABAAR, the human β3 
homopentamer, has revealed architectural elements unique to eukaryotic Cys-loop 
receptors and explained the mechanistic consequences of multiple disease mutations 
(Miller and Aricescu, 2014). Interestingly, the receptor has been co-crystallised with a 
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novel agonist, benzamidin (serine-protease inhibitor) which is capable of inducing 
desensitisation.  
 Although the stoichiometry of native receptors has not been fully described, the 
assembly of heteropentameric GABAARs in heterologous model systems has been 
shown to occur with a stoichiometry of 2α:2β:1γ subunits (Tretter et al., 1997, Farrar et 
al., 1999) (Figure 2). The major benzodiazepine binding site is at the / subunits 
interface while the two GABA binding sites lie between / subunits (Olsen and 
Sieghart, 2008) (Figure 3).  
 Many different combinations of subunits are theoretically possible. 
Nevertheless, due to restrictions imposed during the assembly of GABAARs, only a 
dozen are able to access the neuronal cell surface (Jacob et al., 2008, Olsen and 
Sieghart, 2008). The α, β and γ subunits have to be combined to form a functional 
synaptic GABAAR. The π, δ and ε subunits seem to replace the γ subunit in some 
cases (Sieghart et al., 1999). The δ subunit is almost exclusively present in α6 subunit-
containing GABAARs in cerebellar granule cells. This subunit is also combined with α4 
subunit in dentate gyrus, neostriatum and some cortical layers (Olsen and Sieghart, 
2008). The ε subunit is rare but can replace γ or δ in certain brain areas such as 
hypothalamus. 
 GABAARs composed of α1, α2, α3 or 5 subunit together with β and γ subunits 
are largely synaptically expressed and mediate phasic inhibition in the brain (Saliba et 
al., 2007, Jacob et al., 2008). On the other hand, α4 or α6 subunit combined with β and 
δ subunit GABAARs are predominantly extrasynaptic receptors and mediate tonic 
currents in response to GABA spill-over from synaptic release sites (Jacob et al., 2008) 
(Figure 3). 
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Figure 2: Structure of GABAARs. A. GABAARs consist of a large extracellular N-terminal 
domain, four hydrophobic transmembrane domains (TM1-TM4), a large intracellular loop 
between TM3-TM4 and a small extracellular C-terminal domain. B. GABAARs assemble into 
heteropentameric Cl
- 
permeable channels composed of two , two  and one  subunit. The 
binding of two molecules of GABA (yellow) or Benzodiazepines (green) triggers the entry of 
chloride in to the postsynaptic cell. C. Sixteen genes encode for the different subunits (1-6; 1-
3; 1-3; δ, π, ε, and θ). Benzodiazepine (green) binding site is at the interface between  and  
subunits, whereas GABA (yellow) binding site is between  and  subunit. 
 
 
Figure 3: Localisation of GABAARs. The 1-3 together with  and  subunit containing 
GABAARs are localised to synaptic sites and are responsible for phasic inhibition, whereas 4 
or α6 and δ subunit-containing GABAARs are mainly extrasynaptic and mediate tonic inhibition 
resulting from ambient GABA. The 5 subunit-containing GABAARs are localised to both 
synaptic and extrasynaptic sites. Neurexin and Neuroligin 2 are adhesion molecules exhibiting 
robust synaptogenic effects. Neurexin 2β has been shown to interact with the α1 subunit of 
GABAARs. 
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1.1.2.2 Clustering of GABAARs 
At inhibitory synapses, the postsynaptic density (PSD) is precisely facing the 
presynaptic active zone and contains a high concentration of GABAARs. Sophisticated 
mechanisms enable the assembly of macromolecular complexes and the selective 
clustering of the GABAARs at the appropriate subcellular sites. Although different 
clustering mechanisms exist, the predominant scaffolding protein which clusters 
GABAARs at the postsynaptic membrane is gephyrin (Tyagarajan and Fritschy, 2014).  
1.1.2.2.1 Synaptic clustering of GABAARs 
1.1.2.2.1.1 Gephyrin-dependent clustering and collybistin  
 Gephyrin was originally co-purified with the glycine receptor from the 
mammalian brain (Prior et al., 1992). This 93 kDa protein regulates the clustering of 
these receptors by cross-linking their  subunit to tubulin and microtubules (Kneussel 
and Betz, 2000).  
 Immunocytochemical studies have revealed that gephyrin is present at 
GABAergic synapses (Kneussel and Betz, 2000). In the brain, it is enriched at 
postsynaptic sites which contain GABAARs subtypes composed of (1-3), (2-3) and 2 
subunits (Jacob et al., 2008). It has been shown that gephyrin binds directly to 
GABAARs via the intracellular loop of the α1-3 GABAARs subunits (Tretter et al., 2008, 
Mukherjee et al., 2011, Tretter et al., 2011). Therefore, gephyrin is responsible for 
clustering of GABAARs at the postsynaptic membrane of GABAergic synapses. 
Reducing gephyrin expression affects accumulation of 2- or 2-containing GABAARs 
without modifying the overall cell surface levels of these subunits (Kneussel et al., 
1999, Jacob et al., 2005). Live imaging has revealed that clusters that formed in the 
absence of gephyrin were significantly more mobile compared to the control neurones 
(Jacob et al., 2005).  
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The interaction of gephyrin with GABAARs is not only via a direct binding. Gephyrin 
also interacts with collybistin, a guanylate exchange factor (GEF) (Kins et al., 2000, 
Harvey et al., 2004). A knock-out of collybistin results in a selective loss of synaptic 
GABAARs clusters, increased levels of anxiety and impaired spatial learning memory 
(Papadopoulos et al., 2007, Thomson and Jovanovic, 2010). All together, these data 
suggest that gephyrin and its binding partners promote clustering of synaptic GABAARs 
(Figure 4). 
1.1.2.2.1.2 Gephyrin-independent clustering 
 In gephyrin knock-out mice, synaptic GABAARs clusters are formed at the cell 
surface and mIPSC are detected, suggesting that these receptors are able to form 
functional clusters in the absence of gephyrin (Kneussel and Betz, 2000, Lévi et al., 
2004). Although the mechanisms involved are not fully characterised, it is likely that 
they involve other GABAAR interacting proteins. One such protein is radixin, an ERM 
(ezrin, radixin, moesin)-family protein which has been identified as a specific interactor 
of the 5 subunit of GABAARs (Loebrich et al., 2006). In neurones, depletion of radixin 
significantly decreases 5-containing GABAARs clusters while the total levels of 5 
subunit remained unchanged (Loebrich et al., 2006). Activated radixin is able to bind 
5 subunit and F-actin, which suggests that radixin directly links 5 subunit and actin 
cytoskeleton (Figure 4). Radixin binding domain is highly conserved between 5 and 
1-3 subunits suggesting that radixin plays an important role in clustering of other 
types of GABAARs.  
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Figure 4: Cell surface trafficking and clustering of GABAARs. (Jacob et al., 2008) Newly 
assembled GABAARs are primarily inserted into the plasma membrane outside of synapses. 
Synaptic receptors are recruited from extrasynaptic pools by lateral diffusion mediated by 
unknown mechanisms. Synaptic GABAARs are maintained and stabilised by gephyrin clusters, 
which mediate association between the receptors and the microtubules. An alternative 
mechanism for GABAARs clustering is mediated by radixin which interact with the 5 subunit 
and F-actin. 
1.1.2.2.2 Extrasynaptic clustering of GABA ARs 
In neuronal cells, GABAARs are expressed as synaptic and extrasynaptic receptors. 
Most receptors are distributed first to the extrasynaptic sites. Depending on their 
subunit composition, some subtypes of GABAARs will remain extrasynaptic while 
others will become predominantly synaptic overtime (Bogdanov et al., 2006). For 
example, the α5βγ2 receptors, found in hippocampal pyramidal cells, are mostly 
extrasynaptic and contribute to tonic GABAergic currents, although some α5βγ2 have 
also been found in synapses (Luscher et al., 2011). In addition, 6 are diffused and 
exclusively located at extrasynaptic and perisynaptic sites of cerebellar granule cells. 
Similarly to some of 5 subunit-containing receptors, -containing GABAARs also 
mediate tonic inhibition in the brain (Jacob et al., 2008). The same situation was 
observed in dentate gyrus where 4 are mainly extrasynaptic and mediate tonic 
inhibition (Fritschy and Brünig, 2003). In general,  subunits contained in extrasynaptic 
receptors have a higher affinity for GABA than those present in synaptic GABAARs 
(Saxena and Macdonald, 1994).  
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In contrast, most of the 2 subunit-containing GABAARs are synaptic (Danglot et 
al., 2003, Thomas et al., 2005). Mice deficient for γ2 subunit show a significant 
decrease in the level of synaptic GABAA receptor clusters, while the extrasynaptic 
receptors are only slightly affected (Crestani et al., 1999, Schweizer et al., 2003).  
Over the recent years, it has become clear that cell surface expressed 
GABAARs are relatively dynamic entities because a significant number of receptors can 
move within the plasma membrane in and out of the synaptic compartments (Figure 
3b) (Thomas et al., 2005). Using a fluorescent bungarotoxin and electrophysiological 
recordings, it has been shown that synaptic GABAARs are recruited from the 
extrasynaptic sites (Bogdanov et al., 2006). Single particle tracking of 2 subunit 
revealed that at mixed GABAergic/Glycinergic synapses of motor neurones in culture, 
GABAARs can be rapidly exchanged between synaptic and extrasynaptic 
compartments (Lévi et al., 2008).  
In addition, fluorescent recovery after photobleaching studies (FRAP) have 
shown that extrasynaptic GABAARs have a higher degree of lateral mobility than 
synaptic receptors (Jacob et al., 2008). The retention of GABAARs at synaptic sites 
results from their association with gephyrin clusters. Down regulation of gephyrin 
results in increased lateral mobility of GABAARs, facilitating their accumulation at 
extrasynaptic sites (Jacob et al., 2005). Dynamic regulation of interactions between 
GABAARs and scaffold proteins such as gephyrin, is likely to play a central role in 
regulating the number of postsynaptic receptors (Arancibia-Carcamo and Kittler, 2009). 
1.1.2.3 The functional and pharmacological heterogeneity of GABA AR 
subtypes 
1.1.2.3.1 The subunit composition of GABA AR influences GABAergic 
synaptic pharmacology 
Structural heterogeneity of GABAARs is thought to be the basis of their 
physiological and pharmacological heterogeneity (Olsen and Sieghart, 2009). 
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GABAARs contain binding sites for clinically important drugs such as benzodiazepines, 
barbiturates and anaesthetics (Homanics et al., 1997).  
Benzodiazepines are muscle relaxants, anticonvulsants, sedative and anxiolytic 
drugs (Macdonald and Olsen 1994). They are positive allosteric modulators of 
GABAARs which increase the chloride channel opening frequency (Macdonald and 
Olsen, 1994) and the affinity for GABA. The benzodiazepine binding site is located in a 
pocket between the α and γ subunits (Ernst et al., 2003, Henschel O, 2008) (Figure 2). 
Pharmacological studies have determined that α1-, α2-, α3- and α5- subunit containing 
GABAARs are ‘benzodiazepine-sensitive’, while α4- and α6-GABAARs are not and are 
therefore classified as ‘benzodiazepine-insensitive’ (Benson et al., 1998, Wingrove et 
al., 2002).  
The presence of one histidine residue (H101) in the 1 subunit of GABAARs forms 
a high affinity binding site for diazepam or nonbenzodiazepines such as zolpidem 
(Olsen and Sieghart, 2009) which is classified as benzodiazepine site 1 (BZI). Other 
subclasses of  subunits-containing GABAARs (α2-5), with lower affinity for diazepam 
and zolpidem contain a lower affinity binding site which is classified as benzodiazepine 
site 2 (BZ II).  
By introducing a point mutation in histidine 100 (histidine to arginine substitution) in 
individual α subunits in transgenic mice, Rudolph et al., 1999 have demonstrated that 
α2- GABAARs mediate the anxiolytic effects of diazepam, while α1-subtypes mediate 
the sedative effect of the drug (Benson et al., 1998, Löw et al., 2000, McKernan et al., 
2000, Olsen and Sieghart, 2009). Thus, in mice expressing the mutated 1 subunit, 
sedative effects of diazepam were abolished but the anxiolytic effects were still present 
(Benson et al., 1998, Rudolph et al., 2001). Likewise, the anxiolytic effects of α2 were 
abolished in α2 mutant mice, although the sedative effects mediated by α1 subunit 
containing GABAARs were still present (Rudolph et al., 1999, McKernan et al., 2000). 
Consequently, α1-GABAA receptors are thought to be operating in neuronal circuits that 
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are functionally distinct from those involved in other behavioural responses to 
benzodiazepines (Fritschy and Brünig, 2003). Functional specificity of neuronal circuits 
expressing different types of α subunits was further supported by studies of α5 subunit 
knock-out mice which have demonstrated that these mice show enhanced cognitive 
performance in hippocampal-dependent learning tasks (Collinson et al., 2002, Ali and 
Thomson, 2008, Thomson and Jovanovic, 2010). 
1.1.2.3.2 The kinetic properties of α1 - vs. α2-containing GABAARs 
correspond to the physiological properties of the synapse s 
The structural basis for the functional diversity may be explained by selective 
targeting of GABAA receptors to synapses formed with different types of presynaptic 
inhibitory interneurones. For example, more than 18 types of presynaptic GABAergic 
neurones innervate hippocampal CA1 pyramidal cells which express about 14 different 
subtypes of GABAARs. Using quantitative electron microscopy and electrophysiology, it 
has been determined that α1-GABAARs are significantly more abundant in synapses 
formed with fast-spiking parvalbumin (PV) basket cells, while the α2-GABAARs are 
more often found contacted by regular spiking cholecystokinin (CCK) basket cells  
(Thomson et al., 2000, Nyíri et al., 2001, Klausberger et al., 2002, Fritschy and Brünig, 
2003).  However, these findings are controversial. Using the freeze fracture 
immunogold labelling (FRIL) method, which is a lot more sensitive than standard 
immunogold labelling, both α1- and α2-containing GABAARs were found present in all 
the somatic synapses of the CA1 hippocampal neurones (Kasugai et al., 2010). This 
has suggested that there was no specificity between the α subtype of GABAAR 
expressed in the postsynaptic membrane and the identity of the presynaptic basket cell 
(Kasugai et al., 2010).  
However, in other types of synapses, a specificity of association between 
presynaptic inhibitory interneurones with different firing patterns and postsynaptic 
GABAARs subtypes is observed. Interestingly, this association is also in agreement 
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with the kinetic properties of responses mediated by different  subunits. For example, 
it has been observed that α2-containing GABAARs are predominantly expressed at the 
axon initial segment (AIS) compared to α1-containing GABAARs (Panzanelli et al., 
2011). Interestingly, the α1-GABAARs are characterised by five-fold faster kinetics of 
deactivation than the α2-GABAA receptors (Brussaard et al., 1997, McClellan and 
Twyman, 1999, Vicini et al., 2001). Thus, α1-GABAARs subtypes are more likely to 
carry high-frequency signals whereas α2-GABAARs might be more efficient as an on/off 
switch of neuronal activity, especially at the axon initial segment where they are highly 
concentrated (Fritschy and Brünig, 2003). The fact that a high concentration of α2-
containing GABAARs is present at the AIS is more likely to be related to specific 
clustering mechanisms present in the AIS only rather than the presence of a specific 
presynaptic input (Panzanelli et al., 2011). If GABAARs subtypes were randomly 
distributed over the neuronal compartments, specific behavioural and cognitive 
functions mediated by GABAergic synapses would not be possible (Thomson and 
Jovanovic, 2010). It remains to be determined if the presence of different α subunits is 
sufficient to regulate distribution of GABAARs over different neuronal compartments.  
1.1.2.3.3 Analysis of sequence similarity between α1 and α2 subunit of 
GABAARs 
Pairwise sequence alignment (Needle EMBOSS program) was done with the 
full sequence of α1 and α2 subunits of GABAARs (Figure 5). The GABA binding site 
sequence is highly conserved between the two subunits although one serine in the α1 
sequence is replaced by a lysine in the α2 sequence. This difference could be at the 
origin of a difference in the affinity for GABA between the two subunits.  Although the 
two subunits share 79.5 % of identity and 86.5 % of similarity, different regions could 
be at the origin of the specificity observed between α1 and α2 subunits-containing 
synapses. Notably, while the four transmembrane domains are very similar, the 
extracellular domains (N- and C-terminal) as well as the intracellular loop seem to be 
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the most variable one. This variability suggests that these domains could possibly 
contribute to the specific targeting and synaptic incorporation of different subtypes of 
GABAARs. 
 
A1 1   QPSQDELKDNTTVFTRILDRLLDGYDNRLRPGLGERVTEVKTDIFVTSFG 50 
       ...:||.|:|.|:|||||||||||||||||||||:.:|||.|:|:||||| 
A2 1   NIQEDEAKNNITIFTRILDRLLDGYDNRLRPGLGDSITEVFTNIYVTSFG 50 
 
A1 51  PVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASKIWTPDTFF 100 
       ||||.||||||||||||.||||||||||||.:|||||||||||||||||| 
A2 51  PVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASKIWTPDTFF 100 
 
A1 101 HNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAH 150 
       ||||||||||||||||||||.:||||||||||||:||||||||||||||| 
A2 101 HNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAH 150 
 
A1 151 ACPLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSG 200 
       :|||||||||||.:||.|.||...:.||.||.|||||||||||||::... 
A2 151 SCPLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKE 200 
 
A1 201 IVQSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRES 250 
       .::||||||.|||.|||||||||||||||||||||||||||||||||||| 
A2 201 TIKSSTGEYTVMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRES 250 
 
A1 251 VPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSAL 300 
       |||||||||||||||||||||||||||||||||||||||||||||||||| 
A2 251 VPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSAL 300 
 
A1 301 IEFATVNYFTKRGYAWDGKSVVPEKPKKVKDPLIKKNNTYAPTATSYTPN 350 
       |||||||||||||:||||||||.:| ||.|..::.:||.||....:|.|| 
A2 301 IEFATVNYFTKRGWAWDGKSVVNDK-KKEKGSVMIQNNAYAVAVANYAPN 349 
 
A1 351 LARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKIDRLSRIAFP 400 
       |:: ||.|:||:||||......|||.||.|.||||||||||||:|||.|| 
A2 350 LSK-DPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRMSRIVFP 398 
 
A1 401 LLFGIFNLVYWATYLNREPQL-KAPTPHQ    428 
       :|||.||||||||||||||.| .:|     
A2 399 VLFGTFNLVYWATYLNREPVLGVSP----    423 
 
Figure 5: Pairwise alignment of the α1 and α2 subunits of GABAARs using NEEDLE 
EMBOSS program.  The pairwise alignment of the full length α1 and α2 subunits of GABAARs 
was performed. The region highlighted in green represents the cys-loop which is highly 
conserved between the two subunits. The AAs highlighted in yellow represent the N-
glycosylated sites. The peptide sequence highlighted in cyan is the GABA binding site. Pairwise 
alignment was done using Needle EMBOSS program and revealed that α1 and α2 subunits 
share 79.5 % of identity and 86.5 % of similarity. However, some regions within each of the 
sequence seem to be more variable than others. While the transmembrane domains TM1-4 
(sequences in light blue) do not seem to greatly differ, the intracellular loop (sequence in red) 
and the Nt and Ct extracellular domains (sequence in dark blue and green, respectively) are 
probably the most variable ones. This could explain why these domains are the most frequently 
involved in specific protein-protein interactions.  
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1.1.3 Synaptic cleft spanning proteins 
Neurones receive multiple inputs from different neurotransmitter systems. An 
appropriate match between the released neurotransmitter and its corresponding 
postsynaptic receptors is essential for synapse formation and function (Fritschy and 
Brünig, 2003). For normal functioning of GABAergic synapses, it is essential to have 
GABAARs present at the postsynaptic membrane. The efficacy of transmission is 
further increased by clustering of GABAARs at these postsynaptic sites. However, how 
is this regulated during synapse formation and whether the activation of GABAARs 
plays a role in these processes remains unclear.  
Some evidence suggests that activation of GABAARs by released GABA may not 
be at the origin of clustering of these receptors (Benson et al., 1998, Varoqueaux F, 
2002). Hippocampal neurones were cultured in isolation at a density which allowed 
formation of auto-synapses (Rao et al., 2000). Distribution of the pre and postsynaptic 
markers of GABAergic and glutamatergic synapses has been correlated with the 
neurotransmitter phenotype of the neurone. Under such conditions, 60 % of synaptic 
appositions were mismatched incorporating glutamatergic presynaptic elements and 
GABAA postsynaptic clusters. Moreover, 57 % of clusters were not opposed to any 
presynaptic element. According to this paper, GABAergic input is not necessary for 
clustering of GABAA receptors, but it may be a synaptogenic signal common to 
glutamatergic and GABAergic synapses (Rao et al., 2000). However, in neurones 
receiving extensive GABAergic innervation only, no mismatch was observed, 
suggesting that GABAergic synapse formation may be dependent on specific pre- and 
postsynaptic interactions rather than the activity of GABAARs. Nevertheless, chronic 
blockade of action potential-mediated synaptic events with tetrodotoxin (TTX) or of 
GABAA receptors with bicuculline did not affect GABAAR clustering (Craig et al., 1996).  
Taken together, these data suggest that GABA is not required for differentiation 
and clustering of postsynaptic GABAARs. If GABA is not crucial for formation of 
GABAergic synapses, other components of these synapses may play an important 
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role. Several proteins present pre or postsynaptically that span all or part of the 
synaptic cleft have been identified and studied for their role in GABAergic synapse 
formation and maintenance.  
1.1.3.1 Neurexins/ Neuroligin 
 Interactions between the presynaptic neurexins and postsynaptic neuroligins are 
known to regulate synapse formation. Neurexin (1-3, 1-3) are presynaptic adhesion 
proteins that exhibit robust synaptogenic activity and are essential for the binding of 
proteins involved in neurotransmitter release (Fairless et al., 2008). All three α-
neurexins are composed of six LNS (Laminin Neurexin Sex hormone) binding domains 
which are principal sites for alternative splicing leading to more than 2000 potential 
variants (Missler and Südhof, 1998, Fairless et al., 2008, Thomson and Jovanovic, 
2010). In addition, presynaptic α-neurexins promote clustering of postsynaptic 
GABAARs associated with gephyrin (GABAARs scaffolding protein) and neuroligin-2 
(Kang et al., 2008) (Figure 2). Triple knock-out mice lacking all three α- neurexins show 
50 % reduction in GABAergic synapses in comparison with wild-type mice, and die at 
birth (Missler et al., 2003). The interaction between neurexins and neuroligins is 
thought to be sufficient to induce postsynaptic differentiation of both glutamatergic and 
GABAergic synapses (Graf et al., 2004). In addition, it has been shown that neurexin 
2β directly interacts with the extracellular domain of α1 subunit of GABAARs, and that 
increasing neurexin expression decreased GABAergic but not glutamatergic synaptic 
transmission (Zhang et al., 2010).  
 Neuroligins (NL1-4) are postsynaptic interactors of neurexins and they contain 
only one LNS domain (Kang et al., 2008). Although neuroligins exhibit less extensive 
alternative splicing of their LNS domain, their distribution across different types of 
synapses is specific. It has been demonstrated that NL2 is specifically present and 
involved in GABAergic synapse formation (Varoqueaux et al., 2004), while NL1 
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promotes glutamatergic synapse formation. On the contrary, NL3 aggregates at both 
types of synapses forming complexes with other neuroligins (Budreck and Scheiffele, 
2007). In a model proposed by Huang and Scheiffele (Huang and Scheiffele, 2008), 
NL2 and GABAARs stabilize each other, through extracellular cis-interactions or via 
scaffolding proteins such as gephyrin (Figure 2). In addition, in neuronal cultures, the 
over-expression of NL2 increases specifically the amplitude of inhibitory postsynaptic 
currents (IPSCs), while a pharmacological blockade of neuronal activity prevents this 
synaptogenic effect (Chubykin et al., 2007, Huang and Scheiffele, 2008). This result 
suggests that NL2 promotes a postsynaptic synaptogenic effects and that this partially 
depends on GABAAR activity. 
 Multiple evidence converges to suggest that synaptic signalling mediated by 
GABA may engage the neuroligin-neurexin cell adhesion system to regulate activity-
dependent development of inhibitory synapses and innervation patterns (Huang and 
Scheiffele, 2008).  
 Taken together, these data suggest that neurexin/neuroligin complex and GABA 
signalling play important roles in inhibitory synapse development, stabilising both pre-
and postsynaptic elements.  
1.1.3.2 NCAM 
 Other cell adhesion molecules present in the synaptic cleft could also play a role 
in synapse formation, such as NCAM (neuronal cell adhesion molecule) which is 
enriched at GABAergic synapses (Pillai-Nair et al., 2005). In this study, the role of the 
extracellular domain of NCAM was explored with the use of a transgenic mouse line 
which over-expressed a soluble form of the extracellular domain of this protein. These 
mice exhibited a striking decrease in synaptic innervation arising from a subpopulation 
of GABAergic interneurones in frontal cortical areas and in amygdala. Thus, the 
overexpresion of the extracellular domain of NCAM seems to perturb the cortical and 
amygdala circuitry by interfering with presynaptic function of GABAergic interneurones. 
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1.1.3.3 Dystrophin/glycoprotein complex (DGC)  
Another multiprotein complex co-localised with GABAARs at GABAergic synapses 
is the dystrophin/glycoprotein complex (DGC). Immunohistochemical and functional 
studies have demonstrated that DGC also plays an important role in inhibitory synapse 
formation (Knuesel et al., 1999, Knuesel et al., 2000, Brünig et al., 2002, Lévi et al., 
2002). DGC is a large multiprotein complex containing at least ten proteins such as 
dystrophin and dystroglycan (Blake et al., 2002, Arancibia-Carcamo and Kittler, 2009). 
Dystrophin has been found in α1 and α2 subunit-containing GABAAR synapses in the 
cerebral cortex, hippocampus and cerebellum (Knuesel et al., 2000). The size and 
number of cell surface GABAARs clusters were decreased significantly in dystrophin 
mutant mice (Knuesel et al., 1999). As a consequence, the frequency and amplitude of 
miniature inhibitory post synaptic currents (mIPSC) in Purkinje cells were significantly 
lower than in wild-type mice (Kueh et al., 2008). This result suggests that DGC may 
play an important role in stabilising GABAARs at synapses (Knuesel et al., 2000). Other 
components of DGC are selectively present at inhibitory synapses such as - and - 
dystroglycan and syntrophin (Lévi et al., 2002). The -dystroglycan indirectly binds 
neuroligin-2 via S-SCAM (Synaptic scaffolding molecule) and form a tri-partite complex 
of S-SCAM, β-dystroglycan and neuroligin-2 that may function as a postsynaptic link at 
inhibitory synapses between the DGC/ neurexin complex and the neuroligin/ neurexin 
complex (Sumita et al., 2007, Arancibia-Carcamo and Kittler, 2009). However, the role 
of this complex in cell surface expression and synaptic localisation of GABAARs 
remains unclear. 
1.1.3.4 Slitrack3 and PTPδ  
It has been recently suggested that Slit and NRT-like family member 3 (Slitrk3) 
act as postsynaptic adhesion molecules which selectively interact with the presynaptic 
tyrosine phosphatase receptor PTPδ (Takahashi et al., 2012). This transynaptic 
interaction was shown to promote only inhibitory synaptic formation in co-cultures of 
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fibroblasts expressing slitrk3 and rat hippocampal neurones. In addition, slitrk3-
deficient mice exhibited a decrease in inhibitory synapse number and function in 
hippocampal CA1 neurones as well as increased seizure susceptibility and 
spontaneous epileptiform activity. However, GABAergic synapses were still able to 
form, suggesting that this mechanism is not required to prime the formation of inhibitory 
synapses.  
1.1.3.5 Postsynaptic GABAARs 
Interestingly, it has been recently proposed that GABAARs themselves can 
promote GABAergic synapse formation in a co-culture model of α1/β2/γ2 stably 
transfected HEK 293 cells and GABAergic embryonic medium spiny neurones (Fuchs 
et al., 2013). This study provided the first evidence that GABAARs can be sufficient to 
initiate the formation of synaptic contacts. A significant increase in synapse formation 
and strength was observed when NL2 was co-expressed with GABAARs in the HEK 
293 cells, suggesting a synergetic effect of the two postsynaptic proteins. 
1.2 Intracellular trafficking of GABAARs 
1.2.1 Synthesis and intracellular trafficking of GABAARs 
 GABAARs subunits are assembled within the endoplasmic reticulum (ER). This 
process has a critical role in determining the heterogeneity of GABAARs expression at 
the cell surface (Jacob et al., 2008). Only those receptors which have been assessed 
in the appropriate conformation are able to exit the ER. Misfolded proteins or 
unassembled subunits are retained within the organelle and sent to the proteasome for 
degradation. 
1.2.1.1 Assembly of postsynaptic GABAARs 
Assembly of GABAARs into pentamers involves the initial formation of αβ 
subunit heterodimers. The N-terminal domains of these subunits associate with two 
chaperone proteins involved in the folding control quality in the ER: binding 
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immunoglobulin protein (BiP) and calnexin (Connolly et al., 1996a, Kleizen and 
Braakman, 2004 , Luscher et al., 2011). These two chaperones are the most abundant 
in the ER and play a critical role in folding of every newly translated protein. They are 
both located on the lumenal side of the ER allowing a direct binding to the N-terminal 
domains of nascent subunits (Arancibia-Carcamo and Kittler, 2009, Luscher et al., 
2011) (Figure 6). 
The first insights into the assembly mechanisms of GABAARs originate from 
studies using the heterologous HEK 293 cells systems. To determine the stoichiometry 
and subunit arrangement of GABAARs, the ratio of subunits in recombinant α1β3γ2 
receptors was determined by immunoblotting from the relative signal intensities of 
antibodies directed against the N-terminal or the cytoplasmic loop (Tretter et al., 1997).  
This method allowed determination of the subunit stoichiometry of two α subunits, two 
β subunits, and one γ subunit in fully assembled GABAA receptors. Similar experiments 
showed that while α1β3 and α1β3γ2 receptors expressed in HEK 293 were able to 
form pentamers, α1γ2 or β3γ2 receptors mostly form heterodimers (Tretter et al., 
1997). In addition, the residues 58-67 within α subunit isoforms were shown to be 
important in the assembly of receptors containing αβ and αβγ subunits. Deletions of 
these residues, which are highly conserved in all α subunit isoforms, resulted in the 
retention of α subunits in the endoplasmic reticulum. These residues present on the N-
terminal extracellular domain mediate oligomerisation of the α1 subunit with β3 and 
thus, play a critical role in the assembly of GABAARs (Taylor et al., 2000).   
The fundamental role of the α and β subunits in the first assembly steps has 
been confirmed by the knockout mice studies. Deletion of these subunits resulted in a 
considerable loss of postsynaptic GABAAR (Homanics et al., 1997, Kralic et al., 2002, 
Luscher et al., 2011). In contrast, the γ2 subunit is not necessary for the assembly and 
export to the cell surface of GABAARs but is essential to confer a functional BZ 
sensitivity (Taylor et al., 2000). Following disruption of the γ2 subunit gene, 94 % of the 
BZ sites were absent in brains of neonatal mice. However the level of expression and 
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localisation of GABAAR subunit was not altered when γ2 gene expression was 
disrupted, showing a loss of only 22 % of GABA binding sites, and is therefore 
dispensable for assembly of α and β subunits (Günther et al., 1995).  
GABAARs subunits deficient mice have provided clues for a specific assembly 
of subunits into heteromeric receptors in vivo. For example, deletion of the 6 subunit 
induced a loss of  subunit in cerebellar granules cell surface (Nusser et al., 1999). 
Likewise, 4 subunit levels are decreased in the forebrain of  knock-out mice, 
whereas the level of α1 subunit was unchanged (Korpi et al., 2002, Peng et al., 2002). 
Moreover, 2 subunit levels are increased in these  knock-out mice, suggesting a 
compensatory role of 2 in absence of  subunit (Tretter et al., 2001, Korpi et al., 2002). 
This data suggests that subunits compete to find their preferential oligomerisation 
partners in the ER. However, the underlying mechanisms are still unknown (Jacob et 
al., 2008). 
1.2.1.2 Degradation of misfolded subunits : ERAD 
Misfolded or unassembled subunits are retained and degraded in the ER. The 
exit of GABAAR subunits from the ER is regulated by constitutive ER-associated 
degradation (ERAD) of α and β subunit. ERAD involves protein ubiquitylation and 
degradation by the ubiquitin-proteasome system (UPS) (Jacob et al., 2008) (Figure 6). 
 Exit of GABAA receptor subunits from the ER is mediated by a ubiquitin related 
protein Plic-1/2 (Protein Links Integrin-associated proteins with the Cytoskeleton-1/2) 
which inhibits ubiquitylation and ERAD of α and β subunits (Luscher et al., 2011). It has 
been demonstrated that Plic-1 interacts directly with GABAAR subunits intracellular 
domains using the yeast-two hybrid system (Bedford et al., 2001). This interaction 
protects the subunits from proteasome-dependent degradation in the ER and stabilizes 
receptor assembly (Bedford et al., 2001). Moreover, Plic-1 is concentrated in the 
perinuclear ER, the nucleus and in association with intracellular membranes near 
inhibitory synapses (Bedford et al., 2001, Luscher et al., 2011) (Figure 6). Therefore, by 
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increasing the stability of receptor pools, Plic-1 binding increases the number of 
GABAARs that are available for insertion into the plasma membrane (Bedford et al., 
2001). 
1.2.1.3 Export to the Golgi apparatus and Post -translational 
modification by glycosylation 
After their assembly in the ER, GABAARs are transported to the Golgi apparatus and 
segregated into vesicles to finally reach plasma membrane. Numerous proteins such 
as GABARAP, NSF, PRIPs, BIG2 or GRIF (see Figure 6) can interact (directly or 
indirectly) with the intracellular loop of the β subunits and modify intracellular trafficking 
of GABAA receptors (Connolly et al., 1996b, Wang et al., 1999 , Kittler et al., 2001, 
Kanematsu T, 2002, Chen and Olsen, 2007).  
In addition, post-translational modification by palmitoylation mediated by Golgi-specific 
DHHC Zinc finger protein (GODZ) of the γ subunit, can facilitate GABAARs trafficking 
(Keller et al., 2004, Rathenberg et al., 2004) (Figure 6). 
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Figure 6: Synthesis and intracellular trafficking of GABAA Receptors. (Jacob et al., 2008) 
GABAARs subunits are synthesised and assembled into pentameric channels in the 
endoplasmic reticulum. Misfolded or unassembled proteins are degraded by ubiquitylation in the 
proteasome. Plic-1 prevents ubiquitylation of subunits and degradation, facilitating the 
accumulation of GABAARs at the cell surface. GABARAP allows translocation of assembled 
subunits from ER via Golgi apparatus to the cell surface, by direct interaction with the  subunit. 
BIG2 and NSF are localised in the Golgi apparatus and promote GABAARs insertion into the 
plasma membrane. GODZ is a Golgi-specific enzyme which palmitoylates the intracellular loop 
of 2 subunit which facilitate insertion of GABAARs at synaptic sites. GRIF is involved in 
GABAARs trafficking but the exact role is unclear. PRIPs have essential role in trafficking and 
phosphorylation state of GABAARs. 
 
 
1.2.2 Endocytosis and recycling of GABAARs 
1.2.2.1 Clathrin-dependent endocytosis 
The number of GABAARs expressed at the cell surface is regulated by internalisation 
(endocytosis) into the postsynaptic compartment (Kittler et al., 2000). Endocytosis 
occurs in a clathrin- and dynamin-dependent manner and is mediated by the interaction 
of GABAAR subunit β and γ intracellular domains with the clathrin adaptor protein AP2 
(Kittler et al., 2000, Arancibia-Carcamo and Kittler, 2009) (Figure 7). In hippocampal 
neurones, β and γ subunit intracellular domains can interact directly with the µ2 subunit 
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of the clathrin adaptor protein AP2 (Arancibia-Carcamo and Kittler, 2009). 
Consequently, disruption of this system by blocking the interaction of dynamin and 
amphiphysin results in an increase of GABAAR expression at the cell surface and a 
consequent increase in amplitudes of mIPSC (Kittler et al., 2000). The AP2 binding 
domain present in the intracellular domains of the  subunits contains the site of 
phosphorylation by serine and threonine kinases (Kittler  et al., 2005). 
1.2.2.2 Phosphorylation-dependent regulation of endocytosis 
Phosphorylation of the AP2 binding domain prevents the interaction with AP2, 
indicating that AP2 binds GABAAR with high affinity and facilitates their internalisation 
preferentially when β subunit is dephosphorylated (Kittler  et al., 2005, Luscher et al., 
2011). Therefore, injecting neurones with a non-phosphorylated form of β3 that 
competes with the interaction of the endogenous  subunit with AP2, resulted in an 
increase of mIPSC (Kittler  et al., 2005). This interaction facilitates the recruitment of 
GABAAR into the endocytic pathway and thus is an important mechanism that 
regulates inhibitory synaptic strength and synaptic plasticity (Kittler et al., 2000). More 
importantly, the AP2 binding site of β1 and β3 subunits can be phosphorylated by PKC 
and PKA, while β2 subunit can only be phosphorylated by PKC (Brandon et al., 2003, 
Luscher et al., 2011). This indicates that modulation of GABAARs endocytosis may 
occur in a subtype-specific manner. GABAARs can also bind directly with a high affinity 
to the µ2 subunit of AP2 via the intracellular loop of the γ2 subunit (Kittler et al., 2008) 
(Figure 7). A YGYECL motif in intracellular loop of γ2 subunit exhibits high affinity for 
AP2, and this interaction is negatively regulated by the phosphorylation of the two 
tyrosines by Src Kinases (Kittler et al., 2008) (Figure 7). Similarly to what has been 
already shown with the β3 subunit, the dialysis of a blocking peptide of the γ2/AP2 
interaction leads to an increase of mIPSC amplitude as a consequence of an increase 
in the number of GABAARs at the cell surface (Kittler et al., 2008). Therefore, GABAAR 
cell surface expression can be regulated in a phosphorylation-dependent manner by at 
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least two different mechanisms for AP2/clathrin-dependent internalisation mediated by 
the  and  subunits (Figure 7) (Arancibia-Carcamo and Kittler, 2009). 
1.2.2.3 Recycling of GABAARs  
Over a short time period, GABAAR are internalised and rapidly recycled to the 
cell surface, but over a long-time period, they are degraded. In neuronal cultures, 
Huntigtin associated protein 1 (HAP1) inhibits degradation of GABAAR by interacting 
with β1-3 subunits, facilitating the recycling of the receptor and thus, accumulation of 
GABAAR at the cell surface (Kittler et al., 2004) (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 7: Constitutive endocytosis and recycling of GABAARs  (Jacob et al., 
2008).Clathrin-dependent endocytosis is the major internalisation process for GABAARs 
recycling. Phosphorylation of 3 and 2 subunits by PKA/C and Src respectively, stabilises 
GABAARs at the cell surface. However, dephosphorylation of these sites allows binding of the 
AP2 and receptor endocytosis via clathrin-coated vesicles (CCVs). HAP1 prevents degradation 
of GABAARs by interaction with  subunits and promotes recycling of GABAARs, thus leading to 
an increase in the number of GABAARs at synaptic sites 
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1.3 Development of GABAergic synapses 
1.3.1 Regional expression of GABAARs across the embryonic brain 
 The subunits of GABAARs are differentially expressed both temporally and 
spatially throughout the mammalian brain (Sur et al., 2001). From embryonic to adult 
brain, pattern of expression of each subunit has been characterised using in situ 
hybridisation, immunohistochemistry and co-immunoprecipitation. 
In situ hybridisation and immunohistochemistry studies revealed that in the 
embryonic brain, different patterns of expression have been observed for thirteen 
GABAARs subunit mRNAs tested (Laurie et al., 1992, Fritschy et al., 1994). Initially, the 
2, 3, 5, the three  subunits and  subunits were found to be the most abundant 
subunits in the embryonic brain and during the first two postnatal weeks. After two 
postnatal weeks, the levels of 2 subunit starts to decrease (Fritschy et al., 1994) and 
at the same time, 1, 4, 6, 2 and 2 mRNA levels increase until they become and 
remain the most abundant GABAARs subunits in the adult brain (Laurie et al., 1992). 
This differential subunit expression pattern happens in parallel with the change in the 
functional outcome of GABAARs activation from depolarisation to hyperpolarisation. In 
the developing brain, GABAergic synapses are immature and most GABAARs are 
present outside of the synapses. At this stage, 2, 3 and 5, which have a greater 
affinity for GABA, are the most abundant subunits. However, once mature synapses 
are formed, most of GABAARs contain the 1 subunit. 
1.3.2 Regional expression of GABAARs across the adult brain 
 Among the  subunits, 1 is present in all area of the adult brain and is often 
co-localised with 2 and 2 subunit (Sieghart and Sperk, 2002). A genetic deletion 
(knock-out) of 1 subunit causes a loss of 50 % of total GABAARs in the adult rat brain 
(Sur et al., 2001). The 2 subunit is widely expressed during development but has 
limited expression in the adult brain. This subunit is present in the hippocampus, 
47 
 
cerebral cortex, hypothalamus, basal ganglia, certain thalamic nuclei and amygdala 
(Mohler et al., 1995, Pirker et al., 2000). In addition, 3 subunit is moderately present in 
the adult brain, and mainly found in cerebral cortex and nucleus reticularis (Pirker et al., 
2000). The 4 subunit is mainly expressed in the thalamus, hippocampus and cortex. 
The 5 subunit is rarely expressed in the adult brain except in the hippocampus 
(Sieghart and Sperk, 2002). The expression of 6 subunit is restricted to the cerebellar 
granule cells (Pirker et al., 2000, Olsen and Sieghart, 2008). 
All three  subunits are widely expressed in the adult brain. Nevertheless, 2 is 
the most widely expressed as knock-out mice show a decrease in 50 % of GABAARs in 
brain (Sur et al., 2001). Although the 3 subunit is relatively highly expressed in 
different brain areas, 1 is very rare. Moreover, a deletion of 3 or 2 produces a lethal 
phenotype evident within 1 h after birth, suggesting an essential role played by these 
two subunits in brain development (Homanics et al., 1997, Tretter et al., 2001). 
The vast majority of GABAARs contain the 2 subunit which is the most 
abundant γ subunit in the rat brain based on in situ hybridisation of mRNA (Laurie et 
al., 1992, Wisden and Seeburg, 1992) and immunohistochemistry (Mohler et al., 1995). 
The 1 and 3 subunits are more restricted to certain areas as their level of expression 
decrease during development (Günther et al., 1995). However, the high levels of 1 
subunit expression are found in the substantia nigra, pallidum, amygdala and septum 
(Pirker et al., 2000). 
The  subunit is virtually absent in the developing brain (Mohler et al., 1995). 
Nonetheless, in the adult brain,  subunit is often combined with 6 subunit in 
cerebellar granule cells and associated with 4 subunit in dentate gyrus, neostriatum 
and some cortical layers (Olsen and Sieghart, 2008). 
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1.3.3 Physiological properties of GABAergic synapses throughout 
development 
1.3.3.1 Developmental switch  
Despite the inhibitory role of GABA in the adult brain, it has been demonstrated 
that GABAARs activation leads to depolarisation of cell membrane and excitation in 
developing neurones (Ben-Ari et al., 2007). During development, the intracellular 
chloride concentration gradually decreases (Ben-Ari et al., 2007). These changes of 
neuronal chloride homeostasis are dependent on the differential expression of two 
cation-chloride co-transporters. In immature neurones, Na+/K+/Cl- co-transporter 
NKCC1, which pumps chloride into the neurones, is expressed at approximately 
fourteen times higher levels than in mature cells (Bormann, 2000).  On the other hand, 
the levels of K+/Cl- co-transporter KCC2, which pumps the chloride out of the cell, are 
lower in developing than in mature neurones. Therefore, in developing neurones, when 
postsynaptic GABAARs are activated, an efflux of negatively charged ions causes a 
depolarisation of the cell. This depolarising effect provides a strong excitatory drive that 
can generate action potentials and opening of voltage-dependant Ca2+ channels 
(VDCCs) during the first two post-natal weeks (Ben-Ari et al., 2007).  
1.3.3.2 GABAARs-mediated hyperpolarisation in mature neurones  
 Once GABA is released into the synaptic cleft, it exerts its effect through 
activation of ionotropic GABAA or GABAC receptors, or metabotropic GABAB receptors. 
Fast synaptic inhibition is mainly mediated by GABAA receptors (Macdonald and Olsen, 
1994). The binding of two molecules of GABA to GABAARs triggers the opening of a 
channel permeable to chloride and bicarbonate ions. The Cl- equilibrium potential is 
near the resting membrane potential and, in most mature neurones, intracellular 
chloride is low. Therefore, activation of GABAARs leads to a rapid chloride influx into 
the cell. The entry of negatively charged ions causes hyperpolarisation of the 
membrane potential and inhibition of neuronal activity (Rivera et al., 1999).  
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1.4 The basal ganglia 
1.4.1 Structure and functionality of the basal ganglia  
The basal ganglia consist in a group of subcortical nuclei involved in a variety of 
processes such as motor, associative, cognitive and mnemonic functions (Bolam et al., 
2000). The basal ganglia are composed of the striatum (or caudate-putamen), the 
globus pallidus (external GPe, and internal GPi segments), the subthalamic nucleus 
(STN) and the Substantia Nigra (dorsal part: pars compacta SNc, and ventral part: pars 
reticulata SNr) (Figure 8). While the dorsal part of the basal ganglia is involved in motor 
and associative functions, the ventral part of this area which includes the ventral 
striatum (or nucleus accumbens), the ventral pallidum and the ventral tegmental area, 
is associated with limbic functions. 
 The main structure receiving the cortical information to the basal ganglia is the 
striatum, although the STN is also a primary recipient of information from outside the 
basal ganglia. The striatum is composed of the caudate nucleus, putamen 
(neostriatum) and nucleus accumbens (ventral striatum). Most of the inputs that the 
striatum receives come from nearly all the cerebral cortex in a topographical manner. 
For example, the prefrontal cortex projects to the anterior caudate while the 
somatosensory and motor cortex project onto the posterior putamen (Bolam et al., 
2000) (Figure 9).  
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Figure 8: The basal ganglia (Leisman et al., 2014). The basal ganglia, which regulate motor 
control, are also implicated in the circuits that confer human reasoning and adaptive function. 
The Basal ganglia are key elements in the control of reward-based learning, sequencing, motor 
action and cognitive function. This brain region is made up of five subcortical nuclei: the globus 
pallidus, caudate, putamen, substantia nigra and the subthalamic nucleus. 
 
1.4.1.1 The direct and indirect pathway 
The corticostriatal information is first transmitted to the striatum which conveys 
the information to the output structures of the Basal ganglia via two different pathways 
(Figure 9):  
- A direct inhibitory pathway from the striatum to the SNr and GPi. 
- An indirect pathway which first involves an inhibitory connection from the 
striatum to the GPe, which is then relayed by the inhibitory projection from the GPe to 
the STN and to the output nuclei, and finally via an excitatory connection from the STN 
to the SNr/ GPi. 
 The output signal from the basal ganglia under resting conditions is inhibitory 
because most of the neurones present within the basal ganglia are GABAergic and 
tonically active (Chevalier and Deniau, 1990). Activation of the direct pathway by 
glutamatergic cortical inputs triggers a disinhibition of the medium spiny neurone 
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(MSN) networks, thus triggering activation of the basal ganglia targets and is 
associated with ‘basal ganglia behaviour’. This is explained by the fact that the MSNs 
involved in the direct pathway are directly in contact with the neurones of the GPi and 
of the SNr. As both the MSNs and output neurones of the GPi are GABAergic, the 
release of GABA following their activation will provoke a disinhibition of the targets of 
the basal ganglia.  
In contrast, if the indirect pathway is activated, the firing of basal ganglia output 
neurones is increased, provoking the inhibition of the basal ganglia targets. 
Mechanistically, the MSNs involved in the indirect pathways are forming synapses with 
the neurones of the GPe. These GPe neurones which are also GABAergic are in direct 
contact with the neurones from the STN, which in turn are in contact with those from 
the output nuclei of the basal ganglia. The neurones of the GPe are also in direct 
contact with the output neurones of the basal ganglia. Thus, activation of MSNs via the 
indirect pathway will have two effects. First, disinhibition of the GPe neurones will 
provoke the excitation of the neurones from the STN which in turn will increase the 
excitation of the output neurones. Second, inhibition of the GPe neurones will have a 
direct disinhibitory effect on the GABAergic output neurones of the Basal ganglia. 
Taken together, these two ways taken by the indirect pathway lead to an increase of 
the firing of the output neurones of the basal ganglia which is ultimately, inhibiting the 
targets of the basal ganglia, and potentially providing a termination to any basal ganglia 
associated movement (Mink and Thach, 1993). 
Neurones projecting in the direct or indirect pathway are equal in proportion in 
the striatum. Interestingly, both populations can be distinguished according to the 
peptide transmitter they release when activated on one hand, and by the type of 
dopamine receptor they express on the other hand (Durieux et al., 2011). Neurones 
projecting in the direct pathway release substance P and dynorphine as co-transmitters 
and express type 1 dopamine receptor (D1R) predominantly. Upon the release of the 
dopamine from the SNc, the D1R-expressing MSN are activated and release GABA to 
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the SNr, via the direct pathway. On the other hand, MSNs projecting in the indirect 
pathway co-release enkephalin when activated. In addition, these neurones are 
inhibited when dopamine is released from the SNc as they express mostly D2R (Pauly 
et al., 2012). Interestingly, this indicates the fact that dopamine plays critical role in the 
co-activation of the direct and indirect pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The basal ganglia projections and connections (Lewis et al., 2003). Parallel 
neuronal networks of the striatum connect and integrate functions between the basal ganglia 
nuclei, various region of the cerebral cortex and the thalamus. In the motor circuit, cortical 
neurones project in a somatotopic pattern to the posterolateral putamen, where they synapse 
through glutamatergic neurones onto the medium spiny neurones. These striatal neurones are 
GABAergic and depending on the co-transmitter they release, belong to the direct or indirect 
pathway. The direct pathway connects the striatum to the internal globus pallidus (GPi) and the 
substantia nigra par reticulata (SNr). These two nuclei are the output nuclei of the Basal ganglia 
and project to the brainstem and thalamus, and from the thalamus back to the cortex. The 
projection of the GPi/SNr on the thalamus is inhibitory, while the thalamic projection to the 
cortex is excitatory. The indirect pathway pass through synaptic connections in the external 
segment of the GP (GPe) and then the subthalamic nucleus (STN) before connecting the 
striatum to the output nuclei of the Basal ganglia. The output from the STN to the GPi/SNr is 
excitatory. Excitatory projections are shown in blue; inhibitory projections are shown in black. 
Abbreviation: PPN, pedunculopontine nucleus.  
  
1.4.1.2 Pathophysiology of the basal ganglia 
 Some movement disorders result from imbalances in the direct and indirect 
pathways in the basal ganglia. Hypokinetic disorders (of which Parkinson disease is the 
best-known example) are characterised by impaired initiation of movement and 
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reduced amplitude of voluntary movements. Hyperkinetic disorders (of which 
Huntington’s disease is the most representative example) are characterised by 
excessive motor activity provoking involuntary movements and decreased muscle tone. 
Despite their antagonism, both of these movement disorders are linked with specific 
disturbances within the basal ganglia thalamo-cortical motor circuit. It has been shown 
that over or under activity of the indirect pathway results in hypokinetic or hyperkinetic 
disorders, respectively (Albin et al., 1989). Parkinsonian animal models revealed that 
due to the loss of dopaminergic input from the SNc to the striatum, the indirect pathway 
activity was increased while the direct pathway activity was decreased. This shift leads 
to an increased activity in the GPi which results in increased inhibition of the 
thalamocortical and midbrain tegmental neurones and thus the hypokinetic features of 
the disease (Kandel, 2013). 
1.4.1.3 Development of the basal ganglia  
 The embryonic telencephalon is divided into the pallial and subpallial domains 
which give rise to dorsal structures such as the cortex and ventral structures such as 
the striatum and globus pallidus, respectively (Jain et al., 2001). More specifically, the 
striatum and pallidum derive both from the lateral and the medial ganglionic eminences 
in the telencephalon (LGE and MGE, respectively) (Marin et al., 2000). The adult 
striatum is mostly composed of projecting medium spiny neurones and different 
classes of interneurones such as PV-, SOM- expressing and cholinergic interneurones. 
But when exactly in the development, these neuronal populations coming from the 
ganglionic eminences invade the striatum remains unclear.  
 Striatal projection neurones and SOM+ interneurones derive both from the LGE 
while the cholinergic interneurones derive from the MGE (Olsson et al., 1998). 
Transplantation studies have demonstrated that LGE progenitors from the embryonic 
rat develop into cells with striatal projection neuron phenotype around E14-15 (Deacon 
et al., 1994). In contrast, the progenitors in the MGE develop into cholinergic 
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interneurones around E12-15 in the rat and express Nkx2.1 homeodomain protein 
together with lhx 6/7 LIM-homeobox genes. This proteins are crucial for striatal 
interneurones specification especially for cholinergic and SOM+ interneurones (Olsson 
et al., 1998, Marin et al., 2000). The role of NKX2.1 in the differentiation and 
specification of interneurones has been assessed by staining the striatum of wild type 
and nkx2.1 mutant mice with markers such as ChAT, NPY and CR. As a result, the KO 
mice lacked most of the interneurone populations in the E18 mouse striatum (which 
corresponds to E19 in the rat) compared to wild type and died few hours after they 
were born (Marin et al., 2000). 
1.4.2 Characteristics of the medium spiny neurones  
1.4.2.1 Physiological properties of MSNs  
1.4.2.1.1 Neurochemical characterisation  of cultured MSNs in vitro 
 The properties of cultured MSNs have been analysed extensively by 
immunocytochemistry and fluorescent microscopy (Falk et al., 2006). The 
characterisation of the phenotype of cultured MSNs was first determined using GAD 65 
and GAD 67 immunolabelling. Consistent with the staining in vivo in the adult striatum, 
90 % of MSNs were positive for both isoforms with GAD 65 being largely expressed in 
neurites. 
 In addition, the expression of D1R and D2R was characterised in 4 to 18 DIV 
cultured MSNs. The results show that 92 % of neurones expressed one or the other 
receptor at more mature stages. Interestingly, a shift was observed in the expression of 
dopamine receptors: while D1R expression was decreasing, D2R levels were increasing 
during neuronal maturation. Most of the neurones expressed both subtypes of 
receptors although they were located differently. D1R expression was patchy around 
one side of the soma while D2R were uniformly distributed around the soma. 
Additionally, both were found expressed in neurites. These results indicated that the in 
vitro model is consistent with the in vivo in that there is a relatively high expression of 
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dopamine receptors in the striatum compared to other regions. However, it failed to 
show distinct populations of neurones as most of the neurones expressed both types of 
receptors. The shift in the expression of D1R vs. D2R observed could indicate a 
progression towards a more mature stage in vitro with distinct populations of neurones 
observed in the adult brain. By activating D1- and/or D2-dopamine receptors, it has 
been shown that dopamine decreases the number of functional GABAergic synapses 
formed between the embryonic MSNs with associated changes in the spontaneous 
synaptic activity (Goffin et al., 2010). In DA-MSN co-cultures, after 5 or 10 DIV, the 
presence of DA neurones increased the number of MSN spines containing PSD-95 
together with an increase in mEPSCs frequency (Fasano et al., 2013). These results 
suggest that the newly formed spines presented the functional postsynaptic machinery 
preparing the MSNs to receive additional glutamatergic contacts, thus providing a 
synaptogenic effect of dopamine on MSN development. 
 To characterise further the phenotype of these neurones, substance P and 
enkephalin were labelled and their expression was determined using semi-quantitative 
analysis (Falk et al., 2006). In this culture, 50 % of neurones expressed substance P in 
the somatic compartment but no correlation between the expression of D1R and 
Substance P was observed. In addition, less than 50 % of neurones expressed 
enkephalin which does not correspond to the in vivo labelling. In the striatum, there are 
more than 50 % of enkephalin positive MSNs. This discrepancy could reflect the 
immature stage of the culture system.  
 Finally, the potassium channels expressed in cultured MSNs were 
characterised. Potassium channels are highly diverse group of ion channels important 
for the regulation of electrical excitability of neurones and maintenance of the resting 
membrane potential (Hille, 2001). The potassium channels expression pattern in 
culture of MSNs was similar to that of in vivo in the adult striatum (Falk et al., 2006).  
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1.4.2.1.2 Electrophysiological properties of MSNs in vitro 
 Using single cell patch clamp method, the electrophysiological properties of 
cultured MSNs with studies performed in slices in vitro were compared (Falk et al., 
2006). All the recorded neurones showed rapid inactivation characteristics of the A-
type K+ current. This current represented more than 60 % of the K+ current, 
corresponding to the in vivo studies (Wilson and Kawaguchi, 1996). With voltage clamp 
recordings, a large number of neurones displayed a continuous firing pattern ranging in 
frequency from 0.11 to 1.56 Hz. This low level of electrical activity found in vivo and in 
vitro reflects clearly the intrinsic properties of MSNs (Falk et al., 2006).  
1.4.2.1.3 Characteristics of MSNs in vivo 
 The striatum receives extensive excitatory inputs from the cortex and thalamus 
that predominantly target the spines of MSNs. In order to know if any selectivity applies 
to the formation of such synapses, bacterial artificial chromosomes (BAC) transgenic 
mice were developed with enhanced green fluorescent protein (EGFP) reporting the 
presence of D1 or D2 receptors. Different types of inputs were identified by the 
selective expression of the vesicular glutamate transporter type 1 (VGluT1) by 
corticostriatal afferents and VGluT2 by thalamocortical afferents. It was demonstrated 
that the proportion of synapses formed by cortical or thalamic terminals was similar for 
both D1 and D2-expressing MSNs (Doig et al., 2010). In addition, qualitative analysis 
revealed that individual cortical or thalamic terminals were able to form synaptic 
contacts with both types of MSNs. These findings demonstrate that there is no 
correlation between the origin of the input onto the striatum and the subtype of MSN 
receiving it. Both cortical and thalamic afferents are likely to be critical in the control of 
MSNs and thus provide an equally fundamental role in the Basal ganglia function. 
 Although the degree of segregation between the two populations of MSNs have 
been debated for a long time, recent anatomical studies have shown a specific 
repartition of the two neuronal populations using BAC transgenic mice expressing 
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EGFP under the control of D1 receptor- or D2 receptor-specific promoters (Gangarossa 
et al., 2013). It has been proved that while the striatonigral (D1R
+) and striatopallidal 
(D2R
+) MSNs are randomly distributed in the rostral part of the dorsal striatum, the 
caudal part of the dorsal striatum, adjacent to the GPe, is almost uniquely composed of 
D1R-expressing MSNs. However, the function of this particular region within the 
striatum remains to be established. 
 Interestingly, D1R-expressing MSNs are of particular interest as they are 
activated upon dopamine release. In the striatum, but also in the prefrontal cortex, the 
D1Rs activated by dopaminergic input trigger the cAMP/PKA signalling pathway. In the 
striatum, the cAMP/PKA response is much stronger, faster and longer lasting than in 
the pyramidal cortical neurones (Castro et al., 2013). It has been shown that in the 
striatum, the D1R
+ MSNs express molecular determinants than enable them to conduct 
much more efficiently the cAMP/PKA signal. Indeed, the lower level of type 4 
phosphodiesterase activity (which does not damp the cAMP/PKA signal in the 
striatum), adenylyl cyclase activity and DARPP-32 (phosphatase inhibitor prolonging 
PKA activity) contribute strongly to the efficiency of MSNs in responding to brief 
dopamine stimuli (Castro et al., 2013). 
1.4.3 Inhibitory mechanisms in the neostriatal microcircuitry  
 The GABAergic striatal microcircuitry is composed of a projecting MSNs and 
interneurones, which are in minority. The connectivity within this microcircuitry is 
divided into two main categories: the inhibition mediated by axon collaterals of medium 
spiny neurones, and the inhibition mediated by neighbouring interneurones, mostly by 
fast spiking interneurones (FSIs) onto MSNs (Mallet et al., 2005). There are two main 
classes of interneurones in the striatum: the fast spiking interneurones (FSIs) and the 
persistent and low-threshold spike interneurones (PLTSs) (Kawaguchi, 1993). 
Neurochemically, while FSIs express the calcium-binding protein, parvalbumin (PV), 
the PLTS interneurones express neuropeptides such as somatostatin (SOM), 
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neuropeptide Y (NPY) or the enzyme nitric oxide synthase (NOS) (Gittis and Kreitzer, 
2012). For a long time, the MSN network and their interconnection was considered to 
provide the majority of striatal GABAergic inhibition and to sharpen and shape the 
output of MSNs. GABAergic interneurones represent only 2 % of the total rat 
neostriatum cell population but their input is crucial for a proper functioning of the Basal 
ganglia. Recent studies, mostly from in vivo paired recordings, have shown that the 
feed-forward inhibition provided by the fast spiking interneurones dominates and is 
much more efficient in blocking the generation of spikes in MSNs (Planert et al., 2010).  
1.4.3.1 Feed-forward inhibition of MSNs by GABAergic interneuron es 
 By exerting a powerful and widespread feed-forward inhibition of both 
striatonigral and striatopallidal MSNs, FSIs regulate the way cortical information is 
processed within the striatum (Mallet et al., 2005, Planert et al., 2010). In addition, FSIs 
may not selectively inhibit direct MSNs (dMSNs) or indirect MSNs (iMSNs), but rather 
efficiently and similarly inhibit a large subset of neighbouring MSNs of both types. The 
depressing nature of FSIs mediated inhibition makes it tuned to transmitting the onset 
of FSI activity, enabling FS cells to mediate efficient synchronised inhibition after 
cortical excitation (Mallet et al., 2005). The role of such inhibition may be in preventing 
MSNs to discharge after cortical stimulation but also, to allow synchronisation of output 
target of MSNs without completely silencing them.  
 The FSI-MSN and MSN-MSN inhibition observed in the microcircuitry of the 
striatum is very different in terms of the dynamic and prevalence regardless of the type 
of postsynaptic MSN. The FSI-MSN connectivity was shown to be several times more 
prevalent than MSN-MSN connectivity. This big difference could be attributed to the 
localisation of both types of synapses. As FSI-MSN synapses are perisomatic and 
MSN-MSN synapses are more distal, the signal of the first type of synapse is less likely 
to be attenuated than the second one. Interestingly, the FSIs present in the neocortical 
microcircuit share not only the same physiological properties as those constituting the 
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striatal microcircuitry but also share the similar networks properties and function in 
mediating feed-forward inhibition to their respective targets (Planert et al., 2010). 
 More importantly, the dichotomy between direct and indirect pathway MSNs 
contributes to the regulation of this network (Gerfen and Surmeier, 2011). One of the 
major projections to FSIs originates from GPe neurones and is preferentially controlled 
by the indirect pathway MSNs, complementing the one mediated by the axon collateral 
projections of MSNs (Bevan et al., 1998). It has been shown that bath application of 
dopamine elicited a depolarisation with an increase in membrane input resistance of 
FSIs in vitro (Bracci et al., 2002). These effects were mimicked by the D1-like 
dopamine receptor agonist SKF38393 but not by the D2-like agonist quinpirole. In 
contrast, GABAergic currents evoked by intrastriatal stimulation were reversibly 
depressed by dopamine and D2-like, but not D1-like, agonists. These results showed 
that endogenous dopamine exerts a dual excitatory action on FSIs by directly 
depolarising them (through D1-like receptors) and by reducing their synaptic inhibition 
(through presynaptic D2-like receptors).   
1.4.3.2 Feedback inhibition by axon collaterals of MSNs 
 Although the feedback inhibition mediated by MSNs on neighbouring MSNs is 
not as prevalent as the feedforward inhibition mediated by FSIs on MSNs, they both 
contribute to the processing of cortical input (Plenz, 2003). Unitary connections 
between MSNs are individually weak but in aggregate, they can be at the origin of a 
substantial inhibition that might be important for creating distinct assemblies within the 
striatal microcircuitry (Tepper and Bolam, 2004).  
 In contrast to FSI-mediated inhibition, striatopallidal and striatonigral MSNs 
receive sparse and variable, depressing and facilitating synaptic inputs from nearby 
MSNs (Planert et al., 2010). The dynamics of MSN-MSN synapses are very different 
and a lot more variable than that observed in FSI-MSN synapses. The synaptic 
dynamics does not seem to depend on the type of interconnected MSNs, but 
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interestingly, individual presynaptic neurones induce similar dynamic responses in 
different types of targets, which is not the case in other types of microcircuitry where 
the same presynaptic neurone may induce drastically different response to different 
types of targets (Reyes et al., 1998). 
  Unlike most of the facilitating connections observed in cortical areas, the 
facilitation mediated by MSN-MSN synapses was masked by a simultaneously 
occurring depressing component. This interplay might be at the origin of the variability 
observed in MSN-MSN connectivity (Planert et al., 2010). In addition, the feedback 
inhibition provided by neighbouring MSNs acts principally at the dendrites to control 
local excitability as well as the overall level of activity of the spiny neurones (Wickens et 
al., 1991).  
 Mature MSNs possess a highly polarised resting membrane potential at -80 to -
90 mV. Following the release of GABA from neighbouring MSNs, the relatively 
depolarised ECl- induces a membrane potential range of - 30 mV which is not sufficient 
to create an action potential as the spike threshold of MSNs is -45 mV. For MSNs at 
rest, GABA depolarisation might facilitate further excitatory input. By contrast, for MSNs 
near the action potential threshold, the GABAergic input might control the timing of 
postsynaptic action potential (Plenz, 2003). 
1.4.4 Other neuronal types in the striatum 
1.4.4.1 Cholinergic interneurones 
 The cholinergic interneurones compose approximately 0.3 % of the total striatal 
population. Although their number is low, they play a major role in the striatal 
microcircuitry. These neurones receive excitatory cortical and thalamic inputs as well 
as GABAergic inputs from MSNs and dopaminergic inputs from the SNr (Reynolds and 
Wickens, 2004, Tepper and Bolam, 2004). Their dense and widespread local axon 
collateral plexus is restricted to the striatal matrix where they target mostly MSNs and 
GABAergic interneurones and the effect of releasted acetylcholine is mediated through 
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muscarinic and nicotinic receptors (Koos and Tepper, 2002). In vivo cellular recordings 
showed that cholinergic interneurones fire regularly and slowly, with long duration 
action potentials and slow after-hyperpolarisation spikes, which makes them clearly 
distinguishable from the rest of striatal neurones. These tonically active neurones 
(TANs) respond to visual or auditory cues that predict saliency or reward with a 
stereotypic pause of 200 ms in their activity in response to cues (Reynolds and 
Wickens, 2004, Tepper and Bolam, 2004). The cholinergic interneurones are the 
elements in the neostriatal circuit underlying the reward-based learning and motivated 
behaviour (Tepper and Bolam, 2004). Activation of these interneurones has been 
shown to indirectly increase synaptic GABA events in MSNs through GABAergic 
interneurones (English et al., 2012, Luo et al., 2013a).  
1.4.4.2 The PLTS interneurones 
 The persistent and low threshold spike (PLTS) interneurones are GABAergic 
interneurones distinguished by the absence of PV and the presence of NPY, SOM, 
NOS and NAPDH diaphorase. They compose 0.8 % of the total cell population in the 
neostriatum of the rat and have the least dense axonal arborisation of all 
interneurones. They receive both cholinergic and dopaminergic input. Inhibitory inputs 
from these interneurones onto MSNs are not readily detected with whole-cell 
recordings and connectivity is sparse (Gittis and Kreitzer, 2012).  
 The NPY+ interneurones have been identified as neurogliaform (NGF) cells and 
shown to be crucial in mediating striatal cholinergic regulation (English et al., 2012). 
Although all four subclasses of striatal GABAergic interneurones are activated directly 
by nicotinic agonists, the NPY+ interneurones are most prominent in regulating the 
inhibition of MSNs during nicotinic activation (Luo et al., 2013a). In this paper, it has 
been shown that all the striatal interneurones have nicotinic acetylcholine receptor 
(nAChR) and that they all make detectable direct synaptic connections with MSNs 
except NPY+ PLTS.  
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 Using the striatum slice preparation and chronically dopamine-depleted MSNs, 
it was demonstrated that the chronic removal of dopamine provoked a shift of activity of 
GABAergic PLTS interneurones from single-spike to bursting pattern and an increase 
in the efficacy of GABAergic synaptic transmission (Dehorter et al., 2009). This led in 
turn to the generation of oscillatory giant bursts of GABA currents by one-half of the 
MSN population in the striatum (Dehorter et al., 2009).  
  The last subclass of interneurones is composed of neurones expressing the 
calcium binding protein, calretinin. They represent 0.8 % of the neostriatal cells in the 
rat and are relatively sparse in the caudal part of the striatum. Similar to FSIs, these 
calretinin-expressing interneurones exert a strong monosynaptic inhibition on MSNs 
that can delay or block spiking (Tepper and Bolam, 2004), however, their contribution 
to the striatal microcircuitry functioning remains unclear. 
1.4.5 Expression of GABAAR subunits in the adult striatum   
 The expression of different GABAAR subunits was characterised throughout the 
adult rat basal ganglia using immunohistochemistry. A regional segregation between 
the various α subunit variants was observed, while the β2/3 and γ2 subunits were 
widely expressed throughout the basal ganglia (Fritschy and Mohler, 1995). The α1 
and α2 subunits were the most predominant α subunits found in the striatum. The α5 
subunit was also present. In addition, the sub-cellular localisation of the GABAARs in 
the striatum of the rat was investigated. Post-embedding immunolabelling revealed the 
presence of α1, β2/3 and γ2 subunits of the GABAARs at the soma, dendrites and 
spines at symmetrical synapses of MSNs and/or interneurones (Fujiyama et al., 2000). 
Interestingly, double labelling for the β2/3 subunit and GABA revealed only 60 % of co-
localisation. More recently, the localisation of GABAARs throughout the GPe was 
investigated according to the type of synapses they were part of (Gross et al., 2011). In 
this paper, electrophysiological recordings and pharmacology followed by 
immunolabelling were combined in order to determine the cellular distribution of α1, α2 
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and α3 GABAAR subunits in relation to striatopallidal (Str-GP) and pallidopallidal (GP-
GP) synapses. It has been shown that while α1 subunit is expressed in both synapses 
in the soma and dendrites, the α3 subunit expression was restricted to the perisomatic 
synapses, a region mostly contacted by local axon collaterals (GP-GP synapses). In 
contrast, the α2 subunit was mostly present in dendritic compartments were striatal 
synapses are located (Str-GP synapses). Thus, due to the kinetic properties conferred 
by each individual α subunit, this specific distribution is likely to contribute differentially 
to both physiological and pathological patterns of activity (Gross et al., 2011).  
 Additionally, it has been suggested that the β3 subunit plays a central role in the 
basal tonic current seen in striatopallidal projection neurones from young mice and that 
the deletion of this subunit in KO mice resulted in a high decrease of MSN excitability 
(Janssen et al., 2011).  
It is becoming increasingly clear that different subtypes of GABAARs, the main 
component of the GABAergic synapses, are playing a central role in regulating the 
formation and maintenance of specific GABAergic synapse. GABAARs heterogeneity is 
still poorly understood but the evidence available suggests that GABAAR subtypes 
which are different in subunit composition, represent distinct entities with specific 
functions and pharmacological profiles, and with unique spatio-temporal mRNA and 
protein expression patterns during brain development (Fritschy and Panzanelli, 2014). 
The purpose of this investigation was to determine further the role of GABAAR α1 and 
α2 subunits during specific GABAergic synapse formation. In particular, we were 
interested in the structural role played by the N-terminal extracellular domains of α1 
and α2 subunit during the formation of GABAergic synapses in the developing basal 
ganglia. 
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Chapter two 
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2. Experimental procedures 
2.1 Primary cultures of embryonic medium spiny neurones. 
 One day prior to culture preparation, glass coverslips were placed in 24 well 
plates and incubated in a humidified 37°C/5% CO2 incubator with 120 μl of poly-L-
Lysine (100 µg/ ml) overnight. The coverslips were washed 2 times with water and then 
coated for 3-5 h with laminin (10 µg/ ml). Dissection tools were sterilized in 70 % EtOH. 
Medium spiny neurone cultures were prepared using embryonic striatal tissue 
as described previously (Goffin et al., 2010). Embryonic striatal tissue was isolated 
from rat embryos at gestation stage E16 to E19. First, the pregnant female rat (adult 
Sprague-Dawley, Harlan UK) was euthanized by carbon dioxide inhalation, placed on 
her back and sprayed with 70 % EtOH. The skin was cut around the abdomen with 
care taken to avoid contamination by fur and without breaking the abdominal 
membrane. With smaller scissors and a microsurgery straight-tip forceps, the 
membrane was cut and embryos were removed from the uterus, placed into a 100 mm 
Petri dish containing ice cold phosphate bufferred saline (PBS). Under the Laminar 
Flow Hood (Bassair), embryos were removed from their individual placentas and 
decapitated. The heads were placed in another Petri dish containing ice cold PBS. With 
a pair of microsurgery straight-tip forceps, the skin and skull were peeled away; the 
brain was taken out of the skull and placed into a new 100 mm dish containing Hank’s 
balanced salt solution (HBSS; Invitrogen) at 4ºC. HBSS consisted of the following 
components (mM): NaCl (137.93); KCl (5.33); sodium bicarbonate (NaHCO3; 4.17), 
potassium phosphate monobasic (KH2PO4; 0.44); anhydrous sodium phosphate 
dibasic (Na2HPO4; 0.34); D-Glucose (5.5); pH 7.4. Then, with the dorsal aspect of the 
brain facing up, the rhomb encephalon was removed and the brain was separated into 
two hemispheres. The meninges were removed carefully from the cortices and 
hippocampus. In order to access to the striatum the hippocampus was carefully 
removed. The striatum (containing the caudate nucleus and putamen, including the 
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striatal neuroepithelium and subventricular zone) was removed and transferred to a 
sterile 60 mm Petri dish containing HBSS at 4ºC. 
All the striatal tissue was then minced to small pieces of tissues (<1 mm) with 
the micro dissecting forceps. All the pieces were then collected with a Pasteur pipette 
into a 15 ml conical tube. The tissue was allowed to settle and the remaining medium 
was removed until 0.5-0.8 ml of HBSS was left in the tube. With a fire-polished Pasteur 
pipette, tissue was triturated with six to eight strokes. With a second Pasteur pipette 
polished to approximately 30 % of its original tip diameter, the cells were dissociated 
slowly until the solution was homogeneous. Live cells were counted by Trypan blue 
exclusion test, in which 10 µl of Trypan blue (0.4 %) was added to 10 µl of cells and 40 
µl of HBSS and 10 μl was loaded into haemocytometer (Sigma-Aldrich). Once the total 
number of viable cells was counted, ~75, 000 cells were plated per coverslip into 
Neurobasal medium containing B27 Supplement, glutamine (2 mM), penicillin (100 
Units), streptomycin (100 μg) and glucose (6 mM; all from Invitrogen). B27 supplement 
was included since it significantly improves the differentiation and survival of embryonic 
cultured neurones (Brewer et al., 1993). The cell suspension was swirled several times 
during the course of the plating to ensure even dispersion of cells. Cells were 
incubated in the complete Neurobasal medium in a humidified 37°C/5% CO2 incubator 
for 4 to 14 days prior to experimentation.  
2.2 Fluorescent immunolabelling and confocal imaging 
 Imaging fluorescent staining was performed using confocal laser scanning 
microscopy (CLSM), a widely used high-resolution imaging (optical sectioning) 
technique that offers enhanced contrast and definition compared to more traditional 
widefield fluorescence microscopy. In a conventional light microscope, object-to-image 
transformation takes place simultaneously for all object points. In contrast, in a confocal 
LSM, the specimen is irradiated in a pointwise fashion (serially). A microscope 
objective is used to focus a laser beam onto the specimen, where it excites 
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fluorescence. The fluorescent radiation is collected by the objective and efficiently 
directed onto the detector via a dichroic beam-splitter. The wavelength range of the 
fluorescence spectrum is selected by an emission filter, which also acts as a barrier 
blocking the excitation laser line. The pinhole is arranged in front of the detector, on a 
plane conjugate to the focal plane of the objective.  Light coming from planes above or 
below the focal plane is out of focus when it hits the pinhole, so most of it cannot pass 
the pinhole and therefore does not contribute to forming the image (Wilhelm).   
After 7 or 14 days in vitro (DIV), cells were washed twice briefly with PBS and 
fixed using 4 % (w/v) paraformaldehyde (PFA) and 4 % (w/v) sucrose in PBS for 10 
min at the room temperature with slow agitation. The paraformadehyde preserves the 
tissue by cross-linking proteins and thereby, maintaining the relative positions of 
cellular structures while the sucrose allows cells to preserve their osmolarity, therefore 
preventing the leakage of important constituents. Following fixation, cells were washed 
twice briefly and three times for 5 min with PBS at room temperature with slow 
agitation. In order to quench the excess of PFA, PBS was removed and cells were 
incubated with 0.3 M glycine in PBS (Sigma-Aldrich), followed by 2 quick washes and 
three washes of 5 min in PBS. In order to obtain labelling of cell surface proteins, 
blocking buffer containing bovine serum albumin (BSA) 2 % (w/v) in PBS was added 
for 1 h. Subsequently, blocking buffer was removed and cells were incubated with the 
primary antibodies diluted in 2 % BSA (w/v) / PBS overnight at 4°C. The following day, 
cells were washed twice quickly and three times for 5 min in PBS. Then, they were 
incubated in blocking solution containing 2 % BSA (w/v) in PBS for 30 min. For 
labelling of intracellular proteins, cells were permeabilised with 0.1 % Triton X-100 (v/v) 
in blocking (2 % BSA (w/v) / PBS), for 15 min. The primary antibodies diluted in 2 % 
BSA (w/v) / PBS were added and incubated for 2 h. Cells were washed three times for 
5 min in PBS and blocking buffer containing 1 % BSA in PBS was added for 30 min. 
Fluorescently-labelled Alexa Fluor secondary antibodies were diluted at 1/750 dilution 
(v/v) in 1 % BSA (w/v) / PBS and added to the cells for 1 h protected from light. Cells 
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were washed three times for 5 min with PBS and mounted on glass slides with the 
Prolong Gold anti fade reagent (Invitrogen).  Images were captured with an LSM 710 
laser scanning confocal microscope (Zeiss) with the 63x or 40x 1.4NA Oil DIC Plan-
Apochromat M27 lens.  
2.3 Confocal analysis 
 Immunolabelling was analysed using Zeiss LSM 710 confocal microscope with 
a Plan-Apochromat 63x/1.4 Oil DIC lens. Threshold for each channel was calculated 
from the background staining intensity and then removed from the image. To count the 
density and size of α1- and α2-containing GABAA receptor clusters or gephyrin 
clusters, puncta were defined as immunoreactive profiles greater than 0.1 μm2, with the 
mean intensity of each cluster equal or higher than double the standard deviation of 
intensity which was indicated by the Zen 2009 Programme. The defined clusters were 
encircled and their properties noted by hand.  
The density and size of α1 clusters were first calculated, followed by the α2 clusters. 
Then, α1 clusters which were mixed with α2 (minimum of 50 % overlapping) were 
separated from α1 clusters and analysed as a separate group. The same process was 
applied to α2 mixed clusters. Because the ratio between the density of α1 and α2 
clusters was different among mixed clusters, these populations were kept and analysed 
separately, although in most of the cases, they represented the same population of 
mixed clusters. Therefore, we did not separate these two types of mixed clusters when 
we analysed their co-localisation with gephyrin.  
2.4 Analysis of synaptic parameters 
As a criterion for synaptically localised clusters, I determined whether these clusters 
were in close apposition to the GAD-65-positive presynaptic nerve terminal. A minimum 
of 50 % overlap was used to estimate the close apposition between the postsynaptic 
clusters and the presynaptic terminals. The same criterion was used to determine the 
density and proportion of α1 and/or α2-containing clusters co-localised with gephyrin. 
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The total density of GAD-65 immunoreactive puncta forming contacts along the first 20 
μm length of primary dendrites was counted separately to determine the density of 
presynaptic inputs. 
2.5 Statistical analysis 
 Once all the parameters were measured, they were copied into an Excel file 
and sorted into different groups according to their size, co-localisation with GAD-65 and 
kind, single or mixed clusters:  
- All α1 single clusters  
- α1 single clusters which are co-localised with GAD-65 
- All α2 single clusters  
- α2 single clusters which are co-localised with GAD-65 
- All α1 mixed clusters  
- α1 mixed clusters which are co-localised with GAD-65 
- All α2 mixed clusters 
- α2 mixed clusters which are co-localised with GAD-65 
- All gephyrin clusters 
- α1 single clusters which are co-localised with gephyrin 
- α2 single clusters which are co-localised with gephyrin 
- mixed clusters which are co-localised with gephyrin 
 Subsequently, the data was analysed using Origin Pro 9.0 32 Bit software. 
Normal (Gaussian) distribution of the pooled data was first tested using the Shapiro-
Wilk and Kolmogorov-Smirnov tests. Since the data did not follow a normal distribution 
and the categories were independent, non-parametric statistical analysis was carried 
out using the Mann Whitney test with an interval of confidence of 95 %. Because they 
represent a robust measure of central tendency when distributions are not normally 
distributed, the medians and their interquartile range (Q3-Q1) were used to describe 
the data and evaluate statistical dispersion. With the groups following normal 
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distribution, statistical analysis was done using two sample Student’s t-test. The total 
density of clusters was evaluated along the length of 20 µm of primary dendrite for 
each cell. The density of synaptic clusters was also evaluated along the 20 μm of 
dendrites for each cell in a whole population of clusters. The proportion of synaptic 
clusters was determined as a percentage of the total clusters for each dendrite. The 
percentage of the synaptic/total clusters was tested as above and subsequently 
compared using parametric (Student’s t-test) or non-parametric statistical tests (Mann-
Whitney). A Gaussian fit was added to the bar graphs but most of the populations were 
not following a normal distribution. 
2.6 Protein assays 
2.6.1 Bradford Assay 
 The Coomassie dye protein assay was used to detect the protein concentration 
in non-denatured samples. In this assay, the proteins present in the sample bind to the 
Coomassie dye because of the acidity of the reagent. This binding results in a shift in 
the absorbance of the dye from 465 nm to 610 nm, changing the colour of the dye from 
reddish/brown to blue. The development of colour in Bradford protein assay is 
associated with the presence of arginine, lysine and histidine amino-acids in the 
peptide sequence of proteins. Thus, the amount of Coomassie dye bound to each 
protein is approximately proportional to the density of positively charged amino-acids 
found in the peptide sequence. Usually, standards were prepared by serial dilutions of 
1 mg/ml BSA in H20 + 5 µl of the buffer in which proteins were present. Then, 2 ml of 
the Bradford dye mixture (Bradford dye and deionised water 1:5 ratio, Bio-Rad) was 
added to the sample (5 μl) and the standards. Solutions were quickly vortexed as the 
incubation time is very short. The absorbance at 595 nm was determined using 
spectrophotometer (Beckman-Coulter). The standard curve was constructed by 
determining the absorbance of BSA standards (1, 2, 3, 4, 5, 10, 15, 20 and 25 μg), 
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fitting these points to a linear curve. The concentration of protein lysates was estimated 
using the standard curve.  
 
2.6.2 BCA Assay  
 The concentration of samples denatured with 2 % SDS was measured using the 
BCA Protein Assay (Thermo Scientific Pierce) which is a colorimetric assay detecting 
the reduction of copper by proteins in presence of an alkaline medium (the Biuret 
reaction). This detection relies on a highly sensitive and colorimetric detection of the 
Cu+ by the bicinchoninic acid (BCA). The first step is the chelation of copper with 
protein in an alkaline environment to form a light blue complex. In this reaction, 
peptides containing three or more amino acid residues form a coloured chelate 
complex with cupric ions. In the second step of the colorimetric reaction, the 
bicinchoninic acid (BCA) reacts with the reduced cation that was formed previously 
(Cu1+). The BCA/copper complex has a linear absorbance at 562 nm with increasing 
protein concentrations over a working range of 10-2.000 μg/ml. The reaction leading to 
BCA colour formation is strongly influenced by the presence of four amino acid 
residues (cysteine or cystine, tyrosine and tryptophan) in the sequence of the protein. 
Sample concentrations were determined based on the standards of BSA. After protein 
sample were denatured in 2% SDS, 5 μl of each was diluted in water (100 µl) and 
standards were prepared by serial dilutions of 1 mg/ml Bovine Serum Albumin (BSA) in 
H20 + 5 µl of 2% SDS. Then, 2 ml of the BCA mixture (Reagent A and B at a ratio of 
50:1) was added to the samples and the standards. Solutions were incubated in a 37°C 
water bath over 30 min for the reaction to occur. The absorbance at 562 nm was 
determined using spectrophotometer (Beckman-Coulter). The standard curve was 
constructed by determining the absorbance of known BSA samples (1, 2, 3, 4, 5, 10, 
15, 20 and 25 μg), and fitting these points to a linear curve. The concentration of 
protein lysates was estimated using the standard curve.  
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2.7 Methanol/Chloroform extraction of proteins 
 Detergents (SDS) or salt (NaCl) can be removed from protein samples by 
precipitation of proteins with a mixture of chloroform (organic solvent) and methanol (a 
polar solvent, dissolving polar molecules) resulting in dry protein material. This dry 
protein material can be resuspended in various buffers and used in experiments. 
Moreover, it is often useful to resuspend proteins in a smaller volume in order to load 
small well combs gels.  
The samples were split so that a maximum of 150 μl was present per tube. 
First, four volumes of methanol were added to each sample (600 μl) and vortexed. 
Subsequently, one volume of chloroform was added (150 μl) and vortexed. Finally, 
three volumes of ddH2O (450 µl) were added and vortexed, and the solution 
precipitated. The proteins were centrifuged for 1 min at 14,000 g. Two phases (the top 
phase containing methanol and water, the bottom phase containing chloroform) were 
separated by a white phase in the middle containing the proteins (Folch et al., 1951). 
The top layer was removed, leaving some of the aqueous/organic interphase, and 
three volumes of methanol (450 μl) were added. After mixing, the proteins were 
centrifuged for 4 min at 14,000 g. The supernatants were poured off and the protein 
pellets tap dried for 15 min. 
2.8 SDS PAGE and electrophoresis 
 Proteins were separated according to their molecular mass using sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS/PAGE) (Raymond and 
Weintraub, 1959). In their native form, proteins fold into a variety of shapes and with 
different net charge depending on their amino acid composition. The rate of migration 
of native proteins through a gel matrix depends on their relative compactness and 
charge rather than their molecular mass. To overcome this problem, protein samples 
are denatured with the anionic detergent SDS the reducing agent β-mercaptoethanol 
and by boiling at 95°C. Because SDS binds to proteins with a ratio of 1.4 g of SDS for 
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1g of protein, the denatured proteins are uniformly negatively charged. Thus, when a 
current is applied, all SDS-bound proteins present in a sample migrate through the gel 
towards the positively charged electrode allowing separation of proteins based on their 
mass alone. Proteins with the lowest mass travel faster through the gel than those with 
greater mass because of the sieving effect of the gel matrix. Therefore, the lowest 
mass proteins are detected at the bottom of the gel, while the highest molecular mass 
proteins are at the top of the gel.  
We have used discontinuous SDS/PAGE because this method “stacks” proteins 
into a very narrow zone prior to separation (the stacking gel), resulting in enhanced 
band sharpness and resolution (Ornstein, 1964). This method promotes the use of two 
different gels: an upper, large pore (5% polyacrylamide) “stacking gel” with a pH of 6.8 
and a lower separating gel, varying in pore size (from 8 to 12 %) with a pH of 8.8. 
When electrophoresis starts, the glycine from the running buffer enters the stacking 
gel. Because the pH of the gel is lower than the pKa of glycine, it enters the gel with a 
net charge of zero. It moves slowly through the sieving of the stacking gel, lagging 
behind the strongly charged Cl- ions. As these two species separate, a region of low 
conductivity, with a high voltage drop is created between them. This is known as the 
Kohlrausch discontinuity, which provokes the rapid entrance of the proteins through the 
large pores of the stacking gel. When the Kohlrausch discontinuity enters the 
separation gel, the increase in pH ionises the glycine molecules so that they move 
faster until the discontinuity disappear. The stacked proteins separate as they enter the 
second, higher sieving gel. 
Depending on the molecular mass of the protein of interest, a 7, 10 or 12 % 
polyacrylamide gel was made in a gel sandwich formed using plates of size 16 x 10 cm 
with a spacer of 1 mm thick. The gel was prepared by mixing 30 % acrylamide, 10 % 
SDS, 10 % ammonium per sulphate (polymerising agent) (APS, 2.5 µg/ml), TEMED (N, 
N, N, N’-tetramethylenediamine, catalysing the polymerisation) (1 µg/ml), 1.5 M Tris- 
HCl (pH 8.8, all from Sigma-Aldrich) and water, for a final volume of 30 ml. The gel was 
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poured into the space between the assembled glass plates, over-layed with a layer of 
water-saturated isobutanol and allowed to polymerize. After two to three hours, 
isobutanol was washed off with distilled water. 
After polymerisation, the 5% polyacrylamide stacking gel was prepared with 30 
% acrylamide solution, 10 % SDS, 10 % APS (2.5 µg/ml), TEMED (1 µg/ml), 1.0 M 
Tris- HCl (pH 6.8) and water for a final volume of 10 ml. The mixture was poured on top 
of the separation gel, and a 10-, 15- or 20-well comb was inserted into gel. During the 
polymerisation time (one hour), 120-200 μg of protein were mixed with 30 µl of 5X 
Laemmli sample buffer (312.5 mM Tris, pH 8; 10 % SDS; 50 % glycerol; 25 % β-
mercaptoethanol) and SDS 2% was added to a final volume of 150 µl. The molecular 
weight marker (mixture of standard proteins with known molecular masses, 5 µl, 
GEHealthcare) was mixed with 30 µl of 5X sample buffer and 115 µl of 2% SDS. The 
tubes were vortexed, boiled at 95°C for 5 min and centrifuged for 1 min. Once the gel 
was polymerised, the comb was carefully removed and the wells were washed quickly 
with H2O and running buffer in order to remove un-polymerised polyacrylamide. 
Samples were loaded and the gel was run in the Hoeffer SE 600 Ruby running tank 
unit (Amersham B10) overnight with a constant voltage of 55 V. 
2.9 Immunoblotting 
 The term “blotting” refers to the transfer of biological samples from a gel to a 
membrane and the subsequent detection of protein on the surface of the membrane, 
first introduced by H Towbin in 1979 (Towbin et al., 1979). Following separation, 
proteins were transferred onto a nitrocellulose membrane (Whatman 3 mm 46x57 cm) 
using the Hoefer TE62 Tank transfer unit (Amersham Biosciences UK Ltd.) according 
to manufacturer’s guidelines. Transfer was performed overnight at a constant current of 
150 mA.  Following transfer, nitrocellulose membranes were stained with Ponceau S to 
visualise proteins and thus determine whether the transfer was optimal. To remove 
Ponceau S staining, membranes were washed with deionised water and subsequently 
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washed with TBS (Tris Buffer Saline)/ Tween buffer (50 mM Tris, pH 7.5, 200 mM 
NaCl, and 0.05 % Tween-20). The membranes used in immunoblotting have a high 
affinity for proteins; therefore, after the transfer of the proteins from the gel, it is 
important to block the remaining surface of the membrane to prevent non-specific 
binding of the detection antibodies. Thus, the membranes were incubated in TBS-
Tween with 1.5 % dry milk for 30 min at room temperature with agitation. The primary 
antibodies were diluted to the optimal concentration in the same buffer, added to the 
membranes and incubated overnight at 4°C with agitation. The membranes were 
washed twice quickly with agitation and twice for 10 min in TBS-Tween with 1.5 % dry 
milk in order to remove any exceeding unbound antibodies and to block the 
membranes before the addition of the secondary antibodies. The secondary antibodies 
coupled with either alkaline-phosphatase (AP) or horseradish peroxidise (HRP) 
(prepared in 5 ml of TBS-Tween with 1.5 % skim milk) were incubated with the 
membranes for 1 h at room temperature with agitation. The membranes were washed 
twice quickly and twice for 10 min in the same buffer, followed by washings with TBS/ 
0.05 % Tween and subsequently washed with TBS for the same time. 
If the secondary antibody was coupled to alkaline phosphatase, the proteins of 
interest were revealed by incubating the membrane with 5 ml of alkaline phosphatase 
buffer (1M Tris-HCl pH 9.5; 5M NaCl; 1M MgCl2; 1% Tween 20) containing 17.5 µl of 
BCIP (5-bromo-4-chloro-3’-indolyphosphate p toluidine salt) and 35 µl of NBT (Nitro-
blue tetrazolium chloride, both from Sigma-Aldrich) which yields an intense, insoluble 
purple precipitate when reacted with alkaline phosphatase. The advantage of alkaline 
phosphatase reaction is that its rate remains linear allowing sensitivity to be improved 
by allowing the reaction to proceed for a longer time period. However, the increased 
reaction time leads to higher background and darker colour of the membrane. 
The HRP reaction has a higher activity rate than AP, a good stability and wide 
availability of substrates. The immunoblots which were incubated with secondary 
antibodies coupled with HRP were incubated with the ultra-sensitive enhanced 
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chemiluminescent substrate (SuperSignal West Femto Chemiluminescent, Thermo 
Scientific). This type of substrate offers a signal that is a transient product of the 
enzyme HRP-substrate reaction and which persists only as long as the reaction is 
occurring. Thus, if the substrate is used up or the enzyme becomes inactive, the signal 
is lost. Therefore, the conditions were optimised so that the signal could last for a 
minimum of 8 hours. The images were taken using GeneGnomeXRQ, Syngene; a 
digital chemiluminescence imaging equipment. 
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3. Expression and purification of N-terminal extracellular domains of 
GABAAR α1 and α2 subunits using Bac-to-Bac Baculovirus/ Sf9 cells expression 
system 
3.1 Introduction 
Brain function is based on a balance between excitation and inhibition. In healthy 
brain, this balance is essential for all function activities, including representation of 
sensory information, cognitive processes such as decision making, sleep and motor 
control (Cline, 2005). During development, the balance between excitation and 
inhibition is at the core of the establishment of neuronal projections and synaptic wiring 
(Cline, 2005). An imbalance between excitation and inhibition underlies a large range 
of diseases such as autism (Mariner et al., 1986), Tourette’s syndrome (Singer and 
Minzer, 2003), schizophrenia (Wassef et al., 2003) or epilepsy (Galanopoulou, 2010). 
In the central nervous system, inhibition is mostly mediated by GABAergic synapses. 
The main role of GABAergic synaptic transmission is to control neuronal excitability 
and to synchronize neuronal networks in order to generate oscillations that underlie 
cognitive processes (Ben-Ari et al., 2007). GABAergic synapses regulate probably 
every neuron in the central nervous system and coordinate major neuro-developmental 
processes (Tyagarajan and Fritschy, 2014). Via its action on GABAARs, GABA exerts a 
multitude of actions on developmental processes well before excitatory synapses are 
functional, playing an initial regulatory role in migration, cell growth and synapse 
formation in the immature brain (Ben-Ari et al., 2007). Thus, understanding how 
GABAergic synapses are formed is crucial for our understanding of brain development 
in health and disease. GABAergic synapses are characterised by presynaptic nerve 
terminals where GABA is synthesised, and postsynaptic elements expressing receptors 
for GABA. At the vast majority of synapses, GABAA receptors are accumulated or 
clustered at the postsynaptic membrane, closely apposing the presynaptic nerve 
terminals (Tretter et al., 2008). Sixteen subunits of GABAARs are encoded by different 
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genes grouped in seven different classes (α1-6, β1-3, γ1-3, δ, π, ε, and θ). The 
heteropentameric structure of the receptor subunits is highly conserved (Unwin, 1993). 
At the synaptic contacts, GABAARs are composed of two α, two β and one γ subunit. 
The significance of the GABAARs heterogeneity is still poorly understood but the 
evidence available suggests that GABAAR subtypes which are different in subunit 
composition, represent distinct entities with specific functions and pharmacological 
profiles, and with unique spatio-temporal mRNA and protein expression patterns during 
brain development (Fritschy and Panzanelli, 2014).   
To investigate the role played by GABAAR subtypes during GABAergic synapse 
formation, we decided to focus our study on the most prominent and specifically 
distributed subunits in the embryonic and adult brain, the α1 and α2 subunits (Mohler et 
al., 2002). These two subunits endow GABAARs with different kinetic properties and 
localisation within the brain. Initially, the 2 subunit is one of the most abundant 
subunits in the embryonic and perinatal brain. After the second postnatal week, the 
level of 2 subunit starts to decrease (Fritschy et al., 1994). However, at the same 
time, the level of 1 subunit mRNA increases until it becomes the most abundant 
GABAAR α subunit in the adult brain (Laurie et al., 1992). This differential subunit 
expression pattern happens in parallel with the change in the functional outcome of 
GABAARs activation from depolarisation to hyperpolarisation. Thus understanding the 
structural role played specifically by these two subunits during the brain development is 
of crucial importance.  
To study the role of α1 and α2 subunits of GABAARs during the establishment of 
the first synaptic contacts in the developing brain, we focused our experiments on the 
structural role played by the extracellular domains (ECDs) of each subunit. Each of the 
GABAAR subunits consists of a large (about 200 amino acids) extracellular N-terminal 
hydrophilic domain, followed by four transmembrane domains (TMs) with a large 
cytoplasmic-loop between TM3 and TM4, and a small extracellular C-terminal domain 
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(Sieghart et al., 1999). While the cytoplasmic loop of α subunits is involved in 
intracellular protein-protein interactions, promoting clustering of GABAARs by gephyrin, 
and thus participating in the formation of functional synapses (Tretter et al., 2008, 
Mukherjee et al., 2011, Tretter et al., 2011), the role played by the ECD of the GABAAR 
subunits during the formation of GABAergic synapses is poorly understood. It has been 
recently demonstrated that GABAARs themselves can promote GABAergic synapse 
formation in a co-culture model of α1/β2/γ2 stably transfected HEK 293 cells and 
GABAergic embryonic medium spiny neurones (Fuchs et al., 2013). This study 
provided the first evidence that GABAARs can be sufficient to initiate the formation of 
synaptic contacts. It is likely that, if the α subunits were involved in the proper 
positioning of the pre and postsynaptic elements, this would be promoted by trans-
synaptic interactions involving the ECDs which are the largest domains of these 
subunits exposed in the synaptic cleft.  
To study the role of the α1 and α2 ECDs during GABAergic synapse formation, we 
decided to express and purify these domains from baculovirus/ Sf9 insect cells 
expression system. Because the α1 and α2 ECDs are known to be N-glycosylated 
proteins (Miller and Aricescu, 2014), the use of Sf9 cells in our experiments was 
crucial.  
The first paper illustrating the use of the baculovirus Autographa Californica 
multiple nucleopolyhedrovirus (AcMNPV) to produce recombinant interferons in insect 
cells was published in 1983 (Smith et al., 1983). During the thirty years since this first 
publication, the baculovirus-based expression technology has been largely improved 
and is now used world-wide to produce a large range of proteins of scientific interest 
(van Oers et al., 2014).  The Sf9 cells enable us to produce recombinant proteins on a 
very large scale and are well adapted for glycosylated proteins as their post-
translational modification system have been engineered to produce N-glycans that are 
very similar to those in mammalian cells, thus providing an adequate glycosylation of 
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the proteins of interest (Breitbach and Jarvis, 2001). Previously, Sf9 cells were 
successfully used for the expression of GABAA and glycine receptors (Srinivasan et al., 
1999, Elster et al., 2000, Cascio et al., 2001). Different truncated forms of the ECD of 
GABAAR α1 subunit were expressed in Sf9 cells in order to establish the structural role 
of the α1 subunit ECDs in the formation of the GABA binding site and the assembly of 
GABAARs (Srinivasan et al., 1999). In addition, a better understanding of the assembly 
of GABAARs was provided by experiments in which Sf9 cells were infected with 
α1/β2/γ2 subunits (Elster et al., 2000). Moreover, the expression and purification of the 
α1 glycine receptor from baculovirus infected cells was optimised and provided a better 
understanding of the structure of this receptor (Cascio et al., 2001). All together, these 
findings supported and confirmed the idea that the Sf9 cells expression system was the 
most suited system to purify the extracellular domains of GABAAR subunits α1 and α2.  
3.1.1 Aims  
In this chapter the main aims of our research were: 
1. To produce baculoviruses incorporating the DNA sequences of α1 and α2 ECD. 
2. To optimise the infection of Sf9 cells with each baculovirus and the expression 
of the recombinant proteins. 
3. To optimise the purification of the His-tagged-α1 and -α2 ECDs from infected 
Sf9 cells by affinity chromatography. 
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3.2 Methods 
3.2.1 The Bac-To-Bac Expression System 
 The Bac-to-Bac Baculovirus Expression System is a rapid and efficient method 
to generate recombinant baculoviruses (Ciccarone et al., 1998) from infected Sf9 cells. 
This method is based on a site-specific transposition of an expression cassette 
(pFastBac CT-TOPO vector containing Tn7 transposon) into a baculovirus shuttle 
vector (bacmid) propagated in E.Coli. The Bac-to-Bac Baculovirus Expression System 
provides a pFastBac vector into which the DNA of interest can be cloned. In these 
experiments, the CT-TOPO pFastBac vector was used because it contains 6x 
Histidine-tag at the C-terminus end of the insertion site. Similarly to the other available 
vectors, the expression of the gene of interest is under the control of the Autographa 
californica multiple nuclear polyhedrosis virus, (AcMNPV) polyhedron (PH) promoter, 
which allows a high-level of expression in infected Sf9 cells. This expression cassette 
is flanked by two Tn7 sites, a gentamicin resistance gene and SV 40 polyadenylation 
signal to form a mini Tn7 (Figure 10).  
 The DH10Bac E.Coli strain into which the recombinant vector is transformed 
contains a baculovirus shuttle vector (Bacmid DNA) with a mini-attTn7 target site and a 
helper plasmid. Once the pFastBac expression plasmid is transformed into DH10Bac 
E.Coli cells, transposition occurs between the miniTn7 present on the plasmid and the 
target mini-attTn7 present on the bacmid DNA. The helper plasmid provides specific 
proteins that are required for the transposition to occur (Figure 10). 
 Once the recombinant Bacmid is isolated from DH10Bac E.Coli cells, it is 
transfected into Sf9 cells with the help of Cellfectin II Reagent to generate a 
recombinant baculovirus which will be used for preliminary experiments. First, the P1 
viral stock is generated. This low titer viral stock (generally > 106 plaque forming 
unit (pfu)/ ml) is used to infect another culture of Sf9 cells and amplify the viral 
stock. Post-P1 infection (48 h), the Sf9 cells secrete a large amount of viral 
particles: the high titer P2 viral stock (generally > 107 pfu/ml) is generated, 
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collected and used to infect Sf9 cells from which recombinant proteins are 
extracted.  Once the baculovirus stock is amplified, it is used to infect Sf9 cells at a 
larger scale and purify the Histidine-tagged proteins of interest (Figure 10).  
Figure 10. Generation of recombinant baculovirus using Bac-to-Bac Baculovirus 
Expression System. (1) The sequence of interest is PCR-amplified and inserted into pFastBac/ 
CT TOPO His vector. After transformation in One Shot Mach1 T1R E.Coli, antibiotic-resistant 
positive clones are selected and the recombinant pFastBac CT-TOPO plasmid is extracted from 
cells using the Qiagen Plasmid Maxi kit. (2) Then, the transposition of the recombinant DNA into 
Chemically competent DH10Bac E.Coli cells (containing the Bacmid DNA) is performed. (3) 
Recombinant DNAs is transposed into bacmid DNA and antibiotic selection is performed. The 
resistant clones are selected and purified using the Qiagen Plasmid Maxi kit. (4) Purified 
recombinant baculoviruses are transfected into Sf9 cells in combination with CellFectin II 
reagent (Invitrogen). (5) After infection, the cells secrete viral particles containing the 
recombinant bacmids: the P1 viral stock is generated and collected. (6) P1 viral stock is used to 
infect newly cultured Sf9 cells in order to have a higher titer viral stock (viral amplification/ 
generation of P2). This figure was adapted from Bac-to-Bac Baculovirus Expression System 
User Guide 10359, Life Technologies. 
 
3.2.2 Blunt-End TOPO cloning of α1 and α2 ECDs in pFastBac/CT 
TOPO His vector 
3.2.2.1 Primers design and PCR amplification of the α1 and α2 ECDs 
DNA sequences. 
 Primers were designed using the DNA sequence of α1 and α2 GABAAR 
subunits from Mus Musculus. The forward primers corresponded to the first thirty 
P1
P2
Transformation 1+ maxiprep 1
Transformation 2
Infection of Sf9 
cells with 
CELLfectin II
Maxiprep2 + 
sequencing
Transposition 
into Bacmid
DNA
1
2
3
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6
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nucleotides of the full-length α1 or α2 DNAs. The reverse primers were designed to 
correspond to the last thirty nucleotides before the first predicted transmembrane 
domain of each subunit. The complementary sequence of the last thirty nucleotides 
was determined and subsequently reversed in order to have the 5’-3’ nucleotide 
sequence of the reverse primer. The melting temperature and GC-content of each 
primer were determined in order to check for their compatibility during future PCR 
experiments. 
Table 1. Sequence and characterisation of primers used to amplify α1 and α2 
ECDs. Two- or three- step PCR was carried out with each full-length sequence 
(originally in pRK5 vector). 
 
 
 
 
 
Table 2. PCR amplification of α1 ECD: Reaction mix. 
 
α1 (µl) 
DNA template 
(µl) 
No DNA control 
(µl) 
DNA 100 ng 1 1 0 
10x enhancer solution (1X final) 5 5 5 
10x amplification buffer (1X final) 5 5 5 
50 mM dNTPs (10 mM final) 0.5 0.5 0.5 
50 mM MgSO4 (1 mM final) 1 1 1 
Primers (10 µM final) 1.5 1 1.5 
Platinium pfx DNA polymerase (1 
unit) 
0.5 0.5 0.5 
H2O 35 35 36 
 
Table 3. PCR of α1 ECD: Thermal cycle parameters 
 Time (min) Temperature (°C) 
Initial denaturation 2 94 
denaturation 15 sec 94 
Annealing 0 0 
Extension 1 68 
Final Extension 10 72 
35 cycles   
 
 
  DNA Sequences 5’-3’ (30nt) Tm (°C ) GC (%) 
α1-Forward primer atgaagaaaagtcggggtctctctgactat 46.67 78.58 
α1- Reverse primer aaagtagccaatttttctcttcaagtggaa 43.3 70.15 
α2- Forward primer atgaagacaaaattgagcacatgcaatgtat 40 75.93 
α2-Reverse primer cccaatttttcttttcaagtggaaatgagc 33.3 68.84 
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Table 4. PCR amplification of α2 ECD: Reaction mix. 
 
Table 5. PCR of α2 ECD: Thermal cycle parameters 
 
 
 
 
 
 
The amplified products were analysed by agarose gel electrophoresis (1.2 %) in the 
presence of Ethidium Bromide and visualised under the UV light. 
3.2.2.2 Gel extraction of DNA from agarose gel 
 The bands were cut out from the gel and weighted. Three volumes of gel 
solubilisation buffer (L3) for every volume of gel were mixed and heated up to 50°C for 
15 min. Once DNA was dissolved, it was transferred into filtered column and spun 
down at 14,000 g for 1 min. The DNA remaining in the filter was washed one time with 
washing buffer (W1). After spinning, flow-through was discarded and the tube was 
spun again for 3 min to remove any residual EtOH from the column. Then, DNA was 
eluted with elution buffer and stored at 4°C for short term storage or aliquoted and 
stored at -20°C for longer term storage. 
 
 
 
 α2 (µl) DNA template (µl) 
No DNA control 
(µl) 
DNA 100 ng 1 1 0 
10x amplification buffer (1X final) 5 5 5 
50 mM dNTPs (10 mM final) 0.5 0.5 0.5 
50 mM MgSO4 (1mM final) 1 1 1 
Primers (10 µM final) 1 1 1 
Platinum pfx DNA polymerase (1 
unit) 
1 1 1 
H2O 40.5 40.5 41.5 
 Time (min) Temperature (°C) 
Initial Denaturation 2 94 
Denaturation 1 94 
Annealing 1 55 
Extension 1 72 
Final Extension 10 72 
25 cycles   
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3.2.2.3 Blunt-end TOPO Cloning in pFastBac CT-Topo His vector 
 TOPO cloning was set up as described in the table below (in a final volume of 6 
µl). Insert-to-vector ratio of 1:1 was recommended. The reaction was gently mixed and 
after 5 min at the room temperature (22-23°C), the mixture was placed on ice.   
Table 6. Blunt-End TOPO Cloning of the amplified DNAs into pFastBac CT-TOPO 
vector. 
Reagent 
Vector only 
(negative 
control) (µl) 
Vector +PCR 
Insert (µl) 
Vector +DNA 
template (positive 
control) (µl) 
Control PCR Product 0 1 1 
Sterile Water 4 3 3 
Salt Solution 1 1 1 
pFastBac/ CT-TOPO 1 1 1 
3.2.2.4 Transformation in One Shot Mach1 TM T1R Chemically 
Competent E.Coli 
 Each cloning reaction (2 µl) was added to the chemically competent E.Coli and 
mixed gently. The pUC19 plasmid DNA (2 µl), provided by Invitrogen, was used as a 
positive control for the transformation. The vials were incubated on ice for 30 min, heat-
shocked for 30 sec at 42°C in water bath, and then placed on ice for 2 min. After 
adding 250 µl of warm super optimal broth with catabolite repression (S.O.C medium), 
the vials were placed at 37°C in a shaking incubator (225 g) for 1 h. For each 
transformation reaction, 25 µl or 100 µl was spread onto the pre-warmed agar plates 
containing ampicillin (100 µg/µl). In order to control the transformation efficiency, 10 µl 
of the pUC19 transformation was spread on plates as recommended. All the plates 
were then incubated upside-down at 37°C over-night. After 24 h, 10 colonies of each 
transformation were picked and analysed. 
3.2.2.5 Miniprep protocol: purification of DNA using QIAprep Spin 
Miniprep Kit (QIAGEN) 
 The 10 ampicillin-resistant clones were selected and amplified in a 4 ml 
suspension of lysogeny broth medium (LB medium) with 100 µg/µl of ampicillin over-
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night in a shaking incubator at 37°C. The DNAs were extracted from the suspension 
bacterial culture and purified using Miniprep kit from QIAGEN following the protocol 
provided with this kit.  
3.2.2.5.1 Analysis of positives clones 
 The concentration of purified DNA was measured using nanodrop 
(Thermoscientific) and DNA was loaded on a 1.2 % agarose gel to check purity and 
quality of DNA. In order to confirm the insertion of DNA fragments and their orientation, 
two PCR reactions were performed for each sample using the Phusion PCR Master 
Mix (Finnzymes). The first PCR reaction was carried out using the polyhedrin forward 
and SV40 reverse primers which bind to small sequences in the vector flanking the 
sequence of interest (data not shown). The second PCR reaction was carried out using 
the forward primer overlapping with the first 30 bp of α1 or α2 and the SV40 reverse 
primer (Figure 17). Analysis of this PCR product was carried out by agarose gel 
electrophoresis. Positive clones were confirmed by sequencing. 
3.2.2.5.2 Extraction and purification of pFastBac CT-TOPO His vectors 
containing the α1 or α2 ECD sequences. 
 From each transformation, two positive clones were inoculated in 200 ml of LB 
medium with 100 µg/µl of ampicillin in a shaking incubator at 37°C overnight. The 
culture was centrifuged at 5000 g for 10 min at 4°C. The supernatant was removed and 
pellets were frozen for 1-2 h at -20°C. A Maxiprep was performed using GenElute HP 
Plasmid Maxiprep kit (Sigma-Aldrich) following the protocol provided with the kit. The 
DNA concentration was measured with a nanodrop (Nanodrop 1000 
spectrophotometer, Thermo Scientific). 
3.2.2.6 Transposition of α1 and α2 ECDs into DH10Bac E.Coli  
3.2.2.6.1 Transformation of α1 and α2 recombinant pFastBac CT-TOPO 
plasmids into MAX EfficiencyR DH10BacTM Chemically Competent E.Coli  
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 LB agar plates containing 50 µg/ml of kanamycin, 7 µg/ml of gentamicin, 10 
µg/ml of tetracycline, 100 µg/ml of Bluo-gal and 40 µg/ml of IPTG were prepared in 
advance. For each transposition, one vial of MAX EfficiencyR DH10BacTM Chemically 
Competent E.Coli cells was thawed on ice. Once defrosted, 100 µL of the cells were 
transferred into pre-chilled 15 ml tubes and 1 ng of α1- or α2-containing CT-TOPO 
pFastBac plasmids, or 50 pg of pUC19 were incorporated onto the cells, respectively. 
As a positive control for the future Sf9 cells infection, 1 ng of pFastBac Gus plasmid 
(provided by Invitrogen) was also transformed into E.Coli cells. The bacterial cells were 
incubated on ice for 30 min and heat-shocked for 45 sec at 42°C in a water bath 
without agitation. The tubes were immediately transferred to ice for 2 min and 900 µl of 
room temperature S.O.C medium was added to the cells. Each transformation was 
shaken at 37°C at 225 g for 4 h and the pUC19 transformation at 225 g for 1 h. After 
incubation, three different dilutions (10-1, 10-2, and 10-3) of each transformation were 
plated onto previously prepared agar plates. The pUC19 transformation reaction was 
plated onto agar plates containing 100 µg/ml of ampicillin. The plates were incubated 
upside-down for 48-72 h at 37°C. 
3.2.2.6.2 Isolation of recombinant Bacmid DNAs 
 The bacmid DNA confers a resistance to kanamycin. The insertion of the mini-
Tn7 into mini-attTn7 cassette on the bacmid disrupts the expression of LacZα peptide, 
so colonies containing the recombinant bacmid are white. After incubation, blue/white 
screening was done. Only “truly-white” colonies were picked and re-streaked onto new 
plates (containing 50 µg/ml of kanamycin, 7 µg/ml of gentamicin, 10 µg/ml of 
tetracycline, 100 µg/ml of bluo-gal and 40 µg/ml of IPTG) and incubated for 24 h at 
37°C. All the colonies that had been confirmed to have a white phenotype were 
inoculated into a 2 ml LB medium culture containing 50 µg/ml of kanamycin, 7 µg/ml of 
gentamicin, 10 µg/ml of tetracycline in a shaker incubator (250 g) overnight at 37°C.  
3.2.2.6.3 Miniprep on recombinant Bacmid DNA 
89 
 
 In order to isolate the recombinant Bacmid DNA from MAX EfficiencyR 
DH10BacTM Chemically Competent E.Coli cells, miniprep was performed following the 
PureLinkTM HiPure Plasmid DNA Miniprep Kit protocol (Invitrogen). DNA is re-
suspended in 40 μl of TE buffer, and placed on ice until DNA is completely dissolved. 
Low concentrated Bacmids were aliquoted and kept at -20°C.  
3.2.2.6.4 Analysis of positive clones 
 Analysis of positive clones containing α1 or α2 sequence was done using PCR. 
Reaction mixture and conditions for amplification are included in Table 7 and 8.  
Figure 11. Analysis of recombinant bacmid by PCR. 
Figure adapted from the Bac-to-Bac Baculovirus Expression System User Guide 10359, Life 
Technologies. Recombinant bacmid DNA is greater than 135 kb in size which interferes with a 
reliable detection of the insert. It is therefore recommended to perform PCR instead in order to 
verify the presence and orientation of the inserts into bacmid DNAs by using different 
combinations of primers. Puc/M13 forward and reverse primers were used in the first place to 
confirm the presence of the insert into the bacmid DNA. 
 
 
Table 7. PCR amplification of recombinant bacmid DNAs: reaction mix 1. 
 
 
 
 
 
 
 
 
 
 
 
α1 or α2 
(µl) 
Gus 
control (µl) 
No DNA (-) 
Control (µl) 
DNA 100 ng 10 10 0 
10x PCR buffer (1X final) 5 5 5 
50 mM MgCl2 1.5 1.5 1.5 
10 mM dNTPs (10 µM final) 1 1 1 
Primers  pUC / M13 forward 
and reverse (10 µM final) 
1.25 1.25 1.25 
Platinum Taq DNA 
polymerase 
0.5 0.5 0.5 
H2O 30.75 30.75 30.75 
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Table 8. PCR of recombinant bacmid DNAs: Thermal cycle parameters 1. 
 
 
 
 
 In order to check if α1 and α2 ECDs were inserted in the right orientation in 
selected clones, another PCR was performed using the corresponding specific forward 
primers and the pUC / M13 reverse primer (Figure 11) as shown in Tables 9 and 10. 
Table 9. PCR amplification of recombinant bacmid DNAs: reaction mix 2 
 
α1 or 
α2 (µl) 
Gus 
control (µl) 
No DNA (-) 
control(µl) 
DNA 100 ng 10 1 0 
10x PCR buffer (1X final) 5 5 5 
50 mM MgCl2 1.5 1.5 1.5 
10 mM dNTPs (20 µM final) 1 1 1 
α1 or α2 forward,  and pUC/ 
M13 reverse (10 µM final) 
1.75 1.75 1.75 
Platinum Taq DNA 
polymerase 
0.5 0.5 0.5 
Sterile water 28.5 28.5 28.5 
 
Table 10. PCR of recombinant bacmid DNAs: Thermal cycle parameters 2 
 
 
 
 
 
  
Once the orientation was confirmed, the DNA was extracted from agarose gel 
slices and the eluted DNA was analysed by sequencing using a UCL Sequencing 
Facility (http://www.ucl.ac.uk/stemcells/infrastructure). Once the sequence of each 
clone was confirmed, DNA was isolated using the PureLinkTM HiPure Plasmid DNA 
Maxiprep Kit protocol (Invitrogen), specifically adapted for DNA Bacmid isolation. 
 Time (min) Temperature (°C) 
Initial Denaturation 3 94 
Denaturation 45sec 94 
Annealing 45sec 55 
Extension 5 72 
Final Extension 7 72 
30 cycles   
 Time (min) 
Temperature 
(°C) 
Initial Denaturation 3  94 
Denaturation 45 sec 94 
Annealing 45 sec 55 
Extension 5  72 
Final Extension 7  72 
30 cycles   
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Highly concentrated bacmids were aliquoted and kept at -20°C for future Sf9 cells-
infection experiments. 
3.2.3 Sf9 cell culture 
3.2.3.1 Suspension culture  
 Sf9 cells were isolated from the parental Spodoptera Frugiperda cell line IPLB-
Sf21-AE. They were adapted to suspension growth in Sf-900 II SFM (Serum Free 
Medium, Gibco). The cells were supplied by Invitrogen in a cryogenic vial containing 
1.5x107 viable cells. The pellets were rapidly defrosted in a 37°C water bath added to 
125 ml shake flask containing 27 ml of pre warmed Sf-900 II SFM. The loosen cap 
flask was then placed in a 28 ± 0.5°C non-humidified, ambient air-regulated incubator 
on an orbital shaker platform rotating at 130 rotation per min (g). The cells were split for 
the first time when they reached the density of 2x106 cells/ml. The density of cells was 
determined by Trypan blue exclusion method. Briefly, 10 µl of suspension was taken 
out and added to a micro centrifuge tube. Trypan blue (10 µl) and medium (1/4 dilution) 
were added to the cells. The mixture was loaded onto a haemocytometer chamber. 
The total density of cells contained in the flask was determined using the formula: 
Density of cells x 4 x 1.1= x104 cells/ml. The viability of the culture was calculated using 
the following formula: Viability = (1-(density of dead cells/ total density of cells)) x 100. 
After two weeks in culture, the viability of cells was over 90 % and the cells were ready 
to be split at 5x105 cells/ml by diluting them in pre-warmed Sf-900 II SFM (27°C). If 
cells were kept in mid-log growth (logarithmic phase), the density of cells was doubled 
every 24-30 hours. To reduce the accumulation of cell debris and metabolic waste by-
products in shaker culture, the cells were gently spun down (100 g for 10 min) once 
every three weeks and the pellet re-suspended in fresh medium. 
3.2.4 Adherent cultures 
 SF9 cells were also grown in adherent cultures. To initiate an adherent culture 
from frozen vial (1x107 cells), cells were thawed in a pre-warmed T-25 cm2 flask 
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containing 4 ml of Sf-900 II SFM. After 30 min in the incubator, cells were attached. 
Medium containing DMSO was removed and replaced by 5 ml of fresh Sf-900 II SFM. 
After 24 h, the medium was changed and viability of cells estimated. When cells reach 
confluency (> 80 %), they were sub-cultured by sloughing them with a Pasteur pipette. 
Cells were counted and added to a new flask with a required density. 
3.2.5 Generating P1 and P2 viral stocks from transfected Sf9 cells  
3.2.5.1 Transfection procedure: cationic liposome-mediated 
transfection using Cellfectin II© Reagent  
 Before they were infected, cells were healthy, at low passage (P8-12) and the 
viability was over 95 %. In a 6 well dish containing 2 ml of pre-warmed Sf-900 II SFM, 
9x105 cells/ ml were plated and placed at 28°C for 1 h. During this time, the transfection 
mixture was prepared by adding 2 µg of recombinant bacmid DNA into 100 µL of Sf-
900 II SFM medium. In another tube, 8 µl of Cellfectin II Reagent were diluted in 100 
µL of Sf-900 II SFM. The Cellfectin II solution was added to the bacmid DNA solution, 
mixed gently and incubated at room temperature for 15 min.  While the lipid/DNA 
complexes were forming, the Sf9 cells were washed once with 2 ml of Sf-900 II SFM. 
Then, 0.8 ml of Sf-900 II SFM was added to each tube containing Cellfectin II and 
bacmid DNA and mixed gently. The Sf-900 II SFM was removed from all the wells and 
replaced with 500 µl of the mixture containing Cellfectin and bacmid DNA. After 5 h at 
28°C, the transfection mixture was removed, 2 ml of fresh Sf-900 II SFM were added 
and the cells were incubated for 72 h. To avoid the drying of wells, 2 ml of fresh Sf-900 
II SFM were added again 48 h post infection. 
3.2.5.2 Harvesting P1 viral stock and cell lysis for immunoblot analysis  
 Following 72 h of incubation, the medium containing viral particles was carefully 
removed, centrifuged 6 min at 500 g and filter-sterilized with a 0.22 µm filter. It was 
kept at 4°C and protected from light. The cells were washed in 2 ml of PBS, harvested 
and lysed with 200 µl of 2 % SDS. The cell lysate was collected; the samples were 
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boiled for 10 min at 95°C, sonicated for 15 sec and frozen at -20°C for future analysis 
of protein expression by SDS/PAGE and Immunoblotting. 
3.2.5.3 SDS/PAGE and Immunoblotting 
 Expression of proteins was analysed by SDS/PAGE and immunoblotting as 
described in the Experimental Procedure Chapter, Section 2.8. Once transferred onto 
the nitrocellulose membrane, the proteins were incubated with the 6xHis-tag-, the α1- 
or α2- specific antibodies (Table 11) in 1.5 % milk-TBS-Tween overnight at 4°C. After 
washing, the proteins were revealed using an alkaline phosphatase conjugated 
secondary antibody, and BCIP/NBT colour reaction. 
3.2.5.4 Generating P2: Amplification of the viral stock  
 In order to get a viral stock with a higher titre, the P1 viral stock was used to re-
infect cells. The Multiplicity of Infection (MOI) was estimated as MOI= 0.1.  
The following formula was used to calculate how much P1 viral stock should be added 
to the cells: 
   Inoculums required (ml) =   MOI (pfu/ cell) x density of cells 
     Titre of viral stock (pfu/ ml) 
The titre of P1 was assumed to be 1x106 plaque forming unit (pfu)/ml (low titre). Sf9 
cells were plated at the density of 2x106 cells/ml into 6 well dish, and incubated at 28°C 
for 1 h to allow attachment.  The appropriate amount of P1 viral stock was added and 
cells were incubated for 48 h. Then, the media was collected, spun down and filter-
sterilized and the cells were harvested and lysed in 2 % SDS for further analysis of 
protein expression by SDS/PAGE and Immunoblotting. 
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Table 11. Antibodies used for immunoblotting analysis of α1 and α2 ECD 
expression in Sf9 cells. 
primary antibodies secondary antibodies 
Specificity Origin Dilutions 
Source and 
Characterisation 
Specificity 
(AP) 
Dilutions Source 
GABAA 
α1 
Rabbit 1:500 
(Duggan and 
Stephenson, 1990) 
Goat anti- 
rabbit 
1: 5000 
ThermoScientific 
31340 
GABAA 
α2 
Rabbit 2 µg/ ml 
(Mhatre et al., 
1993) 
Goat anti- 
rabbit 
1: 5000 Same as above 
6xHis-tag Mouse 1: 1000 Abgent AM1010a 
Rabbit anti- 
mouse 
1: 2500 
Pierce 
Biotechnology 
31329 
 
3.2.6 Partial purification of α1 and α2 ECDs under native conditions 
using Tris-HCl buffer and Probond Resin 
 Sf9 cells in suspension culture (40 ml) were infected with α1 and α2 P2-viral 
stocks with an MOI of 2, and incubated for 72 h at room temperature. Cells were spun 
down at 800 g for 10 min, and pellets were resuspended in 1 ml of Tris-HCl buffer (20 
mM Tris pH 7.5, 300 mM NaCl, 1 % NP40, Protease inhibitors cocktail (containing 
antipain, PMSF, chemostatin, leupeptin, pepstatin A, all at 5 µg/µl, Thermoscientific)). 
Then, the cells were lysed by three freeze/thaw cycles and sonicated on ice for 40 sec. 
Solubilisation was carried out for 45 min on ice with gentle agitation. Cell lysates were 
spun down at 3000 g for 15 min at 4°C. The collected supernatant was carefully 
removed from the pellet. Small fractions of lysates were collected at each of these 
steps and analysed by SDS/PAGE and immunoblotting. 
 The ProBond resin is a sepharose resin that is coupled with iminodiacetic acid 
groups (IDA). IDA is loaded with Ni2+ ions and binds Ni2+ by three coordination sites. 
Beads were obtained in 20 % ethanol and 50 % slurry from Invitrogen. Beads were 
prepared by pipetting 1 ml of the resuspended resin into one eppendorf tube per affinity 
chromatography. After the beads were centrifuged at 800 g for 1 min, the supernatant 
was removed and 1 ml of sterilised deionised water was added to wash the beads. The 
beads were re-suspended in water and centrifuged at 800 g for 1 min at 4°C. The same 
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procedure was repeated twice with Tris-HCl buffer (1 ml). Once the buffer was 
removed, 500 µl of Tris-HCl buffer was added to the beads to reach 50/50 slurry.  
The capacity of Ni2+ column was between 1-5 mg of histidine-tagged protein for 1 ml of 
resin. Considering that approximately 10-20 % of the total yield of protein collected 
represented the protein of interest, all the collected supernatant from infected Sf9 cells 
was added to 1 ml of beads. The binding was done at 4°C with rotation for 1.5 h. The 
columns were spun down at 800 g for 1 min, supernatant was collected and 1 ml of 
Tris-HCl buffer was added to the beads. After quick vortex, the mixture was spun down 
and the supernatant was collected. This washing step was repeated 5 times.  
 The following day, 500 µl of the elution buffer (Tris-HCl buffer containing 250 
mM Imidazole, pH 8.0) was added to the beads. After 10 min of incubation, beads were 
spun down at 800 g and the supernatant was collected. Elution step was repeated 6 
times. In order to remove Imidazole, all the collected elution fractions were pulled 
together and dialysed overnight at 4°C against PBS. After dialysis, the sample 
concentration was measured by BCA assay, and proteins were snap-frozen in the 
liquid nitrogen and stored at -20°C. Samples of 100 µl were collected at each step of 
the protein purifications and analysed by SDS/ PAGE and immunoblotting. 
3.2.7 Partial purification of α1 and α2 ECDs under native conditions 
using NaH2PO4 based buffers and Ni-NTA Resin 
 Sf9 cells in suspension culture (100 ml) were infected with α1- or α2- P2 viral 
stocks with an MOI of 2, and incubated for 72 h at room temperature. Cells were split 
into two 50 ml tubes and spun down at 800 g, for 10 min and pellets were washed in 1x 
PBS in order to remove any compounds from the growth medium that could interfere 
with the binding to the nickel beads. Pellets were resuspended in 3 ml of hypotonic 
lysis buffer (20 mM NaH2PO4 pH 8.0, 0.5 % NP-40, Protease inhibitors cocktail 5 µg/µl) 
followed by three freeze/thaw cycles and sonication for 30 sec on ice. The lysates were 
split into two tubes and rotated for 30 min at 4°C to complete cell lysis. Cell lysates 
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were spun down at 3000 g for 15 min at 4°C. The collected supernatant was carefully 
removed from the pellet and snap- frozen with liquid nitrogen. The proteins contained in 
the pellet were resuspended in the solubilisation buffer (50 mM NaH2PO4 pH 8.0, 150 
mM NaCl, 2 % NP-40, 1 % DOC, and protease inhibitors cocktail 5 µg/µl) and pulled 
back together. Once resuspended, proteins were homogenised using a sintered-glass 
homogeniser with which 4 to 5 strokes were done on ice, in order to avoid degradation. 
Subsequently, proteins were solubilised on a rotating plate for 1.5 h at 4°C and spun 
down at 3000 g for 15 min at 4°C. The collected supernatant was dialysed overnight in 
dialysis buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 1 % Triton X-100).  
The following day, the proteins were collected and the protein concentrations 
were measured using the Bradford Assay. Glycerol (20 % final) was added to 1 mg of 
proteins, and they were added to the prepared beads. Ni-NTA agarose uses 
nitrilotriacetic acid (NTA), a tetradendate chelating ligand, in a highly cross-linked 6 % 
agarose matrix. NTA binds Ni2+ ion by four coordination sites. Therefore, NTA resin 
minimizes leaching of the metal from the solid support (resin) and allows for more 
stringent purification conditions than ProBond. Beads were prepared by pipetting 800 
µl of resuspended beads (50/50 slurry) into one eppendorf tube per affinity 
chromatography. After they were spun down at 1000 g for 4 min, 400 µl of water were 
added in order to wash beads. The procedure was repeated one more time. Then, 400 
µl of binding buffer (dialysis buffer containing 20 % glycerol) were added to the 
eppendorf tube which was gently inverted and spun down at 1000 g for 4 min. The 
procedure was repeated one more time. The supernatant was removed and 1 mg of 
extracted proteins was added to the beads to bind overnight at 4°C. The following day, 
the columns were spun down at 800 g for 2 min and the supernatant after binding was 
removed. The beads were washed two times in the binding buffer for 5 min with 
rotation. Then, they were washed three more time in the binding buffer which does not 
contain Triton X-100 for 10 min with rotation. Finally, the proteins were eluted with the 
elution buffer (binding buffer containing 100 mM EDTA pH 6.0; 250 mM Imidazole, and 
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with protease inhibitors) by incubating on the rotating plate overnight at room 
temperature.  
The next day, the columns were spun down at 800 g for 2 min and incubated with 
elution buffer two more times for 10 min with rotation. The elution fractions were then 
dialysed overnight against PBS containing 300 mM NaCl and the concentration of 
proteins was measured the day after with the Bradford assay. The proteins were 
aliquoted and snap-frozen. At each step, samples of 100 µl were lysed with SDS, and 
kept at -20°C for the analysis of the protein purification by SDS/PAGE and 
immunoblotting as described in the Chapter 2, Sections 2.8-2.9.  
3.3 Results 
 We used a commercially available Bac-To-Bac Expression System (Life 
Technologies, Invitrogen) to generate recombinant baculovirus strains expressing the 
large N-terminal Extracellular domains (ECDs) of GABAAR α1 or α2 subunits. The 
procedure included the preparation of the recombinant bacmid DNA, followed by the 
preparation of the recombinant baculovirus stocks. The recombinant baculoviruses with 
α1 or α2 ECD were used to infect the Sf9 cells and test the expression of the proteins. 
Finally α1 and α2 ECDs were partially purified from infected Sf9 cells.   
3.3.1  Insertion of DNA sequence of α1 or α2 N -terminal ECD into 
Baculoviruses. 
 The initial step included preparation of the recombinant pFastBac constructs 
containing the sequence encoding the initial 223 N-terminal amino acids of the α1 and 
α2 subunits terminating at the start of the predicted first transmembrane domain. 
Cloning into the pFastBac CT-TOPO vector required blunt end PCR products which 
were obtained using PCR amplification of these sequences from pRK5 expression 
constructs in the presence of the appropriate primers and Platinum Pfx DNA 
polymerase. As shown in the Figure 12, the blunt-end TOPO cloning is based on the 
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use of the linearised cloning vector with Vaccinia topoisomerase I covalently bound to 
the 3’ end of the each DNA strand. The presence of topoisomerase I facilitates the 
insertion of the blunt-end sequence into the vector. PCR products were obtained using 
a three-step PCR procedure (condition 1) for α1 and a two-step (condition 2) for α2 
constructs. As expected, α1 PCR product contained approximately 756 base pairs and 
α2 approximately 753 base pairs (Figure 13). A positive control for the three-step PCR 
procedure used for generation of the blunt-end α2 PCR product was provided by the 
Invitrogen kit.  
Figure 12. The pFastBac CT-TOPO His vector and the TOPO-cloning. Figure adapted from 
the Bac-to-Bac Baculovirus Expression System User Guide 10359, Life Technologies. A. The 
expression of the gene of interest in controlled by the Polyhedrin promoter (PPH) for high-level 
expression in Sf9 cells. This expression cassette is flanked by the left and right arms of Tn7 
(Tn7L and Tn7R). It also contains a gentamicin and ampicilline resistance genes. In addition, it 
contains an SV40 polyadenylation signal to form a mini Tn7. The pFastBac CT-TOPO His 
vector contains six histidines on 3’ of the insertion site. The Tobacco Etch Virus (TEV) 
recognition site allows removal of the 6xHistag if needed. DNAs of α1 and α2 ECDs were 
inserted into the vector by TOPO cloning by the topoisomerases bound to the vector DNA 
sequence. B. Topoisomerase I from Vaccinia virus is bound to DNA at specific sites in order to 
cleave the phosphodiester backbone after 5’ -CCCTT in one strand of DNA. The released 
energy allows the DNA of interest to be inserted into the vector. 
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Figure 13. Blunt end PCR products of the α1 and α2 ECDs. A. The α1 PCR product was 756 
bp. Only one PCR condition (3 steps PCR) was sufficient to amplify the α1 product. B. The α2 
PCR product was 753 bp. Two conditions of PCR were tested for the α2 insert. The first 
condition was the same as the one used for α1 (three steps PCR) and the second condition was 
a two-step PCR. The first condition did not give any amplification of α2 sequence. The control 
PCR product (750 bp, DNA template only tested with α2) was amplified with a two-step PCR. 
 
 PCR products (α1, α2 and control) were gel-purified and cloned into a pFastBac 
CT-TOPO vector which contains a sequence of six histidines at the 3’ end of the 
inserted sequence (Figure 12). This was followed by the transformation of One Shot 
Mach1 T1 Chemically competent E.coli. Then, positive clones (from 10-16 clones) were 
selected and DNA isolated using PureLink HiPure Mini Plasmid Purification Kit.  
Isolated DNA was analysed using agarose gel electrophoresis as shown in the 
Figure 14. A small difference in size was observed between DNA isolated from different 
colonies (~ 5 kb) and the DNA template, the empty vector (4754 bp) and pUC19. 
Figure 14. Analysis of the α1 and α2 CT-TOPO constructs isolated from positive clones 
after transformation in Mach1 E.Coli. A. and B. The bands above 3 kb correspond to the 
DNA extracted from positive clones. The first lane corresponds to the β3 subunit DNA used as a 
control. The second lane (pUC19) is the miniprep of the control of transformation; the third lane 
is the control of PCR (DNA template). The fourth lane is the DNA extracted from bacteria 
transformed with an empty vector. Other lanes represent the DNA of 10 clones transformed with 
α1 (A) or α2 (B) ECDs in pFastBac CT-TOPO Vector.  
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 In order to test if the inserts were correctly orientated in the vector, PCR 
amplification was carried out using the α1 or α2 forward primer and SV40 reverse 
primers which bind to the vector sequence. A band of approximately 860 bp was 
observed in most clones for α1 (Figure 15) and in only three clones for α2 (Figure 15). 
Clones #5 and #7 for α1, and clones #7 and #9 for α2 were further purified using the 
PureLink Hi Pure Plasmid Prep Kit and sequenced. 
Figure 15. PCR test for the correct orientation of α1 and α2 ECDs sequences inserted into 
pFastBac CT TOPO His Vector. A. Most of the α1 clones have inserted the α1 sequence in the 
right 5’- 3’ orientation (except clone 12). PCR amplification was done with the forward α1 primer 
and the SV 40 reverse primer. B. Only three clones had inserted the α2 sequence in the right 
orientation (clone 7, 9 and 10). PCR amplification was done with the forward α2 primer and 
SV40 reverse primer. In both PCR amplifications, the amplified product was approximately 860 
bp. The clones circled in red were used for transposition into baculovirus DNA. 
Recombinant pFastBac CT-TOPO His vectors were transformed into MAX 
Efficiency DH10 BAC E.coli which contains a baculovirus shuttle vector (bacmid) with a 
mini-attTn7 target site and a helper plasmid which promotes transposition of the mini-
Tn7 element from the pFastBac donor plasmid into the bacmid.  The bacmid 
propagates in DH10 Bac cells as a large plasmid that contains a kanamycin-resistance 
gene and can complement a lacZ deletion present on the chromosome to form colonies 
that are blue (Lac+) in the presence of Bluo-gal and IPTG. Following successful 
transposition into the mini-attTn7 attachment site, expression of the LacZα peptide was 
disrupted giving rise to white colonies on a background of blue colonies which 
contained just the original bacmid. White colonies were selected through a blue/white 
screening and DNA was purified. Successful transposition of the α1 and α2 sequence 
was verified by PCR using primers which bind to the sequences flanking the insert 
(pUC/M13 forward and reverse) obtained from Invitrogen (Figure 16). 
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Figure 16. PCR analysis of the transposition of α1 and α2 ECDs into the bacmid DNA. The 
PCR amplification of α1 and α2 ECDs and control sequence Gus transposed into bacmid DNAs 
was done using Puc/M13 forward and reverse primers (baculovirus sequence primers flanking 
the insert). A. PCR amplification of α1 ECDs sequence (1-12) and control  Gus sequence (A-C). 
B. PCR amplification of α2 ECDs sequence using two different PCR conditions. A clone 
inserted in the bacmid should result in a band at 4420 bp  while an empty vector should result in 
a band at 350 bp. Clones α1.1, α2.2 and Gus.A are situated at the right molecular weight and 
have been selected for further experiments. 
 
 
 All α1 clones contained a band at 3170 bp which reflects the presence of the 
insert. Transposition of the positive control plasmid pFastBac Gus was detected only in 
the clone A yielding a PCR product of ~ 4420 bp. Only two α2 positive clones were 
obtained containing a band of ~ 4 kbp. The α1 positive clone #1 and the α2 positive 
clone #2 (Figure 16) were purified further using the PureLink HiPure Plasmid Prep kit 
(Invitrogen) and confirmed by sequencing.  
The final confirmation of the successful cloning was obtained by PCR using the 
α1 and α2 forward primers and pUC/ M13 reverse primers, which revealed a band of 
expected size (~1100 bp) in lanes containing α1 and α2 bacmid DNAs. The pFastBac 
Gus was used as a negative control in this test (Figure 17). The PCR products were 
sequenced confirming that no mutations in the α1 and 2 sequences were introduced 
during the cloning.  
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Figure 17. PCR analysis of the transposition of α1 and α2 ECD sequences into the 
bacmid DNA. This PCR was done using the maxiprep DNA with different combinations of 
primers. Gus DNA was tested with α1 or α2 forward and reverse primers, as a negative control. 
The α2 DNA was tested with α1 primers and with α2 primers. As expected, only the second 
combination worked, giving a band around 1.1 kb. The DNA was tested with α1 forward and 
reverse primers but also with α2 primers. As expected, only the first combination worked. 
 
 
3.3.2 Baculoviruses-infected Sf9 cells express α1 and α2 ECDs  
 Purified bacmid DNA was transfected into Spodoptera frugiperda Sf9 insect 
cells using the CellFECTIN II reagent which was supplied with the Bac-to-Bac TOPO 
Expression System. Cells were incubated for up to 72 h until the first signs of cell lysis 
were observed. The medium was collected and this was labelled as the P1 baculovirus 
stock. This stock was used to infect a new culture of Sf9 cells in preliminary expression 
assays and for production of the high titre P2 baculovirus stock. After collecting the 
medium from infected cultures, cells were lysed with 2 % SDS and the expression of α1 
and α2 ECDs was detected using SDS/PAGE and immunoblotting with specific 
antibodies (Figure 18). Due to cell lysis provoked by the viral infection, the total protein 
yield of infected cells was generally lower in comparison with the control untransfected 
cells.  Expression of the α1 and α2 ECDs (both at ~ 30 kDa) was detected specifically 
in lanes containing the extracts from cells transfected with the bacmid DNA constructs 
(labelled as P1) and from P1-infected cells (labelled as P2). A major band of ~ 30 kDa 
and two lower minor bands were detected in these extracts which could represent 
different glycosylated forms, degradation or truncation of these proteins. The molecular 
weight of the detected proteins is compatible with the predicted mass of these proteins 
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of ~ 26 kDa. Detection of α2 ECDs revealed significantly weaker bands likely reflecting 
the lower affinity of the α2 specific antibody compared to α1 specific antibody. The 
expression of α1 and α2 ECDs was amplified approximately six times between P1-
labelled infected cells and P2-labelled infected cells. Moreover, production of α1 and 
α2 ECDs was further increased when Sf9 cells are cultured in suspension in 
comparison with the adherent monolayer cultures (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. The α1 and α2 ECDs are expressed in Sf9 cells infected with P1 and P2 viral 
stocks. A. and B. The α1 and α2 protein expression from infected Sf9 cells was analysed by 
loading 200 µg of protein on 12 % SDS/PAGE and immunoblotting with α1 and α2 specific 
antibodies, respectively. The lowest molecular weight bands of α1 and α2 ECDs are around 26 
kDa (as expected). The higher molecular weight bands could correspond to glycosylated forms 
of these proteins (to be confirmed). The level of expression of α1 ECDs in P2-labelled infected 
cells was six times higher than the level of expression α1 ECDs in P1-labelled infected cells.  
3.3.3 Optimising protein expression  
 We decided to perform a time course experiment in order to determine the 
optimal post-infection time to collect infected Sf9 cells. Therefore, we infected cells at 
the same multiplicity of infection of 0.1 (see Methods, 3.2.5.4) and assayed for 
recombinant protein expression at different times post-infection (24, 48, 72 and 96 
hours post-infection). The Sf9 cells were plated in 6 well plates and infected with each 
of the P2 viral stocks (α1- and α2- bacmid DNAs). Non-infected cells were used as a 
negative control. The cells were harvested and lysed at different time points and 
analysis of protein expression was performed by SDS/PAGE and immunoblotting. 
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Immunoblotting with specific antibodies indicated that the level of production of each 
protein increases in time as the virus propagates in culture. The highest level of 
expression was detected 72 h after the infection with α1-bacmid DNA and 96 h after 
the infection with α2-bacmid DNA (Figure 19). However, after 96 h the vast majority of 
cells appeared lysed increasing the risk of protein degradation (data not shown). 
Figure 19. Time course experiment of the expression of α1 and α2 ECDs in infected Sf9 
cells. Adherent cell cultures were infected with P2 viral stock and incubated for 24 h, 48 h, 72 h 
or 96 h. Protein extracts from P3-labelled infected cells were prepared in 2 % SDS and 
analysed by SDS/PAGE and immunoblotting with specific antibodies.  Three bands between 24 
kDa and 35 kDa were observed for α1 and two bands for α2. The production of α1 and α2 
increased from 24 to 96 h. The optimal expression was reached at 72 h for cells infected with α1 
or α2 baculoviruses, and 96 h with α2 baculovirus.  
Three different P2 viral stocks were used to infect Sf9 cells, P3 viral stocks 
(culture medium) were discarded and cells were lysed with 2 % SDS. For each 
experiment, the protein expression was analysed by SDS/PAGE and immunoblotting 
with specific antibodies (Figure 20). The highest level of expression was detected in the 
third experiment. Therefore, the P2 viral stock collected in the third experiment was 
isolated and used to infect Sf9 cells for further purification experiments.  
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Figure 20. Expression of α1 and α2 ECDs from three independent experiments.Three 
independent infections of Sf9 cells were carried out with P2 viral stocks. The medium was 
removed and infected Sf9 cells were lysed with 2 % SDS. 150 µg of extracted proteins were 
loaded on 12 % polyacrylamide gel. The estimation of protein expression was analysed by 
SDS/PAGE and immunoblotting with specific α1 (A) or α2 (B) antibodies and alkaline-
phosphatase conjugated secondary antibodies. Three bands were observed in all the three 
experiments for α1 and α2. However, in the last experiment, the production of α1 and α2 was 
more efficient. The variability between experiments could be explained by differences in cell 
viability or passage. 
 
 
3.3.4 Optimisation of the purification of α1 and α2 ECDs from infected 
Sf9 cells  
3.3.4.1 Purification of α1 and α2 ECDs using ProBond columns . 
The α1- and α2- ECDs expressed in Sf9 cells were initially purified using 
ProBond columns as described in this Chapter, Section 3.2.6. Figure 21 shows the 
total protein distribution after the transfer onto a nitrocellulose membrane visualised 
using Ponceau S staining (staining all the proteins present in the sample). The 
presence of many bands was detected in the supernatants. However, only three bands 
in the case of α1, and two bands in the case of α2 were detected in pellets. The same 
bands were also detected in eluted fractions (1-4, indicated by the blue rectangle). 
These bands could potentially correspond to α1 and α2 ECDs. This will be confirmed 
by incubation with specific α1 or α2 antibodies. In addition, prominent contaminating 
band of ~50 kDa was detected in the supernatants and the eluted fractions (indicated 
by the red rectangle). Following incubation with the specific antibodies, the presence of 
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α1 and α2 proteins was confirmed in all the analysed fractions (Figure 21). The amount 
of these proteins was particularly high in the pellet fraction. Once eluted, all the 
fractions were pulled and dialysed against PBS overnight. The concentration of 
samples was measured using the BCA assay and the total yield of about 2.1 and 1.7 
mg of protein was estimated for α1 and α2 fractions, respectively. However, the 
contribution of the contaminating bands to the total protein yield was significant and it 
precluded the use of these samples in further experiments (Figure 21). 
Figure 21. The distribution of the α1 and α2 ECDs isolated using the ProBond affinity 
chromatography. A. Sf9 cells were infected with P2 viral stocks and lysates were prepared 72 
hours post-P2 infection. Samples were collected at each step of purification (25 µl) and 
analysed by SDS/PAGE and Immunoblotting. This figure shows the Ponceau S staining, after 
transferring the proteins onto the nitrocellulose membrane. The first lane represents the proteins 
contained in the supernatant collected after the first centrifugation following cell lysis. The 
second lane is the pellet resulting from the same step. The lanes 3 to 6 represent the four 
elution fractions. The red rectangles represent a 52 kDa contaminating protein. The blue 
rectangles outline the proteins that may correspond to α1 and α2 ECDs between 24 and 31 
kDa. B and C. The nitrocellulose membranes shown in A were incubated with the α1 or α2 
specific antibodies, respectively, followed by incubation with the secondary alkaline 
phosphatase-conjugated antibody. Approximately the same amount of α1 and α2 ECDs was 
present in the supernatant and pellet after lysis and centrifugation, but also increasing amount 
of each protein was observed in the elution fractions. Three bands between 31 and 38 kDa 
representing the α1 ECDs and two bands representing the α2 ECDs were revealed.   
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 In order to separate α1 and α2 proteins from the contaminating bands, we 
incubated small factions of supernatants with the Pro-bond Ni2+ beads. After binding, 
four different elution buffers were tested: 
1) 20 mM Tris-HCl buffer pH 7.5;  
2) 20 mM Tris-HCl buffer, pH 6.5  
3) Tris-HCl Buffer, pH 7.5 + 10 mM Imidazole 
4) 20 mM Tris-HCl Buffer, pH 7.5 + 300 mM NaCl 
However, none of these conditions proved optimal for the elution of the specific 
proteins in the absence of the contaminating bands (data not shown).  
3.3.4.2 Purification of α1 and α2 ECDs using Ni-NTA columns 
 As we could not avoid this contaminating protein in our pellet using ProBond 
beads, we decided to purify the α1- and α2- ECDs by chromatography affinity using Ni-
NTA resin columns as described in this Chapter, Section 3.2.7. Figure 22 shows the 
total protein distribution after the transfer onto a nitrocellulose membrane visualised 
using Ponceau S (Figure 22A, 22C). The presence of many bands on both membranes 
was detected in the supernatants and throughout the experiment. In this experiment, 
no contaminating bands were detected in the supernatants or in the eluted fractions. 
Following incubation with the specific antibodies and Horseradish-Peroxidase 
secondary antibodies, the presence of α1 and α2 proteins was confirmed in all the 
fractions up to the first elution (Figure 22B, 22D). In the first immunoblot (Figure 22B), 
the α1 ECD was present in high concentration in the first fractions from the supernatant 
after hypotonic lysis up to the dialysed fraction. Finally, the α1 ECD is retrieved in the 
first elution fraction.  In the second immunoblot (Figure 22D), the α2 ECD was present 
in high concentration in the first fractions from the supernatant hypotonic lysis up to the 
dialysed fraction. Finally, the α2 ECD is retrieved in the first two elution fractions but at 
a higher molecular weight, around 70 kDa, suggesting that proteins may have 
aggregated.  
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Figure 22. Ponceau S staining of α1 and α2 ECDs purified from Ni-NTA columns.Sf9 cells 
were infected with α1 baculovirus- or α2 baculovirus P2 viral stocks and lysates were prepared 
72 hours post- P2 infection. Purification of α1- (A and B) and α2- (C and D) ECDs was 
performed with Ni-NTA beads based chromatography affinity. Samples were collected at each 
step of purification and analysed by SDS/PAGE and Immunoblotting. A. This image shows the 
Ponceau S staining. The first lane represents the migration pattern of the molecular weight 
marker. The next two lanes represent the supernatant and pellet after the hypotonic lysis (2-3). 
The next two lanes (4-5) represent the supernatant and pellet after the solubilisation. Then, the 
lane 6 shows the proteins content of the supernatant after dialysis while the lane 7 represent the 
protein content of the supernatant after the binding. The lanes 8-12 represent the protein 
content of the five washes followed by the three elutions (13-15). Finally, the beads fraction 
represents what was left bound to the beads after the last elution. The blue squares represent 
an estimation of the localisation of α1 ECDs on the membrane. B. Immunoblotting with the α1 
specific antibody. The immunoblot was revealed using HRP-coupled secondary antibody. The 
α1 ECD is detected between 28 and 35 kDa. C. This image shows the Ponceau S staining, after 
transferring the proteins onto the nitrocellulose membranes. The first two lanes represent the 
supernatant and pellet after the hypotonic lysis (1-2). The next two lanes (3-4) represent the 
supernatant and pellet after the solubilisation. The lane 5 represents the molecular weight 
marker. Then, the lane 6 shows the proteins content of the supernatant after dialysis while the 
lane 7 represent the protein content of the supernatant after the binding. The lanes 8-12 
represent the protein content of the five washes followed by the three elutions (13-15). Finally, 
the beads fraction represents what was left bound to the beads after the last elution. The blue 
squares represent an estimation of the localisation of α2 ECDs on the membrane. D. The 
membrane was washed and processed through immunoblotting by incubating with α2 specific 
antibody. The immunoblot was revealed using HRP-coupled secondary antibody. The α2 ECD 
is detected between 30 and 38 kDa.  
 
 
 
 
 
 
A 
C 
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3.4 Discussion 
 In this chapter, we employed the baculovirus/Sf9 cells expression system to 
express and purify the N-terminal extracellular domains of GABAAR α1 and α2 
subunits. Once the mouse sequences were inserted by CT-TOPO cloning into the 
bacmid DNA, Sf9 cells were infected with α1 or α2 baculoviruses. After performing a 
time course experiment in order to determine the best infection conditions, the infected 
Sf9 cells were collected and the optimisation of the his-tagged α1 and α2 ECDs 
purification was performed. The baculovirus expression system Bac-to-Bac chosen for 
these experiments proved to be an adequate technique as more than 90 % of 
efficiency was reached in our cloning experiments. Growing Sf9 cells in suspension 
was found to be the most optimal for the Sf9 cell survival and viral infection.  
 Following optimisation of infection and expression conditions, purification under 
native conditions of α1 and α2 ECDs was performed. This was our first priority as we 
planned to use these purified proteins in proteomics and mass spectrometry 
experiments aiming at isolation of potential binding partners of these subunits. In this 
chapter, we have described different steps that were taken in order to obtain partially 
purified GABAAR subunits α1 and α2 ECDs under native conditions. These included a 
first purification of the α1 and α2 ECDs using Tris HCl-based buffer and Probond resin 
which provided us with considerable amount of extracted proteins, but inadequate 
purity, due to the presence of abundant contaminating protein. In addition, under these 
conditions, most of the proteins of interest remained in the pellet (insoluble fraction) 
after solubilisation and centrifugation. More stringent conditions were subsequently 
used in order to reduce the amount of contaminating proteins and to increase the yield 
of proteins of interest in our elution samples following affinity chromatography. In these 
experiments, we used Ni-NTA agarose beads because their binding affinity for his-
tagged proteins is greater than Probond beads. Hypotonic lysis with 20 mM NaH2PO4 
and 0.5 % NP-40 was performed in order to reduce the non-specific interactions prior 
to solubilisation. The presence of a low concentrated detergent in our buffer helped us 
110 
 
to break up membranes and thus, extract more proteins from Sf9 cells without 
modifying the secondary structure of the proteins. As most of the proteins of interest 
remained in the pellet, we decided to increase NP-40 concentration and add 
Deoxycholate (DOC) which helped to extract membrane-bound proteins (Duggan and 
Stephenson, 1990, Duggan et al., 1991). Once proteins were solubilised in the 
phosphate buffer containing 2 % NP-40 and 1 % DOC, a significant amount of α1 and 
α2 ECDs was present in the soluble fraction (supernatant) after centrifugation. Because 
the presence of DOC can interfere with the binding of His-tagged proteins to Ni-NTA 
beads, we have introduced a dialysis steps to remove DOC from our samples before 
the binding to Ni-NTA beads. To avoid protein aggregation, the dialysis buffer 
contained 1 % Triton X-100 and high NaCl concentration (300 mM) (Knight et al., 
1998). Then, the binding was performed in the presence of 20 % glycerol in order to 
conserve the native conformation of the proteins and preserve the non-specific binding 
to the agarose beads. Finally, elution of bound proteins was carried out with 100 mM 
EDTA and 250 mM Imidazole which chelate Ni2+ thus competing with the binding of his-
tagged proteins (Hoffmann and Roeder, 1991). This allowed us to collect elution 
fractions which contained the α1 and α2 ECDs in solution. Following elution of proteins, 
immunoblots were performed in order to assess the affinity chromatography efficiency. 
When α1 and α2 ECDs were revealed by the specific antibodies, they appeared as 
three different molecular weight bands between 25 and 35 kDa which are likely to 
result from post-translational modifications such as glycosylation, protein degradation 
or truncation. Additionally, high molecular weight bands (~80 kDa) were present in the 
immunoblots. As the purified proteins are sticky and tend to aggregate, these bands 
are likely to be doublets or triplets of the α1 or α2 ECDs. We were only able to partially 
purify the α1 and α2 ECDs from infected Sf9 cells as we could not extract all the 
proteins by affinity chromatography. This is likely to be caused by protein aggregation 
which would alter the binding to Ni-NTA beads, thus causing a steric hindrance 
between the his-tag and the Nickel beads. Additionally, a considerable amount of 
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protein was lost during the first steps of purification. Although we were able to extract 
more protein from the pellet with the phosphate buffer than with the Tris-HCl buffer, a 
considerable amount of protein was present in the supernatant after the second spin 
before the solubilisation. In addition, some amount of protein was lost throughout the 
purification steps of the affinity chromatography. Although we decided to load proteins 
according to the binding capacity of the column, it is possible that due to their 
stickiness, the ECDs were bound to the beads in a non-specific manner which may be 
the reason why we had some protein remaining bound to the beads after the elution 
steps.  
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 Chapter four 
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4. Investigating the potential synaptic binding partners of the extracellular 
domains of GABAAR subunits α1 and α2 
4.1 Introduction 
 Most cellular processes rely on a multitude of proteins that assemble into 
multimeric complexes. Thus, a precise understanding of the biological pathways that 
control cellular events relies on identification and biochemical characterisation of the 
proteins involved in such multimeric assemblies. In recent years, it has become clear 
that protein-protein interactions occurring in the synaptic cleft regulate the formation 
and maintenance of synapses. Examples of these proteins, already mentioned in the 
Introduction are Neurexin/Neuroligin, NCAMs, Slitrk3/PTPδ and more recently, 
GABAARs α1 subunits/Neurexins (Biederer et al., 2002 , Graf et al., 2004, Zhang et al., 
2010, Takahashi et al., 2012). These interactions occurring across the synaptic cleft 
have also been postulated to play an important role during specific recognition of the 
pre- and postsynaptic elements and initiation of synaptic contacts.  
 GABAARs belong to a superfamily of pentameric ligand-gated ion channels 
(pLGICs) known as the Cys-loop receptors (Grenningloh et al., 1987). Each subunit of 
the GABAARs is composed of a large N-terminal extracellular domain of 200-250 amino 
acids, four transmembrane domains with an M3-4 intracellular loop of 85-255 residues, 
and a small C-terminal extracellular domain (Karlin and Akabas, 1995).  
Of particular interest here are our recent findings that GABAARs play a 
structural role during GABAergic synapse formation and are capable of promoting this 
process in a heterologous co-culture model system (Fuchs et al., 2013). During the 
course of these experiments, it became clear that in further analysis, particular 
emphasis should be placed on the structure and function of the extracellular domains 
of GABAAR subunits since these domains are large and exposed in the synaptic cleft 
and so, might be responsible for the first contacts between the pre- and postsynaptic 
element.  
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 The first crystallisation of the GABAARs β3 homopentamer revealed that 
GABAAR ECDs are composed of structural elements unique to eukaryotic Cys-loop 
receptors, but more importantly that the highly conserved N-glycans present on the 
ECDs of all the subunits play an important role in the structural assembly of the 
receptor, in the signal transduction of GABAAR ligands and in the gating process of the 
receptor (Miller and Aricescu, 2014).  
In recent years, identification of multi-subunit protein complexes has been done 
routinely using proteomics and mass spectrometry due to high sensitivity and accuracy 
of these techniques (Volkel et al., 2010).  
4.1.1 Aims 
In the next set of experiments, our aim was to further investigate the structural 
role played by the α1 and α2 subunits during specific GABAergic synapse formation by 
identifying potential transynaptic binding proteins which could specifically interact, 
directly or indirectly, with the ECDs of these subunits. These proteins were isolated by 
proteomics and mass spectrometry.  
4.2 Methods 
4.2.1 Proteomics and Mass spectrometry- First and second round 
The cultures of Sf9 cells grown in suspension were infected and solubilised 
following the protocol described in the Chapter 3 section 3.2.7.Throughout these 
experiments, we had to stay in keratin-free environment which is very important for the 
accuracy of mass spectrometry analysis. Therefore, all the steps were carried out in 
the laminar flow hood cabinet with gloves.  
After solubilisation of proteins from Sf9 cells, Ni-NTA beads were prepared by 
pipetting 800 µl of resuspended beads (50/50 slurry) into one eppendorf tube per 
affinity chromatography. After they were spun down at 1000 g for 4 min, 400 µl of water 
was added in order to wash the beads. The procedure was repeated one more time. 
Then, 400 µl of binding buffer (50 mM NaH2PO4, pH 8, 300 mM NaCl, 20 % glycerol, 1 
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% Triton X-100, and protease inhibitors) was added to the eppendorf tube which was 
gently inverted and spun down at 1000 g for 4 min. The procedure was repeated one 
more time. The supernatant was removed and 1 mg of extracted proteins from Sf9 cells 
infected with α1 or α2 bacmid DNA, or control Sf9 cells was added to the beads to bind 
overnight at 4 °C. The following day, the columns were spun down at 800 g for 2 min 
and the supernatant after binding was removed. The beads were washed three times in 
the binding buffer for 5 min with rotation. The last wash was performed with 150 mM 
NaCl and no glycerol in the buffer and the beads were kept separately on ice until 
neuronal lysate was ready to be added. 
Neuronal lysates were prepared from 6 DIV embryonic cortical neurones (4 x 10 
cm dishes) using the lysis buffer containing 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 1 
% Triton X-100, protease inhibitors. Subsequently, the cells were scraped with the cell 
scraper and cell lysates were collected from the bottom of the dish. The plates were 
washed with 500 µl of lysis buffer and all the lysates were pooled (~ 4 ml total) and 
solubilised for one hour at 4 ºC with rotation. The lysates were spun down for 40 
minutes at 10 000 g in the first round of proteomics. The second round of proteomics 
was performed with high speed centrifugation of lysates at 100 000 g (Beckman-
Coulter Table-top ultracentrifuge). Once the supernatant was carefully removed from 
the pellet, the protein concentration was estimated using Bradford assay. The total 
yield obtained was ~ 2 mg of protein in 4 ml.  
Then, the neuronal extract (420 µg total protein per column) was added to the 
400 µl of prepared beads together with 2 mM CaCl2 and 1 mM MgCl2 to facilitate the 
binding. The columns were then incubated for 2 h at 4 ºC. After the binding was 
performed, the beads were washed four times with 10 min rotation at 4 ºC and spun 
down at 1000 g for 2 min. 
The elution of the bound proteins was carried out with the addition of 200 µl of 
0.1 M glycine, pH 2.0 to the beads, and incubation with rotation for 1 h at 4 ºC. The 
columns were then spun down at 1000 g for 2 min and the supernatant was kept on 
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ice. The beads were resuspended in another 200 µl of 0.1 M glycine, pH 2.0 and spun 
down again. The supernatant after spin was kept on ice. The elution step was repeated 
two more times in order to detach as much protein as possible from the beads. Then, 
all the elution fractions were spun down again at 2000 g for 5 min to pellet any 
remaining beads from the proteins. The supernatants were then gently transferred into 
new tubes and the methanol/chloroform extraction of the protein was performed as 
described in the Experimental Procedures Chapter, Section 2.7. 
The air-dried proteins were resuspended in 6 µl of 2 % SDS and all eluted 
fractions were pooled together into one tube containing a small amount of 2 % SDS. 
The tubes were sequentially washed with 5 µl of 2 % SDS to collect any remaining 
proteins and pooled with the first collected fraction. NuPage Sample Buffer (5 µl, 4X) 
and NuPage reducing Agent, (1 µl, 10X, Invitrogen) were added to these samples. The 
samples were heated up at 70 ºC for 10 min without boiling and 200 mM 
iodoacetamide (2 µl to make up the total volume of 20 µl) was added and incubated in 
the dark at room temperature for one hour. The samples were loaded onto a NuPage 
Novex Bis-Tris gel and the electrophoresis was done in MOPS buffer (50 mM MOPS 
pH 7.7, 50 mM Tris Base, 1 mM EDTA, 0.1% SDS) with NuPage antioxidant (both from 
Invitrogen), at 200 V for ~1 h. 
All the following steps were performed in the fume hood cabinet (Bigneat 
Containment Technology, Chempac filtration) to avoid any contamination with keratin. 
Once the gel was removed from the frame and placed carefully in the large sterile 
tissue culture dish, it was incubated with Instant Blue protein stain, (Expedeon) for 15 
min at room temperature with gentle shaking. The Instant Blue was removed and the 
gel was left to incubate in sterile water overnight to remove any background staining. 
The gel was washed one more time and a photograph of the gel was taken when the 
required intensity was achieved.  
The bands of interest were cut out of the gel in the laminar flow hood cabinet 
with protection from direct contact with any potential source of keratin. The gel pieces 
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were transferred into siliconised low-bind Eppendorf tubes labelled according to the gel 
lanes. The gel bands were cut into smaller pieces within the tubes to speed up the 
destaining and digestion.  
The bands were destained with 500 µl of 50 mM ammonium bicarbonate in 
EtOH (50:50 ratio) with rotation for 10 min. This step was repeated as many times as 
necessary until the blue stain disappeared (usually 4 times). Then, 200 µl of 200 mM 
acetonitrile (ACN) was added to the gel pieces and vortexed (Vortex Genie 2, USA 
Scientific, provided by the Dept of Pharmaceutics, School of Pharmacy) for 10 min. The 
tubes were centrifuged and the solvent was discarded. This step was repeated three 
times and samples were air dried or speed vacuum dried. At this step, gel pieces were 
frozen at -20ºC. 
The next step consisted of the in-gel trypsin digestion of proteins. Trypsin is a 
serine protease enzyme that cleaves peptide chains on the carboxyl end site of amino 
acids arginine or lysine. The stock of trypsin, (Promega) was prepared to a final 
concentration of 0.2 µg/µl. Then, 5 μl of trypsin was mixed with 20 µl of chilled 50 mM 
ammonium bicarbonate. Next, 10 µl of this mixture was added to the gel pieces and 
was left on ice for 30 min in order for the enzyme to be fully absorbed into the gel. 
Finally, 50 µl of 50 mM ammonium bicarbonate (enough to cover the gel pieces) was 
added to the gel pieces which were then vortexed and spun down. The mixture of gel 
pieces, trypsin and ammonium bicarbonate was incubated at 37 ºC with slow agitation 
over night in order for the trypsin to digest the proteins contained in the gel pieces into 
smaller peptides. 
To extract the peptides from the gel, 25 µl of 5 % formic acid and 50 % of 
acetonitrile solution mix was added to the gel pieces which were then spun down for 
one minute at 14,000 g. Next, the tubes were vortexed for 20 min. The supernatants 
containing the extracted peptides were transferred into a new siliconised tube. Then, 
30 µl of 100 % ACN was added to the gel pieces, vortexed for 20 min and spun down 
for 1 min. The supernatant was transferred into the tube containing the extracted 
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peptides. This step was repeated four times in total in order to increase the yield of 
extraction of digested peptides. The samples were then dried using the Speed Vac 
(Dominique Dutscher) for 36 hours at maximum speed until the solvent mixture has 
completely evaporated (it usually took 1.5 days to dry these samples). After this step, 
the extracted and dried peptides could be stored at -80 ºC for up to six months.  
In the final step, the peptides were reconstituted in order to be processed by the 
mass spectrometer (Q-TOF analyser). We first diluted the peptides in the loading buffer 
(0.1% formic acid in H2O). To avoid overloading the column during mass spec 
injections, the amount of loading buffer added to the peptides was adapted to their 
relative concentration estimated by looking at the Instant Blue staining. The tubes were 
vortexed quickly with 3-4 strokes and spun down for one minute at maximum speed 
(14,000 g). The supernatant was removed carefully so that 5 µl was left in the tube 
containing the peptides, and transferred into another set of tubes which were in the 
fridge until the mass spectrometry analysis was finished.  
4.2.2 Mass spectrometry and analysis    
The first round of mass spectrometry was performed using the Mass 
Spectrometry Facility at the School of Pharmacy and the second round was performed 
in collaboration with the Swansea University. In both places, a nano ESI (Electrospray 
Ionisation) was used as a source of ionisation followed by Q-TOF (Quadruple Time-of-
flight) MS. One blank between each sample was run. To make sure the system was 
performing, BSA digest standards were injected between each run and their coverage 
was checked before running our samples. Further standard BSA digest were randomly 
run throughout the sequence to make sure no problem occurred during the run. In both 
cases, the Q-TOF mass spectrometer produced a series of .pkl files containing the 
observed mass- to- charge or m/z ratio and other information regarding the peptides 
found in each sample. The mass-to-charge ratio (m/z) is a value representing the mass 
of the ion in relation to its charge.  
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The analysis of both rounds of proteomics was done using GPM database and 
MASCOT. The main difference between two rounds was the fact that we introduced a 
high speed centrifugation step (100 000 g, Beckman-Coulter Table-top ultracentrifuge) 
in the second round to avoid a possible contamination of solubilised proteins with the 
membrane fraction.  
4.2.2.1 Analysis with GPM database 
The GPM (global proteome machine) database was designed to store the minimum 
amount of information necessary to search and retrieve data obtained from the publicly 
available data analysis. This server is one of the best methods for validating the results 
of statistical analysis that constitute the final mapping of a list of tandem mass spectra 
to a list of protein sequences (MS/MS ion search) (Craig et al., 2004).  
Each of the .pkl files were individually downloaded onto the GPM website 
http://rat.thegpm.org/tandem/thegpm_tandem.html and the conditions presented in the 
Figure 23 were selected, including a type of residue medification (oxidation), the 
protein cleavage site (trypsin) and the type of mass spectrometer used (Q-TOF Mass 
Spectrometer). As there was a probability of mismatch, we decided to set up a 
tolerated error of 100 parts per million (ppm) equivalents to 0.1 Da. At the end of the 
search, a log (e) which represents the “peptide sequence to spectrum” matching score 
is determined for each peptide. The Rat Proteome ENSEMBL was selected as the 
source of publicly available information. The list of resulting matching proteins was 
transposed into an Excel table and sorted by increasing log (e) (Appendix). 
As a result, GPM produced a list of potential proteins sorted by log (e) matching the 
peptide sequences found in the sample. The log (e) of each hit is the base -10 log of 
the expectation that any particular protein assignment was made at random. Thus, the 
lower the log (e) is, the more accurate the protein assignment is. In addition, GPM 
results included the total number of tandem mass spectra that can be assigned to one 
hit together with the molecular mass of the protein sequence, in kilodaltons (kDa). 
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Finally, GPM assigns an accession number and description of the protein using the 
ENSEMBL classification. 
Figure 23. Screenshot of the GPM online database. This database research was performed 
using the GPM which is an online database regularly updated with new mass spectra. We used 
the Rat Proteome ENSEMBL as a source of information for the matching proteins. 
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4.2.2.2 Analysis with MASCOT database 
Mascot (Matrix Science) is a powerful engine which uses mass spectrometry 
data to identify proteins from the primary sequence database. Like GPM, Mascot uses 
a probability based scoring. However, it is unique in that it integrates all the proven 
methods of searching:  
- Peptide mass fingerprint: in this method, the only experimental data are peptide 
mass values. 
- Sequence query: in this method, peptide mass data are combined with amino 
acid sequence and composition information. 
- MS/MS ion search: This is the method used by the GPM database which uses 
un-interpreted MS/MS data from one or more peptide. 
As Mascot database is not freely available on the internet, the analysis was performed 
in the laboratory of Dr. Yuqin Wang, at Swansea University. Each of the files was 
individually downloaded onto the Mascot program and conditions were selected. As a 
source of publicly available data, we used the International Protein Index (IPI) Rat 
database. As there was a probability of mismatch, we decided to set up a tolerated 
error of 300 parts per million (ppm) equivalents to 0.3 Da.  
In Mascot, the ion score is based on the calculated probability, P, that the 
observed match between the experimental data and the database sequence is a 
random event. The protein score is derived from the ion score: it is the sum of the 
highest ions score for each distinct sequence 
(http://www.matrixscience.com/help/interpretation_help.html). 
Mascot provides the with access to the mass spectrum of a protein of interest 
from which we could identify the fragment ions and their parent ions as well as other 
details as shown in the Figure 24. Following the search, the list of resulting matching 
proteins was transposed into an Excel table and sorted by decreasing protein score 
(Appendix).  
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Figure 24. Screenshot of the MASCOT website similar to the on-site version. This image 
shows the parameters of an MS/MS Ion Search on Mascot Website. We performed an on-site 
search which was more detailed than the online version. In this search, we selected NCBInr as 
a reference database, allowed up to 2 Trypsin missed cleavages and selected Acetylation, 
Methylation or oxidation as variable modifications. In addition, the peptide and MS/ MS 
tolerances were set up to 0.3 Da.  
 
 
The two rounds of mass spectrometry experiments were analysed using both 
the GPM search engine and the MASCOT. In order to have only specific binding 
proteins, we first compared the proteins which were present in α1 or α2 binding assays 
to those present in the control Sf9 cell extracts binding assays. Those which were 
present in both were not considered. Those proteins which were isolated with α1 ECDs 
were analysed separately from those which were isolated with α2 ECDs in binding 
assays. This was done using an Excel macro in the following order: 
- Candidate binding proteins specifically isolated using the α1-ECD column 
- Candidate binding proteins specifically isolated using the α2-ECD column 
- Candidate binding proteins isolated with both α1- and α2-ECD columns 
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This type of analysis was performed with candidate proteins obtained using GPM 
database separately from candidate obtained using MASCOT. Finally, the candidate 
proteins found in both databases were pooled together for further analysis.  
4.2.3 Binding assays of α1 and α2 ECDs  
We conducted a series of binding assays using α1 ECD-, α2 ECD-, or control 
Sf9 cell extracts- loaded columns and used 7 DIV cortical and striatal neurone extracts. 
The cells were infected with α1 or α2-bacmid DNA and collected using a method 
described in the Chapter 3, section 3.2.7. Then, the proteins from infected and non-
infected Sf9 cells were solubilised and dialysed overnight following the protocol 
described previously in this chapter, section 4.2.1. The preparation of Ni-NTA columns 
was done following the protocol described in Chapter 2, section 2.3.7. Briefly, 400 µl of 
beads (50:50 slurry) were transferred into an eppendorf tube, washed with water and 
incubated over night with the dialysed protein extracts from non-infected or α1- or α2-
infected Sf9 cells. The next day, the cultured neurones were lysed and prepared for 
binding in the lysis buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 1 % Triton X-100, 
and protease inhibitors) following the protocol described in this chapter, section 4.2.1.  
Prior to the incubation of the neuronal extracts with the immobilised columns, we 
performed a “preclear step” which allowed us to decrease the non-specific binding of 
proteins to Ni-NTA. This step included incubation of Ni-NTA beads with neuronal 
extracts for 1 h at 4 °C with a ratio of 100 µl of beads to 140 μg of proteins. Then, the 
supernatant was collected and bound (~ 400 μg of protein per column) to α1-ECD-, α2-
ECD-, or control Sf9-loaded-Ni-NTA columns overnight at 4 °C. The following day, the 
beads were washed four times with 5 min rotation at 4 ºC and spun at 1000 g for 5 min. 
Next, the proteins bound to α1-ECDs- or α2-ECDs- or Sf9-loaded-Ni-NTA columns 
were denatured using 10 % SDS and 5X sample buffer, as described in the Chapter 2, 
Section 2.8. Once the columns and inputs were boiled for 10 min at 95 °C, the columns 
were spun for 10 min at 14,000 g in order to pellet the beads. Then, 100 μl of the 
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collected supernatant was loaded on a 8 % SDS PAGE, transferred onto the 
nitrocellulose membrane and incubated with the specific primary antibodies, followed 
by HRP-conjugated rabbit light-chain secondary (see Table 12 for details of antibodies 
used and their dilutions). 
4.2.4 Immunohistochemistry 
Immunohistochemistry was performed as described previously (Deuchars et al., 
1994). Briefly, E20 brains were isolated from pregnant mouse and fixed in 4% 
PFA/sucrose overnight at 4 °C. In order to protect the tissue against damages during 
freezing procedures, the brains were incubated in gradient of sucrose (10, 20 and 30 
%) until it penetrated completely (usually one day for each gradient). The brains were 
cut in 35 μm coronal slices using a cryostat (Leica Biosystem CM1520). Sections were 
washed twice in PBS for 20 min with rotation. Then, they were washed with 0.3 M 
glycine for 5 min and washed again twice in PBS for 5 min. The slices were then 
blocked in 1 % BSA for 30 min and incubated with the primary guinea-pig anti-α2 
antibody overnight at 4 °C (Table 12). The following day, the sections were washed 
three times in PBS for 10 min. Then, they were blocked and permeabilised in 1 % BSA 
with 0.2 % Triton for 30 min. The primary mouse anti- GAD-65 and rabbit anti-
pikachurin antibodies were added to the brain slices for 3 hours at room temperature 
(Table 12). The slices were then washed three times in PBS for 10 min and blocked in 
1 % BSA for 30 min. The Alexa-conjugated secondary antibodies (Table 12) were 
added in 1 % BSA for 1 h at room temperature, protected from light. The slices were 
washed three times in PBS for 5 min and mounted onto coverslips in Vectashield 
mounting medium (Vectorlabs).  
4.2.5  Immunocytochemistry  
The immunocytochemistry was performed as described in Chapter 2, section 
2.2. Neurones cultured for 7 or 14 DIV, were fixed using 4 % PFA/sucrose for 12 
minutes at room temperature. After fixation, they were incubated with Glycine (0.3 M) in 
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PBS, in order to quench PFA. After washing, cells were incubated in 1 % BSA in PBS 
for 1 hour and subsequently incubated overnight at 4 °C with anti-α2 and anti-
pikachurin antibodies, diluted in 1 % BSA in PBS (Table 12). Cultures were then 
permeabilised by incubating with 1 % BSA, 0.5 % Triton X-100 in PBS for 15 minutes. 
Neurones were subsequently incubated with anti-GAD-65 and anti-MAP-2 (Table 12) 
antibodies diluted in 1 % BSA in PBS for 2 hours at room temperature. Following this 
step, Alexa dye-conjugated secondary antibodies were added and images were 
analysed using Zeiss 710 Confocal microscope.  
4.2.6 Immunoblotting 
Neurones from cortical and striatal cultures at 7 and 14 DIV, and tissue from the 
embryonic and adult cortex, retina, cerebellum and hippocampus were lysed with 2 % 
SDS and boiled for 10 min at 95 °C. Then, they were sonicated until the lysates were 
clear and spun down for 10 min at 14,000 g in order to remove any residual 
aggregates. Protein concentration of each sample was measured using BCA assay 
and 200 μg of each sample was loaded on a 10 % SDS PAGE. After transfer, the 
nitrocellulose membrane was incubated with the antibody directed against the N-
terminal domain of pikachurin (AA 28-354) (1: 10 000 dilution Wako, Japan; (Sato et 
al., 2008)) followed by HRP-conjugated rabbit light-chain IgG. The binding of antibodies 
was visualised using the ECL reagent (GE Healthcare Life Sciences, Amersham ECL 
western blotting detection system) and recorded using GeneGnome Syngene. 
4.2.7 In vitro binding assays 
In order to confirm the binding between α2 ECD and pikachurin found in the first 
round of mass spectrometry, a series of binding assays using 6 DIV cortical or striatal 
neurones were carried out as described previously in this Chapter, Section 4.2.1. 
Following the binding and elution of proteins, they were separated using SDS/PAGE (8 
% gels) and transferred onto the nitrocellulose membrane. Samples were incubated 
with the antibody directed against the N-terminal domain of pikachurin (AA 28-354) 
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(1:10 000 dilution Wako, Japan; (Sato et al., 2008)) followed by HRP-conjugated rabbit 
light-chain IgG and bound proteins were visualised using ECL reagent and recorded 
using the Syngene GeneGnome. 
4.2.8 Co-immunoprecipitation 
The protocol for co-IP was given by Prof. Anne Stephenson, School of 
Pharmacy. Cultured cortical neurones (6 plates, 8x106 cells/ plate) were washed twice 
with ice-cold PBS. The cells were scraped with 500 µl of lysis buffer containing 50 mM 
Tris pH 8.0, 150 mM NaCl, 1 % NP-40, protease inhibitor cocktail. The plates were 
washed with another 500 μl of lysis buffer and the samples were pulled together. The 
lysate was homogenised using a glass sintered homogeniser (Glass Tenbroeck Tissue 
Grinder 2 ml, Omni) with 4 to 5 strokes. Protein concentration was measured using 
Bradford assay and the total yield was 2 mg/ml in 7.5 ml. Extra buffer was added to 
make it up to a final concentration of 1.5 mg/ml. The neuronal lysate was solubilised for 
one hour at 4 °C and subsequently spun down at high speed centrifugation (100 000 g) 
for 40 min at 4 °C. After 10 % of the neuronal lysate was put aside for the input lane 
(~750 µl), the rest was split into four tubes (3 mg/tube) and 5 µg of the following 
antibodies: 
- Alpha1 C-terminal sheep antibody (1.5 mg/ml)  
- Immune sheep IgG (stock conc. 0.3 mg/ml) 
- Alpha2 C-terminal rabbit antibody (PX III at 0.185 mg/ml) 
- Immune rabbit IgG (stock conc.1 mg/ml) 
To facilitate the binding, MgCl2 and CaCl2 (both at 2 mM final) were added to the 
mixture which was incubated overnight on a rotating plate at 4 °C. 
  The following day, the Protein A and G sepharose beads were prepared. As we 
needed 50 μl of slurry per sample, we took 120 μl of each type of beads and washed 
using PBS by vortexing and spinning at 600 g (2500 g) 3 times. The beads were finally 
resuspended in PBS (50:50 slurry) and 50 μl of the mixture was added to the neuronal 
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extracts incubated with primary antibodies. The Protein G sepharose has a higher 
affinity for sheep than for rabbit antibodies. Therefore, we added the Protein G 
sepharose beads to the neuronal lysates which contained the sheep α1 antibody as 
well as the immune sheep IgG. The Protein A sepharose has a higher affinity for rabbit 
antibodies than for sheep antibodies. Therefore, we added the protein A sepharose 
beads to the neuronal lysates which contained the rabbit α2 antibody as well as the 
immune rabbit IgG. The samples were further incubated for 1 h at 4 °C on a rotating 
plate together with the input. The co-IPs were then spun down once for 20 sec at 600 
g. The supernatants were removed from each co-IP and discarded. The co-IPs were 
then washed quickly by adding 1 ml of washing buffer containing 50 mM Tris, pH 8.0, 
150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 0.1 % NP 40, protease inhibitors cocktail. 
The buffer was added carefully down the wall of each tube. After a gentle agitation by 
flicking the tube and a 5 min spin, the buffer was discarded with caution not to touch 
the beads. This step was repeated three times. The rest of the washing buffer was 
removed using to a Hamilton syringe.  
Finally, the proteins contained in the co-IPs or in the input were precipitated 
using the methanol/chloroform extraction method described previously in the Chapter 2 
Section 2.7. The air dried proteins were then resuspended in 20 μl of 3X loading buffer 
with DTT. The loading buffer was prepared using 1.5 μl DTT, 8.5 μl H2O, 5 μl of 3X 
loading buffer. The input lane was resuspended in 55 μl (enough to load twice on a 
small gel) of 1X loading buffer. Then, all the samples were denatured for 8 min at 75 °C 
on a 500 g shaker. Small 10 % SDS PAGE gels were loaded using Hamilton syringe. 
The gels were loaded with an empty space (just loading buffer) between each sample 
and the control Immune IgG were always loaded before the co-IPs to avoid 
contamination with spill over which could lead to a false positive result. The gels were 
run at 20 mA for ~2 h.  
The immunoblotting protocol as described in Chapter 2, Section 2.9, was 
modified to include fewer washes and increase the percentage of milk (Marvel) used as 
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blocking reagent. After transfer, the membrane was incubated in Block containing 5 % 
milk in PBS with 0.02 % Tween-20 for 1h at room temperature. Then, rabbit anti- 
pikachurin antibody was added to 2.5 % milk in PBS with 0.02 % Tween and the 
membrane was incubated overnight at 4 °C (1: 2500 dilution Wako, Japan; (Sato et al., 
2008)). Alternatively, the membrane was incubated with anti α1 (1/100 dilution, rabbit 
anti α1 cys- loop; (Fujiyama et al., 2000)) or α2 antibody (2 μg/ml dilution, rabbit anti α2 
cys-loop; (Poltl et al., 2003)) in order to confirm the presence of the proteins in the co-
IPs.  
Then, the membrane was washed three times for 10 min in 2.5 % milk in PBS 
with 0.02 % Tween-20, and the secondary light chain anti-rabbit HRP antibody (see 
Table 13 for dilution) prepared in 2.5 % milk in PBS and 0.02 % Tween-20 was added 
for 1h at room temperature. This incubation was followed by three 10 min washes with 
2.5 % milk in PBS and 0.02 % Tween, one 10 min wash in PBS and 0.02 % Tween. 
The membrane was then incubated for 5 min in ECL and developed using Syngene 
GeneGNOME. 
The second co-IP followed the same protocol but was done with striatal 
neuronal extracts and in different lysis and washing buffers. In this experiment, we 
used the anti-α2 antibody to pull down the GABAARS and anti-rabbit IgG as a control. 
The lysis buffer contained 10 mM HEPES pH 8.0, 145 mM NaCl, 1 mM CaCl2, 2 mM 
MgCl2, 1% Triton X-100, protease inhibitors. The washing buffer contained 10 mM 
HEPES pH 8.0, 145 mM NaCl, 1 mM CaCl2, 2 mM MgCl2, 0.1 % Triton, protease 
inhibitors. In addition, the proteins were loaded on a 7 % polyacrylamide SDS/PAGE.  
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Table 12. Antibodies used in immunofluorescence experiments. 
 
Table 13. Antibodies used for immunoblotting and co-Immunoprecipitation. 
primary antibodies 
secondary antibodies 
 specificity origin dilutions 
source and 
characteris
ation 
antibodies dilutions source 
ICC GABAAα2 GP 1:400 
Synaptic 
System 
224104 
Goat Anti 
guinea 
pig cy5 
1:750 Alexa Fluor Cy5 
 GAD-65 Ms 1:4000 
Abcam, 
ab26113 
Goat anti 
mouse 
555 
1:750 
Alexa Fluor 
Invitrogen 
a21422 
 pikachurin Rb 5 μg/ml 
Abcam, 
ab91314 
Goat Anti 
rabbit 405 
1:750 
Alexa Fluor 
Invitrogen 
a31556 
IHC GABAAα2 GP 1:400 
Synaptic 
System 
224104 
Goat Anti 
guinea 
pig 488 
1:750 
Alexa Fluor 
Invitrogen 
a11073 
 GAD-65 Ms 1:4000 
Abcam, 
ab26113 
Goat anti 
mouse 
555 
1:750 
Alexa Fluor 
Invitrogen 
a21422 
 pikachurin Rb 1:2000 
(Sato et al., 
2008) 
Goat Anti 
rabbit 405 
1:750 
Alexa Fluor 
Invitrogen 
a31556 
 MAP2 Chk 1:2500 
Abcam, 
ab92434 
Goat Anti 
chicken 
647 
1:750 
Alexa Fluor 
Invitrogen 
a21449 
primary antibodies secondary antibodies 
 specificity origin dilutions 
source 
and 
characteri
sation 
antibodies dilutions source 
Immu
noblot 
Neuroligin 
2 
Rb 1:1000 
Synaptic 
System 
129203 
Anti-Rabbit 
IgG (H+L) 
711-035-152 
1:1000 
Jackson 
Immuno 
Research 
 
Neurexin 
1/2/3 
Rb 1:1000 
Synaptic 
System 
175003 
Same as 
previously 
1:1000 
Same as 
above 
 pikachurin Rb 
1:10 
000 
(Sato et 
al., 2008) 
Same as 
previously 
1:1000 
Same as  
above 
Co-
IPs 
pikachurin Rb 1:2500 
(Sato et 
al., 2008) 
Anti-Rabbit 
IgG, Light 
Chain Specific  
211-032-171 
1:1000 
Same as  
above 
 
α1- cys 
loop 
Shp 1:100 
(Fujiyama 
et al., 
2000) 
Same as 
previously 
1: 1000 
Same as  
above 
 
α2 cys-
loop 
Rb 2 μg/ml 
(Poltl et 
al., 2003) 
Same as 
previously 
1:1000 
Same as  
above 
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4.3 Results 
The structural role of GABAARs in specific GABAergic synapse formation is poorly 
understood. We have hypothesised that the recognition between the presynaptic 
terminal and the postsynaptic cell involves the GABAAR subunits directly or indirectly, 
via protein-protein interactions within the synaptic cleft. In this chapter, our aim was to 
identify presynaptic or synaptic cleft-span proteins which specifically bind to the α1- or 
α2- ECDs of postsynaptic GABAARs using proteomics followed by mass spectrometry 
analysis. Binding assays were carried out with α1-, α2 extracellular domain (ECD)-, or 
Sf9 cell extracts-loaded Ni-NTA columns and protein lysates prepared from 6 DIV 
cultured cortical neurones. Following the binding, the eluted fractions were run on a 
NuPAGE Bis-Tris 4-12 % gradient gel (Invitrogen) and stained with Coomassie blue. 
Each gel lane was cut into eighteen pieces according to the molecular weight marker 
and subjected to in-gel trypsin digestion, extraction and preparation for nano ESI 
(nano-Electro Spray Ionisation) followed by Q-TOF (Quadrupole Time-Of-Flight 
analyser) mass spectrometry. Finally, the MS/MS (Tandem Mass Spectrometry) 
spectra were analysed by two different databases using the precursor ion fingerprinting 
methods: GPM and MASCOT.The second proteomics analysis was carried using the 
same conditions as in the first round with exception that the cortical extracts were 
centrifugated at higher speed (100 000 g) before the binding assays were performed. 
Figure 24 and 25 show the preparation of α1 and α2 ECDs from lysates of Sf9 cells 
expressing these proteins. Following the binding assays, the proteins from cortical 
neuronal extracts bound to the ECD-columns were eluted and resolved by SDS/PAGE 
(Figure 26) using NuPAGE Bis-Tris 4-12 % gradient gel (Invitrogen). Each gel lane was 
cut into eighteen gel pieces and subjected to a series of steps in preparation for mass 
spectrometry analysis. The presence of proteins in collected fractions was detected 
using a 6xHis-tag specific antibody followed by incubation with the alkaline 
phosphatase-conjugated secondary antibody.  
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Figure 24. Preparation of α1 ECD-Ni-NTA 
resin used in proteomics. Fractions 
collected during the α1 ECD-Ni-NTA resin 
preparation were lysed with 2 % SDS. Total 
of 80 μl of each sample was loaded on 
SDS/PAGE and transferred onto the 
nitrocellulose membrane. The membrane 
was then incubated with a mouse anti-
6Histag antibody, followed by the incubation 
with the alkaline phosphatase-conjugated 
secondary antibody. As expected, the α1 
ECD is detected between 25 and 31 kDa. A 
significant amount of α1 ECD was detected 
bound to the Ni-NTA resin. Weak protein 
bands detected at higher molecular weight 
than α1 are likely to be unknown 
contaminating proteins which originate from 
the Sf9 cell extracts and have a high affinity 
for Ni-NTA. In addition a doublet of the α1 
ECD is probably revealed by the 
immunoblot around ~52 kDa. 
 
 
 
 
 
 
 
 
 
 
Figure 25. Purification of α2 ECD-Ni-
NTA resin used in proteomics. 
Fractions collected during the α2 ECD-Ni-
NTA resin preparation were lysed with 2 
% SDS. Total of 80 μl of each sample 
was loaded on SDS/PAGE and 
transferred onto the nitrocellulose 
membrane. The membrane was then 
incubated with a mouse anti-6xHis-tag 
antibody, followed by the incubation with 
the alkaline phosphatase-conjugated 
secondary antibody. As expected, the α2 
ECD is detected between 25 and 35 kDa. 
A significant amount of α2 ECD was 
detected bound to the Ni-NTA resin. 
Weak protein bands detected at higher 
molecular weight than α2 are likely to be 
unknown contaminating proteins which 
originate from the Sf9 cell extracts and 
have a high affinity for Ni-NTA.  
 
 
After the electrophoresis, each gel lane was cut into eighteen pieces according 
to the molecular weight, as shown in the Figure 26. Each gel piece was processed 
(kDa) 
(kDa) 
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through destaining, in-gel trypsin digestion and extraction of proteins, and subsequently 
analysed by Q-TOF Tandem Mass Spectrometry (MS). 
 
 
 
 
 
 
 
Figure 26. Instant blue staining of proteins from 
binding assay between ECDs-loaded columns and 6 
DIV cortical neurones. Instant Blue staining of the 4-
12 % gradient Nu-PAGE gel representing the samples 
that were subjected to Mass Spectrometry. After elution 
from Ni-NTA agarose beads, the proteins were resolved 
using SDS/PAGE and stained with Instant Blue. Each 
lanes was cut into 18 bands from the bottom to the top 
of the gel and prepared for MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.1 HSPG Pikachurin was found bound to α2-ECD-Ni-NTA  
4.3.1.1 GPM DB analysis 
The GPM database enabled us to compare eluted protein peptides from each gel piece 
to already known peptides present in data analysis servers such as ENSEMBL, TIGR 
or UNIGENE. It retrieves information related to the protein matches such as the protein 
sequence, the accession identifier, the measure of the statistical validity of the 
identification of the protein. GPM also allowed us to create an Excel file for each band 
containing details about each of the matches, including the log (e), which is the base -
10 log of the expectation that this assignment is stochastic; the log (I), which is the 
base -10 log of the sum of the intensity of the fragment ion spectra and the molecular 
mass of the protein sequence in kDa. Once we have obtained MS/MS profiles of all the 
samples, we have processed them further using GPM database and identified 
(kDa) 
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candidate proteins listed using Excel. The candidate binding proteins of α1-ECD, α2-
ECD and controls were compared and organised in tables according to the following 
criteria: 
1. The α1-ECD specific candidate proteins (which are not found in Sf9 controls or 
α2-ECD) from the proteomics experiment 1 (Appendix Table 1). 
2. The α1-ECD specific candidate proteins (which are not found in Sf9 controls or 
α2-ECD) from the proteomics experiment 2 (Appendix Table 2). 
3. The α2-ECD specific candidate proteins (which are not found in Sf9 controls or 
α1-ECD) from the proteomics experiment 1 (Appendix Table 3). 
4. The α2-ECD specific candidate proteins (which are not found in Sf9 controls or 
α1-ECD) from the proteomics experiment 2 (Appendix Table 4). 
5. The α1-specific candidate proteins found in proteomics 1 and 2(Appendix Table 
5). 
6. The α2-specific candidate proteins found in proteomics 1 and 2.(Appendix 
Table 6). 
7. The α1 and α2 common candidate proteins found in proteomics 1 (Appendix 
Table 7). 
8. The α1 and α2 common candidate proteins found in proteomics 2 (Appendix 
Table 8). 
In order to compare hits between different assays, we used a VBA coded Excel file 
allowing us to compare the hits according to their accession number. This Excel coded 
file allowed us to rapidly know which hits were specifically found in α1 binding assay 
and not in α2 binding assay, and vice-versa. Then, the resulting protein hits were 
sorted in decreasing log (e).  
In all the Tables (see Appendix) resulting from GPM DS search, matching 
proteins were assigned with a tolerance of error of 0.1 Da (or 100 ppm). The proteins 
were identified by their ENSEMBL accession number and their description from the 
database. According to the GPM, the log (e) is the base -10 log of the expectation that 
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the assignment was stochastic. The log (I) is the base -10 log of the sum of the 
fragment ion intensity in the tandem mass spectra used to make this assignment. The 
% (measured) corresponds to the amino acid coverage of the protein in this 
assignment. The % (corrected) corresponds to the coverage corrected for peptide 
sequences that are unlikely to be observed using normal proteomics method. The next 
column corresponds to the number of unique peptide sequences associated with this 
protein assignment. The total number of tandem mass spectra that can be assigned to 
this protein was also determined together with the molecular mass of the protein in kDa 
(Mr). Finally, GPM provided us with the chromosomal position of the gene related to 
the protein hit. 
A more detailed bibliographic search was then conducted on each of the hits 
found specifically in the binding assays with α1-ECD or α2-ECD using protein 
information from the UniProtKB database. Our aim was to find proteins that would bind 
specifically to α1 or α2 ECDs and that this binding would be, potentially of a 
physiological relevance. We have obtained a large number of candidate proteins with 
no apparent physiological relevance to GABAA receptor function. However, there were 
a small number of potentially relevant candidates which included perlecan and 
pikachurin. 
4.3.1.2 MASCOT DB analysis 
The MASCOT database is a powerful search engine which uses mass spectrometry 
data to identify proteins from primary sequence databases. It is more informative than 
GPM analysis because it integrates the peptide mass fingerprint, the MS/ MS ion 
search and the sequence query methods. By combining these three methods, 
MASCOT provided a high level of confidence, and allowed us to have a detailed 
description of each hit.  
Once the samples from all the eighteen bands for gel lane (α1, α2 and control Sf9 
cell extracts) were processed through Mascot and exported as Excel files, we applied 
135 
 
the same criteria as in the previous section to group them and carefully look for those 
which showed specificity in binding and potential physiological relevance to GABAAR 
function. The candidate binding proteins of α1-ECD, α2-ECD and controls were 
compared and organised in tables according to the following criteria: 
1. The α1-ECD specific candidate proteins (which are not found in Sf9 controls or 
α2-ECD) from the proteomics experiment 1 (Appendix Table 9). 
2. The α1-ECD specific candidate proteins (which are not found in Sf9 controls or 
α2-ECD) from the proteomics experiment 2 (Appendix Table 10). 
3. The α2-ECD specific candidate proteins (which are not found in Sf9 controls or 
α1-ECD) from the proteomics experiment 1 (Appendix Table 11). 
4. The α2-ECD specific candidate proteins (which are not found in Sf9 controls or 
α1-ECD) from the proteomics experiment 2 (Appendix Table 12). 
5. The α1-specific candidate proteins found in proteomics 1 and 2 (Appendix 
Table 13). 
6. The α2-specific candidate proteins found in proteomics 1 and 2 (Appendix 
Table 14). 
7. The α1 and α2 common candidate proteins found in proteomics 1 (Appendix 
Table 15). 
8. The α1 and α2 common candidate proteins found in proteomics 2 (Appendix 
Table 16) 
In order to compare hits between different assays, we used the same Visual 
Basic for Application (VBA) coded Excel file which allowed us to compare the hits 
according to their accession number and sort them according to outlined criteria.  
In all the Tables resulting from MASCOT search, the protein score is the 
probability that the observed match is a random event was described for each hits. This 
score is the result of a -10 Log (P) where P is the absolute probability. The protein 
mass representing the observed mass of each individual hits was also provided. The 
number of matching peptide found in the sample (protein matches) was given. The 
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proportion of the total protein that is covered by the peptide sequence was also 
detailed (protein cover). Finally, the experimental m/z value (peptide experimental m/z 
ratio), and the peptide score which is the ion score, were given.  
A more detailed bibliographic search was conducted on each of the hits found 
specifically in the binding assays with α1-ECD or α2-ECD resin using protein 
information from the UniProtKB database. Our aim was to repeat the previous 
experiment under more stringent conditions which included a high speed centrifugation 
step at 100 000 g to eliminate a possibility that small pieces of cell membranes were 
present in our binding assays. Comparing the candidate binding proteins between 
those obtained with GPM database and Mascot was deemed inappropriate because 
the criteria for the analysis and the databases used were completely different.  
 Considering that the role played by Pikachurin in the Ribbon synapse in retina 
was well documented and that the role of similar heparan sulfate proteoglycans 
glypicans in glutamatergic synapse formation was also recently demonstrated (Siddiqui 
et al., 2013), we have decided to further explore the interaction between α2 subunit 
and Pikachurin.  
4.3.2 Binding assays of α1 or α2 ECDs with Neurexins and Neuroligin 
2 
4.3.2.1 The α1 and α2 ECDs do not bind to Neuroligin 2 but bind 
specifically to Neurexins  
It is now well established that NL2 plays an important role in regulating 
GABAergic synapse formation (Hoon et al., 2009, Frola et al., 2013, Sun et al., 2013). 
We wanted to investigate if this role was mediated, at least in part, by the interaction 
between NL2 and the extracellular domains of α1 or α2 subunits of GABAARs. Towards 
this aim, we performed in vitro binding assays using lysates of cultured cortical 
neurones and α1 ECD-, α2 ECD-, or Sf9 control lysate- loaded Ni-NTA columns. The in 
vitro binding assays have demonstrated that NL2 does not interact with the 
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extracellular domains of α1 or α2 subunits (Figure 27).  NL2 was only found in the input 
lane containing cortical lysates but not in the lanes containing the α1-ECD or α2-ECD. 
A faint band in Sf9 extracts lane was detected at the slightly higher molecular weight 
likely due to non-specific binding of the primary antibody. 
 
Figure 27. NL2 does not bind to α1 or 
α2 ECDs. Detergent-solubilised 7 DIV 
cortical neurone lysates were incubated 
with immobilized α1 or α2 ECDs purified 
from Sf9 cells on Ni-NTA columns. 
Following the binding assays, samples 
were loaded on an 8 % SDS/PAGE. After 
transfer, the nitrocellulose membrane was 
incubated with a specific antibody directed 
against the N-terminal domain of NL2 
(1:1000 dilution Synaptic System) 
followed by HRP-conjugated rabbit light-
chain IgG. Controls were prepared using 
extracts of Sf9 cells which did not express 
the extracellular domains of α1 or α2 
subunits.  
 
It is known that the interaction between neuroligin 2 (NL2) and neurexins plays an 
important role during GABAergic synapse formation (Varoqueaux et al., 2004, Huang 
and Scheiffele, 2008, Hoon et al., 2009). In addition, it has been established that 
neurexins, the presynaptic partners of NL2, can physically interact with GABAARs 
(Zhang et al., 2010). In order to know if the interaction between neurexins and 
GABAARs was mediated by the extracellular domains of α1 and/ or α2 subunit, we 
performed another series of binding assays. 
In the second set of experiments, we used 7 DIV cortical or striatal neuronal lysates 
in binding assays with the α1 ECD or the α2 ECD to investigate the binding of 
neurexins. Figure 28 shows that different isoforms of neurexins bind specifically to α1 
or α2 ECDs and not to control Sf9 cell extracts. Three isoforms of ~55, 60 and 75 kDa 
bound to α1 ECDs specifically, while three different bands of ~52, 55 and 58 kDa 
bound to α2 ECDs specifically. As the antibody does not allow specific recognition of 
the different isoforms of neurexins present in the binding assay, we were unable to 
define specifically which isoforms of Neurexins bind to α1 or α2 ECDs.  
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 We also carried out similar binding assays using 7 DIV striatal neuronal lysates. 
The Figure 29 shows that different Neurexin isoforms to those found in the cortical 
lysates were bound specifically to α1 and α2 ECDs and not to control Sf9 cell extracts. 
In these assays, two main bands around 60 and 75 kDa were found bound to the α1 
ECD, and two bands around 50 and 75 kDa were found in the presence of α2 ECDs.  
Figure 28. Neurexins interact with α1 or α2 
ECDs at 7 DIV in in vitro binding assays 
with cortical neuronal lysates. Detergent-
solubilised 7 DIV cortical neurone lysates were 
incubated with Ni-NTA immobilized α1- or α2-
ECDs columns. Following the binding, samples 
were loaded on an 8 % SDS/PAGE. After 
transfer, the nitrocellulose membrane was 
incubated with a specific antibody directed 
against the C-terminal domain of Neurexin 
1/2/3 (1:1000 dilution, Table 13) followed by 
HRP-conjugated rabbit light-chain IgG. Controls 
were prepared using extracts of Sf9 cells which 
did not express α1 or α2 ECDs.  
 
Figure 29. Neurexins interact with 
α1 or α2 ECDs in in vitro binding 
assays with striatal neuronal 
lysates. Detergent-solubilised 7 DIV 
striatal neurone lysates were 
incubated with Ni-NTA immobilized 
α1- or α2-ECDs columns. Following 
the binding, samples were loaded on 
an 8 % SDS/PAGE. After transfer, the 
nitrocellulose membrane was 
incubated with a specific antibody 
directed against the C-terminal 
domain of Neurexin 1/2/3 (1:1000 
dilution Synaptic System, see Table 
13) followed by HRP-conjugated 
rabbit light-chain IgG. Controls were 
prepared using extracts of Sf9 cells 
which did not express α1 or α2 ECDs.  
 
 
4.3.3 Investigating the binding of Pikachurin to the GABA AR α2 
subunit  
4.3.3.1 Pikachurin is partially co-localised with the GABAAR α2 subunit 
in the embryonic cortex. 
The expression of pikachurin in the retina and its role during ribbon synapse 
formation has been well characterised (Sato et al., 2008, Katoh et al., 2009, Kanagawa 
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et al., 2010, Sato, 2010, Han and Townes-Anderson, 2012, Omori et al., 2012). In this 
subchapter, we wanted to establish the localisation of pikachurin in the brain, the 
pattern of expression of pikachurin during the brain development, and to confirm the 
binding with α2 ECD found in the first round of mass spectrometry.  
Figure 30 shows an example of staining obtained for pikachurin and the α2 subunit 
of GABAARs using specific antibodies (Table 12) in E20 mouse brain sections. The 
pattern of pikachurin labelling is punctate and a considerable number of pikachurin 
puncta was detected in close apposition to the α2 subunit of GABAARs throughout the 
cortical regions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. pikachurin is expressed in the E 20 mouse brain and is partially co-localised 
with the α2 subunit of GABAARs. Immunolabelling of pikachurin (red) and GABAARs α2 
subunit-containing clusters (green) throughout cortical regions of the embryonic mouse brain. A. 
Merged image of an E 20 brain slice representing pikachurin and α2 staining. B. Enlarged 
image of boxed region in A representing pikachurin staining only. C. Enlarged image of boxed 
region in A representing α2 positive clusters of GABAARs. D. Enlarged image of boxed region in 
A in which partially co-localised puncta were circled in white. Scale bar: 10 μm. 
A
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4.3.3.2 Synaptic localisation of pikachurin in cultured neurones  
Expression of pikachurin was analysed in cultured striatal neurones using 
immunocytochemistry and confocal imaging. Figure 31 shows an example of staining 
for pikachurin together with the α2 subunit of GABAARs subunits and the presynaptic 
marker GAD-65 using the antibodies described in Table 12. Although the number of co-
localised puncta was not quantified, it seems that the proportion of pikachurin puncta 
co-localised with the α2-containing GABAARs was increased as neurones matured 
from 7 to 14 DIV. In addition, it is interesting to note that most of the co-localised 
puncta were synaptic as they were also GAD-65 positive. 
Figure 31. Pikachurin is expressed at GABAergic synaptic contacts and the number of 
pikachurin puncta is increased from 7 to 14 DIV. Immunolabelling of pikachurin (red), α2 
subunit-containing GABAARs (green) and presynaptic GABAergic terminals identified by 
staining with GAD65 (cyan). A. Merged image of a 7 DIV striatal neurone. B. Enlarged image of 
boxed region in A representing pikachurin staining only. C. Enlarged image of boxed region in A 
representing α2 subunit-containing GABAARs staining only. D. Enlarged image of boxed region 
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in A representing pikachurin and α2 subunit-containing GABAARs stainings. E. Enlarged image 
of boxed region in A representing pikachurin, α2 and GAD 65 staining. F. Merged image of a 14 
DIV striatal neurone. G. Enlarged image of boxed region in F representing pikachurin staining 
only. H. Enlarged image of boxed region in F representing α2 subunit- containing GABAARs 
staining only. I. Enlarged image of boxed region in F representing pikachurin and α2 subunit-
containing GABAARs stainings. J. Enlarged image of boxed region in A representing pikachurin, 
α2 and GAD 65 stainings. Scale bars: 10 µm. 
 
 
4.3.3.3 Detection of pikachurin in  brain lysates using immunoblotting 
 Using a specific antibody directed against the N-terminal domain of pikachurin 
(AA 28-354), we carried out immunoblotting in order to detect the expression of 
pikachurin in lysates of striatal and cortical neurones at 7 and 14 DIV but also in the 
embryonic (E16-18) and adult rat striatum, cortex, adult retina, cerebellum and 
hippocampus. As shown in the Figure 32, a number of immunoreactive bands were 
detected at different molecular weights. Pikachurin has previously been found to be 
cleaved in retina into two fragments: a predominant N-terminal fragment of 60 kDa and 
another C-terminal fragment of approximately the same molecular weight (which is not 
detectable with the pikachurin antibody used) (Han and Townes-Anderson, 2012).  
 As the expression of pikachurin has never been reported in regions other than 
retina, we were surprised to see so many different bands revealed with this antibody in 
different neuronal lysates. The expression of pikachurin seemed to be decreased from 
7 to 14 DIV in rat striatal cultures with a predominant band ~60 kDa which is not 
present at 14 DIV. The expression of pikachurin in the embryonic striatum was very 
similar to the expression in the embryonic cortex with a predominant band around 35 
kDa. In addition, the pattern of bands in the adult striatum was very similar to the 
pattern detected in the adult cortex with a main band ~40 kDa. While the expression of 
pikachurin in the cortical primary cultures seems quite low at both stages, it is the first 
time that we detected a band around 110 kDa, probably representing the full length 
pikachurin. The expression of pikachurin in the adult retina confirmed the reported 
band of ~60 kDa. However, other unexpected bands around 33 and 40 kDa were also 
observed. A predominant band around 65 kDa was found in both the adult cerebellum 
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and hippocampus, although another highly expressed band around 40 kDa was only 
present in the hippocampus. In addition, the strong low molecular weight band (~10 
kDa) could be reflecting a high level of degradation of the protein. 
Overall, these results suggest that pikachurin may be processed differently in 
the brain than in the retina. The specificity of detection of pikachurin with the available 
antibody remains to be confirmed.  
 
Figure 32. Pikachurin is expressed in 
cortical and striatal primary cultures, and 
in different brain regions. Samples were 
prepared using 2 % SDS, boiled, sonicated 
and spun down. Proteins (200 µg/lane) were 
resolved using SDS/PAGE (10 % gel). After 
transfer onto the nitrocellulose membrane, 
the samples were incubated with the 
antibody directed against the N-terminal 
domain of pikachurin (AA 28-354) (1: 10 000 
dilution Wako, Japan; (Sato et al., 2008)) 
followed by HRP-conjugated anti-rabbit light-
chain IgG. The immunoblot shows that 
different immunoreactive bands can be 
detected in striatal and cortical primary 
cultures and across the adult and embryonic 
brain (n=2). 
 
4.3.3.4 In vitro binding of pikachurin to α1 - or α2-ECD-Ni-NTA columns 
Binding of pikachurin to GABAARs was investigated using lysates of cultured 
cortical and striatal neurones and α1- and α2-ECDs-loaded Ni-NTA resin. The Sf9 cell 
extracts were also loaded onto Ni-NTA beads and incubated with neuronal extracts as 
a control for non-specific binding. In addition, 50 and 100 μg of rat retinal extracts were 
also included in order to control for the specificity of the pikachurin antibody. Figure 33 
shows that an immunoreactive band of 60 kDa (red box) found in the input lane 
containing cortical extracts, and in the retinal extract lane, is also present in lanes 
containing the α1 and α2 ECDs but is not present in the control Sf9 cell extracts. Thus, 
in this experiment, a pikachurin fragment of 60 kDa expressed in cortical neurones at 
early developmental stages, is able to specifically bind to the α1 and α2 ECDs. Figure 
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34 shows that a fragment of 60 kDa (red box) found in the input lane representing the 6 
DIV striatal extracts, and in the retinal extract lane, is present bound to α1 and α2 
ECDs but is not present in the control binding assay. Thus, in this experiment, a 
fragment of 60 kDa of pikachurin, expressed in striatal neurones at early 
developmental stages, is able to specifically bind the α1 and α2 ECDs.  
Figure 33. In vitro binding of 
pikachurin to purified α1 and α2 
ECDs incubated with extracts of 
cultured cortical 
neurones.Detergent-solubilised 6 DIV 
cortical neuronal lysates were 
incubated with Ni-NTA-immobilised α1 
or α2 ECDs and analysed by 
SDS/PAGE. After transfer, the 
nitrocellulose membrane was 
incubated with a specific antibody 
directed against the N-terminal domain 
of pikachurin (AA 28-354) (1:10 000 
dilution Wako, Japan) followed by 
HRP-conjugated rabbit light-chain IgG. 
Controls were prepared using extracts 
of Sf9 cells which did not express α1 or 
α2 ECDs. Retinal extract were used as 
controls for detection of pikachurin 
immunoreactivity.  
 
 
 
 
Figure 34. In vitro binding of 
pikachurin to purified extracellular 
domains of GABAAR α1 and α2 
subunits using 6 DIV striatal 
cultures. Detergent-solubilised 6 DIV 
striatal neuronal lysates were incubated 
with Ni-NTA-immobilised α1 or α2 
ECDs and analysed by SDS/PAGE. 
After transfer, the nitrocellulose 
membrane was incubated with a 
specific antibody directed against the 
N-terminal domain of pikachurin (AA 
28-354) (1:10 000 dilution Wako, 
Japan) followed by HRP-conjugated 
rabbit light-chain IgG. Controls were 
prepared using extracts of Sf9 cells 
which did not express α1 or α2 ECDs. 
Retinal extract were used as controls 
for detection of pikachurin 
immunoreactivity. 
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4.3.3.5 Co- immunoprecipitation of pikachurin with the α2 subunit of 
GABAARs 
Co-immunoprecipitation experiments were carried out using lysates of cultured 
cortical or striatal neurones in order to study further the interaction between pikachurin 
and GABAARs. The lysates were incubated with the rabbit anti α2 C-terminal specific 
(Duggan et al., 1991), sheep α1 C-terminal specific (Pollard et al., 1993) antibodies or 
non-immune rabbit or sheep IgGs. The protein complexes bound to the sheep α1 
antibody or control sheep IgG were pulled down with Protein G-Sepharose beads, 
while complexes bound to the rabbit α2 antibody or control rabbit IgG were pulled down 
with Protein A-Sepharose. The co-IPs were loaded on a 12 % SDS/PAGE and 
transferred onto the nitrocellulose membrane which was subsequently probed with the 
rabbit anti-pikachurin antibody. Figure 35A shows that pikachurin was co-
immunoprecipitated only with α2 antibody as the band of ~110 kDa. As a control for the 
efficiency of co-IP, the membrane was cut and each part was probed with either the 
anti α1- or α2-specific antibodies. Figure 35B demonstrates that α1 subunit (~51 kDa) 
was not efficiently immunoprecipitated in this experiment. However, the Figure 35C 
demonstrates that α2 (~51 kDa) was efficiently immunoprecipitated in this experiment 
(arrow). We noticed that in this experiment, the light chain of sheep IgG cross-reacted 
with the anti rabbit HRP antibody.  
The lysates of cultured striatal neurones were incubated with the rabbit anti α2 
C-terminal antibody or the non-immune rabbit IgG (Figure 36). After incubation with 
Protein G-Sepharose, the co-IP was loaded on a 7 % SDS PAGE in order to allow a 
better separation of high molecular weight proteins. The Figure 36A shows that 
pikachurin was co-immunoprecipitated with the α2 antibody and was not present in the 
non-immune rabbit IgG. In addition, the lower acrylamide percentage allowed us to 
differentiate four different molecular weight bands of pikachurin from 110 to 260 kDa. 
This could be due to the presence of different fragments in the protein complex, the 
presence of oligomers or different degree of glycosylation as suggested in (Han and 
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Townes-Anderson, 2012). Similarly to the previous experiment, the membrane was 
restriped and re-probed with the anti-α2 loop antibody. As shown in The Figure 36B, α2 
subunit was present in the immunocomplex together with pikachurin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Pikachurin interacts with the alpha 2-containing GABAA receptors in cortical 
extracts and can be co-immunoprecipitated using specific antibodies. Detergent-
solubilised 6 DIV cortical extracts were incubated with the rabbit anti α2 C-terminal specific 
sheep α1 C-terminal specific antibody or non-immune rabbit or sheep IgG. The protein 
complexes were pulled down with Protein G-Sepharose in the case of sheep IgG, or Protein A-
Sepharose in the case of rabbit IgG. Proteins were resolved using a 4-12 % NuPAGE gradient 
gel and transferred onto the nitrocellulose membrane. A. The membrane was probed with the 
rabbit anti-pikachurin antibody (1:2500 dilution, Wako, Japan; followed by HRP-conjugated 
rabbit light-chain IgG (1:1000). B. After restriping, the membrane was cut into two parts. The left 
part was incubated with the rabbit anti α1 N-terminal specific antibody (1:300 dilution) followed 
by HRP- conjugated rabbit light-chain IgG (1:1000). The arrow shows the light chain IgG at ~25 
kDa. C. The right part of the membrane was incubated with the rabbit anti α2 intracellular loop 
specific antibody (2 μg/ml dilution). The arrowhead shows the α2 subunit at ~51 kDa. 
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Figure 36 Pikachurin interacts with the 
alpha 2-containing GABAA receptors in 
6 DIV striatal extracts and can be co-
immunoprecipitated using specific 
antibodies. Detergent-solubilised 6 DIV 
striatal extracts were incubated with the 
rabbit anti α2 C-terminal specific antibody 
or non-immune rabbit IgG. The protein 
complexes were pulled down with Protein 
A-Sepharose. Proteins were resolved 
using a 4-12 % NuPAGE gradient gel and 
transferred onto the nitrocellulose 
membrane. A. The membrane was 
probed with the rabbit anti-pikachurin 
antibody (1:2500 dilution, Wako, Japan; 
followed by HRP-conjugated rabbit light-
chain IgG (1:1000). B. After restriping, the 
membrane was incubated with the rabbit 
anti α2 intracellular loop specific antibody 
(2 μg/ml dilution). The arrowhead shows 
the α2 subunit at ~51 kDa. 
 
 
4.4 Discussion 
 In this chapter, our aim was to establish the optimal conditions for proteomics 
and tandem mass spectrometry analysis of proteins that bind to the extracellular 
domains of GABAAR α1 and α2 subunits. These experiments were based on our 
hypothesis that the extracellular domains of GABAA receptor subunits interact with 
specific proteins residing in the synaptic cleft and that identification of these proteins 
could lead to a better understanding of specific GABAergic synapse formation.   
 To do so, we performed two rounds of proteomics and mass spectrometry 
analysis and analysed the candidate binding proteins using two independent 
approaches.  
 The first round of proteomics revealed a large number of candidate binding 
proteins which were analysed using free online-based analysis software the Global 
Proteome Machine (GPM). Subsequently this experiment was analysed using Mascot 
on-site based analysis software at Swansea University. The two databases provided us 
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with different outputs and allowed us to compare the relevance of these outputs. The 
GPM database is based on the use of the Rat Proteome ENSEMBL database. It has 
provided us with the log (e) value of each hit representing the matching score between 
the peptide sequence of the hit protein (from the database) and the experimental 
sequence read in the experimental MS/MS spectrum. In contrast, the Mascot database 
is based on the International Protein Index Rat Database and provided us with the 
protein score of each hit which is based on the calculated probability, P, that the 
observed match between the experimental data and the database sequence is a 
random event. Similarly, a second round of mass spectrometry and proteomics was 
performed and analysed with both databases GPM and Mascot. The analysis of the 
first round with GPM database allowed us to identify a list of proteins that were 
specifically found in the α1 and α2-ECD-column and which were absent from the 
control binding assay. Among them, we identified two proteins which belong to the 
heparan sulfate proteoglycans (HSPG) family, perlecan and pikachurin, which were 
detected bound to the α1-ECD- and α2-ECD-, respectively. Interestingly, these two 
proteins were not retrieved when we analysed the first round with Mascot, suggesting 
that the identification of the experimental peptides and the peptides referenced within 
the database are different. Potentially, this divergence could be explained by the 
different referring databases used by the software (Rat Proteome ENSEMBL was used 
by GPM, and international portein index (IPI) rat proteome was used by Mascot). 
Additionally, this could be due to different flexibility of the software in assigning a peak 
from the tandem MS/MS spectrum to a theoretical peptide. This was supported by the 
fact that the list of proteins retrieved after Mascot analysis was much longer than the 
list of proteins identified with GPM, suggesting a much less stringent screening 
performed by Mascot software.  
In addition, the proteins identified in the second round differed considerably 
from the one found in the first round and we could not retrieve perlecan or pikachurin 
with either software analysis of this round. This could be due to the high speed 
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centrifugation step which was introduced in this round, thus probably changing the 
protein content of the lysate prior the binding assays with α1- or α2-ECDs loaded 
columns.  This could also be due to the fact that the reproducibility of mass 
spectrometry experiments in general is the matter of intensive debate as it involves 
multiple steps and many factors that determine the final outcomes are not always 
possible to control (Wang et al., 1998).  
 Considering pikachurin as a potential hit was of high risk as the log (e) it was 
pulled out with was relatively low, that we did not replicate its presence in the second 
round of proteomics and mass spectrometry, and the lack of information of the role of 
this protein in the brain. However, the low log (e) for pikachurin identification leaves us 
with less than 1 % of chance that the assignment was random. Although pikachurin has 
been described well in retina, its abundance in the brain and its role has not been 
investigated so far, although the mRNA for pikachurin was detected in the brain in the 
original cloning paper (Sato et al., 2008).  
 We were unable to perform experiments with perlecan due to time constrains, 
but it would be interesting to test if perlecan binds to the α1 or α2 ECDs by co-
immunoprecipitation. 
 As a second part in this chapter, we performed a series of binding assay in 
order to have a better understanding of the potential presynaptic partners of α1 and α2 
ECDs already proposed in the literature. In addition, we used co-immunoprecipitation 
techniques to confirm the binding of the GABAAR α2 subunit ECDs with pikachurin. 
In our experiments, NL2 did not bind to the ECDs of α1 or α2 GABAAR subunits. 
This result was in accordance with the literature as NL2 is mostly thought to be 
interacting with neurexins at the presynaptic site and with gephyrin at the postsynaptic 
site in promoting GABAAR synaptic clustering (Graf et al., 2004, Varoqueaux et al., 
2006, Poulopoulos et al., 2009, Kang et al., 2014). As it has already been suggested, 
neurexins are thought to be interacting with the extracellular domain of the α1 subunit 
(Zhang et al., 2010). However, little is known about the capacity of individual subtypes 
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of α subunits or other GABAAR subunits to bind different isoform of neurexins. In our 
binding assays with 6 DIV cortical neurones, we observed a differential binding of 
neurexin isoforms to α1 or α2 ECDs, suggesting that they may be interacting in a very 
specific way. To identify the specific partners would require a very long time given that 
there are ~ 3000 different splice variants of neurexin reported (Missler and Südhof, 
1998).   
 Finally, we characterised the expression of pikachurin in the developing and 
adult brain, and its binding to the ECD of the GABAAR α2 subunit. Our preliminary 
characterisation included immunohistochemical analysis of pikachurin expression in the 
embryonic mouse brain. In addition, we assessed the expression of pikachurin in 
cultured medium spiny neurones by immunocytochemistry and across embryonic and 
adult brain lysates by immunoblotting with pikachurin-specific antibodies. Together, our 
results demonstrated that in the embryonic brain, pikachurin can be found co-localised 
with the α2 subunit and the presynaptic marker GAD-65 at some GABAergic synapses. 
In addition, the expression of pikachurin and its co-localisation with the α2 subunit at 
synaptic contacts appear to be increased as the neurones mature in culture. 
Interestingly, the immunoblotting revealed that many isoforms of this protein can be 
detected in brain lysates and some of these isoforms can also be detected in retinal 
lysates (~60 kDa isoforms) which were used as a control. Binding of pikachurin was 
also detected in vitro, although it seemed weaker than acccross brain region lysates. 
Nevertheless, the co-immunoprecipitation experiments have confirmed that pikachurin 
interacts specifically with the α2 subunit of GABAARs.  
 To further this research, our aim will be to characterise the nature of the 
interaction between pikachurin and the GABAAR receptor α2 subunit to determine 
whether the binding is direct or indirect. In addition, we aim to map the binding sites in 
the α2 ECD and also in pikachurin. It would also be interesting to investigate the 
localisation of pikachurin in the embryonic and adult brain, characterise the time course 
of expression of pikachurin during brain development and to compare this with the time 
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course of GABAergic synapse formation. Once the structural characteristics of the 
binding are established, it would be important to study GABAergic synapse formation in 
pikachurin knock-out (KO) mice, or look at the expression of pikachurin in GABAAR 
subunit α2 KO mice.  
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Chapter five 
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5. GABAergic synapse formation: study of embryonic MSNs development 
5.1 Introduction 
 During the embryonic brain development, the telencephalon gives rise to the 
striatum and the globus pallidus (Jain et al., 2001). The ventral telencephalon is divided 
into two transient structures which are present at the mid-stages of the embryonic rat 
brain development, the ganglionic eminences (Olsson et al., 1998). While the striatum 
is derived from the lateral ganglionic eminence, the globus pallidus is derived from the 
medial ganglionic eminences (Marin et al., 2000).  
 The GABAergic medium spiny neurones (MSNs) account for ~ 95 % of all 
neurones contained in the striatum. The striatum is a central part of the basal ganglia, a 
group of nuclei involved in the selection and execution of voluntary movements, as well 
as cognitive, associative and emotional aspects of motor behaviour (Albin et al., 1989, 
Mink and Thach, 1993). Virtually the whole of the cortical mantle projects in a 
topographic manner onto the striatum. This cortical information is processed by the 
projecting medium spiny neurones within the striatum, and passed via the direct and 
indirect pathways to the output nuclei of the basal ganglia, the internal segment of the 
globus pallidus and the Substantia Nigra pars reticulata (SNpr) (Bolam et al., 2000). 
The basal ganglia transmit the signal by the projections of these output nuclei to the 
thalamus and then back to the cortex or subcortical premotor regions (Bolam et al., 
2000).  
In addition, the MSNs receive an important dopaminergic innervation from the 
Substantia Nigra pars compacta (SNpc) which promotes the structural plasticity of 
MSNs during the development of basal ganglia circuits (Fisone et al., 2007, Fasano et 
al., 2013). Interestingly, it has been shown that via activation of D1- and D2- receptors, 
dopamine limits the extent of collateral inhibitory synaptogenesis between medium 
spiny neurones (Goffin et al., 2010). 
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 The loss of MSNs from the striatum of patients with Huntington’s disease is 
manifested in profound changes in motor movements (Rikani et al., 2014).  In 
Parkinson’s disease, the loss of dopaminergic neurones from the SNpc modifies the 
activity of the striatum and results in motor disturbances (Lewis et al., 2003). Thus, 
understanding the functioning of the striatum is of tremendous physiological and 
pathophysiological importance.  
 In order to understand how the striatum functions it is important to understand 
how the cellular components of the striatum develop and are regulated.  To investigate 
the development of MSNs we have isolated them from the embryonic striatum and 
cultured them for up to 14 DIV.  These cultured neurones have been shown to express 
a number of the in vivo markers of MSNs including D1 and D2 dopamine receptors, 
GAD, Ca2+ binding proteins, cannabinoid receptors, and K+ channels (Falk et al., 2006).  
Furthermore, these neurones have been shown to form GABAergic synapses by axon 
collaterals and generate spontaneous GABAergic currents through activation of the 
ligand-gated channels GABAARs by the neurotransmitter GABA (Kowalski et al., 1995).  
 GABAARs are heteropentamers usually composed of two α, two β and one γ 
subunit. The main subunits expressed at GABAergic synapses in the projecting MSNs 
are the α1-2, β2 and γ2 subunits (Fujiyama et al., 2000). Depending on the type of α 
subunit incorporated in the postsynaptic GABAARs, the regional expression, 
physiological and functional properties of the GABAergic synapse will differ (Nusser et 
al., 1996, Fritschy and Panzanelli, 2014). More specifically, it has been shown that 
while the α1 subunit is expressed in the somatic and dendritic synapses of MSNs, the 
α3 subunit expression was restricted to the perisomatic synapses, a region mostly 
contacted by local axon collaterals. In contrast, the α2 subunit was mostly present in 
dendritic compartments were striatal MSNs contact MSNs from the globus pallidus 
(Gross et al., 2011). Thus, due to the kinetic properties conferred by each individual α 
subunit, this specific distribution is likely to contribute differentially to both physiological 
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and pathological patterns of activity in this complex neuronal network of basal ganglia 
medium spiny neurones (Gross et al., 2011).  
 Immunocytochemical studies have revealed that the scaffolding protein 
gephyrin is present at postsynaptic densities of GABAergic synapses (Kneussel and 
Betz, 2000). In the brain, this protein is enriched at postsynaptic sites which contain 
GABAARs subtypes composed of (1-3), (2-3) and 2 subunits (Jacob et al., 2008). It 
has been shown that gephyrin binds directly to GABAARs via the intracellular loop of 
the α1-3 GABAARs subunits (Tretter et al., 2008, Mukherjee et al., 2011, Tretter et al., 
2011). In doing so, gephyrin plays a central role in the formation of functional 
GABAergic synapse as it is responsible for the clustering of GABAARs into the 
postsynaptic membrane, enabling the synaptic inhibition to be fast and strong 
(Tyagarajan and Fritschy, 2014).  
 Elucidating the way the heterogeneity and clustering of GABAARs are regulated 
during MSNs development will lead us to a better understanding of the way MSNs 
communicate with each other, and in doing so, contribute to the functioning of the 
striatum.  
5.1.1 Aims  
 In this part of the thesis, our main goal was to characterise the formation of α1 
and/or α2-containing clusters of GABAAR and their association with the presynaptic 
GABAergic terminals. The key questions that we wanted to address are: 
1. What is the expression pattern of these subtypes of GABAARs throughout the 
development of medium spiny neurones in vitro?  
2. Are all α1 and α2 GABAAR clusters inserted in synaptic contacts?  
3. Is gephyrin involved in the formation of GABAergic synapses incorporating 
different subtypes of GABAARs? 
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5.2 Methods  
5.2.1 Primary cultures of MSNs 
 Neurones were prepared as described in Chapter 2, Section 2.1 
5.2.2 Immunocytochemistry 
 Immunocytochemistry was performed as described in Chapter 2, Section 2.2. 
Neurones cultured for 7 or 14 DIV, were fixed using 4 % PFA/ sucrose for 12 minutes 
at room temperature. After fixation, they were incubated with Glycine (0.3 M) in PBS, in 
order to quench PFA. After washing, cells were incubated in 1 % BSA in PBS for 1 
hour and subsequently incubated with anti- α1 and anti- α2 antibodies, specifically 
binding to their N-terminal extracellular domains, diluted in 1 % BSA in PBS overnight 
(14-16 hours) at 4 °C (Table 14). Cultures were then permeabilised by incubating with 
1 % BSA, 0.5 % Triton X-100 in PBS for 15 minutes. Neurones were subsequently 
incubated with mouse anti- GAD-65 or gephyrin and chicken anti- MAP-2 antibodies 
(see Table 14 for dilutions) diluted in 1 % BSA in PBS for 2 hours at room temperature. 
Following this step, conjugated secondary antibodies were added as described in 
Chapter 2, Section 2.2 (antibodies used in these experiments are described in the 
Table 14). 
5.2.3 Confocal analysis 
 Immunolabelling was analysed using Zeiss LSM 710 confocal microscope with 
a Plan-Apochromat 63x/1.4 Oil DIC lens. Threshold for each channel was calculated 
from the background staining intensity and then removed from the image.  To count the 
density and size of α1- and α2- containing GABAA receptor clusters or gephyrin 
clusters, puncta were defined as immunoreactive profiles greater than 0.1 μm2, with the 
mean intensity of each cluster equal or higher than double the standard deviation of 
intensity which was indicated by the Zen 2009 Programme. The defined clusters were 
encircled and their properties noted by hand. The density and size of α1 clusters were 
first calculated, followed by the α2 clusters. Then, α1 clusters which were mixed with 
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α2 (minimum of 50 % overlapping) were separated from α1 clusters and analysed as a 
separate group. The same process was applied for α2 mixed clusters. Because the 
proportion of α1 and α2 clusters was different among mixed clusters, these populations 
were kept and analysed separately, although in most of the cases, they represented 
the same population of mixed clusters. Therefore, we did not separate these two types 
of mixed clusters when we analysed their co-localisation with gephyrin.  
5.2.4 Analysis of synaptic parameters 
 As a criterion for synaptically localised clusters, I determined whether these 
clusters were in close apposition with the presynaptic marker GAD-65. A minimum of 
50 % overlap was used to estimate the close apposition between the postsynaptic 
clusters and the presynaptic GAD-65 positive terminals. The same overlapping criterion 
was used to determine the density and ratio of α1 and/or α2- containing clusters co-
localised with gephyrin. The total density of GAD-65 immunoreactive puncta forming 
contacts along the first 20 μm length of primary dendrites was counted to determine the 
density of presynaptic inputs. 
5.2.5 Statistical analysis 
 Once all the parameters were measured, they were copied into an Excel file 
and sorted into different groups according to their size, co-localisation with GAD-65 and 
kind, single or mixed clusters:  
- All α1 single clusters  
- α1 single clusters which are co-localised with GAD-65 
- All α2 single clusters  
- α2 single clusters which are co-localised with GAD-65 
- All α1 mixed clusters  
- α1 mixed clusters which are co-localised with GAD-65 
- All α2 mixed clusters 
- α2 mixed clusters which are co-localised with GAD-65 
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- All gephyrin clusters 
- α1 single clusters which are co-localised with gephyrin 
- α2 single clusters which are co-localised with gephyrin 
- mixed clusters which are co-localised with gephyrin 
 Subsequently, the data was analysed using Origin Pro 9.0 32 Bit software. 
Normal (Gaussian) distribution of the pooled data was first tested using the Shapiro-
Wilk and Kolmogorov-Smirnov tests. Since the data did not follow a normal distribution 
and the categories were independent, non-parametric statistical analysis was carried 
out using the Mann Whitney test with an interval of confidence of 95 %. Because they 
represent a robust measure of central tendency when distributions are not normally 
distributed, the medians and their interquartile range (IQR) were used to describe the 
data and evaluate statistical dispersion. With the groups following normal distribution, 
statistical analysis was done using two sample Student’s t-test. The synaptic and total 
densities of clusters were evaluated along the length of 20 µm of primary dendrite for 
each cell. The percentage of synaptic clusters over the total population was determined 
for each dendrite. 
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Table 14. Antibodies used for immunocytochemical analysis of MSNs in culture 
 
5.3 Results 
5.3.1 A specific decrease in the total density of α1 single and mixed 
GABAAR clusters is observed from 7 to 14 DIV  
 Cultured embryonic (E16-18) striatal neurones form a homogeneous population 
of the precursors of GABAergic medium spiny neurones (MSNs) (Goffin et al., 2010). 
Although formation of synapses between these neurones has been partially 
characterised in our laboratory, how specific α1- and α2-containing synapses are 
established is currently unknown. Cultured embryonic MSNs were previously 
characterised by immuno-reactivity for DARPP-32 (Dopamine- and cyclic AMP-
Regulated Phosphoprotein), a well-established marker of these neurones (Greengard 
et al., 1999). Striatal tissue from embryonic E17 rat brains was dissected, dissociated 
and cultured from 7 to 14 DIV. Following staining, the fluorescence of DARPP-32 was 
increased in all the cells during development. This confirmed that a homogeneous 
population of GABAergic MSN precursors was cultured (Figure 37).  
primary antibodies secondary antibodies 
specificity origin dilutions source and 
characterisation 
antibodies dilutio
ns 
source 
GABAAα1 Rabbit 1:200 Duggan, MJ, 
Stephenson AF., 
1990.     J Biol 
Chem 
Goat anti 
rabbit 405 
1:750 Alexa Fluor 
Invitrogen 
a31556 
GABAAα2 Guinea-
pig 
1:400 Synaptic System 
224104 
Goat Anti 
guinea pig 
488 
1:750 Alexa Fluor 
Invitrogen 
a11073 
GAD65 Mouse 1:4000 Abcam, ab26113 Goat anti 
mouse 555 
1:750 Alexa Fluor 
Invitrogen 
a21422 
MAP2 Chicken 1:2500 Abcam, ab92434 Goat Anti 
chicken 
488 
1:750 Alexa Fluor 
Invitrogen 
a11039 
Gephyrin Mouse 1:500 
Synaptic System, 
147111 
Goat Anti-
mouse 555 
1:750 
Alexa Fluor 
Invitrogen 
a21422 
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Figure 37. The expression of DARPP-32 is increased during development of cultured 
embryonic MSNs (Arama et al., in preparation). Immunolabelling of cultured embryonic 
MSNs representing the level of expression of DARPP-32 (red) and MAP-2 (green) from 7 to 14 
DIV. A. Merged image of a 7 DIV striatal neurone immunostained for DARPP-32 and MAP-2. B. 
Merged image of 14 DIV striatal neurones immunostained for DARPP-32 and MAP-2. 
 
 
 In order to study specific synapse formation, striatal neurones were cultured for 
7 or 14 days and synapse formation was analysed using immunocytochemistry and 
confocal imaging. Figure 38, 39 and 40 show  the same couple of neurones stained for 
α1 and/or α2 extracellular domains of GABAARs subunits, the presynaptic marker 
GAD-65 and MAP-2, using the antibodies described in table 14. The total density of α1 
single-, α2 single- or α1/α2 mixed subunits- containing GABAARs clusters, and the 
density of synaptic clusters in each groups were determined using the Zen 2009 
programme. Synaptic receptor clusters were defined as those closely apposed to the 
presynaptic GAD-65 positive terminals.  
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Figure 38. The density and size of α1 containing GABAAR clusters are modified from 7 to 
14 DIV. Immunolabelling of GABAARs α1 subunit-containing clusters (cyan) and presynaptic 
GABAergic terminals (red) along primary dendrites (blue) of cultured MSNs. A. Merged image of 
a 7 DIV striatal neurone (scale bar: 10 μm). B. (i) Enlarged image of boxed region in A 
representing α1 staining only. (ii) Analysis of image B(i) in which all α1 clusters are circled in 
red. (iii) Analysis of image B(i) in which only α1 single clusters that are not associated with α2 
clusters are circled in red (scale bar: 5 μm). C. (i) Enlarged image of boxed region in A 
representing α1 positive clusters and presynaptic GAD-65 positive nerve terminals. (ii) Analysis 
of image C(i) in which all α1 clusters were circled in red and presynaptic terminals were circled 
in purple. (iii) Analysis of image C(i) in which only α1 single clusters were circled in red and 
presynaptic terminals were circled in purple (scale bar: 5 μm). D. Merged image of a 14 DIV 
striatal neurone (scale bar: 10 μm). E. (i) Enlarged image of boxed region in D representing α1 
staining only. (ii) Analysis of image E(i) in which all α1 clusters are circled in red. (iii) Analysis of 
image E(i) in which only α1 single clusters that are not associated with α2 clusters are circled in 
red (scale bar: 5 μm). F. (i) Enlarged image of boxed region in D representing α1 positive 
clusters and presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image F(i) in which all 
α1 clusters were circled in red and presynaptic terminals were circled in purple. (iii) Analysis of 
image F(i) in which only α1 single clusters were circled in red and presynaptic terminals were 
circled in purple (scale bar: 5 μm).  
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Figure 39. The density and size of α2 containing GABAAR clusters are modified from 7 to 
14 DIV. Immunolabelling of GABAARs α2 subunit-containing clusters (green) and presynaptic 
GABAergic terminals (red) along primary dendrites (blue) of cultured MSNs. A. Merged image of 
a 7 DIV striatal neurone (scale bar: 10 μm). B. (i) Enlarged image of boxed region in A 
representing α2 staining only. (ii) Analysis of image B(i) in which all α2 clusters are circled in 
yellow. (iii). Analysis of image B(i) in which only α2 single clusters that are not associated with 
α1 clusters are circled in yellow. C. (i) Enlarged image of boxed region in A representing α2 
positive clusters and presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image C(i) in 
which all α2 clusters were circled in yellow and presynaptic terminals were circled in purple. (iii) 
Analysis of image C(i) in which only α2 single clusters were circled in yellow and presynaptic 
terminals were circled in purple (scale bar: 5 μm). D. Merged image of a 14 DIV striatal neurone 
(scale bar: 10 μm). E. (i) Enlarged image of boxed region in D representing α2 staining only. (ii) 
Analysis of image E(i) in which all α2 clusters are circled in yellow. (iii) Analysis of image E(i) in 
which only α2 single clusters that are not associated with α2 clusters are circled in yellow (scale 
bar: 5 μm). F. (i) Enlarged image of boxed region in D representing α2 positive clusters and 
presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image F(i) in which all α2 clusters 
were circled in yellow and presynaptic terminals were circled in purple. (iii) Analysis of image 
F(i) in which only α2 single clusters were circled in yellow and presynaptic terminals were 
circled in purple (scale bar: 5 μm).  
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Figure 40. The density and size of α1 and α2 containing GABAAR clusters (mixed 
clusters) are modified from 7 to 14 DIV. Immunolabelling of GABAARs α1 and α2 subunit-
containing clusters (mixed clusters, cyan and green) and presynaptic GABAergic terminals (red) 
along primary dendrites (blue) of cultured MSNs. A. Merged image of a 7 DIV striatal neurone 
(scale bar: 10 μm). B. (i) Enlarged image of boxed region in A representing α1 and α2 staining. 
(ii) Analysis of image B(i) in which all mixed α1 clusters are circled in red and α2 clusters are 
circled in yellow (scale bar: 5 μm). C. (i) Enlarged image of boxed region in A representing α2 
positive clusters and presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image C(i) in 
which all α2 clusters were circled in yellow and presynaptic terminals were circled in purple 
(scale bar: 5 μm). D. Merged image of a 14 DIV striatal neurone (scale bar: 10 μm). E. (i) 
Enlarged image of boxed region in D representing α1 and α2 staining. (ii) Analysis of image E(i) 
in which mixed α1 clusters are circled in red and α2 clusters are circled in yellow (scale bar: 5 
μm). F. (i) Enlarged image of boxed region in D representing mixed α1 and α2 clusters and 
presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image F(i) in which mixed α1 were 
circled in red, mixed α2 clusters were circled in yellow and presynaptic terminals were circled in 
purple (scale bar: 5 μm).  
 
Developing MSNs undergo specific changes in the density of α1 single, α2 
single, α1 mixed and α2 mixed clusters of GABAARs from 7 to 14 DIV. The density of 
synaptic and total α1 single clusters of GABAARs per defined length of primary dendrite 
(the first 20 µm from the cell body) was estimated from 7 to 14 DIV (Figure 41). At 7 
DIV, the median density of synaptic α1 single clusters was 4 (8.5-2) compared to 5 (8-
2) at 14 DIV (p value= 0.78, Mann Whitney test; n=45 dendrites analysed in 7 DIV-
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cultured neurones, and n=48 dendrites analysed in 14 DIV-cultured neurones). In 
contrast, the median density of total α1 single clusters was 18 (25-10) at 7 DIV 
compared to 11.5 (17.75-5.25) at 14 DIV (p value=0.024, Mann Whitney test; n=45 
dendrites analysed in 7 DIV-cultured neurones, and n=48 dendrites analysed in 14 
DIV-cultured neurones). This demonstrates that while the density of synaptic α1 single 
clusters remains unchanged, the total density of α1 single clusters decreases 
significantly. This indicates that the extrasynaptic α1-contaning GABAAR clusters are 
down-regulated from 7 to 14 DIV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. The total density of α1 single clusters per primary dendrite of MSNs is 
decreased from 7 to 14 DIV. The density of α1-containing GABAA receptors clusters (α1 single 
clusters) along the first 20 μm of primary dendrite was counted in MSN cultures after 7 and 14 
DIV. A. Histogram shows the distribution of synaptic α1 single cluster densities (n=42 and n=48 
dendrites, respectively, from two independent experiments). B. Box-plot displays the median 
density (50% of the population) of synaptic α1 single clusters. C. Histogram shows the 
distribution of total α1 single cluster densities (n=45 and n=48 dendrites, respectively, from two 
independent experiments). D. The box plot displays the median density of total α1 single 
clusters. Statistical analysis was performed using Mann Whitney test: * corresponds to p-value 
<0.05. 
 
 In addition, we analysed the density of α2 single clusters in these cultures. The 
density of synaptic and total α2 single cluster of GABAARs per defined length of 
primary dendrite (the first 20 µm from the cell body) was estimated from 7 to 14 DIV 
(Figure 42). At 7 DIV, the median density of synaptic α2 single clusters was 7 (20-2) 
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compared to 5.5 (20.5-1) at 14 DIV (p value=0.84, Mann Whitney test; n=42 dendrites 
analysed in 7 DIV-cultured neurones, n=48 dendrites analysed at 14 DIV-cultured 
neurones). Similarly, the median density of total α2 single clusters was 13 (44.5-6) at 7 
DIV compared to 16 (36.5-9) at 14 DIV (p value=0.98, Mann Whitney test n=45 
dendrites analysed in 7 DIV-cultured neurones; n=48 dendrites analysed at 14 DIV-
cultured neurones). This demonstrates that the density of synaptic and total α2 single 
clusters remains unchanged, and is already determined at 7 DIV. 
 
Figure 42. The density of synaptic and total α2 single clusters per primary dendrites of 
MSNs remains unchanged from 7 to 14 DIV. The density of α2-containing GABAA receptors 
clusters (α2 single clusters) along the first 20 μm of primary dendrite was counted in MSN 
cultures after 7 and 14 DIV. A. Histogram shows the distribution of synaptic α2 single cluster 
density (n=42 and n=48 dendrites, respectively, from two independent experiments). B. Box-plot 
displays the median density (50% of the population) of synaptic α2 single cluster density. C. 
Histogram shows the distribution of total α2 single cluster density (n=45 and n=48 dendrites, 
respectively, from two independent experiments). D. The box plot displays the median density 
of total α2 single clusters. Statistical analysis was performed using Mann Whitney test. 
 
While imaging these neurones, we have noticed that both α1 and α2 single 
clusters were often found in close proximity to each other along the primary dendrites. 
Therefore, we decided to analyse the density of mixed clusters per dendritic length. 
The mixed clusters, which contained a majority of α1 clusters, were defined as α1 
mixed clusters while the mixed clusters containing a majority of α2 clusters were 
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defined as α2 mixed clusters. The density of synaptic and total α1 mixed clusters of 
GABAARs per defined length of primary dendrite (the first 20 µm
 from the cell body) 
was estimated from 7 to 14 DIV (Figure 43). At 7 DIV, the median density of synaptic 
α1 mixed clusters was 1 (7.5-0) compared to 3 (9-0) at 14 DIV (p value=0.85, Mann 
Whitney test; n=42 dendrites analysed in 7 DIV-cultured neurones; n=48 dendrites 
analysed in 14 DIV-treated neurones). In contrast, the median density of total α1 mixed 
clusters was 8 (18-3.5) at 7 DIV compared to 6 (12-0) at 14 DIV (p value=0.04, Mann 
Whitney test; n=45 dendrites analysed in 7 DIV-cultured neurones; n=48 dendrites 
analysed at 14 DIV-cultured neurones). This demonstrates that while the density of 
synaptic α1 mixed clusters remains unchanged, the total density of α1 mixed clusters is 
significantly decreased from 7 to 14 DIV. Similarly to α1 single clusters, this suggests 
that the extra-synaptic α1 mixed clusters are down-regulated from 7 to 14 DIV. 
Figure 43. The density of α1 mixed clusters per primary dendrite of MSNs is decreased 
from 7 to 14 DIV.The density of α1/α2-containing GABAA receptors clusters (α1 mixed clusters) 
along the first 20 μm of primary dendrite was counted in MSN cultures after 7 and 14 DIV. A. 
Histogram shows the distribution of synaptic α1 mixed cluster density (n=45 and n=48 
dendrites, respectively, from two independent experiments). B. Box-plot displays the median 
density (50% of the population) of synaptic α1 mixed clusters. C. Histogram shows the 
distribution of total α1 mixed cluster density (n=45 and n=48 dendrites, respectively, from two 
independent experiments). D. Box-plot displays the median density of total α1 mixed clusters. 
Statistical analysis was performed using Mann Whitney test: * corresponds to p-value <0.05. 
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We have also analysed the population of mixed clusters which contained 
predominantly α2 clusters (α2 mixed clusters). The density of synaptic and total α2 
mixed clusters of GABAARs per defined length of primary dendrite (the first 20 µm
 from 
the cell body) was estimated from 7 to 14 DIV (Figure 44). At 7 DIV, the median density 
of synaptic α2 mixed clusters was 4 (8-1) compared to 6 (9.75-3) at 14 DIV (p 
value=0.20, Mann Whitney test; n=45 dendrites analysed in 7 DIV-cultured neurones; 
n=48 dendrites analysed in 14 DIV-cultured neurones). The median density of total α2 
mixed clusters was 8 (19.5-4) at 7 DIV compared to 9 (12-5.25) at 14 DIV (p 
value=0.46, Mann Whitney test; n=45 dendrites analysed in 7 DIV-cultured neurones; 
n=48 dendrites analysed in 14 DIV-cultured neurones). This demonstrates that the 
density of synaptic and total α2 mixed clusters remains unchanged from 7 to 14 DIV. 
Similarly to α2 single clusters, the density of α2 mixed clusters per dendritic length is 
already determined at 7 DIV. 
Figure 44. The density of synaptic and total α2 mixed clusters per primary dendrite of 
MSNs remains unchanged from 7 to 14 DIV. The density of α2/α1-containing GABAA 
receptors clusters (α2 mixed clusters) along the 20 μm of primary dendrite was counted in MSN 
cultures after 7 and 14 DIV. A. Histogram shows the distribution of synaptic α2 mixed cluster 
densities (n=42 and n=48 dendrites, respectively, from two independent experiments). B. Box-
plot displays the median density (50% of the population) of synaptic α2 mixed clusters. C. 
Histogram shows the distribution of total α2 mixed cluster density (n=45 and n=48 dendrites, 
respectively, from two independent experiments). D. Box-plot displays the median density of 
total α2 mixed clusters. Statistical analysis was performed using Mann Whitney test. 
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Table 15. The total density of α1 single and mixed clusters per primary dendrite 
of MSNs is significantly decreased from 7 to 14 DIV 
 
 
 
 
 
 
5.3.2 The percentage of synaptic over the total GABAAR clusters is 
modified from 7 to 14 DIV  
 Despite the observed decrease in the total density of α1 single and α1 mixed 
clusters, the density of synaptic α1 clusters, or the density of different types of α2 
clusters per dendrite did not seem to significantly change during development of MSNs 
in vitro. In order to analyse further these changes in cluster populations, we estimated 
the proportion of synaptic clusters as a percentage of total clusters in each population 
from 7 to 14 DIV. The proportion of α1 singe clusters as a percentage of total α1 single 
clusters (the first 20 μm from the cell body) was calculated (Figure 45). At 7 DIV, the 
median percentage of synaptic/ total α1 single clusters was 21.42 (11.13-30) % 
compared to 30.78 (19.19-38.88) % at 14 DIV (p value=0.006, Mann Whitney test; 
n=45 dendrites analysed in 7 DIV-cultured neurones, and n=48 dendrites analysed in 
14 DIV-cultured neurones). Despite the apparent stability in the density of synaptic α1 
single clusters per dendrite, their contribution to the overall density of α1 single clusters 
is significantly increased from 7 to 14 DIV, due to a significant decrease in the density 
of total α1 single clusters (Table 15).   
Density of clusters 7-14 DIV P < 0.05 
α1 single clusters 
Synaptic  No  
Total  Yes 
α2 single clusters 
Synaptic  No 
Total  No 
αl mixed clusters 
Synaptic  No  
Total  Yes 
α2 mixed clusters 
Synaptic  No 
Total  No 
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Figure 45. The percentage of synaptic over the total α1 single clusters is increasing from 
7 to 14 DIV. The percentage of synaptic over the total α1 single clusters amongst the total 
population of α1 single clusters along the 20 μm of primary dendrite was estimated in MSNs 
cultures after 7 and 14 DIV. A. Histogram shows the distribution of the ratios between synaptic 
and total α1 single clusters per dendrite (n=45 and n=48 dendrites, respectively, from two 
independent experiments). B. Box-plot displays the median percentage of synaptic over the 
total α1 single clusters per dendrite. Statistical analysis was performed using Mann-Whitney 
test: * corresponds to p-value < 0.05. 
 
In addition, the propotion of synaptic α2 single clusters as a percentage of total 
α2 single per defined length of primary dendrite (the first 20 μm from the cell body) was 
calculated (Figure 46). At 7 DIV, the median percentage of synaptic/ total α2 single 
clusters was 29.28 (22.05-34.13) % compared to 33.33 (18.63-41.09) % at 14 DIV (p 
value=0.11, Mann Whitney test; n=44 dendrites analysed in 7 DIV-cultured neurones, 
and n=44 dendrites analysed in 14 DIV-cultured neurones). This indicates that, 
similarly to the density of synaptic α2 single clusters per dendrite, the proportion of 
synaptic/ total α2 single clusters is not changed from 7 to 14 DIV. 
Figure 46. The percentage of synaptic over the total α2 single clusters remains stable 
from 7 to 14 DIV. The percentage of synaptic over the total α2 single clusters amongst the total 
population of α2 single clusters along the 20 μm of primary dendrite was estimated in MSNs 
cultures after 7 and 14 DIV. A. Histogram shows the distribution of ratios of synaptic/total α2 
single clusters per dendrite (n=44 analysed dendrites, in both developmental stages, from two 
independent experiments). B. Box-plot displays the median percentage of synaptic over the 
total α2 single clusters per dendrite. Statistical analysis was performed using Mann Whitney 
test. 
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Following the previous analysis, we have also analysed changes in the 
proportion of synaptic mixed clusters as a percentage of total mixed clusters during 
MSN development. The proportion of synaptic α1 mixed clusters as a percentage of 
total  α1 mixed clusters of GABAARs per defined length of primary dendrite (the first 20 
µm from the cell body) was estimated from 7 to 14 DIV (Figure 47). The median 
percentage of synaptic over the total α1 mixed clusters was 21.71 (0-33.33) % at 7 DIV 
compared to 39.64 (33.3-45.45) % at 14 DIV (p value=1.46x10-5, Mann Whitney test; 
n=42 dendrites analysed in 7 DIV-cultured neurones, and n=32 dendrites analysed in 
14 DIV-cultured neurones). This demonstrates that, because the density of synaptic α1 
mixed clusters remains unchanged and the total density of α1 mixed clusters is 
significantly decreased from 7 to 14 DIV, the percentage of synaptic over the total α1 
mixed clusters of GABAARs is significantly increased from 7 to 14 DIV. 
 
Figure 47. The percentage of synaptic over the total α1 mixed clusters per primary 
dendrites of MSNs is increased from 7 to 14 DIV. The percentage of synaptic over the total 
α1 mixed clusters amongst the total population of α1 mixed clusters along the 20 μm of primary 
dendrite was estimated in MSN cultures after 7 and 14 DIV. A. Histogram shows the distribution 
of the ratios between synaptic and total α1 mixed clusters per dendrite (n=45 and n=48 
dendrites, respectively, from two independent experiments). B. Box-plot displays the median 
percentage of synaptic over the total α1 mixed clusters per dendrite. Statistical analysis was 
performed using Mann-Whitney test: * corresponds to p-value < 0.05. 
 
We analysed changes in mixed clusters which contained a predominant density 
of α2 clusters in these cultures (α2 mixed clusters). The proportion of synaptic α2 
mixed clusters as a percentage of total α2 mixed clusters of GABAARs per defined 
length of primary dendrite (the first 20 µm from the cell body) was estimated from 7 to 
14 DIV (Figure 48). The median percentage of synaptic over the total α2 mixed clusters 
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was 31.03 (20- 41.66) % at 7 DIV compared to 42.10 (36.36- 46.47) % at 14 DIV (p 
value=0.003, Mann Whitney test; n=43 dendrites analysed in 7 DIV-cultured neurones; 
n=43 dendrites analysed in 14 DIV-cultured neurones). This demonstrates that 
although the density of synaptic and total α2 mixed clusters remains unchanged from 7 
to 14 DIV, the percentage of synaptic over the total α2 mixed clusters of GABAARs is 
increased from 7 to 14 DIV. 
Figure 48. The percentage of synaptic over the total α2 mixed clusters is 
increased from 7 to 14 DIV. The percentage of synaptic over the total α2 mixed clusters 
amongst the total population of α2 mixed clusters along the 20 μm of primary dendrite was 
estimated in MSN cultures after 7 and 14 DIV. A. Histogram shows the distribution of the ratios 
between synaptic and total α2 mixed clusters per dendrite (n=43 dendrites analysed, in both 
developmental stages, from two independent experiments). B. Box-plot displays the median 
percentage of synaptic over the total α2 mixed clusters per dendrite. Statistical analysis was 
performed using Mann-Whitney test: * corresponds to p-value < 0.05. 
 
Table 16. The percentage of synaptic over the total number of all subtypes of 
GABAAR clusters is increased from 7 to 14 DIV 
 
7-14 
DIV 
P value < 
0.05 
% 
(synaptic/total) 
α1 single 
clusters 
 Yes 
% 
(synaptic/total) 
α2 single 
clusters 
 No 
% 
(synaptic/total) 
α1 mixed 
clusters 
 Yes 
% 
(synaptic/total) 
α2 mixed 
clusters 
 Yes 
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5.3.3 The connectivity between MSNs is increased during development 
of GABAergic synapse 
 To investigate further GABAergic synapse formation, we investigated if the 
changes in GABAARs cluster that we observed were accompanied by changes in the 
density of presynaptic terminals forming contacts with the primary dendrites. The total 
density of GAD-65 positive terminals per defined length of primary dendrite (the first 20 
μm from the cell body) was estimated from 7 to 14 DIV (Figure 49). At 7 DIV, the mean 
density of presynaptic terminals was 7.13 (±0.86) (the median was 7 (5-10)) at 7 DIV 
compared to 10.27 (±1.16) (the median was 10 (6-14.25)) at 14 DIV (p value=0.03, Two 
sample t-test; n=23 dendrites analysed in 7 DIV-cultured neurones, and n=18 dendrites 
analysed in 14 DIV-cultured neurones). This indicates that the density in the first 20 μm 
of presynaptic contacts increases from 7 to 14 DIV. 
 Figure 49. The density of presynaptic terminals making contacts with primary dendrites 
is increased from 7 to 14 DIV. The density of presynaptic terminals along the 20 μm of primary 
dendrite was counted in MSN cultures after 7 and 14 DIV. A. Histogram shows the distribution 
of the density of presynaptic inputs (n=23 and n=18 dendrites, respectively, from two 
independent experiments). B. Box-plot displays the mean density (dot in the middle of the box) 
and median (50% of the population) of presynaptic terminals. Statistical analysis was performed 
using Two-sample T-test: * corresponds to p-value < 0.05. 
 
 
5.3.4 Developmental changes in the size of GABAAR clusters are 
determined by the type of α subunit incorporated  
During their development in culture from 7 to 14 DIV, MSNs undergo prominent 
changes in the size of α1 single, α2 single, α1 mixed and α2 mixed GABAAR 
clusters.The size of synaptic and total α1 single clusters of GABAARs per defined 
length of primary dendrite (the first 20 μm from the cell body) was estimated from 7 to 
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14 DIV (Figure 50). At 7 DIV, the median size of synaptic α1 single clusters was 0.26 
(0.43-0.12) μm2 compared to 0.21 (0.7-0.14) μm2 at 14 DIV (p value=0.0017, Mann 
Whitney test; n=194 clusters analysed in 7 DIV-cultured neurones, and n=250 clusters 
analysed in 14 DIV-cultured neurones). Similarly, the median size of total α1 single 
clusters was 0.3 (0.43-0.14) μm2 at 7 DIV compared to 0.17 (0.69-0.12) μm2 at 14 DIV 
(p value=0.62, Mann Whitney test; n=586 clusters analysed in 7 DIV-cultured 
neurones, and n=533 clusters analysed in 14 DIV-cultured neurones). This 
demonstrates that the size of synaptic and total α1 single clusters is reduced although 
their density remains stable during development. In contrast, the size and the density of 
total α1 single clusters are both decreased from 7 to 14 DIV. 
Figure 50. The size of synaptic and total α1 single clusters is decreased from 7 to 14 DIV.  
The size of α1 -containing GABAA receptors clusters (α1 single clusters) along the 20 μm of 
primary dendrite was measured in MSN cultures after 7 and 14 DIV. A. Histogram shows the 
distribution of synaptic α1 single cluster sizes (n=194 and n=250 clusters, respectively, from two 
independent experiments). B. Box-plot displays the median size (50 % of the population) of 
synaptic α1 single clusters. C. Histogram shows the distribution of total α1 single cluster sizes 
(n=586 and n=333 clusters, respectively, from two independent experiments). D. The box plot 
displays the population of total α1 single cluster size. Statistical analysis was performed using 
Mann Whitney test: * corresponds to p-value <0.05. 
 
In addition, we analysed the size of α2 single clusters in these cultures. The 
size of synaptic and total α2 single clusters of GABAARs per defined length of primary 
dendrite (the first 20 μm from the cell body) was estimated from 7 to 14 DIV (Figure 
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51). At 7 DIV, the median size of synaptic α2 single clusters was 0.23 (0.31-0.17) μm2 
compared to 0.26 (0.36 - 0.19) μm2 at 14 DIV (p value= 5.74x10-6, Mann Whitney test; 
n= 492 clusters analysed in 7 DIV-cultured neurones, compared to n=605 clusters 
analysed in 14 DIV-cultured neurones). Similarly, the median size of total α2 single 
clusters was 0.21 (0.31 - 0.16) μm2 at 7 DIV compared to 0.26 (0.36 - 0.21) μm2 at 14 
DIV (p value= 6.19x10-19, Mann Whitney test; n= 1216 clusters analysed in 7 DIV-
cultured neurones, compared to n= 916 clusters analysed in 14 DIV-cultured 
neurones). This demonstrates that while the density of synaptic and total α2 single 
clusters remains unchanged during development of MSNs, their sizes are significantly 
increasing, possibly due to an increased synthesis and insertion of α2-containing 
GABAARs into the plasma membrane. 
 
Figure 51. The size of synaptic and total α2 single clusters is increased from 7 to 14 DIV.  
The size of α2 -containing GABAA receptors clusters (α2 single clusters) along the 20 μm of 
primary dendrite was measured in MSNs cultures after 7 and 14 DIV. A. Histogram shows the 
distribution of synaptic α2 single cluster sizes (n=492 and n=605 clusters, respectively, from two 
independent experiments). B. Box-plot displays the median size (50 % of the population) of 
synaptic α2 single clusters. C. Histogram shows the distribution of total α2 single cluster sizes 
(n=1216 and n=916 clusters, respectively, from two independent experiments). D. The box plot 
displays the population of total α2 single cluster sizes. Statistical analysis was performed using 
Mann Whitney test: * corresponds to p-value <0.05. 
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As described, previously, we have identified that α1 and α2 single clusters were 
in proximity to each other, showing a significant overlap, along primary dendrites. 
Therefore, together with their density, we decided to analyse the changes in the size of 
α1 mixed and α2 mixed GABAAR clusters at 7 and 14 DIV. The size of synaptic and 
total α1 mixed clusters of GABAARs per defined length of primary dendrite (the first 20 
μm from the cell body) was estimated from 7 to 14 DIV (Figure 52). At 7 DIV, the 
median size of synaptic α1 mixed clusters was 0.39 (0.52-0.24) μm2 at 7 DIV compared 
to 0.6 (0.9-0.19) μm2 at 14 DIV (p value=1.73x10-8, Mann Whitney test; n=234 clusters 
analysed in 7 DIV-cultured neurones, and n=234 clusters analysed in 14 DIV-cultured 
neurones). Similarly, the median size of total α1 mixed clusters was 0.39 (0.56-0.28) 
μm2 at 7 DIV compared to 0.625 (0.9-0.16) μm2 at 14 DIV (p value=1.11x10-10, Mann 
Whitney test; n=560 clusters analysed in 7 DIV-cultured neurones and n=384 clusters 
analysed in 14 DIV-cultured neurones). This indicates that the size of α1 mixed clusters 
is increasing while their density is decreasing, suggesting that this population of 
clusters is undergoing significant developmental changes as MSNs differentiate in vitro. 
 Figure 52. The size of synaptic and total α1 mixed clusters is increased from 7 to 14 DIV. 
The size of α1/α2-containing GABAA receptors clusters (α1 mixed clusters) along the 20 μm of 
primary dendrite was measured in MSNs cultures at 7 and 14 DIV. A. Histogram shows the 
distribution of synaptic α1 mixed cluster sizes (n=234 and n=243 clusters, respectively, from two 
independent experiments). B. Box-plot displays the median size (50 % of the population) of 
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synaptic α1 mixed clusters. C. Histogram shows the distribution of total α1 mixed cluster sizes 
(n=560 and n=384 clusters, respectively, from two independent experiments). D. The box plot 
displays the population of total α1 mixed cluster sizes. Statistical analysis was performed using 
Mann Whitney test: * corresponds to p-value <0.05. 
 
Additionally, the size of synaptic and total α2 mixed clusters of GABAARs per defined 
length of primary dendrite (the first 20 μm from the cell body) was estimated from 7 to 
14 DIV (Figure 53). At 7 DIV, the median size of synaptic α2 mixed clusters was 0.39 
(0.69-0.24) μm2 at 7 DIV compared to 0.56 (0.95-0.28) μm2 at 14 DIV (p value=2.9x10-5, 
Mann Whitney test; n=252 clusters analysed in 7 DIV-cultured neurones and n=335 
clusters analysed in 14 DIV-cultured neurones). Similarly, the median size of total α2 
mixed clusters was 0.39 (0.69-0.24) μm2 at 7 DIV compared to 0.56 (0.95-0.28) μm2 at 
14 DIV (p value=2.83x10-8, Mann Whitney test; n=604 clusters analysed in 7 DIV-
cultured neurones, and n=483 clusters analysed in 14 DIV-cultured neurones). This 
indicates that, although their density remains stable during development, the size of 
synaptic and total α2 mixed clusters is increased as MSNs develop in vitro, possibly 
due to increased synthesis and insertion of α2-containing GABAARs into the plasma 
membrane.   
 Figure 53. The size of synaptic and total α2 mixed clusters is increased from 7 to 14 DIV.  
The size of α2/α1-containing GABAA receptors clusters (α2 mixed clusters) along the 20 μm of 
primary dendrite was measured in MSNs cultures at 7 and 14 DIV. A. Histogram shows the 
distribution of synaptic α2 mixed cluster sizes (n=252 and n=335 clusters, respectively, from two 
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independent experiments). B. Box-plot displays the median size (50 % of the population) of 
synaptic α2 mixed clusters. C. Histogram shows the distribution of total α2 mixed cluster sizes 
(n=604 and n=483 clusters, respectively, from two independent experiments). D. Box- plot 
displays the population of total α2 mixed cluster sizes. Statistical analysis was performed using 
Mann Whitney test: * corresponds to p-value <0.05. 
 
Table 17. Significant increase in the size of all α2- containing GABAAR clusters in 
MSNs from 7 to 14 DIV.  
 
 
 
 
 
 
 
 
 
5.3.5 The density and size of gephyrin clusters are increased from 7 to 
14 DIV 
 It is now well established that the scaffolding protein gephyrin plays a central 
role in the maintenance and stability of GABAergic synapses (Yu et al., 2007). 
However, how the properties of gephyrin clusters change during development of 
GABAergic synapses is currently unclear. As described previously, embryonic MSNs 
were cultured for 7 or 14 DIV, and synapse formation was analysed using 
immunocytochemistry and confocal imaging. Figure 54, 55 and 56 show examples of 
staining for α1 and/or α2 extracellular domains of GABAARs subunits, the postsynaptic 
protein gephyrin and MAP-2, using the antibodies described in Table 14. The total 
density of gephyrin clusters was determined using Zen 2009 programme. In order to 
study specific synapse formation, striatal neurones were cultured for 7 or 14 days and 
synapse formation was analysed using immunocytochemistry and confocal imaging. 
Figure 54, 55 and 56 show the same couple of neurones stained for α1 and/or α2 
Size of clusters (μm2) 7-14 DIV P < 0.05 
α1 single clusters 
Synaptic  Yes  
Total  No 
α2 single clusters 
Synaptic  Yes  
Total  Yes   
αl mixed clusters 
Synaptic  Yes 
Total  Yes  
α2 mixed clusters 
Synaptic  Yes  
Total  Yes  
177 
 
extracellular domains of GABAARs subunits, the postsynaptic protein gephyrin and 
MAP-2, using the antibodies described in table 14. The total density and the size of 
gephyrin clusters, and their co-localisation with GABAAR subunits α1 and α2 were 
determined using the Zen 2009 programme. 
Figure 54. The density and size of gephyrin clusters, as well as the density of α1 clusters 
co-localising with gephyrin are increased from 7 to 14 DIV. Immunolabelling of GABAARs 
α1 subunit-containing clusters (cyan) and gephyrin (red) along primary dendrites (blue) of 
cultured MSNs. A. Merged image of a 7 DIV striatal neurone (scale bar: 10 μm). B (i) Enlarged 
image of boxed region in A representing α1 staining only. (ii) Analysis of image B(i) in which all 
α1 clusters are circled in red. (iii) Analysis of image B(i) in which only α1 single clusters that are 
not associated with α2 clusters are circled in red (scale bar: 5 μm). C (i) Enlarged image of 
boxed region in A representing α1 positive clusters and gephyrin clusters. (ii) Analysis of image 
C(i) in which all α1 clusters were circled in red and gephyrin clusters were circled in purple. (iii) 
Analysis of image C(i) in which only α1 single clusters were circled in red and gephyrin clusters 
were circled in purple (scale bar: 5 μm). D. Merged image of a 14 DIV striatal neurone (scale 
bar: 10 μm). E (i) Enlarged image of boxed region in D representing α1 staining only. (ii) 
Analysis of image E(i) in which all α1 clusters are circled in red. (iii) Analysis of image E(i) in 
which only α1 single clusters that are not associated with α2 clusters are circled in red (scale 
bar: 5 μm). F (i) Enlarged image of boxed region in D representing α1 positive clusters and 
gephyrin clusters. (ii) Analysis of image F(i) in which all α1 clusters were circled in red and 
gephyrin clusters were circled in purple. (iii) Analysis of image F(i) in which only α1 single 
clusters were circled in red and gephyrin clusters were circled in purple (scale bar: 5 μm).  
 
 
 
 
A B C
(i)
(ii)
(iii)
(i)
(ii)
(iii)
7 DIV MSN7 DIV MSN
α1 Gephyrin MAP-2
14 DIV MSN
D E F
(i)
(ii)
(iii)
(i)
(ii)
(iii)
14 DIV MSN
α1 α1/ gephyrin 
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Figure 55. The density of α2 clusters co-localising with gephyrin is increased from 7 to 14 
DIV. Immunolabelling of GABAARs α2 subunit-containing clusters (green) and gephyrin (red) 
along primary dendrites (blue) of cultured MSNs. A. Merged image of a 7 DIV striatal neurone 
(scale bar: 10 μm). B (i) Enlarged image of boxed region in A representing α2 staining only. (ii) 
Analysis of image B(i) in which all α2 clusters are circled in red. (iii) Analysis of image B(i) in 
which only α2 single clusters that are not associated with α1 clusters are circled in red (scale 
bar: 5 μm). C (i) Enlarged image of boxed region in A representing α2 positive clusters and 
gephyrin clusters. (ii) Analysis of image C(i) in which all α2 clusters were circled in red and 
gephyrin clusters were circled in purple. (iii) Analysis of image C(i) in which only α2 single 
clusters were circled in red and gephyrin clusters were circled in purple (scale bar: 5 μm). D. 
Merged image of a 14 DIV striatal neurone (scale bar: 10 μm). E (i) Enlarged image of boxed 
region in D representing α2 staining only. (ii) Analysis of image E(i) in which all α2 clusters are 
circled in red. (iii) Analysis of image E(i) in which only α2 single clusters that are not associated 
with α1 clusters are circled in red (scale bar: 5 μm). F (i) Enlarged image of boxed region in D 
representing α2 positive clusters and gephyrin clusters. (ii) Analysis of image F(i) in which all α2 
clusters were circled in red and gephyrin clusters were circled in purple. (iii) Analysis of image 
F(i) in which only α2 single clusters were circled in red and gephyrin clusters were circled in 
purple (scale bar: 5 μm).  
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Figure 56. The density of mixed clusters co-localising with gephyrin is increased from 7 
to 14 DIV.Immunolabelling of GABAARs α1 and α2 subunit-containing clusters (mixed clusters, 
cyan and green) and gephyrin clusters (red) along primary dendrites (blue) of cultured MSNs. A. 
Merged image of a 7 DIV striatal neurone (scale bar: 10 μm). B (i) Enlarged image of boxed 
region in A representing α1 and α2 staining. (ii) Analysis of image B(i) in which all mixed α1 
clusters are circled in red and α2 clusters are circled in yellow (scale bar: 5 μm). C (i) Enlarged 
image of boxed region in A representing α2 positive clusters and gephyrin clusters. (ii) Analysis 
of image C(i) in which all α2 clusters were circled in yellow and presynaptic terminals were 
circled in purple (scale bar: 5 μm). D. Merged image of a 14 DIV striatal neurone (scale bar: 10 
μm). E (i) Enlarged image of boxed region in D representing α1 and α2 staining. (ii) Analysis of 
image E(i) in which mixed α1 clusters are circled in red and α2 clusters are circled in yellow 
(scale bar: 5 μm). F (i) Enlarged image of boxed region in D representing mixed α1 and α2 
clusters and gephyrin clusters. (ii) Analysis of image F(i) in which mixed α1 were circled in red, 
mixed α2 clusters were circled in yellow and gephyrin clusters were circled in purple (scale bar: 
5 μm).  
 
 
 The density of gephyrin clusters per defined length of primary dendrite (the first 
20 µm from the cell body) was estimated from 7 to 14 DIV (Figure 57). At 7 DIV, the 
median density of gephyrin clusters was 10 (6 - 16.25) compared to 24 (17.75 - 31) at 
14 DIV (p value= 1.87x10-13, Mann Whitney test; n= 78 dendrites analysed in 7 DIV-
cultured neurones, and n= 70 dendrites analysed in 14 DIV-cultured neurones). This 
demonstrates that the density of gephyrin clusters is increased from 7 to 14 DIV, 
A B C
(i)
(ii)
(i)
(ii)
7 DIV MSN
α1 Gephyrin MAP-2α2
D E F
(i)
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possibly due to a progressive accumulation of gephyrin at synaptic and extrasynaptic 
sites where GABAARs are clustered, as neurones mature in vitro. 
Figure 57. The density of gephyrin clusters per dendrite is increased from 7 to 14 DIV. 
The density of gephyrin clusters along the 20 µm of primary dendrite was counted in MSN 
cultures after 7 and 14 DIV. The total density of gephyrin clusters is increasing from 7 to 14 DIV. 
A. Histogram shows the distribution of total gephyrin clusters (n=78 and n=70 dendrites, 
respectively, from two different experiments). B. Box-plot displays the median density (50 % of 
the population) of gephyrin clusters. Statistical analysis was performed using Mann Whitney 
test: * corresponds to p-value < 0.05. 
 
In addition, we investigated changes in the size of gephyrin clusters during 
development of MSNs. The size of gephyrin clusters per defined length of primary 
dendrite (the first 20 µm from the cell body) was estimated from 7 to 14 DIV (Figure 
58). At 7 DIV, the median size of gephyrin clusters was 0.375 (0.28-0.54) µm2 
compared to 0.47 (0.35-0.695) µm2 at 14 DIV (p value=7.9x10-19, Mann Whitney test; 
n=914 clusters analysed in 7 DIV-cultured neurones, n=1706 clusters analysed in 14 
DIV-cultured neurones). This demonstrates that not only the density, but also the size 
of gephyrin clusters increases as neurones mature in vitro, possibly due to an 
increased synthesis of gephyrin proteins.   
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Figure 58. The size of gephyrin clusters is increased from 7 to 14 DIV. 
The size of gephyrin clusters along the 20 µm of primary dendrite was measured in MSNs 
cultures after 7 and 14 DIV. A. Histogram shows the distribution of gephyrin clusters (n=76 and 
n=68 clusters, respectively, from two different experiments). B. Box-plot displays the median 
size (50 % of the population) of gephyrin. Statistical analysis was performed using Mann 
Whitney test: * corresponds to p-value < 0.05. 
 
Table 18. The density and size of gephyrin clusters are increased from 7 to 14 
DIV 
Gephyrin clusters 7-14 DIV P < 0.05 
Density of clusters  Yes 
Size of clusters  Yes 
 
5.3.6 The density of α1, α2 and α1/α2 mixed GABAAR clusters co-
localising with gephyrin is increased from 7 to 14 DIV  
 To correlate changes in α1- and/or α2- containing GABAAR clusters with 
changes in gephyrin clusters during development, we analysed the degree of co-
localisation between these proteins from 7 to 14 DIV.  
The density of α1 clusters co-localised with gephyrin clusters per defined length of 
primary dendrite (the first 20 µm from the cell body) was estimated from 7 to 14 DIV 
(Figure 59). At 7 DIV, the median density of α1 clusters which are co-localised with 
gephyrin was 1 (0-3) compared to 2 (1-4) at 14 DIV (p-value=0.003, Mann Whitney 
test; n=76 dendrites analysed in 7 DIV-cultured neurones, and n=68 dendrites 
analysed in 14 DIV-cultured neurones). This result indicates that the co-localisation 
between α1 containing GABAARs clusters and gephyrin is increasing from 7 to 14 DIV. 
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Figure 59. The density of α1 clusters co-localising with gephyrin is increased from 7 to 14 
DIV. The density of α1 clusters co-localising with gephyrin was estimated along the 20 µm of 
primary dendrites in MSN cultures after 7 and 14 DIV. A. Histogram shows the distribution of the 
density of α1-containing GABAAR clusters per dendrite co-localising with gephyrin (n=76 and 
n=68 dendrites, respectively, from two different experiments). B. Box-plot displays the median 
density (50 % of total population) of α1 clusters co-localised with gephyrin. Statistical analysis 
was performed using Mann Whitney test: * corresponds to p-value < 0.05. 
 
The density of α2 clusters co-localised with gephyrin clusters per defined length 
of primary dendrite (the first 20 µm from the cell body) was estimated from 7 to 14 DIV 
(Figure 60). At 7 DIV, the median density of α2 clusters which are co-localised with 
gephyrin was 2 (0.25-5) compared to 5 (3-9) at 14 DIV (p-value=5.19.10-6, Mann 
Whitney test; n=76 dendrites analysed in 7 DIV-cultured neurones, and n=68 dendrites 
analysed in 14 DIV-cultured neurones). This result indicates that the co-localisation 
between α2 containing GABAARs clusters and gephyrin is increased in MSNs from 7 to 
14 DIV. 
Figure 60. The density of α2 clusters co-localising with gephyrin is increased from 7 to 14 
DIV. The density of α2 clusters co-localising with gephyrin was estimated along the 20 µm of 
primary dendrites in MSN cultures after 7 and 14 DIV. A. Histogram shows the distribution of the 
density of α2-containing GABAAR clusters per dendrite co-localising with gephyrin (n=76 and 
n=68 dendrites, respectively, from two different experiments). B. Box-plot displays the median 
density (50 % of total population) of α2 clusters co-localised with gephyrin. Statistical analysis 
was performed using Mann Whitney test: * corresponds to p-value < 0.05. 
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As previously explained, some of the α1 and α2 containing clusters were found 
in close apposition with each other along primary dendrites of MSNs.  We were 
interested to study how the co-localisation between gephyrin and these mixed clusters 
would change during synapse maturation. The density of α1/α2 mixed clusters co-
localised with gephyrin clusters per defined length of primary dendrite (the first 20 µm 
from the cell body) was estimated from 7 to 14 DIV (Figure 61). At 7 DIV, the median 
density of α1/α2 mixed clusters which are co-localised with gephyrin was 3 (0-5.75) 
compared to 5 (3-9.75) at 14 DIV (p-value=7.3.10-5, Mann Whitney test; n=76 dendrites 
analysed in 7 DIV-cultured neurones, and n=68 dendrites analysed in 14 DIV-cultured 
neurones). This result indicates that the co-localisation between α1/α2 containing 
GABAARs clusters and gephyrin is increased in MSNs from 7 to 14 DIV. 
Figure 61. The density of α1/α2 mixed clusters co-localising with gephyrin is 
increased from 7 to 14 DIV. The density of α1/α2 mixed clusters co-localising with 
gephyrin was estimated along the 20 µm of primary dendrites in MSN cultures after 7 
and 14 DIV. A. Histogram shows the distribution of the density of α1/α2 containing 
GABAAR clusters per dendrite co-localising with gephyrin (n=76 and n=68 dendrites, 
respectively, from two different experiments). B. Box-plot displays the median density 
(50 % of total population) of mixed clusters co-localised with gephyrin. Statistical 
analysis was performed using Mann Whitney test: * corresponds to p-value < 0.05. 
 
Table 19. The density of all types of GABAAR clusters co-localising with gephyrin 
are increased from 7 to 14 DIV 
 
 
 
 
Density of GABAARs 
clusters co-localising with 
gephyrin 
7 to 14 
DIV 
P < 0.05 
α1 clusters  Yes 
α2 clusters  Yes 
α1/α2 mixed clusters  Yes 
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5.3.7 The proportion of GABAAR clusters co-localising with gephyrin 
as a percentage of the the total GABAAR clusters is increased from 7 
to 14 DIV. 
 As previously described, the density of α-containing GABAAR clusters co-
localising with gephyrin increases during MSNs development from 7 to 14 DIV. To 
understand further these changes, we investigated if, within their respective 
populations, the percentage of α1-, α2- or α1/α2 mixed- containing GABAAR clusters 
co-localising with gephyrin was also changed. The percentage of α1 containing 
GABAAR clusters overlapping with gephyrin amongst total α1 clusters per defined 
length of primary dendrite (the first 20 µm from the cell body) was calculated from 7 to 
14 DIV (Figure 62). At 7 DIV, 13.66 (0-30.58) % of the total α1 clusters population was 
co-localised with gephyrin compared to 37.5 (20-72.07) % at 14 DIV (p- value= 1.00.10-
6, Mann Whitney test; n=72 dendrites analysed in 7 DIV-cultured neurones, and n=65 
dendrites analysed in 14 DIV-cultured neurones). Together with previous data, this 
shows that not only the density of α1 clusters co-localising with gephyrin is increased, 
but also, that the percentage of α1 clusters co-localised with gephyrin is increased 
amongst all α1 clusters in MSNs from 7 to 14 DIV. 
Figure 62. The percentage of α1 clusters co-localising with gephyrin is increased from 7 
to 14 DIV. The percentage of α1 clusters co-localising with gephyrin was estimated along the 20 
µm of primary dendrites in MSN cultures after 7 and 14 DIV. A. Histogram shows the 
distribution of the ratio of α1 containing GABAAR clusters co-localising with gephyrin amongst 
total α1 clusters (n=72 and n=65 dendrites, respectively, from two different experiments). B. 
Box-plot displays the median percentage (50 % of total population) of α1 clusters co-localised 
with gephyrin amongst total α1 clusters. Statistical analysis was performed using Mann Whitney 
test: * corresponds to p-value < 0.05. 
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The percentage of α2- containing GABAAR clusters overlapping with gephyrin 
amongst total α2 clusters per defined length of primary dendrite (the first 20 µm from 
the cell body) was calculated from 7 to 14 DIV (Figure 63). At 7 DIV, 33.33 (8.17-54.79) 
% of the total α2 clusters population was co-localised with gephyrin compared to 67.54 
(46.59-83.33) % at 14 DIV (p- value=1.74.10-8, Mann Whitney test; n=74 dendrites 
analysed in 7 DIV-cultured neurones, and n=68 dendrites analysed in 14 DIV-cultured 
neurones). Together with previous data, this shows that not only the density of α2 
clusters co-localising with gephyrin is increasing, but also, that the percentage of α2 
clusters co-localised with gephyrin is increased amongst all α2 clusters in MSNs from 7 
to 14 DIV. 
Figure 63. The percentage of α2 clusters co-localising with gephyrin is increased from 7 
to 14 DIV. The ratio of α2 clusters co-localising with gephyrin was estimated along the 20 µm of 
primary dendrites in MSN cultures after 7 and 14 DIV. A. Histogram shows the distribution of the 
ratio of α2 containing GABAAR clusters co-localising with gephyrin amongst total α2 clusters 
(n=74 and n=68 dendrites, respectively, from two different experiments). B. Box-plot displays 
the median percentage (50 % of total population) of α2 clusters co-localised with gephyrin 
amongst total α2. Statistical analysis was performed using Mann Whitney test: * corresponds to 
p-value < 0.05. 
 
The percentage of mixed α1/α2- containing GABAAR clusters overlapping with 
gephyrin amongst total mixed clusters per defined length of primary dendrite (the first 
20 µm from the cell body) was calculated from 7 to 14 DIV (Figure 64). At 7 DIV, 60 
(20-81.81) % of the total mixed clusters population were co-localised with gephyrin 
compared to 87.5 (61.15-100) % at 14 DIV (p- value=7.8.10-6, Mann Whitney test; n=71 
dendrites analysed in 7 DIV-treated cultures, and n=66 dendrites analysed in 14 DIV-
cultured neurones). Together with previous data, this shows that not only the density of 
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mixed clusters co-localising with gephyrin is increasing, but also, that the percentage of 
mixed clusters co-localised with gephyrin is increased amongst all mixed clusters in 
MSNs from 7 to 14 DIV. 
Figure 64. The percentage of mixed α1/α2 clusters co-localising with gephyrin is 
increased from 7 to 14 DIV. The percentage of mixed clusters co-localising with gephyrin was 
estimated along the 20 µm of primary dendrites in MSN cultures after 7 and 14 DIV. A. 
Histogram shows the distribution of the ratios of mixed α1/α2- containing GABAAR clusters co-
localising with gephyrin amongst total mixed clusters (n=71 and n=66 dendrites, respectively, 
from two different experiments). B. Box-plot displays the median ratio (50 % of total population) 
of mixed clusters co-localised with gephyrin amongst total mixed clusters. Statistical analysis 
was performed using Mann Whitney test: * corresponds to p-value < 0.05. 
 
 
Table 20. The percentage of all subtypes of GABAAR clusters co-localising with 
gephyrin is increased from 7 to 14 DIV 
percentage of GABAARs 
co-localising with gephyrin 
7 to 14 
DIV 
p < 0.05 
α1 clusters  Yes 
α2 clusters  Yes 
α1/α2 mixed clusters  Yes 
 
5.4 Discussion 
Synaptic plasticity is exhibited at both excitatory and inhibitory synapses; 
however the cellular and molecular mechanisms underlying inhibitory synaptic plasticity 
are more elusive than those regulating plasticity at excitatory synapses. In the central 
nervous system, fast inhibitory neuronal transmission is mainly mediated by GABAARs. 
Many studies support the fact that the density of synaptic receptor determines the 
strength of the GABAergic synaptic transmission (Bannai et al., 2009). Among other 
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factors, the membrane insertion or removal rate of GABAARs is now considered to be a 
major determinant in the regulation of the density of receptors at inhibitory synapses 
(Moss and Smart, 2001). Although the total density of receptors at the synapse plays a 
major role in determining the synaptic strength, the insertion and internalisation of 
GABAARs occur at the extrasynaptic sites (Bogdanov et al., 2006, Luo et al., 2013b, 
Fritschy and Panzanelli, 2014). Single particle tracking, pulse chase imaging and 
electrophysiology have revealed that the lateral diffusion between synaptic and 
extrasynaptic sites is the main mechanism involved in targeting of the receptor to 
synapses (Triller and Choquet, 2005, Bogdanov et al., 2006) .  
It is becoming increasingly clear that GABAAR α subunits not only influence 
GABAAR physiology, pharmacology, and biological function, but also mediate the 
synaptic and extrasynaptic localisation of these receptor subtypes via distinct protein-
protein interactions (Tretter et al., 2011). In this chapter, our aim was to investigate 
developmental changes of α1 and/or α2 containing GABAAR clusters in MSNs.  
The co-localisation of GABAAR subunits with the presynaptic marker GAD-65 or 
with the postsynaptic scaffolding protein gephyrin was explored in order to distinguish 
the synaptic clusters from the extrasynaptic clusters. By combining 
immunocytochemistry and confocal microscopy, we were able to establish that in 
developing GABAergic neurones, differential changes occur in α1-, α2-, or α1/2- 
GABAAR clusters. These results suggest that as MSNs mature in vitro¸ the overall 
density of synaptic contact is increased and the distribution of α1 and/or α2 containing 
clusters is modified throughout the development.  
Although the total density of α1-containing GABAAR (single and mixed) clusters 
was decreased, the density of synaptic α1-containing GABAAR clusters remained 
unchanged, suggesting that only the density of extrasynaptic α1-containing GABAARs 
was down regulated. This decrease in the density of extrasynaptic clusters may be the 
result of an increased internalisation from extrasynaptic pools as neurones mature in 
vitro, mediated by clathrin-dependent mechanism as it was shown in Kittler et al., 
α
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(Kittler et al., 2000). Additionally, the median size of synaptic α1 containing clusters (α1 
single) was decreased from 7 to 14 DIV. This could further support the down-regulation 
observed in the density of extrasynaptic clusters. To test this hypothesis, it would be 
interesting to test how the clathrin-dependent internalisation of α1-containing GABAARs 
is regulated during the development of MSNs in culture. 
 In contrast, while the density of α2-containing GABAAR clusters (synaptic or 
extrasynaptic) remained unchanged, their size was significantly increased as neuronal 
maturation progressed. Interestingly, our results suggest that maturing MSNs tend to 
favour the formation and stabilisation of predominantly α2-containing GABAAR clusters 
than the α1-containing GABAAR clusters. These results are in accordance with the 
distribution of GABAAR subunits in vivo in the adult striatum, in which the α2 subunit is 
more prominently present than the α1 subunit (Fritschy and Mohler, 1995).  
In these experiments, we have characterised subcellular distribution of GABAAR 
clusters along the first 20 μm of primary dendrites. Although the α2 subunits are also 
highly expressed in the axon initial segment (AIS) where axo-axonic interneurones 
make synapses (Kasugai et al., 2010), we focused our study on the subunit 
composition of the dendritic arborisation of MSNs. However, investigating the regional 
expression and clustering properties of GABAARs subunits in the AIS and more distal 
regions during development of MSNs would also be interesting. 
Our results show that the density of α1 and α2-containing synapses did not 
change during the development of MSNs in vitro, suggesting that the repartition of 
different synapses was already established at early developmental stage. However, 
remodelling of extrasynaptic sites was observed as the total density of α1-containing 
clusters decreased, suggesting that the density of α1-containing extrasynaptic sites 
was decreasing from 7 to 14 DIV. Although we did not directly compare the density of 
α1 clusters to the density of α2 clusters of GABAAR, the numbers indicated a higher 
density of α2-containing GABAAR clusters along dendrites. This is further supported by 
the in vivo study (Gross et al., 2011) in which it was demonstrated that while α1 subunit 
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expression is spread over the MSN cell body and processes, the density of the α2 
subunit is higher in the dendritic compartments.  
Interestingly, we observed an overall increase in the density of presynaptic 
inputs contacting primary dendrites although the density of synaptic clusters did not 
change. This could reflect an increase in newly formed synapses which either do not 
contain any GABAARs yet or contain another α subunit such as α3 or α5 subunits. 
In addition, we were interested in looking at the change in size of clusters. Our 
results indicated that most of the α2-containing GABAAR cluster (α2 single, α1/2 mixed, 
α2/1 mixed) sizes were increased in MSN synapses from 7 to 14 DIV, suggesting that 
the size of α2-containing clusters is more likely to play an important role in synapse 
maturation and maintenance than the density of clusters. 
 We established the development of GABAAR interacting proteins which also 
play an important role during GABAergic synapse formation. Therefore, we looked at 
how the postsynaptic scaffolding protein, gephyrin, clustered throughout the 
development of MSNs, given that gephyrin is known to bind α1, α2 and α3 subunits via 
their intracellular loops (Tretter et al., 2008, Mukherjee et al., 2011, Tretter et al., 2011). 
Although gephyrin-independent clustering also exists, it is mediated by radixin and it 
seems to play an important role in clustering of α5 subunits of GABAAR (Loebrich et al., 
2006). Thus, the main anchoring protein of GABAARs in our culture system is likely to 
be gephyrin.  
 Our data show that the density and the size of gephyrin clusters are increased 
as neurones mature in vitro. The co-localisation of gephyrin clusters with different 
subtypes of GABAARs was also established. Our results suggested that both the 
gephyrin clusters co-localising with α1 and/or α2-containing-GABAARs were increased 
in size and in density. Gephyrin clustering is essential to GABAARs clustering and is 
dependent on the subtype of GABAAR clusters (Tyagarajan and Fritschy, 2014). The 
specificity of gephyrin clustering was established in a series of studies in which knock 
outs (KO) of GABAAR subtype genes were carried out. In Gabra1 KO (encoding the 
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GABAAR α1 subunits), the gephyrin clustering was greatly reduced in Purkinje cells, 
while the α3/gephyrin co-localised clusters were sevenfold increased, suggesting a 
profound network reorganisation in absence of α1 subunit which could explain the 
moderate behavioural consequences observed (Kralic et al., 2006). In addition, knock 
out of gabra3 (encoding the GABAAR α3 subunit) revealed large aggregates of 
gephyrin localised at the cell surface, suggesting that GABAAR are required for 
gephyrin clustering and GABAergic synapse maintenance cells (Studer et al., 2006, 
Tyagarajan and Fritschy, 2014). Intriguingly, although gephyrin clustering is 
significantly reduced in CA1 pyramidal cells of Gabra2 KO mouse, α1-containing 
clusters appear normal (Tyagarajan and Fritschy, 2014). Thus, postsynaptic clustering 
of gephyrin at GABAergic synapses depends on interactions between gephyrin and 
different subtypes of GABAARs, which suggests that these receptors have a 
fundamental role in determining the molecular composition and function of the 
postsynaptic membrane.   
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6. The regulation of GABAergic synapse formation by GABA signalling 
6.1 Introduction 
 Medium spiny neurones (MSNs) are the main neuronal type present in the 
striatum, representing 95 % of the total neuronal population. They are the principal 
output neurones of the striatum and also the sites receiving cortical inputs. Thus, they 
play a crucial role in the input-output operations of the striatum (Bolam et al., 2000). 
These neurones, not only project to other basal ganglia nuclei, but also communicate 
with each other by an extensive local plexus of axon collateral branches (Wilson and 
Groves, 1980). Until recently, there was no direct physiological evidence for functional 
inhibitory interactions between spiny neurones projections. However, simultaneous 
intracellular recordings from pairs of spiny projection neurones revealed that GABAAR-
mediated synaptic connections existed between striatal spiny projection neurones 
(Tunstall et al., 2002). Further characterisation of this network provided evidence that 
MSNs projecting in the globus pallidus of the behaving rat, fired tens of action 
potentials (APs) per second (Benhamou et al., 2012). More interestingly, although this 
was a low firing frequency at which short term depression would be almost complete, 
this sparse and synaptically depressed network can significantly affect postsynaptic 
firing patterns in vitro (Bugaysen et al., 2013). Thus, for the first time, it has been 
shown that the unitary GABAergic synapses composing this network of MSN axon 
collaterals play an important role in the information processing within the striatum. 
However, the extent of collateral inhibition is a matter of debate as it is believed that in 
the striatum, most of the inhibition is mediated by fast spiking interneurones (Planert et 
al., 2010). 
 In the previous chapter, we investigated the development of cultured embryonic 
MSNs and the characteristics of specific GABAergic synapse formation. In this culture 
system, the MSNs compose a network of axon collateral inhibitory connections which 
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are also predominant throughout the different nuclei composing the basal ganglia 
(Tunstall et al., 2002).  
 Understanding the functionality of such network and the role played by GABAAR 
activity in transducing the GABA signalling during GABAergic synapse formation, is of 
crucial importance if we are to understand how this network is established. The effects 
of neuronal activity during GABAergic synapse formation has been a matter of debate 
for some time. To investigate the role played by neuronal activity during GABAergic 
synapse formation, mature hippocampal neuron cultures (14-21 DIV) were treated with 
tetrodotoxin (TTX) to block synaptic activity non-selectively (Penschuck et al., 1999). 
This treatment resulted in a loss of 30 % of the α1, α2 and γ2 subunit immunoreactivity 
after 1- and 12-hours treatment and induced the GABAAR subunit staining to vanish 
from the cell surface. This result provided one of the first pieces of evidence that 
neuronal activity regulated the cell surface expression of GABAARs but was not playing 
a prominent role in the establishment of neuron-specific expression patterns of 
GABAAR subtypes in the developing brain.  
 This result was further emphasised when hippocampal neurones treated with 
TTX during the period of synaptogenesis resulted in a reduction in the number of 
GABAergic presynaptic terminals and of the efficacy of these synapses (Hartman et al., 
2006). This reduction in GABAergic synapse number was visible within 5 days after 
activity suppression, suggesting a general retardation of the GABAergic 
synaptogenesis provoked by the blockade of neuronal activity. Interestingly, the 
reduction in synapse number was accompanied by a reduction in the amplitude and the 
frequency of mIPSCs. 
 This was further supported when it was shown that excitatory neuronal activity 
controls the amount of GABAARs at inhibitory synapses by regulation of their synaptic 
accumulation and diffusion dynamics (Bannai et al., 2009). In this paper, the increase 
of excitation reduced the size of synaptic GABAAR clusters and depolarising currents 
decreased mIPSC amplitude. Although this paper might appear contradictory to the 
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previous ones, it could also reveal an antihomeostatic regulation of excitation-inhibition 
which, if altered, is involved in pathological conditions such as status epilepticus 
(Bannai et al., 2009).    
 In addition, slices from P7 rat hippocampus were cultured by Marty and 
colleagues for 13 days in the presence of bicuculline to increase neuronal activity, or 
DNQX, to decrease neuronal activity (Marty et al., 2004). While an increase in activity 
produced an augmentation of the density of individual α1 or α2-containing GABAAR 
clusters, a decrease in neuronal activity triggered in contrast, a decrease in the density 
of these receptors. Interestingly, the size of the clusters was inversely regulated, with 
bicuculline decreasing the size of the clusters and DNQX increasing it. These results 
indicated that in the hippocampus, neuronal activity regulates the mean size of 
GABAARs and gephyrin-immunoreactive clusters by modifying specifically the density 
of synapses containing small clusters of receptors (Marty et al., 2004). Finally, this was 
confirmed when an increase in the amplitude and frequency of mIPSCs, accompanied 
by an increase in the size of γ2 subunit clusters and of GAD-65 puncta, were observed 
when hippocampal cultures were exposed to depolarising conditions (Rannals and 
Kapur, 2011).  
 Although many studies have shown the role played by neuronal activity during 
GABAergic synapse formation and in homeostatic regulation of networks, the role of 
GABAAR activity during GABAergic synapse formation has never been studied in the 
context of purely GABAergic systems.  
 Towards this aim, we utilised the model system  of embryonic striatal cultures 
(described in the previous chapter) and treated MSNs with bicuculline which is a 
competitive GABA antagonist but is also classified as an allosteric inhibitor of 
GABAARs (Birnir et al., 2000).  
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6.1.1 Aims  
In this chapter, our aims were:  
1. To determine if GABA signalling regulates the pattern of expression of different 
subtypes of receptors during the establishment and maintenance of the 
GABAergic synapses, by analysing the size and density of GABAAR clusters 
containing α1 and/or α2 subunit in presence and absence of bicuculline.  
2. To establish whether these changes were accompanied by modifications of the 
connectivity between MSNs and in gephyrin clustering. 
6.2 Methods 
6.2.1 Primary cultures of medium spiny neurones 
Striatal cultures were prepared as described in Chapter 2, Section 2.1.  
6.2.2 Treatments with bicuculline 
To analyse the role of GABA signalling during GABAergic synapse development, E17 
striatal neurones were cultured and treated with control (DMSO) or 50 μM bicuculline 
after 4 and 6 DIV and fixed at 7 DIV. Another batch of neurones were treated with the 
same concentration of bicuculline after 7, 9 and 11 DIV and fixed at 14 DIV. The same 
time points were used to treat medium spiny neurone cultures with 25 µM bicuculline.  
6.2.3 Immunocytochemistry 
Immunocytochemistry was performed as described in Chapter 2, section 2.2. 
Neurones cultured for 7 or 14 DIV, were fixed using 4 % PFA/ sucrose for 12 minutes 
at room temperature. After fixation, they were incubated with glycine (0.3 M) in PBS, in 
order to quench PFA. After washing in PBS, cells were incubated in 1 % BSA in PBS 
for 1 hour and subsequently incubated with anti- α1 and anti- α2 antibodies, specifically 
binding to their N-terminal extracellular domains, diluted in 1 % BSA in PBS overnight 
(14-16 hours) at 4 °C (Table 21). Cultures were then permeabilised by incubating with 
1 % BSA, 0.5 % Triton X-100 in PBS for 15 minutes. Neurones were subsequently 
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incubated with GAD-65 and MAP-2 (Table 21) antibodies diluted in 1 % BSA in PBS for 
2 hours at room temperature. Following this step, Alexa Fluor-conjugated secondary 
antibodies were added as described in Chapter 2, Section 2.2 (antibodies used in 
these experiments are described in the Table 21). 
6.2.4 Analysis of images using confocal microscopy 
Immunolabelling was analysed using Zeiss LSM 710 with a Plan-Apochromat 
63x/1.4 Oil DIC lens. Threshold for each channel was calculated from the background 
staining intensity and then removed from the image.   
6.2.4.1 Analysis of bicuculline treatment on cell survival  
In order to know if bicuculline had an effect on cell survival, we counted the 
density of cells per image after treatment with 50 or 25 µM bicuculline from 4 to 7 DIV 
and from 7 to 14 DIV. Tile-scan (large field) images (3072 x 2048 pixels) were taken 
using confocal microscopy. Subsequently, the density of cells per image was counted 
using merge staining and statistical analysis was performed 
6.2.4.2 Confocal analysis 
To establish the density and size of α1- and α2- containing GABAA receptor 
clusters along the 20 μm of each primary dendrite, puncta were defined as 
immunoreactive profiles greater than 0.1 μm2, with the mean intensity of each cluster 
equal or higher than double the standard deviation of intensity which was indicated by 
the Zen 2009 Programme. The defined clusters were encircled and their properties 
noted by hand. For each condition, the density and size of α1 clusters were first 
calculated, followed by the α2 clusters. Then, α1 clusters which were mixed with α2 
(minimum of 50 % overlapping) were separated from α1 clusters and analysed as a 
separate group. The same process was applied for α2 mixed clusters. Because the 
density of α1 and α2 clusters was different among mixed clusters, these populations 
were kept and analysed separately, although in most of the cases, they represented 
the same population of mixed clusters.  
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6.2.4.3 Analysis of synaptic parameters 
As a criterion for synaptically localised clusters, I determined whether these 
clusters were in close apposition to the presynaptic marker GAD-65. A minimum of 50 
% overlap was used to estimate the close apposition between the postsynaptic clusters 
and the presynaptic GAD-65 positive terminals. The total density of GAD-65 
immunoreactive puncta forming contacts along the first 20 μm length of primary 
dendrites was counted to determine the density of presynaptic inputs per dendrite 
6.2.5 Statistical analysis 
Once all the parameters for each condition were measured, they were copied 
into an Excel file and sorted into different groups according to their size, co-localisation 
with GAD-65 and kind, single or mixed clusters:  
- All α1 single clusters  
- α1 single clusters which are co-localised with GAD-65 
- All α2 single clusters  
- α2 single clusters which are co-localised with GAD-65 
- All α1 mixed clusters  
- α1 mixed clusters which are co-localised with GAD-65 
- All α2 mixed clusters 
- α2 mixed clusters which are co-localised with GAD-65 
Subsequently, the data were statistically analysed using Origin Pro 9.0 32 Bit software. 
Normality tests were performed first using Shapiro-Wilk and Kolmogorov-Smirnov tests. 
After normality tests were performed on each of the groups, non parametric statistical 
analysis was executed on unpaired data as the groups were not normally distributed 
(non- Gaussian distribution) and independent. The most adapted test to use was Mann 
Whitney test performed with an interval of confidence of 95 %. Because they are robust 
measure of central tendency when distributions are not normally distributed, medians 
and their interquartile range (IQR) were used to describe the data and evaluate 
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statistical dispersion. Similar approach was used to analyse the density of presynaptic 
terminals forming contacts along the first 20 μm of primary dendrites. After normality 
tests were performed, Mann-Whitney test was used to evaluate if the density of 
presynaptic terminals per dendrite was changing after bicuculline treatment compared 
to DMSO. The total density of clusters was evaluated along the 20 µM of primary 
dendrite of each cells. The density of synaptic clusters was also evaluated for the same 
dendrite. The percentage of synaptic clusters was determined by the proportion of 
synaptic clusters as a percentage of the total clusters for each dendrite. The new 
populations (% of synaptic clusters/total) were tested for normality and subsequently 
compared using parametric (Student’s t-test) or non-parametric statistical tests (Mann-
Whitney). 
Table21. Antibodies used for immunocytochemistry performed on medium spiny 
neurone cultures 
 
 
 
 
 
 
 
 
primary antibodies secondary antibodies 
specificity origin dilutions 
source and 
characterisation 
antibodies 
dilution
s 
source 
GABAAα1 Rabbit 1:200 
Duggan, MJ, 
Stephenson 
AF., 1990.     J 
Biol Chem 
Goat anti 
rabbit 405 
1:750 
Alexa Fluor 
Invitrogen 
a31556 
GABAAα2 
Guinea-
pig 
1:400 
Synaptic 
System 224104 
Goat Anti 
guinea pig 
488 
1:750 
Alexa Fluor 
Invitrogen 
a11073 
GAD65 Mouse 1:4000 
Abcam, 
ab26113 
Goat anti 
mouse 555 
1:750 
Alexa Fluor 
Invitrogen 
a21422 
MAP2 Chicken 1:2500 
Abcam, 
ab92434 
Goat Anti 
chicken 488 
1:750 
Alexa Fluor 
Invitrogen 
a11039 
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6.3 Results 
6.3.1 Treatment of MSN cultures with bicuculline from 4 -7 DIV 
6.3.1.1 Treatment of medium spiny neurones with 50 µM bicuculline 
from 4 to 7 DIV provoked cell death 
Cultured embryonic (E16-18) striatal neurones form an homogeneous 
population of the precursors of GABAergic medium spiny neurones (Goffin et al., 
2010). In the previous chapter, we were interested in how specific α1- and α2-
containing synapses are established during GABAergic synapse development. In the 
present chapter, we investigated if activity of GABAA receptors influenced the proper 
positioning and the assembly of different types of inhibitory synapses. To investigate 
this, we have suppressed the GABAA receptor activity in the medium spiny neurone 
cultures using a competitive antagonist bicuculline over two periods of time. We have 
chronically treated medium spiny neurones with 50 or 25 μM bicuculline from 4 to 7 
days in vitro (DIV). As a control, we have treated neurones at the same period of time 
with an equivalent amount of DMSO (dimethyl sulfoxide), a polar solvent in which 
bicuculline was initially prepared in. Figure 65 is a large field image of medium spiny 
neurones treated from 4 to 7 DIV with 50 μM bicuculline or DMSO. This figure shows 
examples of staining for α1 and α2 extracellular domains of GABAARs subunits, the 
intracellular presynaptic marker GAD-65 and MAP-, using the antibodies described in 
Table 19. The total density of cells per image was counted using the Zen 2009 
programme. Figure 66 is a large field image of medium spiny neurones treated from 7 
to 14 DIV with 50 μM bicuculline or DMSO. These figures show examples of staining 
for α1 and α2 extracellular domains of GABAARs subunits, the intracellular presynaptic 
marker GAD-65 and MAP-, using the antibodies described in Table 19. The total 
density of cells per image was counted using the Zen 2009 programme. 
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 Figure 65. The density of cells is decreasing with 50 μM bicuculline treatment from 4 
to 7 DIV compared to DMSO. Immunolabelling of GABAA receptors α1, α2 subunit 
containing clusters (respectively cyan and green) and presynaptic GABAergic terminals 
(red) along primary dendrites (blue) of cultured medium spiny neurones. A. Merged tile-
scan image of a 7 DIV striatal culture treated with DMSO. B. Enlarged image of boxed 
region in A. C. Merged tile-scan image of a 7 DIV striatal culture treated with 50 µM 
bicuculline D. Enlarged image of boxed region in C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 DIV 50 µM BIC
7 DIV DMSO
A
B
C
D
a2 GAD 65 MAP2a1
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Figure 66. The density of cells is not affected by 25 μM bicuculline treatment from 4 to 7 
DIV compared to DMSO. Immunolabelling of GABAA receptors α1, α2 subunit containing 
clusters (respectively cyan and green) and presynaptic GABAergic terminals (red) along primary 
dendrites (blue) of cultured medium spiny neurones. A. Merged tile-scan image of a 7 DIV 
striatal culture treated with DMSO. B. Enlarged image of boxed region in A. C. Merged tile-scan 
image of a 7 DIV striatal culture treated with 25 µM bicuculline D. Enlarged image of boxed 
region in C.  
 
The median density of cells per image was estimated after treatment with 50 μM 
bicuculline or control (Figure 67). At 7 DIV, the median density of cells per image was 
12 (9-58) with control treatment compared to 6 (9-13) with 50 μM bicuculline treatment 
(p value < 0.05, Mann Whitney test, n=15 images analysed with control or bicuculline 
treatment at 7 DIV). This demonstrates that the density of cells is significantly 
decreased by 50 µM bicuculline treatment compared to DMSO from 4 to 7 DIV. 
7 DIV DMSO
7 DIV 25 µM BIC
A
B
C
D
α2 GAD 65 MAP2α1
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Figure 67. The density of cells per image is significantly decreased after treatment with 
50 μM bicuculline from 4 to 7 DIV. The density of medium spiny neurones per tile scan 
images was counted in presence of DMSO or 50 μM bicuculline from 4-7 DIV. A. Histogram 
shows the distribution of the density of cells per image in presence of  DMSO or 50 μM 
bicuculline added at 4 and 6 DIV (n=15 images analysed respectively, from two independent 
experiments). B. The box plot displays the density of cells per image in presence of DMSO or 
50 μM bicuculline added at 4 and 6 DIV. Statistical analysis was performed using Mann Whitney 
test: * corresponds to p-value <0.05. 
 
The median density of cells per image was estimated after treatment with 25 μM 
bicuculline or control (Figure 68). At 7 DIV, the median density of cells per image was 
25 (16.75-30) with control treatment compared to 20 (15-27) with 25 μM bicuculline 
treatment. (p value > 0.05, Mann Whitney test, n=12 images of control-treated 
neurones analysed; n=11 images of bicuculline-treated neurones analysed). This 
demonstrates that the density of cells is not affected by 25 µM bicuculline compared to 
DMSO treatment from 4 to 7 DIV. 
 
Figure 68. The density of cells per image is not changing after treatment with 25 μM 
bicuculline from 4 to 7 DIV. The density of medium spiny neurones per tile scan images was 
counted in presence of DMSO or 25 μM bicuculline from 4-7 DIV. A. Histogram shows the 
distribution of the density of cells per image in presence of DMSO or 25 μM bicuculline added at 
4 and 6 DIV (n=12 and n=11 images analysed respectively, from two independent experiments). 
B. The box plot displays the density of cells per image in presence of DMSO or 25 μM 
bicuculline added at 4 and 6 DIV. Statistical analysis was performed using Mann Whitney test. 
A B
A B
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6.3.1.2 The density of GABAARs per dendrite was not affected after 25 
μM bicuculline treatment from 4 to 7 DIV.  
Developing medium spiny neurones treated with 25 μM bicuculline did not change the 
density of α1 single, α2 single, α1 mixed and α2 mixed clusters of GABAARs from 4 to 
7 days in culture (DIV).  
Figure 69, 70 and 71 represent medium spiny neurones treated from 4 to 7 DIV 
with 25 μM bicuculline or DMSO. This figure shows examples of staining for α1 and α2 
extracellular domains of GABAARs subunits, the intracellular presynaptic marker GAD-
65 and MAP-, using the antibodies described in Table 21. The total density of cells per 
image was counted using the Zen 2009 programme. 
 
Figure 69. The density of α1 clusters is not affected by the 25 µM bicuculline treatment. 
Immunolabelling of GABAARs α1 subunit-containing clusters (cyan) and presynaptic GABAergic 
terminals (red) along primary dendrites (blue) of cultured medium spiny neurones. A. Merged 
image of a 7 DIV striatal neurone treated with DMSO (scale bar: 10 μm). B.(i) Enlarged image 
of boxed region in A representing α1 staining only. (ii) Analysis of image B(i) in which all α1 
clusters are circled in red. (iii) Analysis of image B(i) in which only α1 single clusters that are not 
associated with α2 clusters are circled in red (scale bar: 5 μm). C.(i) Enlarged image of boxed 
D E F
7DIV BIC (i) (i)
(ii) (ii)
(iii) (iii)
A B
(i)
C
(i)
(ii) (ii)
7DIV DMSO
(iii) (iii)GAD 65 MAP2α1
α1 α1/ GAD-65 
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region in A representing α1 positive clusters and presynaptic GAD-65 positive nerve terminals. 
(ii) Analysis of image C(i) in which all α1 clusters were circled in red and presynaptic terminals 
were circled in purple. (iii) Analysis of image C(i) in which only α1 single clusters were circled in 
red and presynaptic terminals were circled in purple (scale bar: 5 μm). D. Merged image of a 14 
DIV striatal neurone (scale bar: 10 μm). E.(i) Enlarged image of boxed region in D representing 
α1 staining only. (ii) Analysis of image E(i) in which all α1 clusters are circled in red. (iii) 
Analysis of image E(i) in which only α1 single clusters that are not associated with α2 clusters 
are circled in red (scale bar: 5 μm). F.(i) Enlarged image of boxed region in D representing α1 
positive clusters and presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image F(i) in 
which all α1 clusters were circled in red and presynaptic terminals were circled in purple. (iii) 
Analysis of image F(i) in which only α1 single clusters were circled in red and presynaptic 
terminals were circled in purple (scale bar: 5 μm).  
 
Figure 70. The density of α2 clusters is not affected by the 25 µM bicuculline treatment. 
Immunolabelling of GABAARs α2 subunit-containing clusters (green) and presynaptic 
GABAergic terminals (red) along primary dendrites (blue) of cultured medium spiny neurones. 
A. Merged image of a 7 DIV striatal neurone treated with DMSO (scale bar: 10 μm). B.(i) 
Enlarged image of boxed region in A representing α2 staining only. (ii) Analysis of image B(i) in 
which all α2 clusters are circled in yellow. (iii) Analysis of image B(i) in which only α2 single 
clusters that are not associated with α1 clusters are circled in yellow (scale bar: 5 μm). C.(i) 
Enlarged image of boxed region in A representing α2 positive clusters and presynaptic GAD-65 
positive nerve terminals. (ii) Analysis of image C(i) in which all α2 clusters were circled in yellow 
and presynaptic terminals were circled in purple. (iii) Analysis of image C(i) in which only α2 
single clusters were circled in yellow and presynaptic terminals were circled in purple (scale bar: 
5 μm). D. Merged image of a 14 DIV striatal neurone (scale bar: 10 μm). E.(i) Enlarged image of 
boxed region in D representing α2 staining only. (ii) Analysis of image E(i) in which all α2 
clusters are circled in yellow. (iii) Analysis of image E(i) in which only α2 single clusters that are 
A B C
(i) (i)
(ii) (ii)
(iii) (iii)
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α2 GAD 65 MAP2
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not associated with α1 clusters are circled in yellow (scale bar: 5 μm). F.(i) Enlarged image of 
boxed region in D representing α2 positive clusters and presynaptic GAD-65 positive nerve 
terminals. (ii) Analysis of image F(i) in which all α2 clusters were circled in yellow and 
presynaptic terminals were circled in purple. (iii) Analysis of image F(i) in which only α2 single 
clusters were circled in yellow and presynaptic terminals were circled in purple (scale bar: 5 
μm).  
Figure 71. The density of α1/α2 mixed clusters is not affected by the 25 µM bicuculline 
treatment. Immunolabelling of GABAARs α1/α2 subunit-containing clusters (cyan and green) 
and presynaptic GABAergic terminals (red) along primary dendrites (blue) of cultured medium 
spiny neurones. A. Merged image of a 7 DIV striatal neurone treated with DMSO (scale bar: 10 
μm). B.(i) Enlarged image of boxed region in A representing α1 and α2 staining. (ii) Analysis of 
image B(i) in which all α1 and α2 clusters are respectively circled in red and yellow (scale bar: 5 
μm). C.(i) Enlarged image of boxed region in A representing α1, α2 positive clusters and 
presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image C(i) in which all α1 and α2 
clusters were respectively circled in red and yellow and presynaptic terminals were circled in 
purple. D. Merged image of a 14 DIV striatal neurone (scale bar: 10 μm). E.(i) Enlarged image 
of boxed region in D representing α1 and α2 staining. (ii) Analysis of image E(i) in which all α1 
and α2 clusters were respectively circled in red and yellow (scale bar: 5 μm). F.(i) Enlarged 
image of boxed region in D representing α1, α2 positive clusters and presynaptic GAD-65 
positive nerve terminals. (ii) Analysis of image F(i) in which all α1 and α2 clusters were 
respectively circled in red and yellow and presynaptic terminals were circled in purple (scale 
bar: 5 μm).  
 
The density of synaptic and total α1 single clusters of GABAARs was estimated 
per defined length of primary dendrite (the first 20 µm from the cell body) after 
treatment with DMSO or 25 μM bicuculline from 4 to 7 DIV (Figure 72). The median 
density of synaptic α1 single clusters was 3 (7-1) with DMSO treatment, compared to 
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4.5 (9.25-2) with bicuculline treatment (p value =0.09, Mann Whitney test, n=49 
dendrites analysed from DMSO treated cultures and n=46 dendrites analysed from 
bicuculline treated neurones). Similarly, the median density of total α1 single clusters 
was 14 (20.5-8) with DMSO treatment, compared to 13.5 (24-8.75) with bicuculline 
treatment (p value=0.47, Mann Whitney test, n=49 dendrites analysed from DMSO 
treated cultures and n=46 dendrites analysed from bicuculline treated neurones). This 
demonstrates that the synaptic and total densities of α1 single clusters are not affected 
by the treatment, indicating that the regulation of the density of these types of clusters 
is independent of GABAAR activity at this developmental stage.  
Figure 72. The density of synaptic and total α1 clusters is not affected by treatment with 
25 µM bicuculline. The density of α1- containing GABAA receptors clusters (α1 single clusters) 
along the 20 μm of primary dendrite was counted in medium spiny neurone cultures in presence 
of DMSO or 25 μM bicuculline from 4 to 7 DIV. A. Histogram shows the distribution of synaptic 
α1 single clusters densities in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV (n=49 
and n=46 dendrites respectively from two independent experiments). B. box plot displays the 
median density (50 % of the population) of synaptic α1 single clusters in presence of DMSO or 
25 μM bicuculline from 4 to 7 DIV. C. Histogram shows the distribution of total α1 single clusters 
density in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV (n=49 and n=46 dendrites 
respectively from two independent experiments). D. Box plot displays the median density (50 % 
of the population) of total α1 single clusters in presence of DMSO or 25 μM bicuculline from 4 to 
7 DIV. Statistical analysis was performed using Mann Whitney test. 
 
We were also interested to analyse the density of α2 single clusters in presence of 
DMSO or 25 µM bicuculline from 4 to 7 DIV. The density of synaptic and total α2 single 
clusters of GABAARs was estimated per defined length of primary dendrite (the first 20 
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µm from the cell body) after treatment with DMSO or 25 μM bicuculline (Figure 73). The 
median density of synaptic α2 single clusters was 5 (11-2) with DMSO treatment, 
compared to 5 (10.5-3) with bicuculline treatment (p value=0.60, Mann Whitney test, 
n=49 dendrites analysed from DMSO treated cultures and n=49 dendrites analysed 
from bicuculline treated neurones). Similarly, the median density of total α2 single 
clusters was 19 (27-9) with DMSO treatment, compared to 21 (30.5-11.5) with 
bicuculline treatment (p value=0.18, Mann Whitney test, n=49 dendrites analysed from 
DMSO treated cultures and n=49 dendrites analysed from bicuculline treated 
neurones). This demonstrates that similarly to α1 single clusters, the synaptic and total 
densities of α2 single clusters are not affected by the treatment, indicating that the 
regulation of the density of these types of clusters is independent of GABAAR activity at 
this developmental stage.  
Figure 73. The density of synaptic and total α2 clusters is not affected by treatment with 
25 µM bicuculline. The density of α2- containing GABAA receptors clusters (α2 single clusters) 
along the 20 μm of primary dendrite was counted in medium spiny neurone cultures in presence 
of DMSO or 25 μM bicuculline from 4 to 7 DIV. A. Histogram shows the distribution of synaptic 
α2 single clusters densities in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV (n=49 
and n=46 dendrites respectively from two independent experiments). B. box plot displays the 
median density (50 % of the population) of synaptic α2 single clusters in presence of DMSO or 
25 μM bicuculline from 4 to 7 DIV. C. Histogram shows the distribution of total α2 single clusters 
density in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV (n=49 and n=46 dendrites 
respectively from two independent experiments). D. Box plot displays the median density (50 % 
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of the population) of total α2 single clusters in presence of DMSO or 25 μM bicuculline from 4 to 
7 DIV. Statistical analysis was performed using Mann Whitney test. 
 
As explained in the previous chapter, we have observed two types of α1/α2 mixed 
clusters. The mixed clusters which contained a majority of α1 clusters were defined as 
α1 mixed clusters while the mixed clusters containing a majority of α2 clusters were 
defined as α2 mixed clusters. The density of synaptic and total α1 mixed clusters of 
GABAARs was estimated per defined length of primary dendrite (the first 20 µm
 from 
the cell body) after treatment with DMSO or 25 μM bicuculline from 4 to 7 DIV (Figure 
74). The median density of synaptic α1 mixed clusters was 3 (8.5-0) with DMSO 
treatment, compared to 3.5 (7-0) with bicuculline treatment (p value=0.79, Mann 
Whitney test, n=49 dendrites analysed from DMSO treated cultures and n=46 dendrites 
analysed from bicuculline treated neurones). Similarly, the median density of total α1 
mixed clusters was 7 (14.5-0) with DMSO treatment, compared to 7 (16-0) with 
bicuculline treatment (p value=0.93, Mann Whitney test, n=49 dendrites analysed from 
DMSO treated cultures and n=46 dendrites analysed from bicuculline treated 
neurones). This demonstrates that the synaptic and total densities of α1 mixed clusters 
are not affected by the treatment, indicating that the regulation of the density of these 
types of clusters is independent of the GABAARs activity at this developmental stage.  
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Figure 74. The density of synaptic and total α1 clusters is not affected by  treatment with 
25 µM bicuculline. The density of α1/α2- containing GABAA receptors clusters (α1 mixed 
clusters) along the 20 μm of primary dendrite was counted in medium spiny neurone cultures in 
presence of DMSO or 25 μM bicuculline from 4 to 7 DIV. A. Histogram shows the distribution of 
synaptic α1 mixed clusters densities in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV 
(n=49 and n=46 dendrites respectively from two independent experiments). B. box plot displays 
the median density (50 % of the population) of synaptic α1 mixed clusters in presence of DMSO 
or 25 μM bicuculline from 4 to 7 DIV. C. Histogram shows the distribution of total α1 mixed 
clusters density in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV (n=49 and n=46 
dendrites respectively from two independent experiments). D. Box plot displays the median 
density (50 % of the population) of total α1 mixed clusters in presence of DMSO or 25 μM 
bicuculline from 4 to 7 DIV. Statistical analysis was performed using Mann Whitney test. 
 
We have also analysed the population of mixed clusters which contained a 
predominant density of α2 clusters (α2 mixed). The density of synaptic and total α2 
mixed clusters of GABAARs was estimated per defined length of primary dendrite (the 
first 20 µm from the cell body) after treatment with DMSO or 25 μM bicuculline from 4 to 
7 DIV (Figure 75). The median density of synaptic α2 mixed clusters was 5 (8.5-2) with 
DMSO treatment, compared to 5 (8.5-2) with bicuculline treatment (p value=0.71, Mann 
Whitney test, n=49 dendrites analysed from DMSO treated cultures and n=49 dendrites 
analysed from bicuculline treated neurones). Similarly, the median density of total α2 
mixed clusters was 9 (14.5-5) with DMSO treatment, compared to 9 (16-5) with 
bicuculline treatment (p value=0.92, Mann Whitney test, n=49 dendrites analysed from 
DMSO treated cultures and n=49 dendrites analysed from bicuculline treated 
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neurones). This demonstrates that the synaptic and total densities of α2 mixed clusters 
are not affected by the treatment, indicating that the regulation of the density of these 
types of clusters is independent of the GABAARs activity at this developmental stage.  
Figure 75.The densities of synaptic and total α2 clusters are not affected by treatment 
with 25 µM bicuculline. The density of α1/α2- containing GABAA receptors clusters (α2 mixed 
clusters) along the 20 μm of primary dendrite was counted in medium spiny neurone cultures in 
presence of DMSO or 25 μM bicuculline from 4 to 7 DIV. A. Histogram shows the distribution of 
synaptic α2 mixed clusters densities in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV 
(n=49 and n=49 dendrites respectively from two independent experiments). B. box plot displays 
the median density (50 % of the population) of synaptic α2 mixed clusters in presence of DMSO 
or 25 μM bicuculline from 4 to 7 DIV. C. Histogram shows the distribution of total α2 mixed 
clusters density in presence of DMSO or 25 μM bicuculline from 4 to 7 DIV (n=49 and n=46 
dendrites respectively from two independent experiments). D. Box plot displays the median 
density (50 % of the population) of total α2 mixed clusters in presence of DMSO or 25 μM 
bicuculline from 4 to 7 DIV. Statistical analysis was performed using Mann Whitney test.  
 
Table 22. The density of GABAAR clusters is not affected by 25 µM treatment 
from 4 to 7 DIV 
Density of clusters 
7 DIV  
DMSO/ BIC 
Significant 
α1 single clusters 
Synaptic 
 
No  
Total 
 
No  
α2 single clusters 
Synaptic 
 
No  
Total 
 
No 
αl mixed clusters 
 
Synaptic 
 
No  
Total 
 
No  
α2 mixed clusters 
Synaptic 
 
No  
Total 
 
No  
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6.3.1.3 The proportion of synaptic clusters as a percentage of  the 
total clusters was not affected by 25 µM bicuculline treatment from 4 
to 7 DIV  
Despite the fact that the densities of all types of clusters were not affected by the 
treatment, we analysed further these changes in cluster populations. We estimated the 
proportion of synaptic clusters as a percentage of the total clusters in each population 
treated from 4 to 7 DIV. The proportion of synaptic α1 single as a percentage of the 
total α1 single clusters of GABAARs per defined length of primary dendrite (the first 20 
μm from the cell body) was calculated after treatment from 4 to 7 DIV (Figure 76). The 
median percentage of synaptic amongst total α1 single clusters was 16.66 (10.10-
33.33) % with DMSO treatment compared to 24.06 (16.03-30.88) % with bicuculline 
treatment ((p value=0.15, Mann Whitney test, n=49 dendrites analysed after DMSO 
treatment and n=46 dendrites analysed after bicuculline treatment). Similarly to the 
density of synaptic α1 single clusters per dendrite, the percentage between the 
synaptic and the total α1 single clusters is not altered by bicuculline (Table 23).   
Figure 76. The percentage of synaptic/total α1 single clusters is not changed after 
treatment with 25 µM bicuculline from 4 to 7 DIV. The percentage of synaptic α1 single 
clusters amongst the total population of α1 single clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
4 to 7 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α1 single 
clusters per dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV  (n=49 and 
n=46 dendrites respectively, from two independent experiments). B. Box-plot displays the 
median percentage (50 % of the represented population) of synaptic/total α1 single clusters per 
dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV. Statistical analysis was 
performed using Mann- Whitney test. 
In addition, the proportion of synaptic α2 single as a percentage of the total α2 single 
clusters of GABAARs per defined length of primary dendrite was calculated after 
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treatment with DMSO or 25 µM bicuculline (Figure 77). After treatment with DMSO 
from 4 to 7 DIV, the median percentage of synaptic/total α2 single clusters was 24.62 
(31.31-11.45) % compared to 22.72 (32.92-11.26) % after treatment with bicuculline (p 
value=0.93, Mann Whitney test, n=48 dendrites analysed after treatment with DMSO 
and n=49 dendrites analysed after treatment with 25 µM bicuculline). This indicates 
that, similarly to the density of synaptic α2 single clusters per dendrite, the percentage 
of α2 single clusters/total density of clusters is not changing with 25 µM treatment of 
bicuculline. 
 Figure 77. The percentage of synaptic/total α2 single clusters is not changed after 
treatment with 25 µM bicuculline from 4 to 7 DIV. The percentage of synaptic α2 single 
clusters amongst the total population of α2 single clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
4 to 7 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α2 single 
clusters per dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV  (n=48 and 
n=49 dendrites respectively, from two independent experiments). B. Box-plot displays the 
median percentage (50 % of the represented population) of synaptic/total α2 single clusters per 
dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV. Statistical analysis was 
performed using Mann- Whitney test. 
 
Following the previous analysis, we analysed changes in the proportion of synaptic 
mixed clusters as a percentage of total mixed clusters during medium spiny neurones 
development. ). The proportion of synaptic α1 mixed as a percentage of the total α1 
mixed clusters of GABAARs per defined length of primary dendrite (the first 20 µm
 from 
the cell body) was calculated after treatment with DMSO or 25 µM bicuculline (Figure 
78). After treatment with DMSO from 4 to 7 DIV, the median percentage of 
synaptic/total α1 mixed clusters was 45.52 (39.09-60) % after treatment with DMSO 
compared to 41.98 (32.33-41.98) % after treatment with 25 µM bicuculline (p 
value=0.43, Mann Whitney test, n=34 dendrites analysed after treatment with DMSO 
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and n=32 dendrites analysed after treatment with 25 µM bicuculline). This 
demonstrates that, the percentage of synaptic/total α1 mixed clusters of GABAARs per 
defined length of primary dendrite is not altered by treatment with 25 µM bicuculline, 
possibly because GABA signalling is not involved in regulating this parameter at early 
stages of development. 
 Figure 78. The percentage of synaptic/total α1 mixed clusters is not changed after 
treatment with 25 µM bicuculline from 4 to 7 DIV. The percentage of synaptic α1 mixed 
clusters amongst the total population of α1 mixed clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
4 to 7 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α1 mixed 
clusters per dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV  (n=34 and 
n=32 dendrites respectively, from two independent experiments). B. Box-plot displays the 
median percentage (50 % of the represented population) of synaptic/total α1 mixed clusters per 
dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV. Statistical analysis was 
performed using Mann- Whitney test. 
 
We estimated changes in mixed clusters which contained a predominant density of α2 
clusters in these cultures (α2 mixed clusters). The proportion of synaptic α2 mixed as a 
percentage of the total α2 mixed clusters of GABAARs per defined length of primary 
dendrite (the first 20 µm from the cell body) was calculated after treatment with DMSO 
or 25 µM bicuculline (Figure 79). After treatment with DMSO from 4 to 7 DIV, the 
median percentage of synaptic/total α2 mixed clusters was 38.53 (23.51-45.99) % after 
treatment with DMSO compared to 35.29 (25-41.74) % after treatment with 25 µM 
bicuculline (p value=0.46, Mann Whitney test, n=46 dendrites analysed after treatment 
with DMSO and n=45 dendrites analysed after treatment with 25 µM bicuculline). This 
demonstrates that, the percentage of synaptic/total α2 mixed clusters of GABAARs per 
defined length of primary dendrite is not altered by treatment with 25 µM bicuculline. As 
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stated before, it is possibly because GABA signalling is not involved in regulating this 
parameter at early stages of development. 
Figure 79. The percentage of synaptic/total α2 mixed clusters is not changed after 
treatment with 25 µM bicuculline from 4 to 7 DIV. The percentage of synaptic α2 mixed 
clusters amongst the total population of α2 mixed clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
4 to 7 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α2 mixed 
clusters per dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV  (n=46 and 
n=45 dendrites respectively, from two independent experiments). B. Box-plot displays the 
median percentage (50 % of the represented population) of synaptic/total α2 mixed clusters per 
dendrite after treatment with DMSO or bicuculline from 4 to 7 DIV. Statistical analysis was 
performed using Mann- Whitney test. 
Table 23. The percentage of synaptic/total density of clusters is in overall 
unchanged by 25 µM bicuculline treatment from 4 to 7 DIV 
 
 
 
 
6.3.1.4  The connectivity between medium spiny neurones was not 
changed after treatment with 25 µM bicuculline from 4 to 7 DIV  
To investigate further the role of GABA signalling in GABAergic synapse formation, 
we applied 25 µM bicuculline in MSN cultures from 4 to 7 DIV and estimated if activity 
of GABAARs would regulate the density of presynaptic terminals forming contacts with 
the primary dendrites at early stages of development. The total density of GAD-65 
positive terminals per defined length of primary dendrite(the first 20 μm from the cell 
body) was estimated after treatment with DMSO or 25 µM bicuculline from 4 to 7 DIV 
 7 DIV DMSO/ BIC Significant 
% (synaptic/total) 
α1 single clusters 
 
No 
% (synaptic/total) 
α2 single clusters 
 
No 
% (synaptic/total) 
α1 mixed clusters 
 
No 
% (synaptic/total) 
α2 mixed clusters 
 
No 
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(Figure 80). After DMSO treatment, the median density of presynaptic terminals was 10 
(5-17) compared to 9 (5.75-13) after treatment with bicuculline (p value > 0.05 Mann 
Whitney test, n=43 dendrites analysed after treatment with DMSO and n=50 dendrites 
analysed after treatment with 25 µM bicuculline from 4 to 7 DIV). This indicates that the 
density of presynaptic contacts per dendrite is not regulated by GABA signalling at 
early developmental stages. 
 
Figure 80. The density of presynaptic terminals making contacts with primary dendrites 
is not changed after treatment with 25 µM bicuculline from 4 to 7 DIV. The density of 
presynaptic terminals along the 20 μm of primary dendrite was counted in medium spiny 
neurones cultures after 7 and 14 DIV. A. Histogram shows the distribution of the density of 
presynaptic inputs after treatment with DMSO or 25 µM bicuculline from 4 to 7 DIV (n=43 and 
n=50 dendrites respectively, from two independent experiments). B. Box-plot displays the 
median density of presynaptic terminals after treatment with DMSO or 25 µM bicuculline from 4 
to 7 DIV. Statistical analysis was performed using Mann Whitney test. 
6.3.1.5 The size of α2-containing GABAAR clusters is decreased after 
treatment with 25 µM bicuculline from 4 to 7 DIV  
During their development in culture, while treated with DMSO or 25 µM bicuculline, 
medium spiny neurones underwent changes in the size of GABAAR cluster. The size of 
synaptic and total α1 single clusters of GABAARs per defined length of primary dendrite 
(the first 20 μm from the cell body) was estimated after treatment with DMSO or 25 µM 
bicuculline (Figure 81). After treatment with DMSO, the median size of synaptic α1 
single clusters was 0.39 μm2 (0.52-0.28) compared to 0.38 μm2 (0.52-0.3) with 25 µM 
bicuculline from 4 to 7 DIV (p value =0.56, Mann Whitney test,   n=194 clusters 
analysed after DMSO treatment and n=231 clusters analysed after treatment with 25 
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µM bicuculline). Similarly, the median size of total α1 single clusters was 0.38 μm2 
(0.52-0.28) after treatment with DMSO compared to 0.36 μm2 (0.52-0.26) after 
treatment with 25 µM bicuculline (p value =0.74, Mann Whitney test, n=461 clusters 
analysed after DMSO treatment and n=622 clusters analysed after treatment with 25 
µM bicuculline). This demonstrates that the size of synaptic and total α1 single clusters 
is not altered by treatment with 25 µM bicuculline from 4 to 7 DIV. This might be 
because at this early stage of development, the size of α1 single GABAARs is not 
dependent on GABA signalling.  
Figure 81. The size of synaptic and total α1 single clusters is not altered by treatment 
from 4 to 7 DIV. The size of α1- containing GABAA receptors clusters (α1 single clusters) along 
the 20 μm of primary dendrite was measured in medium spiny neurones cultures after treatment 
with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α1 single 
clusters sizes after treatment with DMSO or 25 µM bicuculline (n=194 and n=231 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
the population) of synaptic α1 single clusters after treatment with DMSO or 25 µM bicuculline. 
C. Histogram shows the distribution of total α1 single clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=461 and n=622 clusters respectively, from two independent 
experiments). D. The box plot displays the population of total α1 single clusters sizes after 
treatment with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann 
Whitney test. 
The size of synaptic and total α2 single clusters of GABAARs per defined length of 
primary dendrite (the first 20 μm from the cell body) was estimated after treatment with 
DMSO or 25 µM bicuculline (Figure 82). After treatment with DMSO, the median size of 
synaptic α2 single clusters was 0.33 μm2 (0.45-0.24) compared to 0.3 μm2 (0.49-0.23) 
A B
C D
217 
 
with 25 µM bicuculline from 4 to 7 DIV (p value=0.13 Mann Whitney test,   n=328 
clusters analysed after DMSO treatment and n=366 clusters analysed after treatment 
with 25 µM bicuculline). Similarly, the median size of total α2 single clusters was 0.31 
μm2 (0.43-0.24) after treatment with DMSO compared to 0.28 μm2 (0.43-0.21) after 
treatment with 25 µM bicuculline (p value=2.6x10-5, Mann Whitney test, n=745 clusters 
analysed after DMSO treatment and n=741 clusters analysed after treatment with 25 
µM bicuculline). This demonstrates that the size of total α2 single clusters is decreased 
by the treatment with 25 µM bicuculline from 4 to 7 DIV, suggesting that at this early 
stage of development, the size of extrasynaptic α2-containing GABAARs is regulated by 
the depolarising GABA signalling.  
Figure 82. The size of total α2 single clusters is decreased by treatment from 4 to 7 DIV. 
The size of α2 -containing GABAA receptors clusters (α2 single clusters) along the 20 μm of 
primary dendrite was measured in medium spiny neurones cultures after treatment with DMSO 
or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α2 single clusters sizes 
after treatment with DMSO or 25 µM bicuculline (n=328 and n=366 clusters respectively, from 
two independent experiments). B. Box-plot displays the median size (50 % of the population) of 
synaptic α2 single clusters after treatment with DMSO or 25 µM bicuculline. C. Histogram shows 
the distribution of total α2 single clusters sizes after treatment with DMSO or 25 µM bicuculline 
(n=745 and n=741 clusters respectively, from two independent experiments). D. The box plot 
displays the population of total α2 single clusters sizes after treatment with DMSO or 25 µM 
bicuculline. Statistical analysis was performed using Mann Whitney test. 
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The size of synaptic and total α1 mixed clusters of GABAARs per defined length of 
primary dendrite (the first 20 μm from the cell body) was estimated after treatment with 
DMSO or 25 µM bicuculline (Figure 83). After treatment with DMSO, the median size of 
synaptic α1 mixed clusters was 0.43 μm2 (0.6-0.3) compared to 0.43 μm2 (0.6-0.3) with 
25 µM bicuculline from 4 to 7 DIV (p value =0.43 Mann Whitney test,   n=271 clusters 
analysed after DMSO treatment and n=242 clusters analysed after treatment with 25 
µM bicuculline). Similarly, the median size of total α1 mixed clusters was 0.39 μm2 
(0.56-0.28) after treatment with DMSO compared to 0.43 μm2 (0.6-0.26) after treatment 
with 25 µM bicuculline (p value=0.07, Mann Whitney test, n=456 clusters analysed after 
DMSO treatment and n=447 clusters analysed after treatment with 25 µM bicuculline). 
This demonstrates that the size of synaptic and total α1 mixed clusters is not altered by 
treatment with 25 µM bicuculline from 4 to 7 DIV. This might be because at this early 
stage of development, the size of α1 mixed GABAARs is not dependent on GABA 
signalling.  
 Figure 83. The size of synaptic and total α1 mixed clusters is not altered by treatment 
from 4 to 7 DIV. The size of α1/α2-containing GABAA receptors clusters (α1 mixed clusters) 
along the 20 μm of primary dendrite was measured in medium spiny neurones cultures after 
treatment with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α1 
mixed clusters sizes after treatment with DMSO or 25 µM bicuculline (n=456 and n=447 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
the population) of synaptic α1 mixed clusters after treatment with DMSO or 25 µM bicuculline. 
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C. Histogram shows the distribution of total α1 mixed clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=271 and n=242 clusters respectively, from two independent 
experiments). D. The box plot displays the population of total α1 mixed clusters sizes after 
treatment with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann 
Whitney test. 
The size of synaptic and total α2 mixed clusters of GABAARs per defined length of 
primary dendrite (the first 20 μm from the cell body) was estimated after treatment with 
DMSO or 25 µM bicuculline (Figure 84). After treatment with DMSO, the median size of 
synaptic α2 mixed clusters was 0.56 μm2 (0.79-0.36) compared to 0.42 μm2 (0.69-0.26) 
with 25 µM bicuculline from 4 to 7 DIV (p value=2.8x10-5, Mann Whitney test,   n=298 
clusters analysed after DMSO treatment and n=263 clusters analysed after treatment 
with 25 µM bicuculline). Similarly, the median size of total α2 mixed clusters was 0.52 
μm2 (0.73-0.34) after treatment with DMSO compared to 0.43 μm2 (0.69-0.26) after 
treatment with 25 µM bicuculline (p value=2.69x10-5, Mann Whitney test, n=511 
clusters analysed after DMSO treatment and n=517 clusters analysed after treatment 
with 25 µM bicuculline). This demonstrates that the size of total α2 mixed clusters is 
decreased by treatment with 25 µM bicuculline from 4 to 7 DIV, possibly due to a 
regulation by GABA signalling of the size of a specific subtype of clusters containing α2 
clusters predominantly.  
 Figure 84. The size of synaptic and total α2 mixed clusters is decreased by treatment 
from 4 to 7 DIV. The size of α2/α1-containing GABAA receptors clusters (α2 mixed clusters) 
along the 20 μm of primary dendrite was measured in medium spiny neurones cultures after 
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treatment with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α2 
mixed clusters sizes after treatment with DMSO or 25 µM bicuculline (n=298 and n=263 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
the population) of synaptic α2 mixed clusters after treatment with DMSO or 25 µM bicuculline. 
C. Histogram shows the distribution of total α2 mixed clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=511 and n=517 clusters respectively, from two independent 
experiments). D. The box plot displays the population of total α2 mixed clusters sizes after 
treatment with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann 
Whitney test: * corresponds to p < 0.05. 
 
Table 24. The size of α2/α1 mixed- containing GABAAR clusters is decreased by 
25 µM treatment from 4 to 7 DIV 
 
6.3.2 Treatment of MSN cultures with bicuculline from 7 -14 DIV 
6.3.2.1 Treatment of medium spiny neurones with 50 µM bicuculline 
from 7 to 14 DIV provoked cell death 
In order to know if activity of GABAARs would play a different role at later 
developmental stages, when synapses are formed and mature, we have chronically 
treated medium spiny neurones with 50 or 25 μM bicuculline from 7 to 14 days in vitro 
(DIV). As a control, we have treated neurones at the same period of time with an 
equivalent amount of DMSO. Figure 85 is a large field images of medium spiny 
neurones treated from 7 to 14 DIV with 50 μM bicuculline or DMSO. Figure 86 is a 
large field images of medium spiny neurones treated from 7 to 14 DIV with 25 μM 
bicuculline or DMSO. These figures show examples of staining for α1 and α2 
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extracellular domains of GABAARs subunits, the intracellular presynaptic marker GAD-
65 and MAP-, using the antibodies described in table 19. The total density of cells per 
image was counted using the Zen 2009 programme.   
Figure 85. The density of cells is decreased by 50 μM bicuculline treatment from 7 to 14 
DIV compared to DMSO. Immunolabelling of GABAA receptors α1, α2 subunit containing 
clusters (respectively cyan and green) and presynaptic GABAergic terminals (red) along primary 
dendrites (blue) of cultured medium spiny neurones. A. Merged tile-scan image of a 14 DIV 
striatal culture treated with DMSO (scale bar: 20 μm). B. Enlarged image of boxed region in A 
(scale bar: 10 μm). C. Merged tile-scan image of a 14 DIV striatal culture treated with 50 µM 
bicuculline (scale bar: 20 μm). D. Enlarged image of boxed region in C (scale bar: 10 μm). 
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Figure 86. The density of cells is not affected by 25 μM bicuculline treatment from 7 to 14 
DIV compared to DMSO. Immunolabelling of GABAA receptors α1, α2 subunit containing 
clusters (respectively cyan and green) and presynaptic GABAergic terminals (red) along primary 
dendrites (blue) of cultured medium spiny neurones. A. Merged tile-scan image of a 14 DIV 
striatal culture treated with DMSO (scale bar: 20 μm). B. Enlarged image of boxed region in A 
(scale bar: 10 μm). C. Merged tile-scan image of a 14 DIV striatal culture treated with 25 µM 
bicuculline (scale bar: 20 μm). D. Enlarged image of boxed region in C (scale bar: 10 μm). 
 
The median density of cells per image was estimated after treatment with 50 μM 
bicuculline or control (Figure 87). At 7 DIV, the median density of cells per image was 
27 (34-16) with control treatment compared to 7 (10-4) with 50 μM bicuculline treatment 
(p value=1.87x10-4, Mann Whitney test, n=15 images analysed with control or 
bicuculline treatment at 14 DIV). This demonstrates that the density of cells is 
significantly decreased by 50 µM bicuculline treatment compared to DMSO from 7-14 
DIV. 
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Figure 87. The density of cells per image is significantly decreased after treatment 
with 50 μM bicuculline from 7 to 14 DIV.The density of medium spiny neurones per tile scan 
images was counted in presence of DMSO or 50 μM bicuculline from 7-14 DIV. A. Histogram 
shows the distribution of the density of cells per image in presence of DMSO or 50 μM 
bicuculline added at 7,9 and 11 DIV (n=15 images analysed respectively, from two independent 
experiments). B. Box plot displays the density of cells per image in presence of DMSO or 50 μM 
bicuculline added at 7 and 14 DIV. Statistical analysis was performed us ing Mann Whitney test: 
* corresponds to p-value <0.05. 
 
The median density of cells per image was estimated after treatment with 25 μM 
bicuculline or control (Figure 88). At 14 DIV, the median density of cells per image was 
8.5 (13.25-6.75) with control treatment compared to 15 (15.75-7.75) with 25 μM 
bicuculline treatment (p value=0.22, Mann Whitney test, n=15 images analysed). This 
demonstrates that the density of cells is not affected by 25 µM bicuculline compared to 
DMSO treatment from 7 to 14 DIV. 
Figure 88. The density of cells per image is not changed after treatment with 25 μM 
bicuculline from 7 to 14 DIV. The density of medium spiny neurones per tile scan images was 
counted in presence of DMSO or 25 μM bicuculline from 7-14 DIV. A. Histogram shows the 
distribution of the density of cells per image in presence of DMSO or 25 μM bicuculline added at 
7, 9 and 11 DIV (n=15 images analysed, from two independent experiments). B. Box plot 
displays the density of cells per image in presence of DMSO or 25 μM bicuculline added at 7, 9 
and 11 DIV. Statistical analysis was performed using Mann Whitney test. 
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6.3.2.2 The density of synaptic α2 single GABAAR clusters per 
dendrite was increased after 25 μM bicuculline treatment from 7 to 14 DIV.  
An increase in density of synaptic α2 single clusters was the only change in 
density of clusters observed after treatment of medium spiny neurones with 25 μM 
bicuculline from 7 to 14 DIV. Figure 89, 90 and 91 represent MSN medium spiny 
neurones treated from 7 to 14 DIV with 25 μM bicuculline or DMSO. This figure shows 
examples of staining for α1 and α2 extracellular domains of GABAARs subunits, the 
intracellular presynaptic marker GAD-65 and MAP-, using the antibodies described in 
Table 21. The total density of cells per image was counted using the Zen 2009 
programme.   
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 Figure 89. The density of α1 clusters is not affected by the 25 µM bicuculline treatment. 
Immunolabelling of GABAARs α1 subunit-containing clusters (cyan) and presynaptic GABAergic 
terminals (red) along primary dendrites (blue) of cultured medium spiny neurones. A. Merged 
image of a 14 DIV striatal neurone treated with DMSO (scale bar: 10 μm). B.(i) Enlarged image 
of boxed region in A representing α1 staining only. (ii) Analysis of image B(i) in which all α1 
clusters are circled in red. (iii) Analysis of image B(i) in which only α1 single clusters that are not 
associated with α2 clusters are circled in red (scale bar: 5 μm). C.(i) Enlarged image of boxed 
region in A representing α1 positive clusters and presynaptic GAD-65 positive nerve terminals. 
(ii) Analysis of image C(i) in which all α1 clusters were circled in red and presynaptic terminals 
were circled in purple. (iii) Analysis of image C(i) in which only α1 single clusters were circled in 
red and presynaptic terminals were circled in purple (scale bar: 5 μm). D. Merged image of a 14 
DIV striatal neurone treated with 25 µM bicuculline (scale bar: 10 μm). E.(i) Enlarged image of 
boxed region in D representing α1 staining only. (ii) Analysis of image E(i) in which all α1 
clusters are circled in red. (iii) Analysis of image E(i) in which only α1 single clusters that are not 
associated with α2 clusters are circled in red (scale bar: 5 μm). F.(i) Enlarged image of boxed 
region in D representing α1 positive clusters and presynaptic GAD-65 positive nerve terminals. 
(ii) Analysis of image F(i) in which all α1 clusters were circled in red and presynaptic terminals 
were circled in purple. (iii) Analysis of image F(i) in which only α1 single clusters were circled in 
red and presynaptic terminals were circled in purple (scale bar: 5 μm).  
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Figure 90. The density of synaptic α2 single clusters is increased by the 25 µM 
bicuculline treatment. Immunolabelling of GABAARs α2 subunit-containing clusters (green) 
and presynaptic GABAergic terminals (red) along primary dendrites (blue) of cultured medium 
spiny neurones. A. Merged image of a 14 DIV striatal neurone treated with DMSO (scale bar: 
10 μm). B.(i) Enlarged image of boxed region in A representing α2 staining only. (ii) Analysis of 
image B(i) in which all α2 clusters are circled in yellow. (iii) Analysis of image B(i) in which only 
α2 single clusters that are not associated with α1 clusters are circled in yellow (scale bar: 5 μm). 
C.(i) Enlarged image of boxed region in A representing α2 positive clusters and presynaptic 
GAD-65 positive nerve terminals. (ii) Analysis of image C(i) in which all α2 clusters were circled 
in yellow and presynaptic terminals were circled in purple. (iii) Analysis of image C(i) in which 
only α2 single clusters were circled in yellow and presynaptic terminals were circled in purple 
(scale bar: 5 μm). D. Merged image of a 14 DIV striatal neurone treated with 25 µM bicuculline 
(scale bar: 10 μm). E.(i) Enlarged image of boxed region in D representing α2 staining only. (ii) 
Analysis of image E(i) in which all α2 clusters are circled in yellow. (iii) Analysis of image E(i) in 
which only α2 single clusters that are not associated with α1 clusters are circled in yellow (scale 
bar: 5 μm). F.(i) Enlarged image of boxed region in D representing α2 positive clusters and 
presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image F(i) in which all α2 clusters 
were circled in yellow and presynaptic terminals were circled in purple. (iii) Analysis of image 
F(i) in which only α2 single clusters were circled in yellow and presynaptic terminals were 
circled in purple (scale bar: 5 μm).  
 
 
A B C
14 DIV DMSO (i) (i)
(ii) (ii)
(iii) (iii)
α2 GAD 65 MAP2
D E F
14 DIV BIC (i) (i)
(ii) (ii)
(iii) (iii)
α2 α2/ GAD-65 
227 
 
Figure 91. The density of α1/α2 mixed clusters is not affected by the 25 µM bicuculline 
treatment. Immunolabelling of GABAARs α1/α2 subunit-containing clusters (cyan and green) 
and presynaptic GABAergic terminals (red) along primary dendrites (blue) of cultured medium 
spiny neurones. A. Merged image of a 14 DIV striatal neurone treated with DMSO (scale bar: 
10 μm). B.(i) Enlarged image of boxed region in A representing α1 and α2 staining. (ii) Analysis 
of image B(i) in which all α1 and α2 clusters are respectively circled in red and yellow (scale bar: 
5 μm). C.(i) Enlarged image of boxed region in A representing α1, α2 positive clusters and 
presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image C(i) in which all α1 and α2 
clusters were respectively circled in red and yellow and presynaptic terminals were circled in 
purple (scale bar: 5 μm). D. Merged image of a 14 DIV striatal neurone treated with 25 µM 
bicuculline (scale bar: 10 μm). E.(i) Enlarged image of boxed region in D representing α1 and 
α2 staining. (ii) Analysis of image E(i) in which all α1 and α2 clusters were respectively circled in 
red and yellow (scale bar: 5 μm). F.(i) Enlarged image of boxed region in D representing α1, α2 
positive clusters and presynaptic GAD-65 positive nerve terminals. (ii) Analysis of image F(i) in 
which all α1 and α2 clusters were respectively circled in red and yellow and presynaptic 
terminals were circled in purple (scale bar: 5 μm).  
 
The density of synaptic and total α1 single clusters of GABAARs was estimated per 
defined length of primary dendrite (the first 20 µm from the cell body) after treatment 
with DMSO or 25 μM bicuculline from 7 to 14 DIV (Figure 92). The median density of 
synaptic α1 single clusters was 5.5 (10-3) with DMSO treatment, compared to 4 (11-1) 
with bicuculline treatment (p value=0.22, Mann Whitney test, n=84 dendrites analysed 
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from DMSO treated cultures and n=80 dendrites analysed from bicuculline treated 
neurones). Similarly, the median density of total α1 single clusters was 12.5 (17-8) with 
DMSO treatment, compared to 11 (18-6.25) with bicuculline treatment (p value=0.51, 
Mann Whitney test, n=84 dendrites analysed from DMSO treated cultures and n=80 
dendrites analysed from bicuculline treated neurones). This demonstrates that the 
synaptic and total densities of α1 single clusters are not affected by the treatment, 
indicating that the regulation of the density of these types of clusters is independent of 
the GABAARs activity at this developmental stage.  
Figure 92. The density of synaptic and total α1 clusters is not affected by treatment with 
25 µM bicuculline from 7 to 14 DIV. The density of α1- containing GABAA receptors clusters 
(α1 single clusters) along the 20 μm of primary dendrite was counted in medium spiny neurone 
cultures in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. A. Histogram shows the 
distribution of synaptic α1 single clusters densities in presence of DMSO or 25 μM bicuculline 
from 7 to 14 DIV (n=84 and n=79 dendrites respectively from two independent experiments). B. 
Box plot displays the median density (50 % of the population) of synaptic α1 single clusters in 
presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. C. Histogram shows the distribution 
of total α1 single clusters density in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV 
(n=85 and n=79 dendrites respectively from two independent experiments). D. Box plot displays 
the median density (50 % of the population) of total α1 single clusters in presence of DMSO or 
25 μM bicuculline from 7 to 14 DIV. Statistical analysis was performed using Mann Whitney test. 
 
We analysed the density of α2 single clusters in presence of DMSO or 25 µM 
bicuculline from 7 to 14 DIV. The density of synaptic and total α2 single clusters of 
GABAARs was estimated per defined length of primary dendrite (the first 20 µm
 from 
the cell body) after treatment with DMSO or 25 μM bicuculline from 7 to 14 DIV (Figure 
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93). The median density of synaptic α2 single clusters was 5 (16.75-3) with DMSO 
treatment, compared to 10 (32-4) with bicuculline treatment (p value=0.003, Mann 
Whitney test, n=84 dendrites analysed from DMSO treated cultures and n=79 dendrites 
analysed from bicuculline treated neurones). Similarly, the median density of total α2 
single clusters was 16 (31-9.5) with DMSO treatment, compared to 18 (40-9) with 
bicuculline treatment (p value=0.32, Mann Whitney test, n=85 dendrites analysed from 
DMSO treated cultures and n=79 dendrites analysed from bicuculline treated 
neurones). This demonstrates that similarly to α1 single clusters, the synaptic and total 
densities of α2 single clusters are not affected by the treatment, indicating that the 
regulation of the density of these types of clusters is independent of the GABAARs 
activity at this developmental stage.  
 Figure 93. The density of synaptic α2 single clusters is increased by treatment with 25 
µM bicuculline from 7 to 14 DIV. The density of α2- containing GABAA receptors clusters (α2 
single clusters) along the 20 μm of primary dendrite was counted in medium spiny neurone 
cultures in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. A. Histogram shows the 
distribution of synaptic α2 single clusters densities in presence of DMSO or 25 μM bicuculline 
from 7 to 14 DIV (n=84 and n=79 dendrites respectively from two independent experiments). B. 
Box plot displays the median density (50 % of the population) of synaptic α2 single clusters in 
presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. C. Histogram shows the distribution 
of total α2 single clusters density in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV 
(n=85 and n=79 dendrites respectively from two independent experiments). D. Box plot displays 
the median density (50 % of the population) of total α2 single clusters in presence of DMSO or 
25 μM bicuculline from 7 to 14 DIV. Statistical analysis was performed using Mann Whitney test: 
* corresponds to p < 0.05. 
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As explained in the previous chapter, we have observed two types of α1/α2 mixed 
clusters. The mixed clusters which contained a majority of α1 clusters were defined as 
α1 mixed clusters while the mixed clusters containing a majority of α2 clusters were 
defined as α2 mixed clusters. The density of synaptic and total α1 mixed clusters of 
GABAARs was estimated per defined length of primary dendrite (the first 20 µm
 from 
the cell body) after treatment with DMSO or 25 μM bicuculline from 7 to 14 DIV (Figure 
94). The median density of synaptic α1 mixed clusters was 4 (7-0) with DMSO 
treatment, compared to 4.5 (11-0) with bicuculline treatment (p value=0.20, Mann 
Whitney test, n=84 dendrites analysed from DMSO treated cultures and n=80 dendrites 
analysed from bicuculline treated neurones). Similarly, the median density of total α1 
mixed clusters was 6 (9.75-0) with DMSO treatment, compared to 6 (15-1.25) with 
bicuculline treatment (p value=0.11, Mann Whitney test, n=84 dendrites analysed from 
DMSO treated cultures and n=80 dendrites analysed from bicuculline treated 
neurones). This demonstrates that the synaptic and total densities of α1 mixed clusters 
are not affected by the treatment, indicating that the regulation of the density of these 
types of clusters is independent of the GABAARs activity at this developmental stage.  
Figure 94. The density of synaptic and total α1 mixed clusters is not affected by 
treatment with 25 µM bicuculline from 7 to 14 DIV. The density of α1/α2- containing GABAA 
receptors clusters (α1 mixed clusters) along the 20 μm of primary dendrite was counted in 
medium spiny neurone cultures in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. A. 
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Histogram shows the distribution of synaptic α1 mixed clusters densities in presence of DMSO 
or 25 μM bicuculline from 7 to 14 DIV (n=84 and n=80 dendrites respectively from two 
independent experiments). B. Box plot displays the median density (50 % of the population) of 
synaptic α1 mixed clusters in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. C. 
Histogram shows the distribution of total α1 mixed clusters density in presence of DMSO or 25 
μM bicuculline from 7 to 14 DIV (n=84 and n=80 dendrites respectively from two independent 
experiments). D. Box plot displays the median density (50 % of the population) of total α1 mixed 
clusters in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. Statistical analysis was 
performed using Mann Whitney test. 
 
We have analysed the population of mixed clusters which contained a predominant 
density of α2 clusters (α2 mixed) after treatment with DMSO or 25 μM bicuculline from 
7 to 14 DIV (Figure 95). The median density of synaptic α2 mixed clusters was 5 (8-2) 
with DMSO treatment, compared to 5 (11-2) with bicuculline treatment (p value= 0.22, 
Mann Whitney test, n=85 dendrites analysed from DMSO treated cultures and n=79 
dendrites analysed from bicuculline treated neurones). Similarly, the median density of 
total α2 mixed clusters was 7 (11-3.5) with DMSO treatment, compared to 8 (13-3) with 
bicuculline treatment. This demonstrates that the synaptic and total densities of α2 
mixed clusters are not affected by the treatment, indicating that the regulation of the 
density of these types of clusters is independent of the GABAARs activity at this 
developmental stage.  
Figure 95. The density of synaptic and total α2 mixed clusters is not affected by 
treatment with 25 µM bicuculline from 7 to 14 DIV. The density of α1/α2- containing GABAA 
receptors clusters (α2 mixed clusters) along the 20 μm of primary dendrite was counted in 
medium spiny neurone cultures in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. A. 
Histogram shows the distribution of synaptic α2 mixed clusters densities in presence of DMSO 
A B
C D
232 
 
or 25 μM bicuculline from 7 to 14 DIV (n=85 and n=79 dendrites respectively from two 
independent experiments). B. Box plot displays the median density (50 % of the population) of 
synaptic α2 mixed clusters in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. C. 
Histogram shows the distribution of total α2 mixed clusters density in presence of DMSO or 25 
μM bicuculline from 7 to 14 DIV (n=85 and n=79 dendrites respectively from two independent 
experiments). D. Box plot displays the median density (50 % of the population) of total α2 mixed 
clusters in presence of DMSO or 25 μM bicuculline from 7 to 14 DIV. Statistical analysis was 
performed using Mann Whitney test. 
 
Table 25. The density of synaptic α2 single GABAAR clusters is increased after 
treatment with 25 µM bicuculline treatment compared to DMSO from 7 to 14 DIV 
 
6.3.2.3 The proportion of synaptic as a percentage of total α2 single 
GABAA receptor clusters was increased after treatment with 25 µM 
bicuculline from 7 to 14 DIV  
The densities of all types of clusters might not be affected by the treatment. However, 
the proportion of synaptic clusters as a percentage of the total population may vary 
indicating a redistribution of clusters. We estimated the proportion of synaptic clusters 
as a percentage of total density of clusters in each population treated from 7 to 14 
DIV). The proportion of synaptic α1 single clusters as a percentage of the total α1 
single clusters of GABAARs per defined length of primary dendrite (the first 20 μm from 
the cell body) was calculated after treatment with DMSO or 25 μM bicuculline from 7 to 
14 DIV (Figure 96). The median percentage of synaptic amongst total α1 single 
clusters was 34.8 (41.9-25) % with DMSO treatment compared to 31 (43.6-12.1) % 
Density of clusters 
14 DIV  
DMSO/ BIC 
Significant 
α1 single clusters 
Synaptic 
 
No  
Total 
 
No  
α2 single clusters 
Synaptic 
 
No  
Total 
 
Yes 
αl mixed clusters 
 
Synaptic 
 
No  
Total 
 
No  
α2 mixed clusters 
 
Synaptic 
 
No  
Total 
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with bicuculline treatment (p=0.42, Mann Whitney test, n=84 dendrites analysed after 
DMSO treatment and n=78 dendrites analysed after bicuculline treatment). Similarly to 
the density of synaptic α1 single clusters per dendrite, the percentage between the 
synaptic and the total α1 single clusters is not altered by bicuculline (Table 26).   
Figure 96. The percentage of synaptic/total α1 single clusters is not changed after 
treatment with 25 µM bicuculline from 7 to 14 DIV. The percentage of synaptic α1 single 
clusters amongst the total population of α1 single clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
7 to 14 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α1 single 
clusters per dendrite after treatment with DMSO or bicuculline from 7 to 14 DIV (n=84 and n=78 
dendrites respectively, from two independent experiments). B. Box-plot displays the median 
percentage (50 % of the represented population) of synaptic/total α1 single clusters per dendrite 
after treatment with DMSO or bicuculline from 7 to 14 DIV. Statistical analysis was performed 
using Mann- Whitney test. 
In addition, the proportion of synaptic α2 single clusters as a percentage of the total α2 
single clusters of GABAARs per defined length of primary dendrite (the first 20 μm from 
the cell body) was calculated after treatment with DMSO or 25 µM bicuculline (Figure 
97). After treatment with DMSO from 7 to 14 DIV, the median percentage of 
synaptic/total α2 single clusters was 30 (40-16.3) % compared to 42.1 (42.9-28.6) % 
after treatment with bicuculline (p value= 1.01x10-4, Mann Whitney test, n=85 dendrites 
analysed after treatment with DMSO and n=79 dendrites analysed after treatment with 
25 µM bicuculline). This indicates that, similarly to the density of synaptic α2 single 
clusters per dendrite, the percentage of α2 single clusters/total density of clusters 
increases with 25 µM treatment of bicuculline. 
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Figure 97. The percentage of synaptic/total α2 single clusters is not changed after 
treatment with 25 µM bicuculline from 7 to 14 DIV 
The percentage of synaptic α2 single clusters amongst the total population of α2 single clusters 
along the 20 μm of primary dendrite was estimated in medium spiny neurones cultures treated 
with DMSO or 25 µM bicuculline from 7 to 14 DIV. A. Histogram shows the distribution of the 
percentages of synaptic/total α2 single clusters per dendrite after treatment with DMSO or 
bicuculline from 7 to 14 DIV (n=85 and n=79 dendrites respectively, from two independent 
experiments). B. Box-plot displays the median percentage (50 % of the represented population) 
of synaptic/total α2 single clusters per dendrite after treatment with DMSO or bicuculline from 7 
to 14 DIV. Statistical analysis was performed using Mann- Whitney test. 
 
 
Following the previous analysis, we have also analysed changes in the percentage of 
synaptic mixed clusters over total mixed clusters during medium spiny neurones 
development. The proportion of synaptic α1 mixed clusters as a percentage of the total 
α1 mixed clusters of GABAARs per defined length of primary dendrite (the first 20 µm
 
from the cell body) was calculated after treatment with DMSO or 25 µM bicuculline 
(Figure 98). After treatment with DMSO from 7 to 14 DIV, the median percentage of 
synaptic/total α1 mixed clusters was 45.45 (50-38.2) % after treatment with DMSO 
compared to 44.4 (50-34.3) % after treatment with 25 µM bicuculline (p value=0.58, 
Mann Whitney test, n=57 dendrites analysed after treatment with DMSO and n=61 
dendrites analysed after treatment with 25 µM bicuculline). This demonstrates that, the 
percentage of synaptic/total α1 mixed clusters of GABAARs per defined length of 
primary dendrite is not altered by treatment with 25 µM bicuculline, possibly because 
GABA signalling is not involved in regulating this parameter at early stages of 
development.  
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Figure 98. The percentage of synaptic/total α1 mixed clusters is not changed after 
treatment with 25 µM bicuculline from 7 to 14 DIV. The percentage of synaptic α1 mixed 
clusters amongst the total population of α1 mixed clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
7 to 14 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α1 mixed 
clusters per dendrite after treatment with DMSO or bicuculline from 7 to 14 DIV (n=57 and n=61 
dendrites respectively, from two independent experiments). B. Box-plot displays the median 
percentage (50 % of the represented population) of synaptic/total α1 mixed clusters per dendrite 
after treatment with DMSO or bicuculline from 7 to 14 DIV. Statistical analysis was performed 
using Mann- Whitney test. 
 
We analysed mixed clusters which contained a predominant density of α2 clusters in 
these cultures (α2 mixed clusters). The proportion of synaptic α2 mixed clusters as a 
percentage of the total α2 mixed clusters of GABAARs per defined length of primary 
dendrite (the first 20 µm from the cell body) was calculated after treatment with DMSO 
or 25 µM bicuculline (Figure 99). After treatment with DMSO from 7 to 14 DIV, the 
median percentage of synaptic/total α2 mixed clusters was 44.4 (50-36.4) % after 
treatment with DMSO compared to 45.4 (50-36.2) % after treatment with 25 µM 
bicuculline (p value=0.4, Mann Whitney test, n=80 dendrites analysed after treatment 
with DMSO and n=73 dendrites analysed after treatment with 25 µM bicuculline). This 
demonstrates that, the percentage of synaptic/total α2 mixed clusters of GABAARs per 
defined length of primary dendrite is not altered by treatment with 25 µM bicuculline. As 
stated before, it is possibly because GABA signalling is not involved in regulating this 
parameter at early stages of development. 
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Figure 99. The percentage of synaptic/total α2 mixed clusters is not changed after 
treatment with 25 µM bicuculline from 7 to 14 DIV. The percentage of synaptic α2 mixed 
clusters amongst the total population of α2 mixed clusters along the 20 μm of primary dendrite 
was estimated in medium spiny neurones cultures treated with DMSO or 25 µM bicuculline from 
7 to 14 DIV. A. Histogram shows the distribution of the percentages of synaptic/total α2 mixed 
clusters per dendrite after treatment with DMSO or bicuculline from 7 to 14 DIV (n=80 and n=73 
dendrites respectively, from two independent experiments). B. Box-plot displays the median 
percentage (50 % of the represented population) of synaptic/total α2 mixed clusters per dendrite 
after treatment with DMSO or bicuculline from 7 to 14 DIV. Statistical analysis was performed 
using Mann- Whitney test. 
 
Table 26. The percentage of synaptic/total α2 single GABAAR clusters is 
decreased by 25 µM bicuculline treatment from 7 to 14 DIV 
 14 DIV DMSO/ BIC Significant 
% (synaptic/total) 
α1 single clusters 
 
No 
% (synaptic/total) 
α2 single clusters 
 
Yes  
% (synaptic/total) 
α1 mixed clusters 
 
No 
% (synaptic/total) 
α2 mixed clusters 
 
No 
 
6.3.2.4 The connectivity between medium spiny neurones was not 
changed after treatment with 25 µM bicuculline from 7 to 14 DIV  
To investigate further the role of GABA signalling in GABAergic synapse formation, we 
applied 25 µM bicuculline in MSN cultures from 7 to 14 DIV and estimated if activity of 
GABAARs would regulate the density of presynaptic terminals forming contacts with the 
primary dendrites at early stages of development.  
The total density of GAD-65 positive terminals per defined length of primary dendrite 
(the first 20 μm from the cell body) was estimated after treatment with DMSO or 25 µM 
bicuculline from 7 to 14 DIV (Figure 100). After DMSO treatment, the median density of 
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presynaptic terminals was 13 (20-10) compared to 13 (16-9) after treatment with 
bicuculline (p value=0.48, Mann Whitney test, n=74 dendrites analysed after treatment 
with DMSO and n=82 dendrites analysed after treatment with 25 µM bicuculline from 7 
to 14 DIV). This indicates that the density of presynaptic contacts per dendrite is not 
regulated by GABA signalling at early developmental stages. 
Figure 100. The density of presynaptic terminals making contacts with primary dendrites 
is not changed after treatment with 25 µM bicuculline from 7 to 14 DIV. The density of 
presynaptic terminals along the 20 μm of primary dendrite was counted in medium spiny 
neurones cultures after 7 and 14 DIV. A. Histogram shows the distribution of the density of 
presynaptic inputs after treatment with DMSO or 25 µM bicuculline from 7 to 14 DIV (n=74 and 
n=82 dendrites respectively, from two independent experiments). B. Box-plot displays the 
median density of presynaptic terminals after treatment with DMSO or 25 µM bicuculline from 7 
to 14 DIV. Statistical analysis was performed using Mann Whitney test. 
6.3.2.5 α subunit-specific effects on cluster size of bicuculline 
treatment from 7 to 14 DIV  
During their development in culture, while treated with DMSO or 25 µM bicuculline, 
medium spiny neurones underwent changes in the size of GABAAR clusters. The size 
of synaptic and total α1 single clusters of GABAARs per defined length of primary 
dendrite (the first 20 μm from the cell body) was estimated after treatment with DMSO 
or 25 µM bicuculline (Figure 101). After treatment with DMSO, the median size of 
synaptic α1 single clusters was 0.43 μm2 (0.69-0.24) compared to 0.34 μm2 (0.69-0.16) 
with 25 µM bicuculline from 7 to 14 DIV (p value=0.002, Mann Whitney test,   n=481 
clusters analysed after DMSO treatment and n=576 clusters analysed after treatment 
with 25 µM bicuculline). Similarly, the median size of total α1 single clusters was 0.39 
μm2 (0.65-0.22) after treatment with DMSO compared to 0.3 μm2 (0.69-0.16) after 
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treatment with 25 µM bicuculline (p value=2.77x10-4, Mann Whitney test, n=940 
clusters analysed after DMSO treatment and n=898 clusters analysed after treatment 
with 25 µM bicuculline). This demonstrates that the size of synaptic and total α1 single 
clusters is decreased by the treatment with 25 µM bicuculline from 7 to 14 DIV, 
possibly due to regulation by GABA signalling of the size of a specific subtype of 
cluster less predominant in the culture at this developmental stage, containing mostly 
α1 subunit. 
 Figure 101. The size of synaptic and total α1 single clusters is decreased by treatment 
from 7 to 14 DIV. The size of α1- containing GABAA receptors clusters (α1 single clusters) 
along the 20 μm of primary dendrite was measured in medium spiny neurones cultures after 
treatment with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α1 
single clusters sizes after treatment with DMSO or 25 µM bicuculline (n=481 and n=576 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
the population) of synaptic α1 single clusters after treatment with DMSO or 25 µM bicuculline. 
C. Histogram shows the distribution of total α1 single clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=481 and n=576 clusters respectively, from two independent 
experiments). D. Box plot displays the population of total α1 single clusters sizes after treatment 
with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann Whitney test. 
 
The size of synaptic and total α2 single clusters of GABAARs per defined length of 
primary dendrite (the first 20 μm from the cell body) was estimated after treatment with 
DMSO or 25 µM bicuculline (Figure 102). After treatment with DMSO, the median size 
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of synaptic α2 single clusters was 0.24 μm2 (0.35-0.19) compared to 0.28 μm2 (0.4-
0.23) with 25 µM bicuculline from 7 to 14 DIV (p value=2.91x10-12 Mann Whitney test,   
n=859 clusters analysed after DMSO treatment and n=1546 clusters analysed after 
treatment with 25 µM bicuculline). Similarly, the median size of total α2 single clusters 
was 0.24 μm2 (0.33-0.17) after treatment with DMSO compared to 0.28 μm2 (0.42-0.21) 
after treatment with 25 µM bicuculline (p value=1.14x10-22, Mann Whitney test, n=1397 
clusters analysed after DMSO treatment and n=2038 clusters analysed after treatment 
with 25 µM bicuculline). This demonstrates that the size of synaptic and total α2 single 
clusters is increased by treatment with 25 µM bicuculline from 7 to 14 DIV, suggesting 
that the lack of activity provoked compensatory mechanisms favouring the insertion of 
α2-containing GABAARs.   
 Figure 102. The size of synaptic and total α2 single clusters is increased by treatment 
from 7 to 14 DIV.The size of α2-containing GABAA receptors clusters (α2 single clusters) along 
the 20 μm of primary dendrite was measured in medium spiny neurones cultures after treatment 
with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α2 single 
clusters sizes after treatment with DMSO or 25 µM bicuculline (n=859 and n=1546 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
the population) of synaptic α2 single clusters after treatment with DMSO or 25 µM bicuculline. 
C. Histogram shows the distribution of total α2 single clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=1397 and n=2038 clusters respectively, from two independent 
experiments). D. Box plot displays the population of total α2 single clusters sizes after treatment 
with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann Whitney test. 
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The size of synaptic and total α1 mixed clusters of GABAARs per defined length of 
primary dendrite (the first 20 μm from the cell body) was estimated after treatment with 
DMSO or 25 µM bicuculline (Figure 103). After treatment with DMSO, the median size 
of synaptic α1 mixed clusters was 0.56 μm2 (0.78-0.34) compared to 0.47 μm2 (0.78-
0.19) with 25 µM bicuculline from 7 to 14 DIV (p value=0.002, Mann Whitney test,   
n=409 clusters analysed after DMSO treatment and n=518 clusters analysed after 
treatment with 25 µM bicuculline). Similarly, the median size of total α1 mixed clusters 
was 0.56 μm2 (0.78-0.33) after treatment with DMSO compared to 0.47 μm2 (0.73-0.21) 
after treatment with 25 µM bicuculline (p value=6.88x10-4, Mann Whitney test, n=539 
clusters analysed after DMSO treatment and n=729 clusters analysed after treatment 
with 25 µM bicuculline). This demonstrates that the size of synaptic and total α1 mixed 
clusters is decreased by treatment with 25 µM bicuculline from 7 to 14 DIV, possibly 
due to regulation by GABA signalling of the size of a specific subtype of cluster less 
predominant in the culture at this developmental stage, containing mostly α1 subunit. 
 Figure 103. The size of synaptic and total α1 mixed clusters is decreased by treatment 
from 7 to 14 DIV.The size of α1/α2-containing GABAA receptors clusters (α1 mixed clusters) 
along the 20 μm of primary dendrite was measured in medium spiny neurones cultures after 
treatment with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α1 
mixed clusters sizes after treatment with DMSO or 25 µM bicuculline (n=409 and n=518 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
the population) of synaptic α1 mixed clusters after treatment with DMSO or 25 µM bicuculline. 
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C. Histogram shows the distribution of total α1 mixed clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=539 and n=729 clusters respectively, from two independent 
experiments). D. Box plot displays the population of total α1 mixed clusters sizes after treatment 
with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann Whitney test. 
The size of synaptic and total α2 mixed clusters of GABAARs per defined length of 
primary dendrite (the first 20 μm from the cell body) was estimated after treatment with 
DMSO or 25 µM bicuculline (Figure 104). After treatment with DMSO, the median size 
of synaptic α2 mixed clusters was 0.56 μm2 (0.86-0.26) compared to 0.56 μm2 (0.73-
21) with 25 µM bicuculline from 7to 14 DIV (p value=0.04, Mann Whitney test,   n=446 
clusters analysed after DMSO treatment and n=558 clusters analysed after treatment 
with 25 µM bicuculline). The median size of total α2 mixed clusters was 0.52 μm2 (0.82-
0.24) after treatment with DMSO compared to 0.6 μm2 (0.9-0.34) after treatment with 
25 µM bicuculline (p value=5.7x10-6, Mann Whitney test, n=610 clusters analysed after 
DMSO treatment and n=773 clusters analysed after treatment with 25 µM bicuculline). 
This demonstrates that the size of total α2 mixed clusters is increased by treatment 
with 25 µM bicuculline from 7 to 14 DIV, suggesting that the lack of activity provoked 
compensatory mechanisms favouring the insertion of α2-containing GABAARs.   
 Figure 104. The size of synaptic and total α2 mixed clusters is increased by treatment 
from 7 to 14 DIV. The size of α2/α1-containing GABAA receptors clusters (α2 mixed clusters) 
along the 20 μm of primary dendrite was measured in medium spiny neurones cultures after 
treatment with DMSO or 25 µM bicuculline. A. Histogram shows the distribution of synaptic α2 
mixed clusters sizes after treatment with DMSO or 25 µM bicuculline (n=446 and n=558 clusters 
respectively, from two independent experiments). B. Box-plot displays the median size (50 % of 
A B
C D
242 
 
the population) of synaptic α2 mixed clusters after treatment with DMSO or 25 µM bicuculline. 
C. Histogram shows the distribution of total α2 mixed clusters sizes after treatment with DMSO 
or 25 µM bicuculline (n=610 and n=773 clusters respectively, from two independent 
experiments). D. Box plot displays the population of total α2 mixed clusters sizes after treatment 
with DMSO or 25 µM bicuculline. Statistical analysis was performed using Mann Whitney test: * 
corresponds to p < 0.05. 
 
 Table 27. The size of α2-containing GABAAR clusters is increased while the size 
of α1-containing GABAAR clusters is decreased by the 25 µM treatment from 7 to 
14 DIV. 
6.4 Discussion  
It has now been well established that GABA is the first neurotransmitter released in 
the embryonic brain (Ben-Ari et al., 2007). Due to high expression of the chloride co-
transporter NKCC1 and low expression of the chloride extruder KCC2 in the embryonic 
brain, opening of the GABAA receptors leads to a decrease of chloride intracellular 
concentration, thus resulting in a depolarising current (Ben-Ari et al., 2007). These 
depolarising potentials have been shown to contribute to proper axonal wiring of the 
developing brain (Fritschy and Panzanelli, 2014). In the adult brain, the expression of 
the chloride transporter NKCC1 is lower and the KCC2 becomes the predominant 
chloride extruder leading to hyperpolarising currents and influx of chloride when 
GABAARs are activated (Ben-Ari et al., 2007). However, it is important to remember 
that at any developmental stage, the main effect of GABA signalling is to increase the 
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membrane conductance opposed to the influx of positively charged ions into the 
postsynaptic cell induced by other neurotransmitters signalling.  
Although the role played by neuronal activity on diffusion properties, size and 
efficacy of GABAARs has been widely studied (Saliba et al., 2007, Bannai et al., 2009), 
little is known about the effect of GABA signalling during the construction of GABAergic 
synapses. It has been shown that in mature hippocampal cultures, the excitatory 
activity decreases the GABAAR and gephyrin cluster sizes and reduces GABAergic 
miniature inhibitory postsynaptic currents (mIPSCs) (Bannai et al., 2009). At the 
synapse, homeostatic plasticity has been observed as an increase or a decrease in 
synaptic strength following corresponding changes in neuronal network activity (Cline, 
2005). Although studies of activity-dependent changes at excitatory synapses have 
furthered our understanding of homeostatic mechanisms, the effects of chronic activity 
changes at inhibitory synapses is not as clearly defined. Studies of homeostatic 
plasticity at inhibitory synapses have shown decreased synaptic strength following 
chronic activity blockade (Hartman et al., 2006). This work suggested that presynaptic 
mechanisms regulate homeostatic plasticity during 9 days treatments of activity 
blockade in hippocampal cultures. More recently, Rannals et al., demonstrated that in 
hippocampal neurones challenged by chronic depolarisation, an increase of inhibitory 
postsynaptic GABAAR expression followed by an increase in the presynaptic marker 
GAD-65 were observed (Rannals and Kapur, 2011). These increases were paralleled 
to increase in synaptic strength measured by mIPSC amplitude, confirming that 
postsynaptic mechanisms were in play. In addition, the rate of internalisation of 
GABAARs was slowed down.  
These experiments have been conducted in a mixed culture environment where 
glutamatergic and GABAergic neurones are contacting each other, hence providing 
excellent conditions to study homeostatic regulations. But what are the effects 
mediated by GABAARs signal transduction on GABAergic synapse development when 
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depolarising GABA is the only neurotransmitter present in the embryonic and postnatal 
brain, and when GABA becomes hyperpolarising later on? 
Prior to our experiments, calcium imaging was performed in our culture model in 
order to confirm that the switch of GABA signalling observed in vivo during GABAergic 
synapse maturation was also present in our culture model. This experiment showed 
that activation of GABAARs by the agonist muscimol from 4 to 7 DIV induced 
intracellular calcium increase. In contrast, when GABAAR activity was triggered by 
addition of muscimol in MSN cultures from 7 to 14 DIV, no increase in intracellular 
calcium was observed. These results indicated that at early developmental stages, 
activating GABAARs caused a depolarisation of MSNs, which was not observed at later 
developmental stages, suggesting that GABAA receptor activation caused 
hyperpolarisation (Arama et al., manuscript in preparation). 
Additionally, electrophysiology recordings have been performed in the MSN 
cultures. When recorded from 4 to 7 DIV, MSNs only exhibited mIPSCs and 
spontaneous inhibitory postsynaptic currents (sIPSCs), reflecting the immature stage of 
development they were in. However, action potential-(AP) driven activity was recorded 
in 12 DIV neurones, suggesting that MSNs attained their maturity and GABAergic 
synapses were stabilised enough to mediate AP-triggered neurotransmitter release 
(Arama et al., manuscript in preparation). 
GABAAR subtypes are thought to subserve individual functions in GABAergic 
synaptic transmission. The existence of different combinations of subunits probably 
contributes to synaptic variety and sensitivity to the endogenous GABA. This is 
emphasised by extrasynaptic receptors being 20 times more sensitive to GABA than 
synaptic receptors (Saxena and Macdonald, 1996). In the study by Bohme et al.,  it 
was demonstrated that a specific four amino-acid motif present in the N-terminal 
extracellular domain of the α1-6 subunits controls the sensitivity to GABA of GABAARs 
(Bohme et al., 2004). By exchanging this 4aa motif, they were able to transfer these 
sensitivity properties from one α subunit type to another. It was already known that α1 
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had the highest affinity for GABA of all the synaptic α subunits (Ebert et al., 1994). 
When different α subunits in combination with the β3 and γ2 subunits were expressed 
in HEK 293, the EC50 of the chloride currents induced by GABA was determined. In 
decreasing order of affinity for GABA, it was showed that α6 > α1> α2> α4> α5>> α3 
(Bohme et al., 2004). The exchange of four amino acids between α1, α3, α4 and α5 
subunits resulted in the exact transfer of their respective GABA sensitivities. 
Interestingly, when the four amino acids of α2 subunit were exchanged, a drastic loss 
in GABA sensitivity was observed, potentially explained by a conformational change 
only occurring in this synaptic subunit. In addition, the motif exchange in the α6 subunit 
resulted in the partial transfer of the GABA sensitivity, suggesting that another motif 
only present in the α6 subunits could explain its highly sensitivity to GABA (Bohme et 
al., 2004). 
Considering all these criteria, to investigate the effects of GABAAR activity during 
maturation of GABAergic synapses, we have suppressed the GABAA receptor activity 
in the medium spiny neurone cultures using a competitive antagonist bicuculline from 4 
to 7 days in vitro (DIV) or from 7 to 14 DIV. As a control, we have treated neurones in 
parallel with an equivalent amount of DMSO, a polar solvent in which bicuculline was 
initially dissolved.  
 Our results demonstrated that the addition of 50 µM bicuculline to MSN cultures 
at any developmental stages had deleterious effects on cell survival, causing a 
prominent loss of MSNs. We concluded that at this dose, bicuculline is toxic. This was 
likely to be a consequence of the complete inhibition of GABAAR activity which had 
irreversible effects on cell survival. Thus, we decided to treat MSNs with bicuculline at 
25 μM dose which was sufficient to block GABAergic activity (established in 
electrophysiological recordings) without causing toxicity.  
 Once these conditions were confirmed, GABAergic synapse formation was 
analysed during maturation of MSNs in vitro. When neurones were chronically treated 
from 4 to 7 DIV, the density of GABAAR clusters was not affected. This result indicated 
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that at this early developmental stage, the density of GABAAR clusters per dendrite is 
not regulated by the depolarising GABA signalling. In contrast, under the same 
conditions, the median size of all α2-single or mixed clusters was decreased. This 
suggests that at early developmental stages, GABAAR activity is important for 
clustering α2-containing GABAARs specifically and that in absence of this signalling, 
the α2-containing GABAAR clusters are down-regulated. Additionally, the density of 
presynaptic terminals contacting dendrites of MSNs was not affected by blocking 
GABAARs, suggesting that at early developmental stages in culture, wiring between 
MSNs is not regulated by GABA signalling. Other mechanisms such as adhesion 
molecules recognition between the pre and postsynaptic elements could be at the 
origin of GABAergic wiring.  
 When neurones were chronically treated from 7 to 14 DIV with 25 µM 
bicuculline, different phenotypes were observed. At a time when GABA is 
hyperpolarising, blocking this signal increased the density and the size of α2-containing 
GABAARs. In contrast, the size of α1-containing GABAARs was decreased significantly 
upon this treatment. As observed in early developmental stage treatments, the density 
of GAD-65 positive terminals contacting MSN dendrites was not altered by blocking 
GABA signalling. These results suggest that when MSNs are deprived of GABA 
signalling at a time it becomes hyperpolarising; compensatory mechanisms involving 
clustering of GABAARs are preferentially driven towards the formation of the α2-
containing synapses. The α2-containing receptors function is probably broader as they 
are known to be involved in diverse processes such as reward and alcohol/drug abuse, 
schizophrenic symptomatology, depression and chronic pain (Engin et al., 2012). 
However, so many implications could not be directly reflecting the reason why the 
formation of α2-containing receptors is promoted in the absence of GABA signalling in 
MSNs. This increase of the α2-containing GABAARs clustering in a GABA signalling-
deprived context could be explained by the fact that this subunit is preferentially 
localised to proximal dendrites of MSNs (Gross et al., 2011). Considering that we only 
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characterised synapse formation in the region of proximal dendrite, different regulatory 
mechanisms could be occurring at the same time in the soma or axons of MSNs and 
may involve a modulation of other GABAAR subtypes.  
In addition, the fact that α1-containing synapses were down-regulated in absence of 
GABA signalling suggested that at this developmental stage, when GABA is 
hyperpolarising, α1-containing synapses are promoted and maintained by GABAAR 
activity. This was confirmed in the previous chapter in which we showed that the size of 
α1 mixed cluster is increased from 7 to 14 DIV. Potentially, this could be explained by 
the fact that α1 subunit has the highest GABA sensitivity of all synaptic α subunits 
(Bohme et al., 2004), and so, is the most efficient subunit in transducing the GABA 
signalling. Nevertheless, when GABA signalling is blocked, the α2 subunit, which is the 
most prominent subunit in the striatum (Fritschy and Mohler, 1995), is preferentially 
incorporated into GABAAR clusters. It would be interesting to further the relevance of 
such mechanisms in an in vivo model where GABA signalling is altered and to confirm 
these results with pharmacology and electrophysiological recordings. 
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7. The formation of GABAergic synapses is enhanced in the presence of the 
exogenous extracellular domains (ECDs) of GABAA R α1 and α2 subunits 
 
7.1 Introduction 
 While in the previous chapter, we studied the role played by the activity of 
GABAARs, in the present chapter, we investigated the structural role played by 
GABAARs during GABAergic synapse formation. 
Structural heterogeneity of GABAARs is thought to be the basis of their 
physiological and pharmacological heterogeneity (Olsen and Sieghart, 2009). Each 
subunit of the GABAARs is composed of a large N-terminal extracellular domain of 200-
250 amino acids, four transmembrane domains with an M3-4 intracellular loop of 85-
255 residues, and a small C-terminal extracellular domain (Karlin and Akabas, 1995).  
Many studies have focused on the role played by the intracellular loop of GABAAR 
α subunits, showing their role in intracellular protein-protein interactions involved in the 
clustering and stability of GABAARs at synapses by binding to Gephyrin and Neuroligin 
2 (Kneussel et al., 1999, Jacob et al., 2005, Tretter et al., 2008, Poulopoulos et al., 
2009, Mukherjee et al., 2011, Tretter et al., 2011). However, little is known about the 
structural role played by the extracellular domains of GABAA receptor subunits. 
Assembly of GABAARs into pentamers involves the initial formation of αβ subunit 
heterodimers. The N-terminal extracellular domains of α and β subunits associate 
within the luminal part of the endoplasmic reticulum with two chaperone proteins 
involved in the folding control quality called Binding Immunoglobulin Protein (BiP) and 
Calnexin (Connolly et al., 1996a, Kleizen and Braakman, 2004 , Arancibia-Carcamo 
and Kittler, 2009, Luscher et al., 2011). In addition, GABA binding sites and binding 
sites for clinically important drugs such as benzodiazepines, are also located in the N-
terminal extracellular domain (Homanics et al., 1997). While the GABA binding site is 
located between the extracellular domains of α and β subunits, the benzodiazepine 
binding site is located in a pocket between the ECDs of α and γ subunits (Ernst et al., 
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2003, Henschel O, 2008, Olsen and Sieghart, 2008). The binding of each of these 
molecules between the GABAAR subunits causes a conformational change in the 
receptor, opens the channel gate and allows the entrance (or exit) of chloride ions into 
the postsynaptic cell (Macdonald and Olsen, 1994). 
Using radioligand binding assays and electrophysiology combined with 
mutagenesis, four amino acids within the extracellular domain of the α subunits have 
been shown to mediate the distinct sensitivity to GABA (Bohme et al., 2004). The 
exchange of the whole motif between different subunit conferred the respective GABA 
sensitivity for most receptors. This study provided a better understanding of the 
mechanistic features responsible for the molecular diversity of GABAergic synapses 
and hence, emphasized on the important role played by individual α subunits in the 
transmission of the GABAergic signal. 
 In addition, the first crystallisation of the GABAAR β3 homopentamer revealed 
that GABAAR ECDs are composed of structural elements unique to eukaryotic Cys-
loop receptors, but more importantly that the highly conserved N-glycans present on 
the ECDs of all the subunits play an important role in the structural assembly of the 
receptor, in the signal transduction of GABAAR ligands and in gating process of the 
receptor (Miller and Aricescu, 2014). 
Finally, it has recently been shown that GABAARs play a structural role during 
GABAergic synapse formation and are capable to promote this process in a 
heterologous co-culture model system (Fuchs et al., 2013). A particular interest should 
be focused on the structure and function of the extracellular domains of GABAAR 
subunits in this process since these domains are present in the synaptic cleft and so, 
they may be responsible for initiation of first contact between the pre- and postsynaptic 
elements.  
Together, these data suggest that the extracellular domains play an important 
role in the global functioning of the GABAARs. In the last chapter of my thesis, we 
aimed to define and investigate the role played by the ECDs of α1 and α2 subunits 
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during specific GABAergic synapse formation.  Purified α1 and α2 ECDs from infected 
Sf9 cells under sterile conditions, and prepared Sf9 cell protein extracts. 
7.1.1 Aims  
In this chapter, our aims were: 
1. We proved that purified α1 and α2 ECDs were glycosylated using 
deglycosylation enzyme assay. 
2. We have treated embryonic MSN cultures with the purified α1 or α2 ECDs, 
and applied Sf9 cell protein extracts as a control.  
3. We have investigated the structural role played by the exogenous α1 or α2 
ECDs during GABAergic synapse formation by analysing the density, size 
and synaptic location of GABAAR clusters. 
7.2 Methods 
7.2.1 Purification of ECDs under sterile conditions  
 Cultures of Sf9 cells grown in suspension and infected with baculovirus stocks 
were spun down and resuspended in the filtered lysis buffer containing 20 mM 
NaH2PO4 pH 8.0, 0.5 % NP-40 and protease inhibitors cocktail. After three freeze/thaw 
cycles, lysates were centrifuged at 10,000 g for 15 min at 4 ºC using a MIKRO 22R 
Hettich Zentrifugen centrifuge (14,000 g rotor). The pellets were collected and 
resuspended in the filter-sterilised solubilisation buffer containing 50 mM NaH2PO4, 150 
mM NaCl pH 8.0, 2 % NP-40, 1 % DOC. Subsequently, the samples were 
homogenised with a sintered-glass homogeniser (4-5 strokes on ice) and incubated for 
90 min on a rotating plate at 4 ºC to solubilise. After rotating, the proteins were spun at 
10,000 g for 15 min at 4 ºC; the pellets were resuspended in the solubilisation buffer 
and snap-frozen for further analysis. The supernatant containing the proteins was 
dialysed against the dialysis buffer containing 50 mM NaH2PO4, 300 mM NaCl, pH 8, 1 
% Triton X-100. The following day, 1 mg of total protein was added to sterile 0.2 ml 
resin columns (HisPur Ni-NTA spin column, 0.2 ml resin bed, Thermo Scientific) 
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prepared in filtered binding buffer (dialysis buffer with the addition of 20 % sterile 
glycerol). The proteins were incubated for binding overnight at 4 ºC with rotation. The 
Ni-NTA agarose columns were chosen because they are composed of nitrilotriacetic 
acid (NTA), a tetradentate chelating ligand, in highly cross-linked 6 % agarose matrix. 
NTA binds Ni2+ ions by four co-ordination sites which allow 6 Histidine-tagged proteins 
to bind with micro molar affinity. The binding capacity of the resin is 5-10 mg of 
recombinant protein per ml of resin. The following day, three washes were performed in 
400 µl binding buffer and two more washes were carried out with the same buffer in the 
absence of Triton X-100, in order to remove any trace of this non-ionic detergent from 
the proteins. Subsequently, columns were incubated on a rotating plate, overnight at 
room temperature with 400 µl of the elution buffer containing 50 mM NaH2PO4, 300 mM 
NaCl, pH 6.0, 100 mM EDTA, 500 mM imidazole, and protease inhibitors cocktail. The 
next day, columns were spun and the first elution fraction (E1) was collected. Two 
subsequent elutions were also carried out for 10 min at room temperature (E2 and E3). 
Finally, elution fractions were dialysed overnight at 4 ºC in PBS containing 300 mM 
NaCl. The protein concentration was measured using the Bradford Assay; small 
aliquots of protein samples were prepared and snap frozen in liquid nitrogen. At each 
stage of purification, small fractions of samples were collected, denatured in 2 % SDS 
and analysed by SDS/PAGE and immunoblotting with the Histidine-tag specific 
antibody (see Chapter 2, section 2.8-2.9 for immunoblotting details). As a control, we 
have eluted proteins from non-infected Sf9 cells in parallel with the samples containing 
α1 and α2 ECDs.  
7.2.2 Deglycosylation of ECDs  
In the amino-acid sequence of the α1 and α2 ECDs there are two and three N-
glycosylation sites, respectively (Miller and Aricescu, 2014). Deglycosylation 
experiments were performed under denaturing conditions with 20 µg of purified α1 and 
α2 ECDs using the glycoprotein, deglycosylation kit, Millipore). The Sf9 cell extracts 
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and Bovine fetuin protein were run alongside the ECDs, as positive controls. Samples 
were dissolved in 5 X reaction buffer (250 mM sodium phosphate buffer, pH 7) and 
denaturation solution containing 2 % SDS/ 1M β-mercaptoethanol, pH 7.0 and boiled at 
100 ºC for 5 min. After cooling, Triton X-100 detergent solution was added in excess in 
order to complex any free SDS which could reduce the rate of the N-glycosidase F 
cleavage. Then, 1 µl of each enzyme was added (see list below) and incubated with 
the proteins for 3 hours at 37 ºC. Although there is no evidence that the α1 and α2 
ECDs are O-glycosylated, we used a mixture of the following deglycosylation enzymes 
to test if the purified ECDs incorporated any oligosaccharides: 
 N-glycosidase F: this enzyme cleaves all asparagine-linked complex, hybrid, or 
high mannose oligosaccharides. 
 Endo-α-N-acetylgalactosaminidase: this enzyme cleaves serine- or threonine- 
linked unsubstituted Galβ1,3GalNaca. 
 The α2-3,6,8,9-Neuraminidase: this enzyme cleaves all the non-reducing 
terminal branched and unbranched sialic acids.  
 The β1,4-Galactosidase: this enzyme releases only β1,4-linked, non-reducing 
terminal galactose from complex carbohydrates and glycoproteins. 
 The β-N-Acetylglucosaminidase: this enzyme cleaves all non-reducing terminal 
β-linked-N-acetylglucosamine residues from complex carbohydrates and 
glycoproteins. 
Each of the reactions was loaded on two different 12 % SDS/PAGE. Then, they 
were transferred onto the nitrocellulose membrane and, after blocking with 1.5 % milk/ 
TBS-Tween 20, membranes were incubated with the Histidine-tag specific antibodies in 
1.5 % milk/ TBS-Tween 20 overnight at 4 ºC. After washing, the membranes were 
incubated with an alkaline-phosphatase conjugated secondary antibody and the 
immuno-reactivity was visualised using a colour reaction based on NBT/ BCIP 
substrate (see chapter 2, sections 2.8-2.9 for details on immunoblotting).  
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7.2.3 Treatment of MSN cultures with α1 or α2 ECDs  
To analyse the role of the N-terminal extracellular domains of α1 and α2 
GABAAR subunits during synapse formation, E17 striatal neurones were cultured and 
treated from 4 to 7 DIV or 7 to 14 DIV with 5 µg of the eluted control Sf9 cell extracts or 
α1 ECDs or α2 ECDs. In the first set of treatments, these reagents were added at 4 
and 6 DIV and the cells were fixed at 7 DIV. In the second set of experiment, neurones 
were treated with 5 µg of control Sf9 cell extracts or α1 ECDs or α2 ECDs at 7, 9 and 
11 DIV and subsequently fixed at 14 DIV. 
7.2.4 Immunocytochemistry 
Immunocytochemistry was performed as described in the Chapter 2, Section 2.2. 
Neurones cultured for 7 or 14 DIV were fixed using 4 % PFA/ sucrose for 12 min at 
room temperature. After fixation, they were incubated with 0.3 M glycine in PBS in 
order to quench the PFA. After washing, cells were incubated in 2 % BSA in PBS for 1 
h and subsequently incubated with specific antibodies. In order to visualise the binding 
of the exogenous α1 or α2 ECDs, neurones were incubated with rabbit anti-α1 and 
guinea-pig anti-γ2, or guinea-pig anti-α2 and rabbit anti-γ2 antibodies, respectively 
(Figure 107 and 108 for treatment from 4 to 7 DIV; Figure 118 and 119 for treatment 
from 7 to 14 DIV), each specifically binding to the N-terminal domains of the 
corresponding subunit, diluted in 2 % BSA in PBS, overnight at 4 ºC (14- 16 h, Table 
28). Neurones were then permeabilised by incubation with 0.1 % Triton X-100 / 2 % 
BSA in PBS for 15 min. They were subsequently incubated with chicken anti-MAP2 
antibody (see Table 26 for dilutions) diluted in 2 % BSA in PBS for 2 h at room 
temperature. Following this step, fluorescently-labelled secondary antibodies were 
added as described in the Chapter 2, Section 2.2 (Table 28).  
In a second set of experiments (Figures 109 and 120), immunolabelling was done 
using a mouse anti-6Histag proteins antibody in combination with the guinea-pig anti- 
γ2 subunit antibody overnight at 4 ºC. The following day, neurones were permeabilised 
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as described above and incubated with chicken anti-MAP2 and rabbit anti-VGAT 
antibodies for 2 h, followed by incubation with fluorescently labelled secondary 
antibodies which were added as described in the Chapter 2, Section 2.2 (antibodies 
used in these experiments are described in Table 26).  
In a third set of experiments (Figures 110 and 121), neurones treated with the ECDs, 
were fixed and stained with the guinea-pig anti-γ2 antibody specifically binding to the 
extracellular domain of γ2 subunit, overnight at 4 ºC. The following day, neurones were 
permeabilised as described above and incubated with mouse anti-GAD-65 and chicken 
anti-MAP2 antibodies (See Table 26 for description). The protocol previously described 
for immunocytochemistry was followed throughout the staining.  
In a fourth set of experiments (Figures 117 and 128), neurones treated with the ECDs 
were fixed and stained with the guinea-pig anti-γ2 antibody specifically binding to the 
extracellular domain of γ2 subunit, overnight at 4 ºC. The following day, neurones were 
permeabilised as described above and incubated with mouse anti- gephyrin, rabbit 
anti-VGAT and chicken anti-MAP2 antibodies (see Table 26 for description). The 
protocol previously described for immunocytochemistry was followed throughout the 
staining. In all four sets of experiments, immunolabelling was analysed using Zeiss 
LSM 710 with a Plan-Apochromat 63x/ 1.4 Oil DIC lens. Threshold for each channel 
was calculated from the background intensity and then removed from the image, as 
described in the Chapter 2, Section 2.2.  
7.2.5 Analysis of synaptic parameters 
To estimate the density and size of γ2-containing GABAAR clusters, puncta 
were defined as immunoreactivity greater than 0.1 µm2, with the mean intensity of each 
cluster equal or higher than double the standard deviation of intensity as indicated by 
the Zen 2009 programme. The defined clusters were circled and their sizes noted by 
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hand. The total density of γ2-positive clusters and GAD-65-positive presynaptic 
terminals were analysed using Excel and Origin programmes.  
 
7.2.6 Statistical analysis  
Subsequently, the data was analysed using Origin Pro 9.0 32 Bit software. Normal 
(Gaussian) distribution of the pooled data was first tested using the Shapiro-Wilk and 
Kolmogorov-Smirnov tests. Since the data did not follow a normal distribution and the 
categories were independent, non-parametric statistical analysis was carried out using 
the Mann Whitney test with an interval of confidence of 95 %. Because they represent 
a robust measure of central tendency when distributions are not normally distributed, 
the medians and their interquartile range (IQR) were used to describe the data and 
evaluate statistical dispersion. With the groups following normal distribution, statistical 
analysis was done using two sample Student’s t-test. The total density of clusters was 
evaluated along the length of 20 µm of primary dendrite for each cell. The density of 
synaptic clusters was also evaluated along the 20 μm of dendrites for each cell in a 
whole population of clusters. The proportion of synaptic clusters was determined as a 
percentage of the total clusters for each dendrite. The proportion of the synaptic 
clusters/total clusters was tested as above and subsequently compared using 
parametric (Student’s t-test) or non-parametric statistical tests (Mann-Whitney). 
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Table 28. Antibodies used for immunocytochemical analysis of GABAAR clusters 
and presynaptic terminals in MSN cultures 
 
7.3 Results 
GABAARs, the essential functional components of the inhibitory synapses in the 
brain, have recently been demonstrated to play a structural role during synapse 
formation by promoting the adhesion of inhibitory axon terminals (Fuchs et al., 
2013). The aim of the present study was to investigate whether these synaptogenic 
effects may be mediated by the large N-terminal extracellular domains (ECDs) of 
GABAARs. Towards this aim, we have cloned and expressed the glycosylated N-
terminal ECDs of the α1 and α2 subunits of GABAARs (α1 and α2 ECDs) using the 
Bac-to-Bac CT-TOPO expression system in Sf9 cells (see Chapter 3).  
 
Primary antibodies Secondary antibodies 
Specificity Origin dilutions 
Source and 
characterisation 
Antibodies 
(host: 
Goat) 
Dilutions 
Source 
(Alexa 
Fluor, 
Invitrogen) 
GABAA α1 Rb 1:200 
(Duggan and 
Stephenson, 
1990) 
Anti-rabbit 
555 
1:750 A31556 
GABAA γ2 Gp 1:3000 
(Fujiyama et al., 
2000) 
Anti-
guinea-pig 
488 
1:750 A11073 
GABAA α2 Gp 1:250 
Synaptic System, 
224104 
Anti- 
guinea-pig 
488 
1:750 A11073 
GABAA γ2 Rb 1:500 
Synaptic System, 
224003 
Anti-rabbit 
555 
1:750 A31556 
6xHis-tag Ms 1:500 
GeneTex 
3H2201 
Anti-mouse 
555 
1:750 A21422 
VGAT Rb 1:500 
Synaptic System, 
131013 
Anti-rabbit 
555 
1:750 A31556 
GAD-65 Ms 1:4000 Abcam, ab26113 
Anti-mouse 
555 
1:750 A21422 
MAP2 Ch 1:2500 Abcam, ab92434 
Anti-
chicken 
647 
1:750 A21469 
Gephyrin Ms 1:500 
Synaptic System, 
147111 
Anti-mouse 
405 
1:750 A31553 
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7.3.1 Purification of α1 and α2 ECDs under sterile condition  
In the present chapter, we have established a protocol for the purification of 
these two proteins and confirmed that they were glycosylated proteins. In order to 
test whether these ECDs would affect the formation of synaptic contacts, we 
treated developing MSN cultures, at different time intervals, with the purified α1 
and α2 ECDs. As the purified ECDs were added throughout the development of 
MSNs, these proteins had to be purified under sterile conditions. Therefore, we 
decided to use pre-stacked Ni-NTA columns and all the steps of purification of α1, 
α2 ECDs and control Sf9 cell extracts were carried out under sterile conditions. As 
we tried to purify these proteins in a sufficient amount, each step of the protocol 
was changed and optimised until the best extraction, binding and elution conditions 
were reached. One of the most important steps was to completely remove Triton X-
100 from our samples to avoid lysis of cells and cell death. Once these steps were 
optimised, 5 μg (0.38 µM) of the α1, α2 ECDs and control Sf9 cell extracts were 
added to the cell culture.  
Figure 105 shows the protein distribution of α1 and α2 ECDs through purification 
after transferring onto a nitrocelllose membrane and immunoblotting with anti- 
Histidine Tag antibody. Both α1 and α2 ECDs were present in the input lane 
indicating that we were able to extract a considerable amount of proteins from Sf9 
infected cells. Proteins were not detected in the supernatant after binding, 
indicating that the binding step was efficient and that the binding was within the 
binding capacity of the column. A significant amount of each protein was found in 
the first elution fraction indicating that bound proteins were efficiently eluted from 
the column at this step. However, some quantity of α1 an α2 ECDs was found 
bound to beads even after the third elution, indicating that this fraction was not 
efficiently removed from the column under these elution conditions.  
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Figure 105. The purification of extracellular domains of α1 and α2 subunits of GABAARs 
using Ni-NTA pre-stack columns. Immunoblot analysis of fractions collected during the 
purification of α1 and α2 ECDs as Histidine-tagged proteins. Non-infected Sf9 cell extracts 
were used as a negative control throughout the experiment. Samples were collected 
throughout the purification and lysed with 2 % SDS. Total of 80 μl of each sample was 
loaded on the SDS/PAGE and transferred onto the nitrocellulose membrane. The 
membranes were then incubated with a mouse anti-6xHis-tag antibody, followed by the 
incubation with the alkaline phosphatase-conjugated secondary antibody. A. Immunoblot 
showing the purification steps of α1 ECDs. B. Immunoblot showing the purification steps of 
α2 ECDs. The first lane represents the extracts of α1- or α2- baculovirus infected Sf9 cells. 
The second lane shows the supernatant after binding. The five next lanes represent the 
washing steps of the column after binding. The three next lanes represent the elution steps 
from the Ni-NTA column (E1-3). The last lane shows the remaining ECDs left bound to the 
beads after the last elution. C. Immunoblot showing the purification steps of non-infected 
Sf9 cell extracts. The first lane represents the extracts from non- infected Sf9 cells. The 
second lane shows the supernatant after binding. The four next lanes represent the 
washing steps of the column after binding with the extracts from non- infected Sf9 cells.  
7.3.2 Deglycosylation of α1 and α2 ECDs  
As observed previously, our purification experiments have revealed different 
molecular weight bands immunoreactive with the 6xHis-tag-specific and α1 and α2-
extracellular domains-specific antibodies. Sequence analysis using Uniprot 
Knowledgebase (UniprotKB) has suggested that the extracellular domains of α1 and α2 
GABAAR subunits incorporate potential glycosylation sites for N-linked 
oligosaccharides (source for α1 subunit: http://www.uniprot.org/uniprot/P62812; source 
for α2 subunit: http://www.uniprot.org/uniprot/P26048). These two mouse sequences 
contained two or three glycosylation sites each: α1 ECD could potentially be 
glycosylated on Asn 37 and Asn 137, while α2 ECD could potentially be glycosylated 
on Asn 38 and Asn 138, and maybe Asn 114 (only found in the rat sequence so far). 
The deglycosylation experiments were performed using the glycoprotein 
deglycosylation kit from Millipore. This kit contains all enzymes and reagents needed to 
remove all N-linked and O-linked oligosaccharides from glycoproteins. The 
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deglycosylation was performed in denaturing conditions with 20 μg of α1 and α2 ECDs, 
and samples were analysed using immunoblotting with anti-α1 or α2 extracellular 
domains-specific antibodies.  
Figure 106 shows the purified α1 and α2 ECDs incubated in absence or in 
presence of the deglycosylating enzymes. Both α1 and α2 ECDs are recognised by 
their specific antibodies, respectively, as indicated by the typical pattern of two or 
three bands detected in both immunoblots. In both cases, the pattern of bands 
changed after incubating the extracellular domains with deglycosylating enzymes, 
and the bands were detected at the lowest molecular weight. This shift to the 
lowest molecular weight observed after incubation indicated the efficient removal of 
glycosylation groups from purified of α1 and α2 ECDs. In both α1 and α2 ECD 
immunoblots, the highest molecular weight band is likely to represent the isoform 
containing N-linked oligosaccharides at all the potential glycosylated sites, while 
the middle molecular weight band(s) is likely to represent the isoform(s) only partly 
glycosylated. Finally, the lowest bands of the two extracellular domains of α1 and 
α2 GABAAR subunits detected at the predicted molecular weight (between 26 and 
27 kDa) likely represent the isoforms which were not glycosylated. 
Figure 106. The α1 and α2 ECD purified from infected Sf9 cells are glycosylated. 
Immunoblot analysis following incubation of the purified α1 (A) or α2 ECDs (B) in absence or in 
presence of deglycosylating enzyme mix. After incubation, samples (20 µg) were collected and 
loaded on the SDS/PAGE and transferred onto the nitrocellulose membranes. The membranes 
were then incubated with anti-histidine tag specific antibody, followed by the incubation with the 
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alkaline phosphatase-conjugated secondary antibodies. Representative blots from two 
independent experiments. 
 
 
7.3.3 Treatment of 4-7 DIV MSN cultures with purified α1 or α2 ECDs  
7.3.3.1 Treatment of MSN cultures with α1 or α2 ECDs from 4 to 7 DIV 
revealed that the exogenous proteins adhere to the neuronal cell surface  
We have demonstrated that we were able to purify glycosylated α1 and α2 
ECDs by affinity chromatography using Ni-NTA resin columns. Our next aim was to 
investigate how the addition of these proteins to the MSN in culture affects the 
formation of GABAergic synapses. We have decided to test this by adding 5 μg of the 
purified proteins to cultured MSNs from 4 to 7 DIV. Subsequently, synapse formation 
was analysed using immunocytochemistry and confocal imaging. 
Figure 107 shows an example of each of i) untreated 7 DIV neurones (A-D), ii) 
neurones treated from 4 to 7 DIV with control Sf9 cell extracts (E-H), and iii) neurones 
treated with the α1 ECDs (I-L). After fixation, these neurones were stained with the 
rabbit anti-α1 extracellular domain and guinea-pig anti-γ2 extracellular domain specific 
antibodies. After permeabilisation, they were incubated with the chicken anti-MAP2 
specific antibody. Similarly, Figure 108 shows an example of each of i) untreated 7 DIV 
neurones (A-D), ii) neurones treated from 4 to 7 DIV with the control Sf9 cell extracts 
(E-H), and iii) neurones treated with the α2 ECDs (I-L). After fixation, these neurones 
were stained with the guinea-pig anti-α2 extracellular domain and rabbit anti-γ2 
extracellular domain specific antibodies. After permeabilisation, they were incubated 
with the chicken anti- MAP2 specific antibody (see Table 28 for details). Figure 109 
shows an example of each of i) 7 DIV neurones treated from 4 to 7 DIV with control Sf9 
cell extracts (A-E), ii) neurones treated from 4 to7 DIV with α1 ECDs (F-J), and iii) 
neurones treated from 4 to 7 DIV with α2 ECDs (K-O). After fixation, these neurones 
were stained with the mouse anti-6xHis-tag proteins and guinea-pig anti-γ2 
extracellular domain specific antibodies. After permeabilisation, they were incubated 
with the chicken anti-MAP2 and rabbit anti-VGAT specific antibodies (see Table 26 for 
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details). The adhesion of the exogenous α1 and α2 ECDs to the cell surface of MSNs 
was visualised using confocal microscopy after immunolabelling with the N-terminal 
specific antibodies. The added proteins were present in the extracellular space and 
also on the surface of cultured neurones, but with this antibody combinations, they 
were not distinguishable from the endogenous subunit of receptors (Figure 107 and 
108). To visualise the localisation of the exogenous α1 and α2 ECDs, we decided to 
stain neurones with the anti-6xHis-tagged proteins together with anti-γ2 extracellular 
domain specific antibodies (Figure 110). This immunolabelling confirmed that the 
exogenous ECDs adhered to the cell surface of MSNs and were also sparsely 
distributed in the extracellular space. 
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Figure 107. The exogenous α1 ECDs adhere to the cell surface of MSNs treated from 4 to 
7 DIV but are not distinguishable from endogenous α1- containing GABAARs. 
Immunolabelling of GABAARs containing the γ2 subunit (green) and the α1 subunit (red) at the 
cell surface of cultured MSNs. Somatodendritic compartment is labelled with the MAP2 antibody 
(blue). A. Merged image of a 7 DIV MSN untreated (scale bar=10 μm). B. Enlarged image of the 
boxed region in A representing γ2 staining only. C. Enlarged image of the boxed region in A 
representing α1 staining only. D. Enlarged image of the boxed region in A showing all the three 
channels (scale bar=5 μm). E. Merged image of a 7 DIV MSN treated with control Sf9 cell 
extracts (scale bar=10 μm). F. Enlarged image of the boxed region in E representing γ2 staining 
only. G. Enlarged image of the boxed region in E represeing α1 staining only. H. Enlarged 
image of the boxed region in E showing all the three channels (scale bar=5 μm). I. Merged 
image of a 7 DIV MSN treated with the α1 ECDs (scale bar=10 μm). J. Enlarged image of the 
boxed region in I representing γ2 staining only. K. Enlarged image of the boxed region in I 
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representing α1 staining only. L. Enlarged image of the boxed region in I representing all the 
three channels (scale bar=5 μm). 
 
Figure 108. The exogenous α2 ECDs adhere to the cell surface of MSNs treated from 4 to 
7 DIV but are not distinguishable from endogenous α2- containing GABAARs. 
Immunolabelling of GABAARs containing the γ2 subunit (red) and the α2 subunit (green) at the 
cell surface of cultured MSNs. Somatodendritic compartment is labelled with the MAP2 antibody 
(blue). A. Merged image of a 7 DIV MSN untreated (scale bar=10 μm). B. Enlarged image of the 
boxed region in A representing γ2 staining only. C. Enlarged image of the boxed region in A 
representing α2 staining only. D. Enlarged image of the boxed region in A showing all the three 
channels (scale bar=5 μm). E. Merged image of a 7 DIV MSN treated with control Sf9 cell 
extracts (scale bar=10 μm). F. Enlarged image of the boxed region in E representing γ2 staining 
only. G. Enlarged image of the boxed region in E representing α2 staining only. H. Enlarged 
image of the boxed region in E showing all the three channels (scale bar=5 μm). I. Merged 
image of a 7 DIV MSN treated with the α2 ECDs (scale bar=10 μm). J. Enlarged image of the 
boxed region in I representing γ2 staining only. K. Enlarged image of the boxed region in I 
representing α2 staining only. L. Enlarged image of the boxed region in I representing all the 
three channels (scale bar=5 μm). 
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Figure 109.The histidine-tagged α1 and α2 ECDs adhere to the cell surface of medium 
spiny neurones treated from 4 to 7 DIV. Immunolabelling of the exogenous α1 and α2 ECDs 
using 6xHis-tag antibody (red), γ2-containing GABAARs (green) and the VGAT positive 
presynaptic terminals (cyan). The somatodendritic tree is labelled with the MAP2 antibody 
(blue). A. Merged image of a 7 DIV MSN treated with control Sf9 cell extracts (scale bar=10 
μm). B. Enlarged image of the boxed region in A representing 6xHis-tag proteins staining only. 
C. Enlarged image of the boxed region in A representing γ2 staining only. D. Enlarged image of 
the boxed region in A representing VGAT staining only. E. Enlarged image of the boxed region 
in A representing all three channels (scale bar=5 μm). F. Merged image of a 7 DIV MSN treated 
with the α1 ECDs (scale bar=10 μm). G. Enlarged image of the boxed region in F representing 
6xHis-tag proteins staining only. H. Enlarged image of the boxed region in F representing γ2 
staining only. I. Enlarged image of the boxed region in F representing VGAT staining only. J. 
Enlarged image of the boxed region in F representing all the three channels (scale bar=5 μm). 
K. Merged image of a 7 DIV MSN treated with the α2 ECDs (scale bar=10 μm). L. Enlarged 
image of the boxed region in K representing 6xHis-tag proteins staining only. M. Enlarged 
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image of the boxed region in K representing γ2 staining only. N. Enlarged image of the boxed 
region in K representing VGAT staining only. O. Enlarged image of the boxed region in K 
representing all the three channels (scale bar=5 μm).  
 
7.3.3.2 The total density of γ2-containing GABAARs per dendrite of 
MSNs is increased after the treatment with α1 or α2 ECDs from 4 to 7 DIV 
 It has been established that the γ2 subunit is mostly found at synaptic contacts 
(Somogyi et al., 1996). To test if the addition of α1 or α2 ECDs affects the formation of 
synapses, developing MSNs were treated with the control Sf9 cell extracts, α1 ECDs or 
α2 ECDs from 4 to 7 DIV, fixed and immunolabelled with γ2-, GAD-65- and MAP2-
specific antibodies (Figure 110). The properties of γ2-containing GABAAR clusters, i.e. 
the total density and the size, were analysed using confocal imaging.  
267 
 
 
Figure 110. The density and the size of γ2-containing GABAAR clusters are increased 
after the treatment of MSNs with the α1 or α2 ECDs from 4 to 7 DIV. Immunolabelling of 
GABAARs containing the γ2 subunit (green) and of the presynaptic terminals containing GAD-65 
(red) along the primary dendrites of cultured MSNs stained for MAP2 (blue). A. Merged image 
of a 7 DIV striatal neurone treated with control Sf9 cell extracts (scale bar=10 μm). B. Enlarged 
image of the boxed region in A representing γ2 staining only. C. Enlarge image of boxed region 
in A representing GAD-65 staining only. D. Enlarged image of the boxed region in A 
representing γ2 and GAD-65 staining. E. Enlarged image of the boxed region in A showing all 
the three channels (scale bar=5 μm). F. Merged image of a 7 DIV striatal neurone treated with 
α1 ECD (scale bar=10μm).G. Enlarged image of the boxed region in F representing γ2 staining 
only. H. Enlarged image of the boxed region in F representing GAD-65 staining only. I. Enlarged 
image of the boxed region in F representing γ2 and GAD-65 staining. J. Enlarged image of the 
boxed region in F showing all the three channels (scale bar= 5μm). K. Merged image of a 7 DIV 
striatal neurone treated with the α2 ECDs (scale bar= 10μm). L. Enlarged image of the boxed 
region in K representing γ2 staining only. M. Enlarged image of the boxed region in K 
representing GAD-65 staining only. N. Enlarged image of the boxed region in K representing γ2 
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and GAD-65 staining. O. Enlarged image of the boxed region in K showing all the three 
channels (scale bar=5μm). 
 
The density of γ2- containing GABAAR clusters was estimated per defined length of 
primary dendrite (the first 20 μm from the cell body) after treatment with the control Sf9 
cell extracts or α1 ECDs from 4 to 7 DIV (Figure 111). The median density of γ2 
clusters was 4 (5.75-2) with the control Sf9 cell extracts treatment, compared to 6 (10-
3) with the α1 ECD treatment (p value=0.003, Mann-Whitney test; n=56 dendrites, and 
n=71 dendrites, respectively). This demonstrates that the total density of γ2 clusters is 
increased by the treatment, indicating that the exogenous α1 ECDs promote either the 
insertion of the γ2 subunit-containing GABAARs or their clustering, or both, at this 
developmental stage. 
Figure 111. The density of γ2-containing GABAAR clusters per primary dendrite of MSNs 
is increased by the treatment with α1 ECDs from 4 to 7 DIV.The density of γ2-containing 
GABAAR clusters along the first 20 μm of primary dendrites was counted in MSN cultures in the 
presence of control Sf9 cell extracts or α1 ECDs from 4 to 7 DIV. A. Histogram shows the 
distribution of γ2 cluster densities per dendrite in the presence of control Sf9 cell extracts or α1 
ECDs (n=56 and n=71 dendrites, respectively, from two independent experiments). B. Box plot 
displays the median density (50 % of the population) of γ2 clusters in the presence of control 
Sf9 cell extracts or α1 ECDs. Statistical analysis was performed using Mann-Whitney test: * 
corresponds to p < 0.05. 
 
The density of γ2-containing GABAAR clusters was estimated per defined length of 
primary dendrite (the first 20 μm from the cell body) after the treatment with the control 
Sf9 cell extracts or α2 ECDs from 4 to 7 DIV (Figure 112). The median density of γ2 
clusters was 4 (5.75-2) with the control Sf9 cell extracts treatment, compared to 6 (10-
4) with the α2 ECDs treatment (p value=4.21x10-5, Mann-Whitney test; n=56 dendrites, 
and n=57 dendrites, respectively). This demonstrates that the total density of γ2 
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clusters is increased by the treatment, indicating that the exogenous α2 ECDs promote 
either the insertion of the γ2 subunit-containing GABAARs or their clustering, or both, at 
this developmental stage. 
Figure 112. The density of γ2-containing GABAAR clusters per primary dendrite of MSNs 
is increased by the treatment with α2 ECDs from 4 to 7 DIV. The density of γ2-containing 
GABAAR clusters along the first 20 μm of primary dendrites was counted in MSN cultures in the 
presence of control Sf9 cell extracts or α2 ECDs from 4 to 7 DIV. A. Histogram shows the 
distribution of γ2 cluster densities per dendrite in the presence of Sf9 cell extracts or α2 ECDs 
(n=56 and n=57 dendrites, respectively, from two independent experiments). B. Box plot 
displays the median density (50 % of the population) of γ2 clusters in the presence of Sf9 cell 
extracts or α2 ECDs. Statistical analysis was performed using Mann-Whitney test: * 
corresponds to p < 0.05. 
 
Table 29. The density of γ2-containing GABAAR clusters per primary dendrite of 
MSN is increased by the α1 or α2 ECD treatments from 4 to 7 DIV 
 
7.3.3.3 The connectivity between MSNs is increased by the α1 or α2 
ECD treatments from 4 to 7 DIV 
To investigate further the structural role of GABAARs in GABAergic synapse 
formation, we applied extracellular domains of α1 or α2 subunits of GABAARs to MSN 
cultures from 4 to 7 DIV and estimated if the exogenous ECDs affect the density of 
presynaptic terminals forming contacts with the primary dendrites in these cultures. The 
total density of GAD-65 positive terminals per defined length of primary dendrite (the 
 Density of γ2 clusters at 7 DIV P < 0.05 
Sf9 cell extracts- Vs. α1- 
treated neurones 
 
Yes 
Sf9 cell extracts- Vs. α2-
treated neurones 
 
Yes 
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first 20 μm from the cell body) was estimated after the treatment with control Sf9 cell 
extracts or α1 ECDs from 4 to 7 DIV (Figure 113). After the control Sf9 cell extracts 
treatment, the median density of presynaptic terminals was 3 (5 - 1.25) compared to 6 
(9 - 3) after the treatment with α1 ECDs (p value = 5.34x10-6, Mann-Whitney test; n=60 
dendrites, and n=67 dendrites, respectively). This indicates that the density of 
presynaptic contacts per 20 μm primary dendrite is increased by the treatment with α1 
ECDs from 4 to 7 DIV, indicating that the connectivity between MSNs could be 
regulated by α1 ECDs early in development. 
Figure 113. The density of presynaptic terminals per primary dendrite of MSNs is 
increased after the α1 ECD treatments from 4 to 7 DIV. The density of presynaptic terminals 
along the first 20 μm of primary dendrites was counted in MSN cultures after the treatment with 
control Sf9 cell extracts or α1 ECDs from 4 to 7 DIV. A. Histogram shows the distribution of the 
density of presynaptic inputs after the treatment with control Sf9 cell extracts or α1 ECDs (n=60 
and n=67 dendrites, respectively, from two independent experiments). B. Box plot displays the 
median density of presynaptic terminals after the treatment with control Sf9 cell extracts or α1 
ECDs. Statistical analysis was performed using Mann-Whitney test: * corresponds to p<0.05. 
 
The total density of GAD-65 positive terminals per defined length of primary dendrite 
(the first 20 μm from the cell body) was estimated after the treatment with control Sf9 
cell extracts or α2 ECDs from 4 to 7 DIV (Figure 114). After the Sf9 cell extracts 
treatment, the median density of presynaptic terminals was 3 (5 - 1.25) compared to 6 
(8 - 4) after the treatment with α2 ECDs (p value = 1.72x10-6, Mann-Whitney test; n=60 
dendrites, and n=57 dendrites, respectively). This indicates that the density of 
presynaptic contacts per dendrite is increased by the treatment with α2 ECDs from 4 to 
7 DIV, indicating that the connectivity between MSNs could be regulated by α2 ECDs 
early in development. 
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Figure 114. The density of presynaptic terminals per primary dendrite of MSNs is 
increased after the α2 ECD treatments from 4 to 7 DIV. 
The density of presynaptic terminals along the first 20 μm of primary dendrites was counted in 
MSN cultures after the treatment with control Sf9 cell extracts or α2 ECDs from 4 to 7 DIV. A. 
Histogram shows the distribution of the density of presynaptic inputs after the treatment with 
control Sf9 cell extracts or α2 ECDs (n=60 and n=57 dendrites, respectively, from two 
independent experiments). B. Box plot displays the median density of presynaptic terminals 
after the treatment with control Sf9 cell extracts or α2 ECDs. Statistical analysis was performed 
using Mann-Whitney test: * corresponds to p<0.05. 
7.3.3.4 The size of γ2-containing GABAARs is increased after the 
treatment with α1 or α2 ECDs from 4  to 7 DIV 
We estimated whether the addition of the α1 or α2 ECDs affects the size of the 
γ2-containing GABAAR clusters in MSNs treated from 4 to 7 DIV. The size of γ2-
containing GABAAR clusters per defined length of primary dendrite (the first 20 μm from 
the cell body) was estimated after the treatment with control Sf9 cell extracts or α1 
ECDs from 4 to 7 DIV (Figure 115). After the treatment with control Sf9 cell extracts, 
the median size of γ2 clusters was 0.47 (0.61 - 0.36) μm2 compared to 0.52 (0.75 - 
0.35) μm2 with α1 ECDs (p value=0.01, Mann-Whitney test; n=243 clusters, and n=495 
clusters, respectively). This demonstrates that the size of γ2-containing GABAAR 
clusters is increased by the treatment with α1 ECDs from 4 to 7 DIV. This suggests that 
at this early stage of development, the exogenous α1 ECDs could promote the 
clustering of synaptic GABAARs. 
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Figure 115. The size of γ2-containing GABAAR clusters is increased by the treatment with 
α1 ECDs from 4 to 7 DIV. The size of γ2-containing GABAAR clusters along the first 20 μm of 
primary dendrites was measured in MSN cultures after the treatment with control Sf9 cell 
extracts or α1 ECDs from 4 to 7 DIV. A. Histogram shows the distribution of sizes of γ2 clusters 
per dendrite after the treatment with control Sf9 cell extracts or α1 ECDs (n=243 and n=495 
clusters, respectively, from two independent experiments). B. Box plot displays the median size 
(50 % of the population) of γ2 clusters after the treatment with control Sf9 cell extracts or α1 
ECDs. Statistical analysis was performed using Mann-Whitney test: * corresponds to p < 0.05. 
 
The size of γ2-containing GABAAR clusters per defined length of primary dendrite (the 
first 20 μm from the cell body) was estimated after the treatment with control Sf9 cell 
extracts or α2 ECD from 4 to 7 DIV (Figure 116). After the treatment with control Sf9 
cell extracts, the median size of γ2 clusters was 0.47 (0.61 - 0.36) μm2 compared to 
0.52 (0.66 - 0.40) μm2 with α2 ECDs (p value=4.35x10-4, Mann-Whitney test; n=243 
clusters, and n=436 clusters, respectively). This demonstrates that the size of γ2-
containing GABAAR clusters is increased by the treatment with α2 ECDs from 4 to 7 
DIV. This suggests that at this early stage of development, the exogenous α2 ECDs 
could promote the clustering of synaptic GABAARs. 
Figure 116. The size of γ2-containing GABAAR clusters is increased by the treatment with 
α2 ECDs from 4 to 7 DIV. The size of γ2-containing GABAAR clusters along the first 20 μm of 
primary dendrites was measured in MSN cultures after the treatment with the control Sf9 cell 
extracts or α2 ECDs from 4 to 7 DIV. A. Histogram shows the distribution of sizes of γ2 clusters 
per dendrite after the treatment with control Sf9 cell extracts or α2 ECDs (n=243 and n=436 
clusters, respectively, from two independent experiments). B. Box plot displays the median size 
(50 % of the population) of γ2 clusters after the treatment with control Sf9 cell extracts or α2 
ECDs. Statistical analysis was performed using Mann-Whitney test: * corresponds to p < 0.05. 
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Table 30. The size of γ2-containing GABAAR clusters per primary dendrite of 
MSN is increased by the treatment with α1 or α2 ECDs from 4 to 7 DIV 
7.3.3.5 Analysis of gephyrin clusters in MSN following the treatments 
with α1 or α2 ECDs from 4 to 7 DIV  
It has been established that, together with the γ2 subunit, the scaffolding protein 
gephyrin clusters contributes to the anchoring of GABAARs at inhibitory synapses 
(Essrich et al., 1998, Jacob et al., 2005). In cultured neurones, it has been shown that 
this protein facilitated α2-containing GABAAR clustering by a direct interaction with a 10 
amino acid sequence in the cytoplasmic loop of the α2 subunit (Tretter et al., 2008).  
In the present chapter, we were interested to establish whether the treatment with α1 or 
α2 ECDs would alter gephyrin clustering process during GABAergic synapse formation. 
Therefore, we decided to perform immunolabelling with the gephyrin specific antibody 
in MSN cultures treated with the control Sf9 cell extracts, α1 or α2 ECDs. Developing 
MSNs treated with the control Sf9 cell extracts, α1 ECDs or α2 ECDs from 4 to 7 DIV 
were immunolabelled with the mouse anti-gephyrin, rabbit anti-VGAT, guinea-pig anti-
γ2 and chicken anti-MAP2 specific antibodies. Changes in the density and size of 
gephyrin clusters were analysed by confocal microscopy (Figure 117). 
From this preliminary experiment, gephyrin clusters appeared to increase in both the 
size and the density after the treatment with α1 ECDs or α2 ECDs compared to Sf9 cell 
extracts treatment from 4 to 7 DIV. This would be consistent with the observed 
changes in the γ2-containing GABAAR clusters after treatment. However, statistical 
analysis must be performed to confirm these results. 
 
 
 Size of γ2 clusters at 7 DIV P < 0.05 
Sf9 cell extracts- Vs. α1- 
treated neurones 
 
Yes 
Sf9 cell extracts- Vs. α2- 
treated neurones 
 
Yes 
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Figure 117. The density and the size of gephyrin clusters appear to be increased after the 
treatment of MSN cultures with the α1 or α2 ECDs from 4 to 7 DIV. Immunolabelling of 
gephyrin (cyan), γ2 subunit (green) and the presynaptic marker VGAT (red). The 
somatodendritic compartment is labelled with the MAP2 antibody (blue). A. Merged image of a 
7 DIV striatal neurone treated with the control Sf9 cell extracts (scale bar=10μm). B. Enlarged 
image of the boxed region in A representing gephyrin staining only. C. Enlarge image of boxed 
region in A representing γ2 staining only. D. Enlarged image of the boxed region in A 
representing VGAT staining only. E. Enlarged image of the boxed region in A showing all the 
three channels (scale bar=5μm). F. Merged image of a 7 DIV striatal neurone treated with the 
α1 ECDs (scale bar=10μm). G. Enlarged image of the boxed region in F representing gephyrin 
staining only. H. Enlarged image of the boxed region in F representing γ2 staining only. I. 
Enlarged image of the boxed region in F representing VGAT staining. J. Enlarged image of the 
boxed region in F showing all the three channels (scale bar=5μm). K. Merged image of a 7 DIV 
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MSN treated with the α2 ECDs (scale bar=10μm). L. Enlarged image of the boxed region in K 
representing gephyrin staining only. M. Enlarged image of the boxed region in K representing γ2 
staining only. N. Enlarged image of the boxed region in K representing VGAT staining. O. 
Enlarged image of the boxed region in K showing all the three channels (scale bar=5μm). 
 
 
7.3.4 Treatment of 7-14 DIV MSN cultures with purified α1 or α2 ECDs  
7.3.4.1 The treatment of MSN cultures with purified α1 or α2 ECDs 
from 7 to 14 DIV revealed that the exogenous proteins are adhering to the 
neuronal cell surface 
In parrallel to our previous study in which the effect of the treatment of MSN 
cultures with α1 ECDs or α2 ECDs was established at early developmental stages, we 
have decided to test the effects of the addition of 5 μg of the purified proteins to MSNs 
starting from 7 to 14 DIV. Subsequently, synapse formation was analysed using 
immunocytochemistry and confocal imaging. Figure 118 shows an example of each of 
i) untreated 14 DIV neurones (A-D), ii) neurones treated from 7 to 14 DIV with control 
Sf9 cell extracts (E-H), and iii) neurones treated with the α1 ECDs (I-L). After fixation, 
these neurones were stained with the rabbit anti- α1 subunit and guinea-pig anti-γ2 
subunit specific antibodies. After permeabilisation, they were incubated with chicken 
anti-MAP2 specific antibody. Similarly, Figure 119 shows an example of i) untreated 14 
DIV neurones (A-D), ii) neurones treated from 7 to 14 DIV with control Sf9 cell extracts 
(E-H), and iii) neurones treated with the α2 ECDs (I-L). After fixation, these neurones 
were stained with the guinea-pig anti-α2 and rabbit anti-γ2 specific antibodies. After 
permeabilisation, they were incubated with the chicken anti-MAP2 specific antibody 
(see Table 26 for details). Figure 120 shows an example of each of i) 14 DIV neurones 
treated from 7 to 14 DIV with control Sf9 cell extracts (A-E), ii) neurones treated from 7 
to 14 DIV with α1 ECDs (F-J), and iii) neurones treated from 7 to 14 DIV with α2 ECDs 
(K-O). After fixation, these neurones were stained with the mouse anti-6xHis-tag 
proteins and guinea-pig anti-γ2 subunit specific antibodies. After permeabilisation, they 
were incubated with the chicken anti-MAP2 and rabbit anti-VGAT specific antibodies 
(see Table 26 for details). The adhesion of the exogenous α1 and α2 ECDs to the ce ll 
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surface of MSNs was visualised using confocal microscopy after immunolabelling with 
the N-terminal specific antibodies. The added proteins were present in the extracellular 
space and also on the surface of cultured neurones, but they were not distinguishable 
from the endogenous receptors using this antibody combinations (Figure 118 and 119). 
To visualise the localisation of the exogenous α1 and α2 ECDs, we decided to stain 
neurones with anti-6xHis-tagged proteins together with anti-γ2 subunit specific 
antibodies (Figure 121). This immunolabelling confirmed that the exogenous ECDs 
adhered to the cell surface of MSNs and were also sparsely distributed in the 
extracellular space. 
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Figure 118. The exogenous α1 ECDs adhere to the cell surface of MSNs treated from 7 to 
14 DIV but are not distinguishable from the endogenous α1-containing GABAARs. 
Immunolabelling of GABAARs containing γ2 subunit (green) and the α1 subunit (red) at the cell 
surface of cultured MSNs. Somatodendritic compartment is labelled with the MAP2 antibody 
(blue). A. Merged image of an untreated 14 DIV MSN (scale bar=10 μm). B. Enlarged image of 
the boxed region in A representing γ2 staining only. C. Enlarged image of the boxed region in A 
representing α1 staining only. D. Enlarged image of the boxed region in A showing all the three 
channels (scale bar=5 μm). E. Merged image of a 14 DIV MSN treated with the control Sf9 cell 
extracts (scale bar=10 μm). F. Enlarged image of the boxed region in E representing γ2 staining 
only. G. Enlarged image of the boxed region in E representing α1 staining only. H. Enlarged 
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image of the boxed region in E showing al the three channels (scale bar=5 μm). I. Merged 
image of a 14 DIV MSN treated with the α1 ECDs (scale bar=10 μm). J. Enlarged image of the 
boxed region in I representing γ2 staining only. K. Enlarged image of the boxed region in I 
representing α1 staining only. L. Enlarged image of the boxed region in I representing all the 
three channels (scale bar=5 μm). 
 
Figure 119. The exogenous α2 ECDs adhere to the cell surface of MSNs treated from 7 to 
14 DIV but are not distinguishable from endogenous α2- containing GABAARs. 
Immunolabelling of GABAARs containing γ2 subunit (red) and the α2 subunit (green) at the cell 
surface of cultured MSNs. Somatodendritic compartment is labelled with the MAP2 antibody 
(blue). A. Merged image of an untreated 14 DIV MSN (scale bar=10 μm). B. Enlarged image of 
the boxed region in A representing γ2 staining only. C. Enlarged image of the boxed region in A 
representing α2 staining only. D. Enlarged image of the boxed region in A showing all the three 
channels (scale bar=5 μm). E. Merged image of a 14 DIV MSN treated with the control Sf9 cell 
extracts (scale bar=10 μm). F. Enlarged image of the boxed region in E representing γ2 staining 
only. G. Enlarged image of the boxed region in E represeing α2 staining only. H. Enlarged 
image of the boxed region in E showing al the three channels (scale bar=5 μm). I. Merged 
image of a 14 DIV MSN treated with the α2 ECDs (scale bar=10 μm). J. Enlarged image of the 
boxed region in I representing γ2 staining only. K. Enlarged image of the boxed region in I 
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representing α2 staining only. L. Enlarged image of the boxed region in I representing all the 
three channels (scale bar=5 μm). 
 
Figure 120. The histidine-tagged α1 and α2 ECDs adhere to the cell surface of MSNs 
treated from 7to 14 DIV. Immunolabelling of the exogenous α1 and α2 ECDs using 6xHis-tag 
antibody (red), γ2-containing GABAARs (green) and VGAT positive presynaptic terminals 
(cyan). The somatodendritic tree is labelled with the MAP2 antibody (blue). A. Merged image of 
a 14 DIV MSN treated with the control Sf9 cell extracts (scale bar=10 μm). B. Enlarged image of 
the boxed region in A representing 6xHis-tag proteins staining only. C. Enlarged image of the 
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boxed region in A representing γ2 staining only. D. Enlarged image of the boxed region in A 
representing VGAT staining only. E. Enlarged image of the boxed region in A representing all 
three channels (scale bar=5 μm). F. Merged image of a 14 DIV MSN treated with the α1 ECDs 
(scale bar=10 μm). G. Enlarged image of the boxed region in F representing 6xHis-tag proteins 
staining only. H. Enlarged image of the boxed region in F representing γ2 staining only. I. 
Enlarged image of the boxed region in F representing VGAT staining only. J. Enlarged image of 
the boxed region in F representing all the three channels (scale bar=5 μm). K. Merged image of 
a 14 DIV MSN treated with the α2 ECDs (scale bar=10 μm). L. Enlarged image of the boxed 
region in K representing 6xHis-tag proteins staining only. M. Enlarged image of the boxed 
region in K representing γ2 staining only. N. Enlarged image of the boxed region in K 
representing VGAT staining only. O. Enlarged image of the boxed region in K representing all 
the three channels (scale bar=5 μm).  
 
 
7.3.4.2 The total density of γ2-containing GABAARs per dendrite of 
MSNs is increased after the treatment with α1 or α2 ECDs from 7 to 14 DIV  
 Following the treatments of MSN from 7 to 14 DIV, the total density of γ2 
clusters per dendrite was counted, and their size estimated using the Zen 2009 
Programme.  Developing MSNs treated with Sf9 cell extracts, α1 ECD or α2 ECD from 
7 to 14 DIV were immunolabelled with the γ2-, GAD-65- and MAP2-specific antibodies, 
and the properties of γ2-containing GABAAR clusters were analysed using confocal 
imaging (Figure 121). The density of γ2-containing GABAAR clusters was estimated per 
defined length of primary dendrite (the first 20 μm from the cell body) after treatment 
with the control Sf9 cell extracts or α1 ECD from 7 to 14 DIV (Figure 122). The median 
density of γ2 clusters was 4 (7 - 2) with the Sf9 cell extracts treatment, compared to 5 
(8 - 3) with the α1 ECD treatment (p value=0.08, Mann-Whitney test; n=69 dendrites, 
and n=58 dendrites, respectively). This demonstrates that the total density of γ2 
clusters did not change significantly, indicating that the effects of exogenous α1 ECDs 
are less pronounced at this developmental stage. 
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Figure 121. Immunolabelling of the γ2-containing GABAAR clusters in MSN cultures 
following the treatments with control Sf9 cell extracts, α1 or α2 ECDs from 7 to 14 DIV.  
Immunolabelling of GABAARs containing the γ2 subunit (green) and of the presynaptic marker 
GAD-65 (red) along the primary dendrites of cultured MSNs stained for MAP2 (blue). A. Merged 
image of a 14 DIV striatal neurone treated with the control Sf9 cell extracts (scale bar=10 μm).  
B. Enlarged image of the boxed region in A representing γ2 staining only. C. Enlarge image of 
boxed region in A representing GAD-65 staining only. D. Enlarged image of the boxed region in 
A representing γ2 and GAD-65 staining. E. Enlarged image of the boxed region in A showing all 
the three channels (scale bar=5 μm). F. Merged image of a 14 DIV striatal neurone treated with 
α1 ECDs (scale bar=10 μm). G. Enlarged image of the boxed region in F representing γ2 
staining only. H. Enlarged image of the boxed region in F representing GAD-65 staining only. I. 
Enlarged image of the boxed region in F representing γ2 and GAD-65 staining. J. Enlarged 
image of the boxed region in F showing all the three channels (scale bar=5 μm). K. Merged 
image of a 14 DIV striatal neurone treated with the α2 ECDs (scale bar=10 μm). L. Enlarged 
image of the boxed region in K representing γ2 staining only. M. Enlarged image of the boxed 
region in K representing GAD-65 staining only. N. Enlarged image of the boxed region in K 
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representing γ2 and GAD-65 staining. O. Enlarged image of the boxed region in K showing all 
the three channels (scale bar=5 μm). 
 
 
 
 
Figure 122. The density of γ2-containing GABAAR clusters per primary dendrite of MSNs 
remains unchanged after the treatment with α1 ECDs from 7 to 14 DIV.The density of γ2-
containing GABAAR clusters along the first 20 μm of primary dendrites was counted in MSN 
cultures in the presence of control Sf9 cell extracts or α1 ECDs from 7 to 14 DIV. A. Histogram 
shows the distribution of γ2 cluster densities in the presence of control Sf9 cell extracts or α1 
ECDs (n=81 and n=59 dendrites, respectively, from two independent experiments). B. Box plot 
displays the median density (50 % of the population) of γ2 clusters in the presence of control 
Sf9 cell extracts or α1 ECDs. Statistical analysis was performed using Mann-Whitney test: * 
corresponds to p < 0.05. 
 
The density of γ2-containing GABAAR clusters was estimated per defined length of 
primary dendrite (the first 20 μm from the cell body) after the treatment with control Sf9 
cell extracts or α2 ECDs from 7 to 14 DIV (Figure 123). The median density of γ2 
clusters was 5 (9-3) with the control Sf9 cell extracts treatment, compared to 7 (11.5 - 
4.5) with the α2 ECDs treatment (p value=0.01, Mann-Whitney test; n=82, and n=65 
dendrites, respectively). This demonstrates that the total density of γ2 clusters is 
increased by the treatment, indicating that the exogenous α2 ECDs promote either the 
insertion of the γ2 subunit-containing GABAARs or their clustering, or both, at this 
developmental stage. 
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Figure 123. The density of γ2-containing GABAAR clusters per primary dendrite of MSNs 
is increased by the treatment with α2 ECDs from 7 to 14 DIV.The density of γ2-containing 
GABAAR clusters along the first 20 μm of primary dendrites was counted in MSN cultures in the 
presence of control Sf9 cell extracts or α2 ECDs from 7 to 14 DIV. A. Histogram shows the 
distribution of γ2 cluster densities in the presence of control Sf9 cell extracts or α2 ECDs (n=82 
and n=65 dendrites, respectively, from two independent experiments). B. Box plot displays the 
median density (50 % of the population) of γ2 clusters in the presence of control Sf9 cell 
extracts or α2 ECDs. Statistical analysis was performed using Mann-Whitney test: * 
corresponds to p < 0.05. 
 
Table 31. The density of γ2-containing GABAAR clusters per primary dendrite of 
MSN is increased by the α2 ECD treatments from 7 to 14 DIV 
 
 
7.3.4.3 The connectivity between MSNs is increased by the α2 ECD 
treatments from 7 to 14 DIV 
To investigate further the structural role of GABAARs in GABAergic synapse 
formation at later developmental stages, we applied α1 or α2 ECDs to MSN cultures 
from 7 to 14 DIV and estimated if the exogenous ECDs affected the density of 
presynaptic terminals forming contacts with the primary dendrites in these cultures. The 
total density of GAD-65 positive terminals per defined length of primary dendrite (the 
first 20 μm from the cell body) was estimated after the treatment with the control Sf9 
cell extracts or α1 from 7 to 14 DIV (Figure 124). After the treatment with the control 
Sf9 cell extracts, the median density of presynaptic terminals was 10 (13 - 7) compared 
to 10 (13 - 6) after the treatment with α1 ECDs (p value =0.52, Mann-Whitney test; 
n=66 dendrites analysed in Sf9 cell extracts- treated cultures, and n=56 dendrites 
 Density of γ2 clusters at 7 DIV P < 0.05 
Sf9 cell extracts- Vs. α1- 
treated neurones 
 
No 
Sf9 cell extracts- Vs. α2- 
treated neurones 
 
Yes 
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analysed in α1 ECDs- treated cultures). This indicates that the density of presynaptic 
contacts did not change following the treatment with α1 ECDs from 7 to 14 DIV. This 
result indicates that the effects of α1 ECDs on the connectivity between MSNs is less 
prominent at this later stage of development. 
Figure 124. The density of presynaptic terminals per primary dendrite of MSNs remains 
unchanged after the α1 ECDs treatment from 7 to 14 DIV. The density of presynaptic 
terminals along the first 20 μm of primary dendrites was counted in MSN cultures after the 
treatment with the control Sf9 cell extracts or α1 ECDs from 7 to 14 DIV. A. Histogram shows 
the distribution of the density of presynaptic inputs per dendrites after the treatment with control 
Sf9 cell extracts or α1 ECDs (n=66 and n=56 dendrites, respectively, from two independent 
experiments). B. Box plot displays the median density of presynaptic terminals after the 
treatments with control Sf9 cell extracts or α1 ECDs. Statistical analysis was performed using 
Mann-Whitney test. 
 
The total density of GAD-65 positive terminals per defined length of primary dendrite 
(the first 20 μm from the cell body) was estimated after the treatment with the control 
Sf9 cell extracts or α2 ECDs from 7 to 14 DIV (Figure 125). After the Sf9 cell extract 
treatments, the median density of presynaptic terminals was 9 (12 - 6) compared to 10 
(15.25 - 7) after the treatment with α2 ECDs (p value =0.038, Mann-Whitney test; n=78 
dendrites analysed in Sf9 cell extracts-treated cultures, and n=62 dendrites analysed in 
α2 ECDs-treated cultures). This indicates that the density of presynaptic contacts per 
dendrite is increased by the treatment with α2 ECDs from 7 to 14 DIV, indicating that 
the connectivity between MSNs could be also regulated by α2 ECDs later in 
development. 
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Figure 125. The density of presynaptic terminals per primary dendrite of MSNs is 
increased after the α2 ECDs treatment from 7 to 14 DIV. The density of presynaptic 
terminals along the first 20 μm of primary dendrites was counted in MSN cultures after the 
treatment with control Sf9 cell extracts or α2 ECDs from 7 to 14 DIV. A. Histogram shows the 
distribution of the density of presynaptic inputs per dendrites after the treatment with control Sf9 
cell extracts or α2 ECDs (n=78 and n=62 dendrites, respectively, from two independent 
experiments). B. Box plot displays the median density of presynaptic terminals per dendrite 
after the treatment with control Sf9 cell extracts or α2 ECDs. Statistical analysis was performed 
using Mann-Whitney test: * corresponds to p<0.05. 
7.3.4.4 The size of the γ2 -containing GABAARs is increased after the 
trea tment with α1 or α2 ECDs from 7 to 14 DIV  
We were also interested to investigate whether the addition of the α1 or α2 
ECDs affects the size of the γ2-containing GABAAR clusters in MSNs treated from 7 to 
14 DIV. The size of γ2-containing GABAAR clusters per defined length of primary 
dendrite (the first 20 μm from the cell body) was estimated after the treatment with α1 
ECDs from 7 to 14 DIV (Figure 126). After the treatment with control Sf9 cell extracts, 
the median size of γ2 clusters was 0.42 (0.54 - 0.35) μm2 compared to 0.45 (0.55 - 
0.36) μm2 with α1 ECDs (p value=0.003, Mann-Whitney test; n=333 clusters, and 
n=353 clusters, respectively). This demonstrates that the size of γ2-containing 
GABAAR clusters is increased by the treatment with α1 ECDs from 7 to 14 DIV. This 
suggests that even at this later stage of development, the exogenous α1 ECDs could 
promote the clustering of synaptic GABAARs. 
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Figure 126. The size of the γ2-containing GABAAR clusters is increased by the treatment 
with α1 ECDs from 7 to 14 DIV. The size of the γ2-containing GABAAR clusters along the first 
20 μm of primary dendrites was measured in MSN cultures after the treatment with control Sf9 
cell extracts or α1 ECDs from 7 to 14 DIV. A. Histogram shows the distribution of γ2 cluster 
sizes after the treatment with the control Sf9 cell extracts or α1 ECDs (n=333 and n=353 
clusters, respectively, from two independent experiments). B. Box plot displays the median size 
(50 % of the population) of γ2 clusters after the treatment with the control Sf9 cell extracts or α1 
ECDs. Statistical analysis was performed using Mann-Whitney test: * corresponds to p < 0.05. 
 
The size of the γ2-containing GABAAR clusters per defined length of primary dendrite 
(the first 20 μm from the cell body) was estimated after the treatment with α2 ECDs 
from 7 to 14 DIV (Figure 127). After the treatment with control Sf9 cell extracts, the 
median size of γ2 clusters was 0.47 (0.56 - 0.38) μm2 compared to 0.54 (0.73 - 0.4) 
μm2 with α2 ECDs (p value=4.82x10-12, Mann-Whitney test; n=475 clusters, and n=603 
clusters, respectively). This demonstrates that the size of γ2-containing GABAAR 
clusters is increased by the treatment with α2 ECDs from 7 to 14 DIV. This suggests 
that even at this later stage of development, the exogenous α2 ECDs could promote 
clustering of synaptic GABAARs. 
Figure 127. The size of γ2-containing GABAAR clusters is increased by the treatment with 
α2 ECD from 7 to 14 DIV. The size of γ2-containing GABAAR clusters along the first 20 μm of 
primary dendrites was measured in MSN cultures after the treatment with the control Sf9 cell 
extracts or α2 ECDs from 7 to 14 DIV.B. Histogram shows the distribution of γ2 cluster sizes 
after the treatment with control Sf9 cell extracts or α2 ECDs (n=475 and n=603 clusters, 
respectively, from two independent experiments). B. Box plot displays the median size (50 % of 
the population) of γ2 clusters after the treatment with control Sf9 cell extracts or α2 ECDs. 
Statistical analysis was performed using Mann-Whitney test: * corresponds to p < 0.05. 
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Table 32. The size of γ2-containing GABAAR clusters per primary dendrite of 
MSNs is increased by the treatment with α1 or α2 ECD from 7 to 14 DIV. 
7.3.4.5 Analysis of gephyrin clusters in MSNs following the treatments 
with α1 or α2 ECDs from 7 to 14 DIV  
Developing MSNs treated with the control Sf9 cell extracts, α1 ECDs or α2 
ECDs from 7 to 14 DIV, were immunolabelled with the mouse anti-gephyrin, rabbit anti-
VGAT, guinea-pig anti-γ2 and chicken anti-MAP2 specific antibodies. Changes in 
density and size of gephyrin clusters were analysed by confocal microscopy (Figure 
128). From this preliminary experiments, gephyrin clusters seem to be increased in 
size after the α2 ECDs treatment compared to control Sf9 cell extracts treatment from 7 
to 14 DIV. However, statistical analysis must be performed to confirm these 
observations. 
 
 Size of γ2 clusters at 7 DIV P < 0.05 
Sf9 cell extracts- Vs. α1- 
treated neurones 
 
Yes 
Sf9 cell extracts- Vs. α2- 
treated neurones 
 
Yes 
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Figure 128. The density of gephyrin clusters appears to be increased after the treatments 
of MSN with the α2 ECDs from 7 to 14 DIV. Immunolabelling of gephyrin (cyan), γ2 subunit 
(green) and the presynaptic marker VGAT (red). The somatodendritic compartment is labelled 
with the MAP2 antibody (blue). A. Merged image of a 14 DIV striatal neurone treated with the 
control Sf9 cell extracts (scale bar=10μm). B. Enlarged image of the boxed region in A 
representing gephyrin staining only. C. Enlarge image of boxed region in A representing γ2 
staining only. D. Enlarged image of the boxed region in A representing VGAT staining only. E. 
Enlarged image of the boxed region in A showing all the three channels (scale bar=5μm). F. 
Merged image of a 14 DIV striatal neurone treated with α1 ECDs (scale bar=10μm). G. 
Enlarged image of the boxed region in F representing gephyrin staining only. H. Enlarged image 
of the boxed region in F representing γ2 staining only. I. Enlarged image of the boxed region in 
F representing VGAT staining. J. Enlarged image of the boxed region in F showing all the three 
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channels (scale bar=5μm). K. Merged image of a 14 DIV striatal neurone treated with the α2 
ECDs (scale bar=10μm). L. Enlarged image of the boxed region in K representing gephyrin 
staining only. M. Enlarged image of the boxed region in K representing γ2 staining only. N. 
Enlarged image of the boxed region in K representing VGAT staining. O. Enlarged image of the 
boxed region in K showing all the three channels (scale bar=5μm). 
 
7.4 Discussion  
GABAARs are the essential functional postsynaptic components of GABAergic 
synapses in the mammalian brain (Sieghart, 2006). Gene deletion studies of the most 
abundant subunits of GABAARs in mice have demonstrated specific structural changes 
in inhibitory synapse formation (Fritschy et al., 2012). To investigate whether GABAARs 
alone could promote inhibitory synapse formation, Fuchs et al. developed a model in 
which GABAARs were expressed in HEK 293 cells and co-cultured with GABAergic 
medium spiny neurones (Fuchs et al., 2013). In this study, it was showed that when 
stably transfected into HEK 293 cells, the α1/β2/γ2 GABAARs were able to promote 
synaptic contact formation and functional maturation. Interestingly, the density of 
synaptic inputs on the surface of transfected HEK cells and synaptic strength were 
reinforced when GABAARs were co-transfected with NL2. However, molecular 
mechanisms that mediate this process are currently unknown. 
We hypothesised at the start of these experiments that amongst different domains, 
due to their architecture and their presence in the extracellular space, the large N-
terminal extracellular domains of GABAAR subunits is likely to play a role in the 
recognition process between the pre and postsynaptic terminals. It is now well 
recognised that amongst all the subunits, the diversity of α subunits is the best 
candidate to explain the physiological and regional diversity of GABAARs and hence, 
the specificity of GABAergic synapses present throughout the brain (Fritschy and 
Panzanelli, 2014).  
In this chapter, our aim was to identify the structural role played by the extracellular 
domains of α1 and α2 GABAAR subunits during specific GABAergic synapse formation. 
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To do so, we have utilised the α1 and α2 extracellular domains (ECDs) produced in Sf9 
cells which were purified under sterile conditions. In order to study the specific role of 
each domain during GABAergic synapse formation, we applied 5µg of α1 or α2 ECDs 
to MSN cultures from 4 to 7 DIV or from 7 to 14 DIV. Using immunocytochemistry and 
confocal microscopy, we have been able to study the effects of these treatments on 
GABAAR clusters density, size and synaptic localisation along the first 20 µm of primary 
dendrites of MSNs. 
 Prior to the treatment, we wanted to confirm that the purified extracellular 
domains were glycosylated as we knew that glycosylation plays a major role in the 
extracellular domain function and protein-protein interactions (Miller and Aricescu, 
2014). Thus we performed deglycosylation assay in which the purified α1 and α2 ECDs 
were incubated with deglycosylation enzymes. After incubation, the degree of 
glycosylation was assessed by immunoblotting. As expected, the immunoblots 
confirmed that both α1 ECD and α2 ECD were glycosylated. 
 In addition, before synapse formation analysis was carried out, we observed 
that at both developmental stages 7 and 14 DIV, the α1 and α2 exogenous ECDs 
adhered to the neuronal cell surface along dendrites of most of the cultured neurones. 
 The treatments of MSNs with α1 or α2 ECDs resulted in an increase in synapse 
formation and in GABAAR clustering, suggesting synaptogenic effects of these 
domains. We found that when MSNs were treated with either ECD, the density and 
size of γ2-containing GABAAR clusters were increased as well as the connectivity 
between MSNs, in comparison with the neurones treated with extracts from non-
infected Sf9 cells.  Interestingly, when MSNs were treated from 7 to 14 DIV, the density 
of γ2-containing clusters and the MSNs connectivity was increased with the α2 ECDs 
treatment, but not with the α1 ECDs treatment.  
These results suggested that at early developmental stages, when synapses 
are still immature, both the α1 and α2 ECDs have the capacity to promote synapse 
formation, while later on during development, when synaptic contact are made and 
291 
 
synapses are becoming functional, only the α2 ECDs were able to promote the 
increase of functional synapses. These synaptogenic effects of the extracellular 
domains of α1 and α2 ECDs could be explained by different mechanisms.  
 The N-terminal extracellular domain of α, β and γ subunits plays a crucial role 
during GABAAR assembly in the ER. When expressed in heterologous systems, each 
of the individual subunits are able to form homomers or dimers (Connolly et al., 1996b, 
Luscher et al., 2011). Thus, α subunits are capable of oligomerisation via their N-
terminal extracellular domains. However, very little is known about the existence and 
relevance of homomers of any GABAAR subunits in vivo. In our model, the 
oligomerisation of the exogenous extracellular domains with the endogenous, surface-
expressed GABAAR subunits could be potentially one of the mechanisms that could 
mediate the increase in GABAAR clusters size and synaptic contact formation, 
observed after treatment. Hence, by adhering to the cell surface of neurones, the 
exogenous domains would oligomerise with endogenous receptors making the clusters 
larger and thus, stabilising their association with the presynaptic terminals and 
promoting formation of synaptic contacts.  
Alternatively, oligomerisation with endogenous receptors could block their 
activation by GABA and thus, could lead to compensatory mechanisms similar to those 
observed in the previous result chapter. Electrophysiological recordings would help us 
to explore this possibility. By recording postsynaptic currents, we would be able to 
know if the strength of synapses has been increased or decreased after the treatment. 
 Additionally, the synaptogenic effects observed after treatment with α1 or α2 
ECDs at early developmental stages, could be explained by the potential interaction of 
these domains with some presynaptic proteins involved in specific GABAergic synapse 
formation. By adhering to the cell surface of neurones, and being available for trans-
synaptic interactions, the exogenous domains could attract presynaptic proteins to bind 
and this process itself could lead to a further recruitment of the endogenous GABAARs 
to these sites either from the extrasynaptic or intracellular receptor pools.  
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 All together, these results could be linked with the previous findings showing 
that α2-containing GABAAR clusters are the most readily available for modulation by 
GABA signalling and also are the most abundant types of receptors in the adult 
striatum. The role played by the potentially α2 subunit-interacting protein pikachurin 
would be interesting to study under the treatment of developing MSNs with the α2 
ECDs. In addition, to understand further the role played by these glycosylated domains, 
it would be interesting to treat MSN cultures with deglycosylated ECDs and determine if 
the synaptogenic effects of these domains are still observed. Additionally, it would be of 
interest to determine the exact amino acid sequence in α1 and α2 ECDs which is 
necessary for these synaptogenic effects to occur. Finally, it would be important to 
establish the synaptogenic effects of other GABAAR subunits such as β and γ which 
probably also play an important role in the GABAergic synapse formation.  
In conclusion, by investigating the role of GABAAR subunits α1 and α2 in 
GABAergic synapse formation, a better understanding of the role of each subunit was 
established. We found that as MSNs mature in vitro, the formation of α2-containing 
synapses is predominantly promoted as the median size of α2-containing GABAAR 
clusters was increased from 7 to 14 DIV. It would be interesting to establish if these 
newly inserted subunits are readily available from extrasynaptic pools or the result of 
intracellular mechanisms. On the second hand, it would be interesting to understand if 
this specificity towards the formation of α2-containing receptors is related to the 
pharmacological properties of this particular α subunit, or is related to the structure of 
this subunit promoting specific intracellular pathways activated by specific protein-
protein interactions. We found that the Heparan sulfate proteoglycan pikachurin was 
able to bind the extracellular domain of α2 subunit at early developmental stages. The 
role of pikachurin in the striatum will have to be established, and the relevance of its 
binding to α2 subunit ECD during synapse formation will need to be further confirmed.     
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Chapter eight 
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8. Discussion 
GABAARs are the main receptors in the brain transducing inhibitory signals. 
These signals play a crucial role in regulating the proper functioning of the mammalian 
brain. The networks of GABAergic neurones are involved in a very wide range of 
functions from cognitive perception to motor control or breathing. Although they play a 
central role in the functioning of GABAergic synapses, little is known about the role 
played by individual subunits composing the GABAA heteropentamers during 
GABAergic synapse formation. In this thesis, my main goal was to investigate the role 
played by the extracellular domains of GABAAR α1 and α2 subunits during the 
formation and maturation of GABAergic synapses. In addition, we also studied the role 
played by GABAARs activity in regulating GABAA receptor clustering and synaptic 
localisation. The α1 and α2 subunits are of particular interest because they are widely 
expressed throughout the brain and their expression varies dramatically during the 
brain development, hence playing a pivotal role during GABAergic synapse formation. 
The extracellular domains of GABAAR α subunits incorporate the GABA and 
benzodiazepine binding sites, but also may play a central role in transynaptic 
interactions, as they are situated in the synaptic cleft.  
To investigate the role of α1 and α2 subunits during synapse formation, we 
have first expressed and purified their extracellular domains (ECDs) using the 
baculovirus/Sf9 cells expression system. We have then utilised these purified ECDs in 
order to address two important questions: Are there presynaptic or synaptic cleft 
proteins with which α1 and α2 ECDs could specifically interact? Do these domains play 
any direct structural role during GABAergic synapse formation in the embryonic 
neuronal cultures?  
In addition, we were interested in understanding the role of GABAAR activity during 
GABAergic synapse development. To do so, we have treated embryonic MSNs 
cultures with the GABA antagonist bicuculline, and studied the effect of GABA 
signalling blockade on GABAergic synapse formation and stabilisation. 
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8.1 The HSPG protein pikachurin binds to the extracellular domain of 
GABAAR α2 subunit  
In the first chapter, the optimisation of expression and purification of α1 and α2 ECDs 
enabled us to investigate the potential binding partners of the α1 and α2 subunits. 
Proteomics and mass spectrometry experiments revealed a large density of candidate 
binding proteins, but only some of these proteins were chosen to be studied further 
because of their known involvement in synaptic function. One of these proteins was 
pikachurin, a heparin sulfate proteoglycan which was shown to play an important role in 
synapse formation in retina (Sato, 2010). We were able to demonstrate that this protein 
can be co-immunoprecipitated with the α2 subunit from neuronal lysates and that it is 
highly co-localised with this subunit of GABAARs at synapses. Supporting our findings, 
a recent study showed that similar HSPG contribute to the excitatory synapse 
formation by interacting with Leucine rich repeated transmembrane neuronal protein 
(LRRTMs) and promoting their synaptogenic effects (Siddiqui et al., 2013). LRRTMs 
were first identified in fibroblast-neurone co-culture model where they were able to 
mediate excitatory presynaptic and postsynaptic differentitation (Linhoff et al., 2009). In 
the manuscript by Siddiqui et al., it was shown that the synaptogenic effects observed 
on denate gyrus granule cells mediated by LRRTM4 required the presence of HSPGs 
(Siddiqui et al., 2013). In addition, when glycosylated, pikachurin has been shown to 
interact with the dystroglycan protein complex and regulate the apposition between the 
dendrites of bipolar neurones and photoreceptor in the ribbon synapse in retina (Sato 
et al., 2008, Sato, 2010, Hu et al., 2011, Omori et al., 2012). The protein Agrin is 
another HSPGs known to play a central role during NMJ formation (Wu et al., 2010). In 
the brain, this transmembrane protein is released following proteolytic cleavage 
triggered by neural activity in the hippocampus (Matsumoto-Miyai et al., 2009). It has 
been shown that in vitro, agrin may be implicated in the regulation of dendrite extension 
and clustering of GABAARs (Ferreira, 1999). In addition, it was showed that agrin is 
present at GABAergic synapses and treating cultures with agrin significantly increased 
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the total cluster area of α-DG and β3 GABAARs (Pribiag et al., 2014). The treatment 
was also sufficient to increase mIPSC amplitude. These data suggest that ligand-
induced signalling through DG or ligand-induced clustering of DG is sufficient to 
increase GABAAR cluster size and GABAergic neurotransmission. In this paper, it was 
demonstrated that the dystroglycan subunits α and β (αDG and βDG), gephyrin and α1 
and β2/3 subunits of GABAARs can be co-immunoprecipitated as a supramolecular 
complex (Pribiag et al., 2014). However, Levi et al. showed that DG is not necessary 
for GABAergic synapse formation and is recruited after the appearance of GABAAR 
clusters in hippocampal neurones, suggesting that DG is not required for GABAAR 
clustering (Lévi et al., 2002). Thus, DG could contribute to synapse stabilisation rather 
than synapse formation, as it does in the neuromuscular junction (NMJ), by contributing 
to activity-dependent regulation of the density of synaptic GABAARs. To test this 
possibility, Pribiag et al., showed that by increasing neuronal firing in hippocampal 
culture they were able to promote GABAergic synapse formation (Pribiag et al., 2014). 
By applying 10 µM bicuculline for 24 hours or by elevating extracellular K+ 
concentration, they observed homeostatic increase in the total cluster area of GABAAR 
β3 subunit and increased levels of γ2 subunits, but also an increase in the total cluster 
area of functionally glycosylated α-DG. These results suggested a homeostatic up-
regulation of GABAARs and DG consistent with a function for DG in GABAARs 
clustering and stabilisation (Panzanelli et al., 2011).  
All together, this data give us directions to follow to study further the interaction 
between the α2 GABAAR subunits and Pikachurin and to understand better the role 
played by pikachurin in GABAergic synapse formation and homeostatic plasticity as a 
potential upstream regulator of the DG complex at GABAergic synapses. To further the 
understanding of the role of this interaction during brain development, it would be very 
helpful to study GABAergic synapse formation in the brain of pikachurin knock-out (KO) 
mice (Kanagawa et al., 2010). 
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8.2 The α2-containing synapses are favoured compared to α1-containing 
synapses during maturation of GABAergic MSNs in vitro 
In the third chapter of this thesis, the structural analysis of embryonic MSN cultures 
allowed us to understand further how GABAergic synapses are formed and maintained 
throughout in vitro development. In our study, we were interested in looking at the 
change in size of clusters. Our results indicated that α2-containing GABAAR cluster (α2 
single, α1/2 mixed, α2/1 mixed clusters) sizes were increased in MSN synapses from 7 
to 14 DIV while the size of single α1 synaptic clusters was decreased. Although we did 
not directly compare the density of α1 clusters to the density of α2 clusters of 
GABAARs, the densities indicated a higher density of α2-containing GABAAR clusters 
along dendrites. These results are in accordance with the distribution of GABAAR 
subunits in vivo in the adult striatum, in which the α2 subunit is more prominently 
present than the α1 subunit (Fritschy and Mohler, 1995). This is further supported by a 
study showing that in vivo the density of α2-containing synapses is higher in the 
proximal dendrites of MSNs, while the α1-containing receptors are widely spread over 
the perisomatic and dendritic regions (Gross et al., 2011). Due to their different affinity 
for zolpidem, the α1 and α2/3-containing GABAARs were distinguished by using 100 
nM or 400 nM of this hypnotic drug, respectively. In this paper, the authors were able to 
show that in the globus pallidus, the specific subcellular distribution of α1 and α3 
subunits is believed to be related to the innervation by axon collaterals of other GP 
neurones, while the presence of α2-containing synapses in proximal dendrites of MSNs 
would be related to the striatal innervation (Gross et al., 2011). 
 A dissociated culture system using striatal and cortical neurones was used to 
describe the axon collateral-mediated inhibition (Lalchandani and Vicini, 2013). 
Interestingly, it was shown that in 14 DIV MSN cultures, autaptic currents were found in 
50 % of MSNs at 7-8 DIV and 57 % of MSNs at 13-16 DIV (Lalchandani and Vicini, 
2013). All together, these data suggest that via axon collateral inhibition, MSNs shape 
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neurone firing and striatal output of the striatum. They also suggest that these inhibitory 
inputs are probably mediated by α2-containing synapses.  
However, which molecular mechanisms are at the origin of the formation of such 
synapses, remains unclear. In the light of the first two chapters of this thesis, we could 
hypothesise that formation of these synapses may be, at least in part, promoted by the 
interaction between the HSPG Pikachurin and the α2 ECDs of GABAARs. The role of 
this interaction could be established by studying the GABAergic synapse formation in 
cultured MSNs from Pikachurin Knock-Out mice. 
8.3 Activity-dependent regulation of GABAergic synapse formation 
GABAA receptor heterogeneity is based on the combinatorial assembly of a large family 
of subunits into distinct receptor subtypes. This suggests that genetic programs 
established during ontogeny govern the expression of GABAAR subtypes (Penschuck 
et al., 1999). The role played by neuronal activity on the expression levels of GABAAR 
subtypes was tested in the hippocampus in vitro and in vivo (Penschuck et al., 1999). 
As this paper and many others have shown, the activity-dependent mechanisms 
regulate GABAAR clustering and thereby, help to regulate homeostatic plasticity in the 
brain (Hartman et al., 2006, Saliba et al., 2007, Bannai et al., 2009, Muir and Kittler, 
2014). But what do we know about the role played by GABA signalling during 
GABAergic synapse formation and maturation? It is now well established that 
GABAAR-mediated signalling plays a pivotal role in mediating activity-dependent 
synapse formation. In the embryonic brain, GABA acts as a trophic factor that 
depolarises neuronal progenitors and early post mitotic granule cells, enabling network 
activity to regulate cell proliferation, survival and growth (Dieni et al., 2013). Following 
the appearance of glutamatergic synapses, a switch in GABA signalling from an 
excitatory to an inhibitory signal is observed. However, whether depolarising or 
hyperpolarising, GABAAR-mediated signalling occurs in two different modes termed 
phasic and tonic inhibition. While phasic inhibition refers to conventional synaptic 
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transmission, in which GABA is released from the presynaptic terminals and activates 
low-affinity postsynaptic GABAARs, tonic inhibition refers to the activation of high-
affinity extrasynaptic GABAARs by low ambient concentrations of GABA (Nusser and 
Mody, 2002, Luo et al., 2013b). In addition, perisynaptic GABAA receptors mediate an 
intermediate form of inhibition that is mediated in vivo by the NPY-positive basket cells 
(English et al., 2012). The subunit composition of GABAARs that mediate striatal tonic 
inhibition is of crucial interest in understanding the underlying factors that control MSN 
output and neuronal excitability (Luo et al., 2013b).  
Due to precise dissection of the embryonic striatal region at the stage when the 
dopaminergic neurones are the only input received (Goffin et al., 2010), our MSNs 
culture model presents unique features of purely GABAergic culture. In addition, no 
interneurones are present in these embryonic cultures as they would normally appear 
during the postnatal brain development (Kawaguchi, 1993). It is also important to note 
that in vivo, the MSNs are projecting out of the striatum, primarily targeting other areas 
of the basal ganglia. In contrast, in our model system, MSNs are “forced” to synapse 
with each other as they have no other possible cells to target. That has been confirmed 
by electrophysiological recordings (data not shown), which showed that MSNs are able 
to promote action-potential driven activity from 12 DIV. 
Other roles played by GABA have been investigated. For the first time, 
Chattopadhyaya and colleagues demonstrated a function of GABA in regulating 
GABAergic innervation in the postnatal brain, when GABA is inhibitory 
(Chattopadhyaya et al., 2007). By using conditional knock down of GAD-67 but not 
GAD-65 in basket interneurones of the visual cortex, they showed a cell autonomous 
deficit in axon branching, perisomatic synapse formation around pyramidal neurones 
and complexity of the innervation fields. As intracellular GABA levels are modulated by 
neuronal activity, these results implicated GAD-67-mediated GABA synthesis in activity 
dependent regulation of inhibitory patterns. These results showed that GABA acts 
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beyond its classical role in inhibitory transmission in the adolescent brain and regulates 
the maturation of inhibitory synapses and innervation patterns, thus revealing a new 
effect of GABA function different from its early trophic action in the prenatal brain 
(Huang and Scheiffele, 2008). GABA is the main neurotransmitter released in our 
culture model. Thus, any activity-dependent mechanism, whether excitatory or 
inhibitory, triggering phasic or tonic inhibition, would be altered by the treatment with 25 
µM bicuculline.  In our experiments, we found differential alterations of GABAergic 
synapses depending on the developmental stages the bicuculline was applied at, but 
also depending on the subtype of GABAARs observed. Our results suggest that at early 
developmental stages, when excitatory, GABA signalling promotes the formation of α2 
containing clusters specifically. However, from 7 to 14 DIV, blocking GABA signalling 
caused compensatory mechanisms favouring the formation of α2-containing synapses 
and decreasing the formation of α1-containing synapses. Potentially, this could be 
explained by the fact that α2 subunit is the most abundant subunit present in the 
striatum (Fujiyama et al., 2000), thereby, α2-containing GABAARs are probably readily 
available in MSNs in vitro. This could also be explained by the pharmacological 
properties of α2-containing GABAARs which kinetics of deactivation are slower than α1-
containing receptors, thus are probably more appropriated to an environment where 
GABA is the main neurotransmitter (Brussaard et al., 1997). 
8.4 The N-terminal extracellular domains of α1 and α2 GABAAR subunits have 
synaptogenic effects 
Treating MSN cultures with α1 or α2 ECDs at immature and mature developmental 
stages has revealed that GABAARs can play a structural role during GABAergic 
formation and maintenance, and that this structural role is mediated by the large N-
terminal extracellular domains of α1 and α2 subunits. Although both types of 
exogenous α1 and α2 ECDs had synaptogenic effects during formation of synapses 
(compared to Sf9 cell extracts treatment), only the α2 exogenous ECDs were capable 
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of promoting functional synapse formation at more mature stages, when neurones 
were able to form functional synapses. This was confirmed by monitoring an increase 
in γ2-containing GABAARs clusters following treatment with α2 ECDs from 7 to 14 DIV. 
These findings are preliminary and would need extensive work in order to establish the 
mechanisms that mediate the observed synaptogenic effects. The modification of 
gephyrin clustering during these treatments would be important to analyse even though 
the binding between α subunits and gephyrin is mediated by intracellular domains 
(Tretter et al., 2008). As the ECDs adhere to the cell surface of neurones, the increase 
in synapse formation could be due to oligomerisation of the exogenous and 
endogenous receptors, making them more “attractive” for presynaptic terminals. The 
synaptogenic effects could also be due to pikachurin interaction (or another presynaptic 
protein) with GABAARs which could enhance the stability of synapses by the presence 
of α2 ECDs in mature cultured neurones.  
The final Table 33 provides an overview of our results. Firstly, we wanted to 
establish what subtypes of GABAARs were predominantly expressed during the 
formation of GABAergic synapses between MSNs in vitro. From 7 to 14 DIV, MSNs 
showed an increase in the size of α2-containing GABAAR clusters and a decrease in 
the density of α1-containing GABAAR clusters. Thus, as they mature, MSNs tend to 
promote the formation of α2-containing synapses, suggesting an important role played 
by this subunit in the striatal GABAergic synapse formation. These findings are 
supported by the expression pattern of GABAARs in the adult striatum in vivo, which is 
known to express high levels of α2 subunits and low levels of α1 subunits of GABAARs 
(Fujiyama et al., 2000).  
By treating purely GABAergic MSN cultures with the GABAARs antagonist 
bicuculline, we tried to establish the role played by GABAAR activity during GABAergic 
synapse formation. We have analysed the way MSNs responded to the GABA-
deprived environment and concluded that while the size of α1-containing clusters was 
decreased, the size and the density of α2-containing GABAARs was increased. This 
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suggested that compensatory mechanisms involving α2-containing receptors were 
triggered in GABAergic activity-deprived environment. In addition, this revealed that the 
lack of activity induced a down-regulation of α1-containing receptors. However, the link 
between GABAergic activity and the regulation of postsynaptic GABAARs including α1 
or α2 subunits remains to be elucidated.  
 The extracellular domains (ECDs) of GABAARs are large glycosylated domains 
and are exposed in the synaptic cleft. Thus, we hypothesised that they might play an 
important structural role during the initiation of GABAergic synapse formation by 
interacting with presynaptic proteins. We focused our study on α1 and α2 subunits 
because α subunits are known to provide the GABAARs with specific kinetics and 
physiological properties (Olsen and Sieghart, 2009) and also because they are the 
most predominant subunits expressed throughout the formation of the striatum 
(Fujiyama et al., 2000). We decided to screen for a protein that would specifically bind 
the ECDs of α1 or α2 subunits using proteomics and mass spectrometry. As a result, 
we found that a heparan sulfate proteoglycans pikachurin was specifically binding the 
ECD of α2 subunit. The expression of pikachurin was established across embryonic 
and adult brain areas in vivo, but also in the MSN cultures in vitro. In addition, co-
localisation of pikachurin with synaptic α2-containign GABAARs was observed in the 
E20 brain. This binding was confirmed by binding assays and co-immunoprecipitation 
between the two proteins. However, the binding site where this interaction occurs and 
the role played by this interaction during GABAergic synapse formation has not been 
established yet. 
Finally, we treated MSNs with purified α1 or α2 ECDs in early synapse formation 
stages (from 4 to 7 DIV) or during synapse stabilisation (from 7 to 14 DIV). These 
experiments showed that α1 and α2 ECDs were capable of promoting synapse 
formation at early developmental stages, although α2 ECDs and not α1 ECDS were 
able to promote synapse formation and stabilisation. This suggested that α1 but mostly 
α2 ECDs had synaptogenic effects on synapse formation and stabilisation, 
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emphasising the structural role played by these domains. However, the mechanisms by 
which these exogenous domains would trigger synapse formation remain unclear.  
In conclusion, these results suggest that the extracellular domains of GABAARs 
play a role in both activity-dependent and structure-dependent functions. Interestingly, 
similarities shared by these mechanisms exist. Indeed, formation of α2-containing 
synapses is facilitated during normal development together with the accumulation of 
gephyrin at postsynaptic sites. In addition, the formation of α2-containing GABAARs is 
promoted when the system is deprived of GABAergic currents, possibly as 
compensatory mechanism. Finally, both the α1 and the α2 exogenous ECDs were able 
to increase the density of GABAARs and the density of functional GABAergic synapses 
per dendrites. These results are interestingly linked with each other as they both 
suggest a dominant structural and functional role of α2-containing GABAARs during the 
formation of GABAergic synapses in the embryonic basal ganglia. All together, our data 
show a prominent structural and physiological role of the α2 subunit in the striatum 
cultures which may lead us to a better understanding of the particular abundance of the 
GABAAR α2 subunit in the adult striatum.   
8.5 Limits of the analysis of GABAergic synapses 
In the result chapters 5, 6 and 7 of this thesis, we were interested in understanding the 
role played by α1 and α2 GABAAR subunits at the early stages of GABAergic synapse 
formation. To do so, we have cultured GABAergic medium spiny neurones at different 
developmental stages, fixed them with 4% (w/v) paraformaldehyde, performed 
immunostaining, and analysed the synaptic contacts under different treatments and 
conditions. Although we conducted a throrough and detailed study of synaptic contact 
formation in these three chapters, the inherent variability of the experiments depends 
on many different parameters. What are the technical limits and bias of these three 
result chapters? 
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The paraformadehyde preserves the tissue by cross-linking proteins and 
maintains the relative positions of cellular structures. However, we noticed that it 
provoked a slight membrane disruption which could potentially alter the staining and 
interfer with the precision of the analysis. Indeed, the fixation with paraformaldehyde 
provoked an uncontrolled permeabilisation of the membrane which then led in some 
cases, to unwanted intracellular staining. 
The primary and secondary antibodies used throughout immunolabelling 
sometimes lack of specificity, resulting in a misleading staining. In this thesis, the 
specificity of the antibodies used was already characterised. The rabbit antibody 
directed against the α1 subunit of GABAARs was developed and characterised by 
Duggan and colleagues (Duggan and Stephenson, 1989), while the other antibodies 
were commercially available and also previously tested in the laboratory. However, the 
specificity of some conjugated secondary antibodies was unclear and some would 
cross-react with the MSN cultures. To prevent this trouble and determine which 
conjugated antibody to use, the MSN cultures were stained in the absence of primary 
antibodies and in the presence of secondary antibodies only (data not shown). 
Immunolabelling was analysed using Zeiss LSM 710 confocal microscope with 
a Plan-Apochromat 63x/1.4 Oil DIC lens. Selecting cells could sometimes trigger a bias 
as the selection should be done randomly throughout the coverslip. However, the 
density of cells was not always even across the field. Some neurones were isolated 
from the rest of the network and showed different morphology compared to the group 
of neighbouring cells. To be consistent with the study of synapse formation within a 
GABAergic network, we selected the cells that were included within a network of 
neighbouring MSNs and avoided to image isolated neurones. 
Although several washings were performed at different stages of the 
immunostaining, and a thorough control of the specificity of antibodies was done, 
background staining was inevitable. Therefore, the image was modified before the 
measurement of clusters was performed. First, the background staining intensity was 
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measured from a circle randomly placed in the extracellular space. Subsequently, the 
average intensity threshold of the image was adjusted for each channel so that any 
staining with lower or equal intensity to the background was removed from the image. 
Although the value of the background intensity could vary depending on where the 
circle was placed in the extracellular space, it was similar across the image.   
In order to established the density and size of α1- and α2-containing GABAA 
receptor clusters or gephyrin clusters, puncta were defined as immunoreactive profiles 
greater than 0.1 μm2, with the mean intensity of each cluster equal or higher than 
double the standard deviation of intensity which was indicated by the Zen 2009 
Programme. These criterions were previously defined (Goffin et al., 2010) and allowed 
us to determine which puncta could be classified as a cluster with more restricition and 
precision.  
The density and size of α1 clusters were first calculated, followed by the α2 
clusters. Then, α1 clusters which were co-localised with α2 clusters (α1 mixed clusters) 
were separated from α1 clusters and analysed as a separate group. The same 
selection was applied to α2 mixed clusters. A minimum of 50 % overlap between the 
two stainings was defined by eye. Although this method could decrease the strength of 
our results because it is subjective, the estimation was consistently and carefully 
performed throughout the analysis and carried by the same experimenter. The same 
criterion was applied to identify synaptic clusters which were in close apposition to the 
GAD-65-positive presynaptic nerve terminal and also to determine the density and 
proportion of α1 and α2-containing clusters co-localised with gephyrin.  
All together, a careful look at the way the analysis was carried throughout these three 
result chapters reveals technical limits and some bias. However, care and precision 
were maintained throughout the experiments, supporting the strength of the data. It 
would certainly be a major improvement if this analysis was carried by a specifically 
designed program adapated to our experiments. 
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Table 33: Activity and structural role of GABAAR subunits α1 and α2 ECDs during 
GABAergic synapse formation.  
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10. Appendix  
Table 1. Proteomics round 1: Hits identified in the α1 ECDs-binding assay and absent 
from the α2 ECDs- binding assay analysed with GPM.  
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Accession Hits log(e) log(I) Mr
ENSRNOP00000033950 Ubiquitin-like modifier-activating enzyme 1 (Ubiquitin-activating enzyme E1) Source: UniProtKB/Swiss-Prot Q5U300IPR009036 Molybdenum cofac synth MoeBIPR000594 ThiF NAD FAD bdIPR018075 UBQ-activ enz E1IPR000011 UBQ-activ enz E1-likeIPR018074 UBQ-activ enz E1 ASIPR000127 UBact repeat-53.6 3.14 117.7
ENSRNOP00000060177 Tubulin beta-5 chain Source: UniProtKB/Swiss-Prot P69897IPR002453 Beta tubulinIPR002967 Delta tubulinIPR004057 Epsilon tubulinIPR002454 Gamma tubulinIPR008280 Tub FtsZ CIPR018316 Tubulin/FtsZ 2-layer-sand-dom-26.4 3.19 24.3
ENSRNOP00000031061 Transcription intermediary factor 1-beta (TIF1-beta)(Tripartite motif-containing protein 28)(Nuclear corepressor KAP-1)(KRAB-associated protein 1) Source: UniProtKB/Swiss-Prot O08629IPR000104 Antifreeze 1IPR003649 Bbox CIPR001487 BromodomainIPR002219 Prot Kinase C-like PE/DAG bdIPR019786 Zinc finger PHD-type CSIPR000315 Znf B-boxIPR020457 Znf B-box chordataIPR018957 Znf C3HC4 RING-typeIPR011011 Znf FYVE PHDIPR001965 Znf PHDIPR019787 Znf PHD-fingerIPR001841 Znf RING-23.5 2.82 88.9
ENSRNOP00000061208 Glyceraldehyde-3-phosphate dehydrogenase Source: UniProtKB/TrEMBL D4A6J7IPR020831 GlycerAld/Erythrose P DHIPR020830 GlycerAld 3-P DH ASIPR020828 GlycerAld 3-P DH NAD(P)-bdIPR020829 GlycerAld 3-P DH catIPR006424 Glyceraldehyde-3-P DH 1-23.4 2.72 35.7
ENSRNOP00000005990 Alpha-actinin-1 (Alpha-actinin cytoskeletal isoform)(Non-muscle alpha-actinin-1)(F-actin cross-linking protein) Source: UniProtKB/Swiss-Prot Q9Z1P2IPR001589 Actinin actin-bd CSIPR016146 Calponin-homologyIPR001715 Calponin act bdIPR014837 EF-hand Ca insenIPR018249 EF HAND 2IPR018248 EF Hand calmodulinIPR002048 EF hand Ca bdIPR018159 Spectrin/alpha-actininIPR002017 Spectrin repeat-20.5 2.73 102.5
ENSRNOP00000013305 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform (EC 3.1.3.16)(Calmodulin-dependent calcineurin A subunit alpha isoform)(CAM-PRP catalytic subunit) Source: UniProtKB/Swiss-Prot P63329IPR004843 M-pesteraseIPR006186 Ser/Thr-sp prot-phosphatase-17.5 2.72 58.6
ENSRNOP00000062817 type I keratin KA11 IPR016044 FIPR018039 Intermediate filament CSIPR002957 Keratin IIPR009053 Prefoldin-12.8 2.64 52.6
ENSRNOP00000005285 Keratin, type I cytoskeletal 14 (Cytokeratin-14)(CK-14)(Keratin-14)(K14)(Type I keratin Ka14) Source: UniProtKB/Swiss-Prot Q6IFV1IPR016044 FIPR018039 Intermediate filament CSIPR002957 Keratin IIPR009053 Prefoldin-12.5 2.46 52.7
ENSRNOP00000012640 Keratin, type II cytoskeletal 75 (Cytokeratin-75)(CK-75)(Keratin-75)(K75)(Type-II keratin Kb18)(Type II keratin-K6hf)(Keratin-6 hair follicle) Source: UniProtKB/Swiss-Prot Q6IG05IPR016044 FIPR018039 Intermediate filament CSIPR002957 Keratin IIPR003054 Keratin IIIPR009053 PrefoldinIPR003536 Transloc intimin rcptIPR000533 Tropomyosin-12.4 4.13 59
ENSRNOP00000024895 similar to 2610301G19Rik protein (RGD1309922), mRNA -11.8 2.23 102.7
ENSRNOP00000033922 no protein text annotation availableIPR003594 ATP bd ATPaseIPR001404 Chaperone htpGIPR019805 Heat shock protein 90 CSIPR020576 Hsp90 CIPR020575 Hsp90 NIPR020568 Ribosomal S5 D2-typ fold-10.2 3.3 76.9
ENSRNOP00000013629 AP-2 complex subunit beta (Adapter-related protein complex 2 beta subunit)(Adaptor protein complex AP-2 subunit beta)(Beta-2-adaptin)(Beta-adaptin)(Plasma membrane adaptor HA2/AP2 adaptin beta subunit)(Clathrin assembly protein complex 2 beta large /.../(AP105B) Source: UniProtKB/Swiss-Prot P62944IPR016342 AP complex bsuIPR016024 ARM-type foldIPR000225 ArmadilloIPR009028 Calthrin/coatomer app sub CIPR002553 Clathrin/coatomer adapt-like NIPR013041 Clathrin/coatomer app Ig-likeIPR008152 Clathrin a/b/g-adaptin app IgIPR015151 Clathrin b-adaptin app sub CIPR000357 HEAT-8.9 2.31 105.6
ENSRNOP00000011484 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 IPR008011 Complex1 LYRIPR016488 NADH Ub cplx-1 asu su-6-8.6 1.97 5.2
ENSRNOP00000014004 importin 7 IPR016024 ARM-type foldIPR003006 Ig/MHC CSIPR001494 Importin-b N-8.2 2.39 119.4
ENSRNOP00000031020 Complement component 1 Q subcomponent-binding protein, mitochondrial Precursor (Glycoprotein gC1qBP)(C1qBP)(GC1q-R protein) Source: UniProtKB/Swiss-Prot O35796IPR003428 MAM33-7.6 3.2 31
ENSRNOP00000003277 General vesicular transport factor p115 (Protein USO1 homolog)(Transcytosis-associated protein)(TAP)(Vesicle-docking protein) Source: UniProtKB/Swiss-Prot P41542IPR016024 ARM-type foldIPR000225 ArmadilloIPR006955 Uso1 p115 CIPR006953 Uso1 p115 head-6.9 2.02 107.1
ENSRNOP00000004725 Gamma-aminobutyric acid receptor subunit alpha-1 Precursor (GABA(A) receptor subunit alpha-1) Source: UniProtKB/Swiss-Prot P62813IPR006028 GABAA rcptIPR001390 GABAAa rcptIPR005431 GABBAa1 rcptIPR005432 GABBAa2 rcptIPR005437 GABBAg rcptIPR006029 Neu channel TMIPR006202 Neur chan lig bdIPR006201 Neur channelIPR018000 Neurotransmitter ion chnl CS-6.6 2.15 51.7
sp|CASB_BOVIN|  Beta-casein; Contains: Casoparan; Contains: Antioxidant peptide; Contains: Casohypotensin; Flags: Precursor; -5.5 3 25.1
ENSRNOP00000015083 Arginase-2, mitochondrial Precursor (EC 3.5.3.1)(Type II arginase)(Non-hepatic arginase)(Kidney-type arginase) Source: UniProtKB/Swiss-Prot O08701IPR005924 ArginaseIPR014033 Arginase subIPR006035 UreohydrolaseIPR020855 Ureohydrolase Mn BS-5.5 2.28 38.7
ENSRNOP00000037110 60S ribosomal protein L11 Source: UniProtKB/Swiss-Prot P62914IPR002132 Ribosomal L5IPR020929 Ribosomal L5 CSIPR022803 Ribosomal L5 domain-5 2.3 2 .
ENSRNOP00000036123 No description -5 2.3 90.5
ENSRNOP00000018149 GTPase activating protein (SH3 domain) binding protein 1 IPR002343 Hud Sxl RNAIPR002075 NTF2IPR018222 Nuclear transport factor 2 eukIPR000694 PRO richIPR000504 RRM RNP1-4.7 1.77 51.8
ENSRNOP00000026696 Stress-70 protein, mitochondrial Precursor (75 kDa glucose-regulated protein)(GRP-75)(Heat shock 70 kDa protein 9)(Peptide-binding protein 74)(PBP74)(mtHSP70)(Mortalin) Source: UniProtKB/Swiss-Prot P48721IPR012725 Chaperone DnaKIPR018247 EF HAND 1IPR018181 Heat shock 70 CSIPR001023 Hsp70IPR013126 Hsp 70-4.5 2.28 73.7
ENSRNOP00000053926 translocase of inner mitochondrial membrane 50 homolog (yeast) Gene -4.2 2.18 14.3
ENSRNOP00000004370 Phenylalanyl-tRNA synthetase alpha chain (EC 6.1.1.20)(Phenylalanine--tRNA ligase alpha chain)(PheRS) Source: UniProtKB/Swiss-Prot Q505J8IPR002319 Phe-tRNA-synth IIc-relIPR004529 Phe-tRNA-synth IIc asuIPR006195 aa-tRNA-synth II cons-dom-3.6 2.42 57.7
ENSRNOP00000006890 Tetratricopeptide repeat protein 35 (TPR repeat protein 35) Source: UniProtKB/Swiss-Prot B0BNG0IPR013026 TPR-containIPR019734 TPR repeat-3.4 2 34.8
ENSRNOP00000023606 V-type proton ATPase subunit d 1 IPR016727 ATPase V0-cplx dsuIPR002843 ATPase V0/A0-cplx csu/dsu-3 2.28 40.3
ENSRNOP00000014859 no protein text annotation availableIPR016024 ARM-type foldIPR000357 HEATIPR001494 Importin-b N-2.6 2.42 123.6
ENSRNOP00000010419 EH domain-containing protein 3 Source: UniProtKB/Swiss-Prot Q8R491IPR001401 Dynamin GTPaseIPR018247 EF HAND 1IPR018249 EF HAND 2IPR002048 EF hand Ca bdIPR000261 EPS15 homology-2.4 2.24 60.8
sp|CASK_BOVIN| Kappa-casein; Contains: Casoxin-C; Contains: Casoxin-6; Contains: Casoxin-A; Contains: Casoxin-B; Contains: Casoplatelin; Flags: Precursor; -2.2 2.7 21.3
ENSRNOP00000052297 RAP1, GTP-GDP dissociation stimulator 1 IPR016024 ARM-type foldIPR000225 ArmadilloIPR000357 HEAT-2.1 1.99 61.9
ENSRNOP00000004956 Collagen alpha-1(III) chain Source: UniProtKB/Swiss-Prot P13941IPR008160 CollagenIPR000885 Fib collagen CIPR002181 Fibrinogen a/b/g CIPR006552 VWC outIPR001007 VWF C-2 2.38 138.9
ENSRNOP00000046203 Voltage-dependent anion-selective channel protein 3 (VDAC-3)(rVDAC3)(Outer mitochondrial membrane protein porin 3) Source: UniProtKB/Swiss-Prot Q9R1Z0IPR001925 Porin Euk-1.8 2.25 30.9
ENSRNOP00000026881 immunity-related GTPase family, Q IPR001208 DNA-dep ATPase MCMIPR002185 Dopa D4 rcptIPR001984 Peptidase S16 C-1.7 2.93 59.2
ENSRNOP00000024198 Bifunctional protein NCOAT (Nuclear cytoplasmic O-GlcNAcase and acetyltransferase)(Meningioma-expressed antigen 5) Source: UniProtKB/Swiss-Prot Q8VIJ5IPR016181 Acyl CoA acyltransferaseIPR011496 Beta-N-acetylglucosaminidase-1.7 2.12 107
ENSRNOP00000027145 RNA-binding protein 34 (RNA-binding motif protein 34) Source: UniProtKB/Swiss-Prot Q5M9F1IPR000504 RRM RNP1-1.6 2.1 47.6
ENSRNOP00000033847 RAB, member of RAS oncogene family-like 3 IPR003593 ATPase AAA+ coreIPR001401 Dynamin GTPaseIPR006073 GTP1 OBGIPR003579 GTPase RabIPR003577 GTPase RasIPR003578 GTPase RhoIPR013684 MIRO-likeIPR002078 RNA pol sigma 54 intIPR013753 RasIPR001806 Ras GTPase-1.6 2.28 26.3
sp|CAS2_BOVIN| Alpha-S2-casein; Contains: Casocidin-1; Casocidin-I; Flags: Precursor; -1.6 2.36 26
ENSRNOP00000017805 Neutral cholesterol ester hydrolase 1 (NCEH)(EC 3.1.1.-)(Arylacetamide deacetylase-like 1) Source: UniProtKB/Swiss-Prot B2GV54IPR017157 Arylacetamide deacetylaseIPR002168 Lipase GDXG AS-1.6 1.68 45.8
ENSRNOP00000038639 tubulin tyrosine ligase-like family, member 12 IPR004344 Tub tyr ligase-1.6 2.55 73.9
ENSRNOP00000006361 Vesicle-fusing ATPase (EC 3.6.4.6)(N-ethylmaleimide-sensitive fusion protein)(NEM-sensitive fusion protein)(Vesicular-fusion protein NSF) Source: UniProtKB/Swiss-Prot Q9QUL6IPR003593 ATPase AAA+ coreIPR003960 ATPase AAA CSIPR003338 ATPase AAA VAT NIPR003959 ATPase AAA coreIPR009010 Asp de-COase-like foldIPR004201 Cell division protein CDC48 2IPR001984 Peptidase S16 C-1.6 2.21 82.6
ENSRNOP00000020568 cartilage acidic protein 1 IPR001881 EGF Ca bdIPR013091 EGF Ca bd 2IPR018097 EGF Ca bd CSIPR013517 FG-GAPIPR011519 UnbV ASPIC-1.5 2.11 70.4
ENSRNOP00000019935 No description available.Protein Family: CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT 1 CALCIUM ACTIVATED POTASSIUM CHANNEL SUBFAMILY M ALPHA SUBUNIT 1 MAXI K CHANNEL MAXIK BK CHANNEL K VCA ALPHA BKCA ALPHA KCA1 1 SLOWPOKE HOMOLOG SLO HOMOLOG SLO ALPHA SLO1-1.5 2.17 125.8
ENSRNOP00000034954 perlecan (heparan sulfate proteoglycan 2) Gene IPR008985 ConA-like lec glIPR006209 EGFIPR006210 EGF-likeIPR013032 EGF-like reg CSIPR001438 EGF 2IPR000742 EGF 3IPR001881 EGF Ca bdIPR002049 EGF lamininIPR007110 Ig-likeIPR013106 Ig V-setIPR003596 Ig V-set subIPR003599 Ig subIPR003598 Ig sub2IPR002172 LDL rcpt classA cys-richIPR018031 Laminin BIPR000034 Laminin B type IVIPR001791 Laminin GIPR012680 Laminin G 2IPR009138 Neural cell adhIPR000082 SEAIPR009134 Tyr prot kinase VEGFR rcpt N-1.5 2.05 375
ENSRNOP00000006628 COMM domain containing 9 IPR009886 HCaRG-1.4 1.67 22
ENSRNOP00000029833 Gliomedin Source: UniProtKB/Swiss-Prot Q80WL1IPR008160 Collagen IPR003112 (&times;3) Olfac-like IPR000694 PRO rich -1.4 2.75 59.3
ENSRNOP00000052173 no protein text annotation availableIPR004087 KHIPR004088 KH type 1IPR018111 KH type 1 subgrIPR004044 KH type 2-1.3 2.59 30.6
ENSRNOP00000022555 kinesin family member 11 IPR001752 Kinesin motorIPR019821 Kinesin motor CS-1.3 2.79 118.2
ENSRNOP00000014191 cDNA sequence BC024139 (BC024139), mRNA IPR003108 GAS2IPR022272 Lipocalin CSIPR018159 Spectrin/alpha-actinin-1.1 1.62 85.9
ENSRNOP00000012853 Hydroxymethylglutaryl-CoA lyase, mitochondrial Source: UniProtKB/Swiss-Prot P97519IPR000138 HMG CoA lyase ASIPR000891 PYR CT-1.1 0.92 34.2
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Table 2. Proteomics round 2: Hits identified in the α1 ECDs-binding assay and absent 
from the α2 ECDs- binding assay analysed with GPM.  
Accession Hits log(e) log(I) Mr
ENSRNOP00000008504  Hspa2:p , Heat shock-related 70 kDa protein 2 (Heat shock protein 70.2)(Testis-specific heat shock protein-related)(HST ...-82.7 5.74 69.6
ENSRNOP00000023447  Acly:p , ATP-citrate synthase ( EC 2.3.3.8 )(ATP-citrate (pro-S-)-lyase)(Citrate cleavage enzyme) Source: UniProtKB/Swi ...-81.6 4.94 121
ENSRNOP00000022892  Atp5a1:p , ATP synthase subunit alpha, mitochondrial Source: UniProtKB/Swiss-Prot P15999 -45.3 4.71 59.8
ENSRNOP00000015535  Aldoc:p , Fructose-bisphosphate aldolase C ( EC 4.1.2.13 )(Brain-type aldolase) Source: UniProtKB/Swiss-Prot P09117 -30.5 4.52 39.
ENSRNOP00000004725  Gabra1:p , Gamma-aminobutyric acid receptor subunit alpha-1 Precursor (GABA(A) receptor subunit alpha-1) Source: UniPro ...-29.8 4.5 51.7
ENSRNOP00000020681  Vapa:p , Vesicle-associated membrane protein-associated protein A (VAMP-associated protein A)(VAMP-A)(VAP-A)(33 kDa VAM ...-27.4 4.17 27.8
ENSRNOP00000010512  Tmed10:p , transmembrane emp24 domain-containing protein 10 precursor [ Source: RefSeq NP_445919 ]-26.5 4.53 24.8
ENSRNOP00000001227  Cct6a:p , T-complex protein 1 subunit zeta [ Source: RefSeq NP_001028856 ]-23.7 4.52 58
ENSRNOP00000045650  Sodium/potassium-transporting ATPase subunit alpha-1 -21.7 4.16 13
ENSRNOP00000002037  Psmb1:p , Proteasome subunit beta type-1 Precursor ( EC 3.4.25.1 )(Proteasome component C5)(Macropain subunit C5)(Multi ...-20.2 4.54 26.4
ENSRNOP00000018711  Cap1:p , Adenylyl cyclase-associated protein 1 (CAP 1) Source: UniProtKB/Swiss-Prot Q08163 -16.8 5.15 51.6
ENSRNOP00000015779  Eif5a2:p , no protein text annotation available-15.1 4.28 16.8
ENSRNOP00000059233  Nckap1:p , -14 3.75 125
ENSRNOP00000022779  Actr1b:p , ARP1 actin-related protein 1 homolog B [ Source: RefSeq NP_001034117 ]-13.7 4.03 42.3
ENSRNOP00000001201  Hsph1:p , -11.9 3.95 96.4
ENSRNOP00000025086  Nup93:p , Nuclear pore complex protein Nup93 (Nucleoporin Nup93)(93 kDa nucleoporin) Source: UniProtKB/Swiss-Prot Q66HC ...-11.3 3.4 93.2
ENSRNOP00000026297  Cleavage and polyadenylation specificity factor subunit 5 (Nucleoside diphosphate-linked moiety X motif 21)(Nudix motif  ...-11 3.32 26.2
ENSRNOP00000018934  RGD1562948:p , -11 4.15 35.8
ENSRNOP00000059847  Actbl2:p , beta-actin-like protein 2 [ Source: RefSeq NP_001099879 ]-10.7 4.15 41.9
ENSRNOP00000048250  Hemoglobin subunit beta-1 -9.9 4.06 16
ENSRNOP00000008337  Aco1:p , -9.5 4.18 98.1
ENSRNOP00000056260  Rps14:p , 40S ribosomal protein S14 Source: UniProtKB/Swiss-Prot P13471 -9.1 4.29 16.3
ENSRNOP00000026016  Ctnnb1:p , Catenin beta-1 (Beta-catenin) Source: UniProtKB/Swiss-Prot Q9WU82 -7.9 4.07 85.4
ENSRNOP00000061544  Fubp1:p , -7.5 4.48 67.2
ENSRNOP00000008329  Sec61b:p , Sec61 beta subunit [ Source: RefSeq NP_001100124 ]-6.4 3.02 10
ENSRNOP00000025794  Sod2:p , Superoxide dismutase [Mn], mitochondrial -5.8 3.83 24.7
ENSRNOP00000006190  Ppp1cb:p , Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PP-1B)( EC 3.1.3.16 ) Source: UniProtKB/Swi ...-5.5 3.11 37.2
ENSRNOP00000028020  budding uninhibited by benzimidazoles 3 homolog [ Source: RefSeq NP_001041371 ]-5 3.32 67.7
ENSRNOP00000018145  Mvd:p , Diphosphomevalonate decarboxylase ( EC 4.1.1.33 )(Mevalonate pyrophosphate decarboxylase)(Mevalonate (diphospho ...-4.9 3.93 43 9
ENSRNOP00000030902  Rpl38:p , -4.9 3.1 8.2
ENSRNOP00000012842  Uchl3:p , Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3)( EC 3.4.19.12 )(Ubiquitin thioesterase L3) Source:  ...-4.9 3.87 26.1
ENSRNOP00000006607  Actr2:p , Actin-related protein 2 (Actin-like protein 2) Source: UniProtKB/Swiss-Prot Q5M7U6 -4.7 4.18 44.7
ENSRNOP00000002478  Dynamin-1-like protein ( EC 3.6.5.5 )(Dynamin-like protein) Source: UniProtKB/Swiss-Prot O35303 -4.7 3.23 83.9
ENSRNOP00000022574  Stmn1:p , Stathmin Source: UniProtKB/Swiss-Prot P13668 -4.6 4.25 7.3
ENSRNOP00000020940  Aldh18a1:p , pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase) [ Source: RefSeq NP_001101994 ...-4.1 3.93 87.3
ENSRNOP00000061516  Arpc5:p , -4 3.7 16.3
ENSRNOP00000016495  Atp6v1e1:p , V-type proton ATPase subunit E 1 Source: UniProtKB/Swiss-Prot Q6PCU2 -4 3.51 26.1
ENSRNOP00000024471  Ndufab1:p , acyl carrier protein, mitochondrial [ Source: RefSeq NP_001099764 ]-4 3.84 17.5
ENSRNOP00000012425  Ndufs3:p , NADH dehydrogenase [ Source: RefSeq NP_001099959 ]-4 3.79 30.2
ENSRNOP00000019405  Arpc5l:p , -3.9 3.79 17.1
ENSRNOP00000025224  Rpsa:p , 40S ribosomal protein SA -3.8 3.94 32.8
ENSRNOP00000020402  Sae1:p , no protein text annotation available-3.8 3.72 38.5
ENSRNOP00000029702  DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked [ Source: RefSeq NP_001101716 ]-3.7 3.18 34.3
ENSRNOP00000020478  Pdia3:p , Protein disulfide-isomerase A3 -3.7 3.8 56.6
ENSRNOP00000004438  Cops3:p , COP9 signalosome complex subunit 3 (Signalosome subunit 3)(SGN3) Source: UniProtKB/Swiss-Prot Q68FW9 -3.6 .85 47.8
ENSRNOP00000004520  Actin-related protein 3 (Actin-like protein 3) Source: UniProtKB/Swiss-Prot Q4V7C7 -3.5 3.2 47.3
ENSRNOP00000009999  kinesin family member 3a [ Source: RefSeq_peptide (XP_340797) ]&nbsp;-3.3 3.28 80.2
ENSRNOP00000008328  LOC100359421:p , -3.3 4.69 15.4
ENSRNOP00000015218  Sec11a:p , Signal peptidase complex catalytic subunit SEC11A ( EC 3.4.-.- )(SEC11 homolog A)(SEC11-like protein 1)(Micr ...-3.1 3.02 20.6
ENSRNOP00000026021  Fbl:p , rRNA 2&#39;-O-methyltransferase fibrillarin ( EC 2.1.1.- )(Nucleolar protein 1) Source: UniProtKB/Swiss-Prot P2 ...-3 3.68 34.2
ENSRNOP00000037163  Sec24b:p , SEC24 family, member B [ Source: RefSeq NP_001099944 ]-3 2.62 135
ENSRNOP00000046491  Hnrpd:p , Heterogeneous nuclear ribonucleoprotein C Source: UniProtKB/Swiss-Prot P17132 -2.9 3.54 38.2
ENSRNOP00000007567  Ndufa4:p , NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 [ Source: RefSeq NP_001121156 ]-2.9 3.16 9.3
ENSRNOP00000001675  Pcbp3:p , -2.9 3.74 33.8
ENSRNOP00000028687  Prdx5:p , Peroxiredoxin-5, mitochondrial Precursor ( EC 1.11.1.15 )(Peroxiredoxin V)(Prx-V)(Peroxisomal antioxidant enz ...-2.9 3.82 22.2
ENSRNOP00000057942  heterogeneous nuclear ribonucleoprotein A0 Gene [ Source: MGI:1924384 ]-2.8 3.5 30.3
ENSRNOP00000015757  Psmc3:p , 26S protease regulatory subunit 6A (Proteasome 26S subunit ATPase 3)(Tat-binding protein 1)(TBP-1)(Spermatoge ...-2. 4.02 49.5
ENSRNOP00000044122  Fam190a:p , -2.5 3.82 79.7
ENSRNOP00000007351  Snrpf:p , small nuclear ribonucleoprotein polypeptide F [ Source: RefSeq NP_001119563 ]-2.5 3.43 9.7
ENSRNOP00000014250  Syn1:p , Synapsin-1 (Synapsin I) Source: UniProtKB/Swiss-Prot P09951 -2.5 3.3 73.9
ENSRNOP00000004942  Tmed7:p , transmembrane emp24 protein transport domain containing 7 [ Source: RefSeq NP_001099228 ]-2.4 3.21 25.5
ENSRNOP00000046414  Cytochrome c oxidase subunit 2 Source: UniProtKB/Swiss-Prot P00406 -2.3 4.22 25.9
ENSRNOP00000019737  Clta:p , Clathrin light chain A (Lca). Source: Uniprot/SWISSPROT P08081 -2.2 3.37 27
ENSRNOP00000010956  Cul5:p , Cullin-5 (CUL-5)(Vasopressin-activated calcium-mobilizing receptor 1)(VACM-1) Source: UniProtKB/Swiss-Prot Q9J ...-2.1 3.48 90.8
ENSRNOP00000023526  Ndufs8:p , NADH dehydrogenase ubiquinone Fe-S 8 [ Source: RefSeq NP_001099792 ]-2.1 3.87 24
ENSRNOP00000002358  Psmd2:p , 26S proteasome non-ATPase regulatory subunit 2 Source: UniProtKB/Swiss-Prot Q4FZT9 -2.1 3.75 100
ENSRNOP00000001609  RGD1303003:p , ES1 protein homolog, mitochondrial Precursor Source: UniProtKB/Swiss-Prot P56571 -2.1 3.3 28.2
ENSRNOP00000021514  Uqcrc2:p , Cytochrome b-c1 complex subunit 2, mitochondrial Precursor (Ubiquinol-cytochrome-c reductase complex core pr ...-2.1 3.73 48.4
ENSRNOP00000007100  Ywhae:p , 14-3-3 protein epsilon (14-3-3E)(Mitochondrial import stimulation factor L subunit)(MSF L) Source: UniProtKB/ ...-2.1 3.77 29.2
ENSRNOP00000031281  Usp32:p , ubiquitin specific protease 32 [ Source: RefSeq NP_001100502 ]-1.9 3.27 162
ENSRNOP00000027828  Fam189b:p , -1.8 3.11 71.8
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Accession Hits log(e) log(I) Mr
ENSRNOP00000010811 Protein NDRG1 Source: UniProtKB/Swiss-Prot Q6JE36IPR000073 AB hydrolase 1IPR004142 NdrIPR006162 PPantetheine attach site-23.9 2.54 42.9
ENSRNOP00000004895 protein canopy homolog 2 IPR011001 Saposin-likeIPR008139 SaposinB-12.1 2.63 20.7
ENSRNOP00000012842 Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3)(EC 3.4.19.12)(Ubiquitin thioesterase L3) Source: UniProtKB/Swiss-Prot Q91Y78IPR001578 Peptidase C12-11.7 2.77 25.8
ENSRNOP00000058898 -9.4 3.46 29.3
ENSRNOP00000002091 Neuromodulin (Axonal membrane protein GAP-43)(Growth-associated protein 43)(Protein F1) Source: UniProtKB/Swiss-Prot P07936IPR000048 IQ CaM bd regionIPR001422 NeuromodulinIPR017454 Neuromodulin CIPR018243 Neuromodulin palmitoyl/P-5.3 2.14 23.6
ENSRNOP00000015234 40S ribosomal protein S9 Source: UniProtKB/Swiss-Prot P29314IPR001912 Ribosomal S4IPR005710 Ribosomal S4/S9 euk/arcIPR018079 Ribosomal S4 CSIPR002942 S4 RNA bd-3.8 2.24 22.6
ENSRNOP00000010087 Proteasomal ubiquitin receptor ADRM1 (Adhesion-regulating molecule 1)(ARM-1)(110 kDa cell membrane glycoprotein)(Gp110)(Rpn13 homolog) Source: UniProtKB/Swiss-Prot Q9JMB5IPR006773 26S Psome Ubiquitin-recp Rpn13IPR000104 Antifreeze 1-3.8 2.39 42.1
ENSRNOP00000027305 Elongation factor 1-gamma (EF-1-gamma)(eEF-1B gamma) Source: UniProtKB/Swiss-Prot Q68FR6IPR004046 GST CIPR010987 Glutathione-S-Trfase C-likeIPR004045 Glutathione S-Trfase NIPR012336 Thioredoxin-like foldIPR001662 Transl elong EF1 G con-3.7 2.41 50
ENSRNOP00000028576 EH domain-containing protein 1 Source: UniProtKB/Swiss-Prot Q641Z6IPR022812 DynaminIPR001401 Dynamin GTPaseIPR002917 MMR HSR1 GTP-bd-3.6 1.7 55.4
ENSRNOP00000017942 UPF0160 protein MYG1, mitochondrial Precursor Source: UniProtKB/Swiss-Prot Q641W2IPR003226 Met-dep prot hydro-3.3 2.24 42.9
ENSRNOP00000043519 Moesin Source: UniProtKB/Swiss-Prot O35763IPR019749 Band 41 domainIPR019750 Band 41 famIPR011174 ERMIPR011259 ERM CIPR000798 Ez/rad/moesinIPR019747 FERM CSIPR019748 FERM centralIPR000299 FERM domainIPR008954 MoesinIPR000533 Tropomyosin- 2.29 67.6
ENSRNOP00000022854 Protein phosphatase 1 regulatory subunit 7 (Protein phosphatase 1 regulatory subunit 22) Source: UniProtKB/Swiss-Prot Q5HZV9IPR001611 Leu-rich rptIPR003591 Leu-rich rpt typical-subtypIPR020474 Toll-like rcpt LRRIPR003603 U2A&apos; phosphoprotein32A C-2. 2.21 41.3
ENSRNOP00000014609 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform (PP2A subunit A isoform PR65-beta)(PP2A subunit A isoform R1-beta) Source: UniProtKB/Swiss-Prot Q4QQT4IPR016024 ARM-type foldIPR000357 HEATIPR021133 HEAT type 2IPR001160 Peptidase M20C-2. 2.17 76.1
ENSRNOP00000014780 Glycyl-tRNA synthetase Fragment (EC 6.1.1.14)(Glycine--tRNA ligase)(GlyRS)(Diadenosine tetraphosphate synthetase)(AP-4-A synthetase) Source: UniProtKB/Swiss-Prot Q5I0G4IPR004154 Anticodon bdIPR002316 Pro-tRNA-synth IIa cons-regIPR009068 S15 NS1 RNA bdIPR000738 WHEP-TRSIPR002314 aa-tRNA-synt IIb cons-domIPR006195 aa-tRNA-synth II cons-domIPR002315 tRNA-synt gly-2.4 2.08 81.7
ENSRNOP00000007554 Vesicle-associated membrane protein-associated protein B (VAMP-associated protein B)(VAMP-B)(VAP-B) Source: UniProtKB/Swiss-Prot Q9Z269IPR000535 Major spermIPR008962 PapD-likeIPR016763 Vesicle-associated membrane-2.1 3.07 26.9
ENSRNOP00000000599 AH receptor-interacting protein (AIP)(Aryl-hydrocarbon receptor-interacting protein)(Immunophilin XAP2) Source: UniProtKB/Swiss-Prot Q5FWY5IPR001179 PPIase FKBPIPR013026 TPR-containIPR019734 TPR repeat-2.1 2.76 37.6
ENSRNOP00000054270 Uncharacterized protein Source: UniProtKB/TrEMBL F1M6Q3IPR016187 C-type lectin foldIPR008160 CollagenIPR001442 Collagen VI NC-1.9 2.4 161.3
ENSRNOP00000003840 PH domain leucine-rich repeat protein phosphatase 1 (EC 3.1.3.16)(Pleckstrin homology domain-containing family E member 1)(PH domain-containing family E member 1)(Suprachiasmatic nucleus circadian oscillatory protein) Source: UniProtKB/Swiss-Prot Q9WTR8IPR001611 Leu-rich rptIPR003591 Leu-rich rpt typical-subtypIPR001932 PP2C-relatedIPR014045 PP2C NIPR001849 Pleckstrin homologyIPR020474 Toll-like rcpt LRR-1.6 2.9 18 .5
ENSRNOP00000005122 arsA arsenite transporter, ATP-binding, homolog 1 IPR003593 ATPase AAA+ coreIPR003348 ATPase anion-transpIPR000392 Nitogenase NifH/Reductase ChlL-1.6 2.52 39
ENSRNOP00000028117 Small conductance calcium-activated potassium channel protein 3 (SKCa 3)(SKCa3)(SK3) Source: UniProtKB/Swiss-Prot P70605IPR004178 CaM-bd domIPR013099 Ion trans 2IPR003091 K chnlIPR011996 K chnl Ca-activ SK conIPR003931 K chnl Ca-activ SK con subIPR000694 PRO rich-1.6 2.49 81.3
ENSRNOP00000004942 transmembrane emp24 protein transport domain containing 7 IPR000348 Emp24 gp25L p24IPR009038 GOLD-1.5 2.61 25.5
ENSRNOP00000018711 Adenylyl cyclase-associated protein 1 (CAP 1) Source: UniProtKB/Swiss-Prot Q08163IPR013912 Adenylate cyclase-assoc CAP CIPR013992 Adenylate cyclase-assoc CAP NIPR018106 CAP CSIPR006599 CARP motifIPR000694 PRO rich-1.5 1.72 51.6
ENSRNOP00000024404 integrin alpha L IPR013517 FG-GAPIPR013519 Int alpha beta-pIPR000413 Integrin alphaIPR013649 Integrin alpha-2IPR013513 Integrin alpha CIPR018184 Integrin alpha C CSIPR002035 VWF A-1.5 1.97 127.6
ENSRNOP00000008356 Calumenin Precursor (Crocalbin)(CBP-50) Source: UniProtKB/Swiss-Prot O35783IPR018247 EF HAND 1IPR018249 EF HAND 2IPR018248 EF Hand calmodulinIPR002048 EF hand Ca bd-1.3 2.4 37
ENSRNOP00000059909 Actin-related protein 3 Source: UniProtKB/Swiss-Prot Q4V7C7IPR004000 Actin-likeIPR020902 Actin/actin-like CS-1.3 1.79 4 .3
ENSRNOP00000041192 Pikachurin Precursor (EGF-like, fibronectin type-III and laminin G-like domain-containing protein) Source: UniProtKB/Swiss-Prot B4F785IPR008985 ConA-like lec glIPR006209 EGFIPR006210 EGF-likeIPR013032 EGF-like reg CSIPR001438 EGF 2IPR000742 EGF 3IPR001881 EGF Ca bdIPR003961 FN IIIIPR008957 Fibronectin typ-III-like foldIPR003962 FnIII subdIPR001791 Laminin GIPR012680 Laminin G 2-1.3 2.53 110.5
ENSRNOP00000047793  ret proto-oncogene isoform a Source: RefSeq_peptide NP_036775 IPR002126 CadherinIPR015919 Cadherin-likeIPR011009 Kinase likeIPR000719 Prot kinase coreIPR002290 Ser thr pkinaseIPR001245 Tyr pkinaseIPR008266 Tyr pkinase AS-1.2 2.39 124.2
ENSRNOP00000049627 Ac2-008 Source: UniProtKB/TrEMBL Q7TPK9IPR000910 HMG HMG1/HMG2IPR017967 HMG boxA CSIPR009071 HMG superfamily-1.2 2.75 24.5
ENSRNOP00000013073 aldo-keto reductase family 1, member B8 IPR001395 Aldo/ket redIPR018170 Aldo/ket reductase CSIPR020471 Aldo/keto reductase sgIPR001512 Somatstn rcpt 4-1.2 2.81 36.1
ENSRNOP00000043232 Protein sel-1 homolog 1 Precursor (Suppressor of lin-12-like protein 1)(Sel-1L) Source: UniProtKB/Swiss-Prot Q80Z70IPR000562 FN type2 col bdIPR013806 Kringle-likeIPR000694 PRO richIPR006597 Sel1-like-1.2 2.42 88.5
ENSRNOP00000017776 G protein-coupled receptor 124 Gene IPR002173 Carboh/pur kinase PfkB CSIPR000483 Cys-rich flank reg CIPR017981 GPCR 2-likeIPR001879 GPCR 2 extracellularIPR017983 GPCR 2 secretin-like CSIPR000203 GPS domIPR007110 Ig-likeIPR003599 Ig subIPR003598 Ig sub2IPR001611 Leu-rich rptIPR003591 Leu-rich rpt typical-subtypIPR020474 Toll-like rcpt LRR-1.2 2.93 143.2
ENSRNOP00000022622 leucine rich repeat containing 36 IPR001611 Leu-rich rptIPR020474 Toll-like rcpt LRR- .2 2.19 84.1
ENSRNOP00000008274 galectin-related protein IPR008985 ConA-like lec glIPR001079 Galectin CRD-1.1 2.32 18.9
ENSRNOP00000024762 Shootin-1 Source: UniProtKB/Swiss-Prot A0MZ67IPR013992 Adenylate cyclase-assoc CAP NIPR000694 PRO rich-1.1 2.16 70.4
Table 3. Proteomics round 1: Hits identified in the α2 ECDs-binding assay and absent 
from the α1 ECDs- binding assay analysed with GPM.  
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Table 4. Proteomics round 2: Hits identified in the α2 ECDs-binding assay and absent 
from the α1 ECDs-binding assay analysed with GPM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accession Hits log(e) log(I) Mr
ENSRNOP00000001517 Gcn l1:p , GCN1 general control of amino-acid synthesis 1-like 1 [ Source: RefSeq NP_001162135 ]-81 4.84 292.5
ENSRNOP00000008522 Rab a:p , Ras-related protein Rab-2A Source: UniProtKB/Swiss-Prot P05712 -52 5.1 21.7
ENSRNOP00000007528 Fam49b:p , family with sequence similarity 49, member B (Fam49b), mRNA [Source:RefSeq DNA;Acc:NM_001126267]-45.9 4.97 36.8
ENSRNOP00000003658 Nme1:p , Nucleoside diphosphate kinase A (NDP kinase A)(NDK A)( EC 2.7.4.6 )(Tumor metastatic process-associated protei ...-41.3 5.32 17.2
ENSRNOP00000008210 spectrin beta chain, brain 1 [ Source: RefSeq NP_001013148 ]-34.7 4.46 273.3
ENSRNOP00000022343 Eif5a:p , Eukaryotic translation initiation factor 5A-1 Source: UniProtKB/Swiss-Prot Q3T1J1 -23 4.84 16.8
ENSRNOP00000026528 40S ribosomal protein S5 [Contains 40S ribosomal protein S5, N-terminally processed] Source: UniProtKB/Swiss-Prot P24050 ...-22.8 4.72 22.9
ENSRNOP00000037217 Capza2:p , F-actin-capping protein subunit alpha-2 -19.7 4.27 32.9
ENSRNOP00000008458 Rps21:p , 40S ribosomal protein S21 Source: UniProtKB/Swiss-Prot P05765 -15.2 4.01 9.1
ENSRNOP00000029234 Cct2:p , T-complex protein 1 subunit beta -13.5 4.1 57.4
ENSRNOP00000003611 Nme2:p , Nucleoside diphosphate kinase B -13.1 4.31 17.3
ENSRNOP00000022406 Glrx3:p , Glutaredoxin-3 Source: UniProtKB/Swiss-Prot Q9JLZ1 -11.8 3.96 37.8
ENSRNOP00000062690 Flna:p , no protein text annotation available -10 3.49 280.3
ENSRNOP00000017692 Arf4:p , ADP-ribosylation factor 4 Source: UniProtKB/Swiss-Prot P61751 -9.9 4.65 20.4
ENSRNOP00000065463 no protein information available -9.7 3.51 14.8
ENSRNOP00000015186 Prdx3:p , thioredoxin-dependent peroxide reductase, mitochondrial precursor [ Source: RefSeq NP_071985 ]-9.3 4.37 28.3
ENSRNOP00000010429 Arf5:p , ADP-ribosylation factor 5 Source: UniProtKB/Swiss-Prot P84083 -8.9 4.66 20.5
ENSRNOP00000049629 Eif4g1:p , no protein text annotation available -8.1 3.48 175.6
ENSRNOP00000023963 Npm :p , -8.1 3.85 18.9
ENSRNOP00000014833 Nup205:p , nucleoporin 205 [ Source: RefSeq NP_001102090 ]-7.3 3.44 227.1
ENSRNOP00000023460 Map1b:p , Microtubule-associated protein 1B (MAP-1B)(Neuraxin) [Contains MAP1 light chain LC1] Source: UniProtKB/Swiss- ...-7.1 3.51 269.5
ENSRNOP00000030696 Usp24:p , -6 3.02 293.8
ENSRNOP00000016784 triple functional domain (PTPRF interacting) [ Source: RefSeq NP_001101128 ]-5.8 3.57 348.1
ENSRNOP00000019104 Psmd7:p , proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 [ Source: RefSeq NP_001100896 ]-5.5 2.94 36.5
ENSRNOP00000059647 Asna1:p , -5.1 2.07 38.8
ENSRNOP00000022309 Got1:p , Aspartate aminotransferase, cytoplasmic ( EC 2.6.1.1 )(Transaminase A)(Glutamate oxaloacetate transaminase 1)  ...-5 3.26 46.4
ENSRNOP00000036882 Eef1b2:p , eukaryotic translation elongation factor 1 beta 2 [ Source: RefSeq NP_001102269 ]-4.7 3.78 24.7
ENSRNOP00000006591 Npm :p , Nucleophosmin Source: UniProtKB/Swiss-Prot P13084 -4.7 2.72 32.5
ENSRNOP00000022487 Cox5b:p , Cytochrome c oxidase subunit 5B, mitochondrial Precursor (Cytochrome c oxidase polypeptide Vb)(Cytochrome c o ...-4.1 3.71 13.9
ENSRNOP00000011314 Rps20:p , 40S ribosomal protein S20 Source: UniProtKB/Swiss-Prot P60868 -4 4.18 13.4
ENSRNOP00000042447 RGD1311659:p , similar to Proteasome subunit alpha type 7-like (RGD1311659), mRNA [Source:RefSeq DNA;Acc:NM_001108884]-3.9 3.68 27.9
ENSRNOP00000021215 no protein text annotation available -3.7 3.15 29.2
ENSRNOP00000004895 Cnpy2:p , protein canopy homolog 2 [ Source: RefSeq NP_001071053 ]-3.6 3.86 20.7
ENSRNOP00000064391 Triosephosphate isomerase -3.6 4.11 26.4
ENSRNOP00000015318 Ppp2r2a:p , Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PP2A subunit B isoform a ...-3.4 3.62 51.6
ENSRNOP00000016563 Cnot1:p , RGD1308009 protein Fragment Source: UniProtKB/TrEMBL B4F783 -3.3 3.22 266.7
sp|CAS1_BOVIN| Alpha-S1-casein; Bos d 8; Contains: Antioxidant peptide; Flags: Precursor; -2.9 3.79 24.5
ENSRNOP00000025625 Fa2h:p , -2.9 3.52 42.6
ENSRNOP00000017965 Ldhb:p , L-lactate dehydrogenase B chain Source: UniProtKB/Swiss-Prot P42123 -2.9 4.46 36.6
ENSRNOP00000016965 Ndufv2:p , NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Source: UniProtKB/Swiss-Prot P19234 -2.7 4.37 27.4
ENSRNOP00000032320 Aldoa:p , Fructose-bisphosphate aldolase A Source: UniProtKB/Swiss-Prot P05065 -2.6 2.5 39.3
ENSRNOP00000038770 Fndc3b:p , no protein text annotation available -2.5 3.33 132.7
ENSRNOP00000001065 RGD1303066:p , -2.5 2.96 47.3
ENSRNOP00000044856 Sumo2:p , Small ubiquitin-related modifier 2 Precursor (SUMO-2)(Ubiquitin-like protein SMT3B)(SMT3 homolog 2)(Sentrin-2 ...-2.4 4.16 10.9
ENSRNOP00000043308 LOC296300:p , similar to zinc finger protein 341 [ Source: RefSeq NP_001041324 ]-2.2 4.5 45.8
ENSRNOP00000054197 Col4a1:p , collagen alpha-1(IV) chain [ Source: RefSeq NP_001128481 ]-2.1 3.73 160.5
ENSRNOP00000015946 Psma1:p , Proteasome subunit alpha type-1 ( EC 3.4.25.1 )(Proteasome component C2)(Macropain subunit C2)(Multicatalytic ...-2.1 2.84 29.5
ENSRNOP00000058595 Rab5b:p , RAB5B, member RAS oncogene family [ Source: RefSeq NP_001073405 ]-2.1 3.7 23.7
ENSRNOP00000024711 RGD 560648:p , Protein DJ-1 (Parkinson disease protein 7 homolog)(Contraception-associated protein 1)(Protein CAP1)(Fer ...-2.1 3.58 20
ENSRNOP00000034815 Adprh:p , [Protein ADP-ribosylarginine] hydrolase (ADP-ribosylarginine hydrolase)( EC 3.2.2.19 )(ADP-ribose-L-arginine  ...-2 3.72 39.9
ENSRNOP00000024828 Pafah1b2:p , platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (Pafah1b2), mRNA [Source:RefSeq mRNA;Ac ...-1.6 3.63 25.6
ENSRNOP00000006356 Sec24a:p , SEC24 family, member A [ Source: RefSeq NP_001099250 ]-1.6 3.62 118.8
ENSRNOP00000013463 Asah1:p , Acid ceramidase Precursor (AC)( EC 3.5.1.23 )(Acylsphingosine deacylase)(N-acylsphingosine amidohydrolase) So ...-1.5 3.58 44.4
ENSRNOP00000023215 COX15 homolog, cytochrome c oxidase assembly protein Source: RefSeq_peptide NP_001028871 -1.5 3.69 45.9
ENSRNOP00000020483 Lrrc38:p , -1.4 2.91 32.4
ENSRNOP00000048846 Col11a2:p , -1.3 3.87 158.9
ENSRNOP00000019080 Mfsd2:p , -1.2 3.76 58.6
ENSRNOP00000062146 Psmd11:p , -1.2 3.75 49.6
ENSRNOP00000036443 No description &nbsp; -1.1 3.02 106.5
ENSRNOP00000004249 Rab26:p , RAS-RELATED PROTEIN RAB-26. [ Source: SWISSPROT (P51156) ]&nbsp;-1.1 3.53 28.2
ENSRNOP00000042082 RGD1564142:p , -1.1 3.95 337.5
ENSRNOP00000053358 RGD1562747:p , similar to RIKEN cDNA 1110012L19 (predicted) (RGD1562747_predicted), mRNA Source: RefSeq_dna NM_00110621 ...-1 3.87 19.8
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Table 5: Hits identified in the α1 ECDs-binding assay and absent from the α2 ECDs-
binding assay analysed with GPM found in Proteomics round 1 and 2 
 
 
 
 
Table 6: Hits identified in the α2 ECDs-binding assay and absent from the α1 ECDs-
binding assay analysed with GPM found in Proteomics round 1 and 2 
 
Table 7. Proteomics round 1: Hits identified in the α1 ECDs- binding assay and present in 
the α2 ECDs- binding assay analysed with GPM. 
 
 
Table 8. Proteomics round 2: Hits identified in the α1 ECDs- binding assay and present in 
the α2 ECDs- binding assay analysed with GPM. 
 
 
Accession Hits log(e) log(I) Mr
ENSRNOP00000008504 Heat shock-related 70 kDa protein 2 (Heat shock protein 70.2)(Testis-specific heat shock protein-related)(HST) Source: UniProtKB/Swiss-Prot P14659IPR018181 Heat shock 70 CSIPR001023 Hsp70IPR013126 Hsp 70-63.7 3.58 69.6
ENSRNOP00000025064 78 kDa glucose-regulated protein Source: UniProtKB/Swiss-Prot P06761IPR018181 Heat shock 70 CSIPR001023 Hsp70IPR013126 Hsp 70-20.5 3.19 72.3
ENSRNOP00000049998 Tubulin alpha-3 chain Source: UniProtKB/Swiss-Prot Q68FR8IPR002452 Alpha tubulinIPR002453 Beta tubulinIPR000158 Cell division FtsZ NIPR002967 Delta tubulinIPR004057 Epsilon tubulinIPR002454 Gamma tubulinIPR008280 Tub FtsZ CIPR000217 TubulinIPR018316 Tubulin/FtsZ 2-layer-sand-domIPR017975 Tubulin CSIPR003008 Tubulin FtsZ GTPase-11.7 2.74 49.9
ENSRNOP00000015851 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Source: UniProtKB/Swiss-Prot Q66HF1IPR001041 FerredoxinIPR006656 Mopterin OxRdtaseIPR000283 NADH UbQ OxRdtase 75kDa su CSIPR010228 NADH UbQ OxRdtase GsuIPR015405 NuoG C-8.1 2.6 79.4
ENSRNOP00000031564 tubulin, alpha-like 3 IPR002452 Alpha tubulinIPR002453 Beta tubulinIPR000158 Cell division FtsZ NIPR000183 De-COase2IPR002967 Delta tubulinIPR004057 Epsilon tubulinIPR002454 Gamma tubulinIPR008280 Tub FtsZ CIPR000217 TubulinIPR018316 Tubulin/FtsZ 2-layer-sand-domIPR017975 Tubulin CSIPR003008 Tubulin FtsZ GTPaseIPR019746 Tubulin FtsZ N-5.2 2.36 49.9
ENSRNOP00000037217 F-actin-capping protein subunit alpha-2 (CapZ alpha-2) Source: UniProtKB/Swiss-Prot Q3T1K5IPR002189 F-actin cap asuIPR017865 F-actin cap asu CSIPR018315 F-actin cap asu actin bd-4.8 2.19 32.9
ENSRNOP00000057097 Protein RUFY3 (Rap2-interacting protein x)(RIPx)(Single axon-regulated protein)(Singar) Source: UniProtKB/Swiss-Prot Q5FVJ0IPR009053 PrefoldinIPR004012 RunIPR000533 TropomyosinIPR000306 Znf FYVEIPR011011 Znf FYVE PHD-4.2 2.18 74.3
ENSRNOP00000018009 protein kinase C substrate 80K-H IPR018247 EF HAND 1IPR018249 EF HAND 2IPR002172 LDL rcpt classA cys-richIPR009011 Man6P isomerase rcpt bdIPR012913 PRKCSHIPR000694 PRO rich-3.3 3.1 59.2
ENSRNOP00000003667 similar to RIKEN cDNA 2610029G23 (RGD1562502), mRNA -3.3 2.39 22.4
ENSRNOP00000024306 26S proteasome non-ATPase regulatory subunit 1 (26S proteasome regulatory subunit RPN2)(26S proteasome regulatory subunit S1)(26S proteasome subunit p112) Source: UniProtKB/Swiss-Prot O88761IPR016642 26S Psome Rpn2IPR016024 ARM-type foldIPR004155 PBS lyase HEAT-2.5 1. 9 105.6
ENSRNOP00000025794 Superoxide dismutase , mitochondrial Precursor (EC 1.15.1.1) Source: UniProtKB/Swiss-Prot P07895IPR001189 Mn/Fe SODIPR019833 Mn/Fe SOD BSIPR019832 Mn/Fe SOD CIPR019831 Mn/Fe SOD N-2.5 2.37 24.7
sp|K1C15_SHEEP|  Keratin, type I cytoskeletal 15; Cytokeratin-15; CK-15; Keratin-15; K15; -2.4 2.34 48.7
ENSRNOP00000051848 mitochondrial ribosomal protein L12 IPR014719 Ribosomal L7/12 C/ClpS-likeIPR013823 Ribosomal L7/L12 CIPR008932 Ribosomal L7/L12 oligo-2.4 2.37 29.4
ENSRNOP00000010674 Tyrosyl-tRNA synthetase, cytoplasmic (EC 6.1.1.1)(Tyrosyl--tRNA ligase)(TyrRS) Source: UniProtKB/Swiss-Prot Q4KM49IPR016027 NA-bd OB-fold-likeIPR002307 Tyr-tRNA-synth Ib bac/mitoIPR002305 aa-tRNA-synth IbIPR002547 tRNA-bd dom-2.3 .93 63
ENSRNOP00000055173 no protein text annotation availableIPR002113 Aden trnslctorIPR002067 Mit carrierIPR001993 Mitochondria substrate carrierIPR018108 Mitochondrial sb/sol carrier-2. 2.42 31.7
ENSRNOP00000028440 no protein text annotation availableIPR002928 Myosin tailIPR008374 SF assemblinIPR000533 Tropomyosin-1.1 2.39 136.3
Accession Hits log(e) log(I) Mr
ENSRNOP00000042382  Spectrin alpha chain, brain (Spectrin, non-erythroid alpha chain)(Alpha-II spectrin)(Fodrin alpha chain) Source: UniProt ...-95.4 4.75 284.5
ENSRNOP00000063671  Crmp1:p , Dihydropyrimidinase-related protein 1 Source: UniProtKB/Swiss-Prot Q62950 -74.3 5.86 62.2
ENSRNOP00000022951  Plexin-A1 Precursor (Plexin-1)(Plex 1) [ Source: UniProt P70206 ] -35.5 4.1 211
ENSRNOP00000018005  Psmb5:p , Proteasome subunit beta type-5 Precursor ( EC 3.4.25.1 )(Proteasome epsilon chain)(Macropain epsilon chain)(M ...-34.1 4 77 28.5
ENSRNOP00000028484  Proteasome subunit beta type-4 Precursor (Proteasome beta chain)( EC 3.4.25.1 )(Macropain beta chain)(Multicatalytic end ...-28.5 4.96 29.2
ENSRNOP00000026373  Gnao1:p , Guanine nucleotide-binding protein G(o) subunit alpha Source: UniProtKB/Swiss-Prot P59215 -18.8 4.93 40
ENSRNOP00000027305  Eef1g:p , Elongation factor 1-gamma (EF-1-gamma)(eEF-1B gamma) Source: UniProtKB/Swiss-Prot Q68FR6 -17.7 4.68 50
ENSRNOP00000008608  Mif:p , Macrophage migration inhibitory factor Source: UniProtKB/Swiss-Prot P30904 -15.9 4.64 12.5
ENSRNOP00000024863  Taldo1:p , Transaldolase ( EC 2.2.1.2 ) Source: UniProtKB/Swiss-Prot Q9EQS0 -13.1 3.91 37.4
ENSRNOP00000020322  Idh1:p , Isocitrate dehydrogenase [NADP] cytoplasmic Source: UniProtKB/Swiss-Prot P41562 -10.4 3.93 46.7
ENSRNOP00000027226  no protein text annotation available -8.4 5.52 14.4
ENSRNOP00000025282  Ppp1ca:p , Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Source: UniProtKB/Swiss-Prot P62138 -5.9 3.81 37.5
ENSRNOP00000010753  Psma3:p , No description &nbsp; -4.6 2.9 28.4
ENSRNOP00000044971  Ddah1:p , N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 -4.1 3. 31.4
ENSRNOP00000045992  Myl12b:p , Myosin regulatory light chain 12B Source: UniProtKB/Swiss-Prot P18666 -3.7 3.88 19.8
ENSRNOP00000001738  Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SR Ca(2+)-ATPase 2)(SERCA2)( EC 3.6.3.8 )(Calcium pump 2)(Calcium-t ...-3.2 3.19 110.2
ENSRNOP00000006856  no protein information available -2.1 4.08 81.1
ENSRNOP00000018646  Snrpd1:p , no description available -1.9 4.17 13.3
ENSRNOP00000027774  Pafah1b3:p , -1.6 2.99 25.8
Accession Description log(e) log(I) Mr
ENSRNOP00000004725 Gabra1:p , Gamma-aminobutyric acid receptor subunit alpha-1 Precursor (GABA(A) receptor subunit alpha-1) Source: UniPro ...-29.8 4.5 51.7
Accession Description log(e) log(I) Mr
ENSRNOP00000004895Cnpy2:p , protein canopy homolog 2 [ Source: RefSeq NP_001071053 ]-3.6 3.86 2 .7
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Table 9. Proteomics round 1: Hits identified in the α1 ECDs- binding assay and absent 
from α2 ECDs- binding assay analysed with MASCOT. 
 
 
 
 
 
 
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00734561 Hsp90b1 Isoform 2 of Endoplasmin 222 74162 7 12.1 122 508.2581 5.33
IPI00287835 Hba-a2 Hemoglobin subunit alpha-1/2 221 15319 12 57 106 409.7324 5.36
IPI00557715 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) 126 45771 4 9.5 390 685.3758 57.34
IPI00213463 Actn4 Alpha-actinin-4 112 104849 6 7 337 608.358 13.76
IPI00201410 Ppp3ca Isoform 1 of Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform75 58606 4 9.4 150 536.8204 0.53
IPI00817078 Proteasome subunit alpha type 73 19524 3 20.1 472 817.9443 39.47
IPI00421539 Aco2 Aconitate hydratase, mitochondrial 69 85380 4 7.2 249 634.834 16.96
IPI00382233 Acat3 Ab2-076 67 103244 3 2.7 359 436.6032 25.61
IPI00200773 Actn3 Uncharacterized protein 66 102948 2 2.7 342 622.3861 4.97
IPI00231829 Arg2 Arginase-2, mitochondrial 65 38616 1 4.2 493 786.4208 64.98
IPI00203723 Arg2 Arginase-related protein 65 37776 1 4.4 493 786.4208 64.98
IPI00210233 Fdft1 Squalene synthase 64 48075 1 3.4 335 738.3983 64
IPI00370073 Krt17 Keratin, type I cytoskeletal 17 61 48093 6 13.6 66 405.2244 1.7
IPI00199865 Farsa Phenylalanyl-tRNA synthetase alpha chain 60 57684 2 2.2 251 655.3625 25.74
IPI00561918 Uncharacterized protein (Fragment) 60 34410 2 8.8 333 615.3471 3.61
IPI00201403 Ppm1a Protein phosphatase 1A 58 42390 1 4.7 513 678.0007 58.25
IPI00778370 Uncharacterized protein 53 33108 2 7.7 245 594.8339 53.08
IPI00554194 Calu calumenin isoform b 51 37124 2 4.1 229 640.8072 45.13
IPI00382267 Ilf2 Interleukin enhancer-binding factor 2 51 51348 2 4.5 125 521.3234 51.42
IPI00230775 Tpm2 Isoform 1 of Tropomyosin beta chain 50 32817 2 9.2 344 622.3338 50.01
IPI00191354 Tpm3 Uncharacterized protein 50 33129 2 7.7 344 622.3338 50.01
IPI00551673 Krt10 Uncharacterized protein 47 57598 2 4.6 169 545.7702 46.71
IPI00764232 LOC687295 Uncharacterized protein 46 14258 1 8.2 330 629.3278 46.22
IPI00869568 Vps35 maternal embryonic message 3 44 91669 7 9.9 103 492.8252 23.93
IPI00764841 Slc25a31 Uncharacterized protein 42 35231 3 8.1 445 723.8742 11.91
IPI00363182 Slc25a6 ADP/ATP translocase 2-like 42 33155 5 12.4 327 610.3417 4.77
IPI00208170 Trmt112 hypothetical protein LOC293700 40 14118 1 10.4 505 759.4155 39.58
IPI00366247 Ttc35 Tetratricopeptide repeat protein 35 38 34847 1 4.4 417 740.3746 38.24
IPI00476086 Atp6v0d1 Uncharacterized protein 37 40275 2 6.8 312 615.8455 7.33
IPI00199980 Psmb7 Proteasome subunit beta type-7 37 29908 1 3.6 162 508.7786 37.42
IPI00957729 LOC100363716;LOC100359928 microtubule-associated protein 1 light chain 3 beta-like35 17616 3 16.9 47 546.2952 7.38
IPI00371269 Rab5b Uncharacterized protein 35 23660 3 11.6 198 543.3011 2.46
IPI00190943 Gfap Isoform 1 of Glial fibrillary acidic protein 32 49927 2 5.6 234 639.3619 31.8
IPI00369480 RGD1565010 otubain 1-like 31 31059 1 3.3 148 525.8023 31.17
IPI00362534 Ddx3x Uncharacterized protein 30 73100 1 1.8 233 646.376 29.66
IPI00205374 Hmgcl Hydroxymethylglutaryl-CoA lyase, mitochondrial 30 34170 1 4.3 430 763.9011 29.92
IPI00951917 LOC100362339 Uncharacterized protein 30 16108 2 12.4 169 485.81 2.49
IPI00203574 Hspbp1 Hsp70-binding protein 1 29 39166 1 3.1 347 649.3559 29.46
IPI00210564 Lsm5 Uncharacterized protein 29 9931 2 20.9 566 1019.0818 20.49
IPI00365595 Asap2 Uncharacterized protein (Fragment) 28 103130 1 0.9 149 487.2804 27.8
IPI00470254 Ezr Ezrin 28 69348 2 3.6 152 552.8027 27.67
IPI00372976 Gga3 Uncharacterized protein 28 78710 1 1.7 296 679.389 28.38
IPI00212186 RGD1562259 ribosomal protein S20-like 28 13368 2 10.1 407 450.9318 0.73
IPI00367724 Hcfc1 Uncharacterized protein 27 209022 1 0.8 517 873.5378 27.44
IPI00198904 Mat2b Methionine adenosyltransferase 2 subunit beta 27 37351 1 3.6 278 585.8649 27.36
IPI00369788 RGD1561230;LOC100360876 Uncharacterized protein 27 77710 1 2.1 433 839.4315 26.95
IPI00192586 Csnk2a1 Casein kinase II subunit alpha 26 45045 1 4.6 467 622.3495 25.75
IPI00390762 MGC95210 Uncharacterized protein 26 58048 1 2.4 439 700.8768 25.51
IPI00230917 Rpl18 60S ribosomal protein L18 25 21645 1 6.9 376 673.3804 24.69
IPI00957926 Arhgap42 Rho-type GTPase-activating protein FLJ32810-like isoform 224 94449 1 1.1 167 519.7761 24.4
IPI00213457 Atp6v1c1 V-type proton ATPase subunit C 1 24 43873 5 9.9 147 538.8046 2.78
IPI00191485 Pkd1 Uncharacterized protein 24 465927 1 0.3 271 746.2993 24.43
IPI00422076 Thbs1 Thrombospondin 1 24 129588 1 0.9 228 639.9035 24.19
IPI00368799 Esf1 ESF1 homolog 23 97474 1 1.1 320 604.3825 23.15
IPI00553976 LOC682097 LOC682097 protein (Fragment) 23 19269 1 5.9 177 629.3079 22.51
IPI00212838 Otud3 Uncharacterized protein 23 44104 3 5.6 195 566.7824 0.4
IPI00778032 Rap1gds1 Uncharacterized protein (Fragment) 23 61874 2 4 129 514.3114 21.4
IPI00191728 Calr Calreticulin 22 47966 1 3.6 403 595.6175 22.07
IPI00360340 Ehd1 EH domain-containing protein 1 22 60565 3 6.6 278 684.8395 5.95
IPI00364866 Erp44 Uncharacterized protein 22 46848 1 3.2 336 493.9234 22.21
IPI00192912 Rcn1 Uncharacterized protein 22 38067 2 5.8 37 400.7701 17.26
IPI00359278 Cnrip1 CB1 cannabinoid receptor-interacting protein 1 21 18647 1 9.8 475 856.9562 21.32
IPI00189759 Ndufa10l1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10-like20 40519 2 7.3 263 575.3272 19.97
IPI00195109 Shmt2 Serine hydroxymethyltransferase 20 55730 1 2.2 370 648.3566 20.38
IPI00366924 RGD1560073 Uncharacterized protein 19 18747 2 10.9 202 555.3392 18.86
IPI00565628 Wdr62 Uncharacterized protein (Fragment) 19 157952 1 0.8 384 671.3588 19.34
IPI00959479 Ckap2l Uncharacterized protein 17 82658 2 1.6 272 697.3962 8.39
IPI00366007 Eif4g2 Uncharacterized protein (Fragment) 17 102379 2 2.5 229 513.3304 5.34
IPI00188196 Pde4a Isoform 1 of cAMP-specific 3~,5~-cyclic phosphodiesterase 4A17 93380 2 3.1 270 495.8849 17.38
IPI00367636 RGD1566373 ribosomal protein L36a-like 16 13668 4 8.4 198 582.3254 16.34
IPI00325195 Cpz Carboxypeptidase Z 15 73035 3 3.7 57 696.4081 14.94
IPI00207390 Anxa3 Annexin A3 14 36341 1 5.9 562 541.0974 14.28
IPI00200751 Flcn Folliculin 14 64081 3 4.7 551 903.4465 14.28
IPI00201057 Hk2 Hexokinase-2 14 102478 3 3.5 286 563.3101 6.28
IPI00363160 Sephs1 selenide, water dikinase 1 14 42865 1 3.8 417 560.6511 13.94
IPI00358065 Mrpl44 Uncharacterized protein 13 37417 1 2.1 56 839.4248 13.47
IPI00202428 Pde4b Isoform 1 of cAMP-specific 3~,5~-cyclic phosphodiesterase 4B13 83322 1 1.8 454 495.8925 13.23
IPI00389624 Tsen2 tRNA-splicing endonuclease subunit Sen2 13 52918 1 1.5 56 839.4248 13.47
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Table 10 Proteomics round 2: Hits identified in the α1 ECDs- binding assay and absent 
from the α2 ECDs- binding assay analysed with MASCOT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00656375 RGD1562758 glyceraldehyde-3-phosphate dehydrogenase-like359 35834 12 18 64 435.2771 19.98
IPI00328017 Map2 Microtubule-associated protein 336 198705 12 7.3 118 494.2996 33.78
IPI00960040 LOC680097 histone cluster 1, H2ae-like 236 51695 13 19.9 59 425.7722 26.43
IPI00958096 LOC100360950 GF20391-like isoform 1 205 24560 8 31.5 103 477.3126 25.09
IPI00206406 Ppp3r1 Isoform 1 of Calcineurin subunit B type 1158 19288 4 25.9 68 400.737 14.5
IPI00231955 Calm2;Calm3;Calm1 Calmodulin 158 16827 5 27.5 127 478.7761 32.8
IPI00951891 Ap1b1 Uncharacterized protein 138 103888 7 7.7 97 461.2837 4.92
IPI00209258 Sptan1 Uncharacterized protein 125 284865 10 3.9 68 415.7481 5.67
IPI00959265 LOC100363379;LOC100365936 peroxiredoxin-1-like118 22150 7 30.2 62 416.2454 42.22
IPI00363265 Hspa9 Stress-70 protein, mitochondrial 107 73812 3 6 173 667.4033 49.08
IPI00192642 Gabra1 Gamma-aminobutyric acid receptor subunit alpha-1100 51721 5 10.1 60 449.285 13.49
IPI00230897 Hbb Hemoglobin subunit beta-1 95 15969 4 27.9 95 456.7762 24.61
IPI00362229 Actr1b ARP1 actin-related protein 1 homolog B 91 42255 2 8.2 264 767.4379 65.73
IPI00869806 Actr1a Alpha-centractin 91 42587 2 8.2 264 767.4379 65.73
IPI00203723 Arg2 Arginase-related protein 86 37776 1 4.4 217 786.4623 86.04
IPI00231829 Arg2 Arginase-2, mitochondrial 86 38616 1 4.2 217 786.4623 86.04
IPI00191444 Capzb Uncharacterized protein 81 31326 3 10.5 124 554.8489 20.1
IPI00203730 Rasl2-9 GTP-binding nuclear protein Ran, testis-specific isoform78 24436 2 10.2 100 508.3192 68.06
IPI00369913 Sarm1 Uncharacterized protein 77 79638 1 2.2 317 864.5264 76.55
IPI00679210 Microtubule-associated protein 74 35874 6 15.7 50 431.2434 33.77
IPI00188924 Uqcrc2 Cytochrome b-c1 complex subunit 2, mitochondrial73 48366 1 2.2 166 609.8629 72.62
IPI00325912 Ctnnb1 Catenin beta-1 73 85400 2 4.2 224 693.4071 57.77
IPI00208286 Uchl3-ps1;Uchl3 Ubiquitin carboxyl-terminal hydrolase isozyme L372 26107 1 5.7 229 762.3955 71.95
IPI00188330 Ndufs8 Uncharacterized protein 71 23955 1 5.2 204 637.3755 70.82
IPI00394032 Tom1l2 Uncharacterized protein 70 55610 1 2.6 237 737.4757 69.92
IPI00190348 Hist1h2bc histone H2B 70 13882 2 19 126 477.3047 32.91
IPI00196987 Adrbk1 Beta-adrenergic receptor kinase 1 69 79734 1 2.6 361 1022.0796 68.96
IPI00362072 Actr2 Actin-related protein 2 64 44705 1 3 218 677.3986 63.5
IPI00359978 Rps28 40S ribosomal protein S28 63 7836 2 17.4 232 680.8837 46.6
IPI00339164 Mtor Serine/threonine-protein kinase mTOR 63 288610 2 0.9 190 605.3741 5.14
IPI00214192 Sh3gl1 Endophilin-A2 61 41466 1 1.9 61 436.2566 61.05
IPI00768793 LOC680322 Histone H2A 61 14202 8 40.8 59 425.7722 26.43
IPI00366436 Eif3s6ip Eukaryotic translation initiation factor 3, subunit 6 interacting protein61 66668 2 3.2 45 404.2386 10.32
IPI00230837 Ywhab Isoform Long of 14-3-3 protein beta/alpha 60 28037 3 19.1 64 452.2774 40.98
IPI00363489 Nudt21 Cleavage and polyadenylation specificity factor subunit 560 26224 1 12.8 379 1038.969 59.59
IPI00188249 Bri3bp Uncharacterized protein 58 28298 1 3.6 185 569.3382 58.13
IPI00201500 Rps14 40S ribosomal protein S14 57 16249 1 7.3 147 527.7986 57.44
IPI00231639 Gstm1 Glutathione S-transferase Mu 1 57 25897 1 7.3 312 895.532 56.9
IPI00200069 Sfxn3 Sideroflexin-3 56 35411 1 4 201 760.9496 56.2
IPI00362534 Ddx3x Uncharacterized protein 56 73100 1 1.8 156 646.4171 56.1
IPI00195123 Atp5o ATP synthase subunit O, mitochondrial 56 23383 2 8.5 93 444.2736 31.53
IPI00194567 Trim28 Transcription intermediary factor 1-beta 55 88900 2 2.8 87 443.7826 31.67
IPI00213408 Arpc5l;Arpc5l-ps1 Isoform 2 of Actin-related protein 2/3 complex subunit 5-like protein55 11228 1 11.9 182 563.8804 54.86
IPI00372840 Ybey Uncharacterized protein 54 19059 1 4.9 89 479.7905 54.09
IPI00464805 Pcbp2 Poly(RC) binding protein 2 54 38556 1 3 146 579.8226 54.24
IPI00191860 Uncharacterized protein 52 9443 1 15.7 257 777.3402 51.81
IPI00366422 Pycrl Pyrroline-5-carboxylate reductase 3 52 28860 1 4 123 543.8546 51.94
IPI00372976 Gga3 Uncharacterized protein 52 78710 1 1.7 211 679.4208 52.38
IPI00211593 Sod2 Superoxide dismutase [Mn], mitochondrial 51 24659 2 9.5 63 416.2497 13.98
IPI00567919 Ap2a1 Uncharacterized protein 51 105385 3 3.5 129 511.3586 15.87
IPI00202111 Usmg5;LOC100366152;LOC100360002 Up-regulated during skeletal muscle growth protein 550 6403 1 17.2 203 611.3298 50.01
IPI00203390 Ppp1cb Serine/threonine-protein phosphatase PP1-beta catalytic subunit50 37163 1 4 201 722.9158 50.28
IPI00192736 Drg1 Uncharacterized protein 50 40487 1 3.8 244 740.4821 49.73
IPI00205036 Hba2 hemoglobin alpha 2 chain 49 15275 2 12 51 408.2672 25.66
IPI00421513 Got1 Aspartate aminotransferase, cytoplasmic 49 46400 3 4.8 82 474.7928 49.29
IPI00373481 Wdr5 WD repeat-containing protein 5 47 36565 1 3.9 210 501.279 47.47
IPI00562293 Uncharacterized protein (Fragment) 47 14932 1 6.2 70 436.2885 46.7
IPI00365118 Tmed7 Uncharacterized protein 47 25463 1 4 110 531.3005 46.98
IPI00364734 Slc2a9 Uncharacterized protein 47 57351 1 1.7 127 538.3525 47.19
IPI00367223 Katnal2 katanin p60 subunit A-like 2 47 58705 1 2.3 188 586.8543 46.63
IPI00371236 Tufm Elongation factor Tu, mitochondrial 46 49491 2 2 38 408.2581 39.15
IPI00562254 Tnik Uncharacterized protein 46 146631 1 0.5 53 415.3009 46.06
IPI00231051 Map2 Isoform MAP2b of Microtubule-associated protein 246 198932 3 1.5 65 424.2549 8.26
IPI00767085 Kctd12 potassium channel tetramerisation domain containing 1246 3585 1 3.7 208 747.9272 45.57
IPI00198720 Idh3a Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial46 39588 1 2.7 143 608.8453 46.17
IPI00359022 Trappc3 Trafficking protein particle complex subunit 345 20289 1 4.4 135 488.8061 44.88
IPI00417753 Kif5a Kinesin heavy chain isoform 5A 45 116843 3 3.9 59 413.3149 1.53
IPI00191728 Calr Calreticulin 45 47966 2 3.8 46 414.2554 28.79
IPI00372727 Sec24b Uncharacterized protein 44 134631 1 1.1 108 644.8688 44.04
IPI00367441 Elongation factor 1-alpha 44 49659 2 3.3 89 455.8251 2.54
IPI00208197 Adprh [Protein ADP-ribosylarginine] hydrolase 44 39935 1 4.1 215 782.4611 44.25
IPI00196791 Psmb8 Proteasome subunit beta type-8 43 30550 1 4.7 250 713.8652 43.02
IPI00464648 Ccdc91 Coiled-coil domain-containing protein 91 43 50135 1 1.6 93 444.2736 43.31
IPI00562724 Wdr13 WD repeat domain 13 (Predicted), isoform CRA_b42 53630 1 1.6 60 419.2917 42.2
IPI00959788 LOC687739 nuclear apoptosis inducing factor 1 42 35276 3 2.4 79 450.7561 33.25
IPI00231677 Ywhah 14-3-3 protein eta 41 28194 2 8.5 64 452.2774 40.98
IPI00230835 Ywhag 14-3-3 protein gamma 41 28285 2 6.9 64 452.2774 40.98
IPI00471526 LOC298795 Similar to 14-3-3 protein sigma 41 27899 1 3.2 64 452.2774 40.98
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00326948 Hsd17b4 Uncharacterized protein 41 81038 1 1.7 179 680.8844 41.43
IPI00421451 Rps16 40S ribosomal protein S16 40 16435 2 14.4 159 547.8792 39.8
IPI00231028 RGD1303003 ES1 protein homolog, mitochondrial39 28155 1 3.8 121 542.3047 38.58
IPI00372860 Eif4ebp2 Uncharacterized protein 39 12878 2 11.7 230 684.8499 20.14
IPI00231788 Myl3 Myosin light chain 3 38 22142 2 8.5 122 498.3106 4.82
IPI00557744 MGC114440 UPF0490 protein C1orf201 homolog 38 37510 1 2.6 111 488.7609 38.43
IPI00198118 Map1a Uncharacterized protein 38 324819 1 0.3 151 514.8324 38.14
IPI00870119 Usp32 Ubiquitin carboxyl-terminal hydrolase 37 161818 1 0.7 155 578.8997 37.22
IPI00190181 Pygm Glycogen phosphorylase, muscle form 37 97212 1 1.3 208 617.8746 37.16
IPI00201032 Hnrpd Isoform 1 of Heterogeneous nuclear ribonucleoprotein D037 38168 3 8.5 74 457.7902 19.96
IPI00213457 Atp6v1c1 V-type proton ATPase subunit C 1 37 43873 2 6.3 82 474.7928 11.04
IPI00196530 Ap2m1 AP-2 complex subunit mu 37 49623 1 1.8 49 429.2661 37.29
IPI00196167 Mt-nd1 NADH-ubiquinone oxidoreductase chain 136 36153 1 2.8 109 518.7865 36.34
IPI00870884 Vps29 Isoform 2 of Vacuolar protein sorting-associated protein 2935 20877 1 5.4 146 540.8397 34.69
IPI00363444 Gli1 zinc finger protein GLI1 35 118144 1 0.8 108 502.3063 34.97
IPI00470246 Ddc Aromatic L-amino acid decarboxylase 35 54322 2 1.4 109 419.2278 34.61
IPI00359491 Ctnnd1 Uncharacterized protein 34 92407 1 1 91 476.2756 33.89
IPI00207980 Rpl23 60S ribosomal protein L23 33 14856 1 7.1 82 450.7797 33.14
IPI00198643 Sec11a Signal peptidase complex catalytic subunit SEC11A31 20586 1 6.1 258 670.3829 30.83
IPI00366795 Sae1 SUMO-activating enzyme subunit 1 31 38488 1 3.7 259 760.9846 30.98
IPI00362341 RGD1565297 RAN binding protein 1-like 31 23722 1 4.4 106 517.7965 31.18
I I 211261 687679;Snrpg;LOC100364111;LOC100360635 small nuclear ribonucleoprotein polypeptide G31 849 2 2 11.7682 17.65
10038 Li a Lysos mal acid lipas /cholesteryl ester hydrolase31 45157 1 3 3 251 75 .9645 30.73
36210 Ps c6;LOC100365869 proteasome (prosome, macropain) 26S subunit, ATPase, 630 45768 1 3 234 720 9515 29.69
I I 765647 LOC686456 te shirt 2-like 0 14512 1 0.8 72 50.769 30.08
IPI00411232 Ccbl1 Isoform 1 of Kynurenine--oxoglutarate transaminase 1, mitochondrial29 51619 1 3.7 330 915.0573 29.33
IPI00214563 Mvk Mevalonate kinase 28 41961 1 3.3 178 680.4041 28.36
IPI00951886 Isl2 Uncharacterized protein 28 19085 1 4.6 69 438.7661 27.76
IPI00358206 Cul1 Uncharacterized protein 28 89635 2 1.7 260 757.5021 28.4
IPI00767739 Asmtl acetylserotonin O-methyltransferase-like 28 24235 1 4.4 134 567.4039 28.12
IPI00371042 Rbm15b RNA binding motif protein 15B 27 97105 1 0.9 82 452.2662 26.59
IPI00366327 Lrrc16a Uncharacterized protein (Fragment) 27 143066 2 1.2 255 858.4806 27.48
I I00208091 Fbl rRNA 2~-O-methyltransferase fibrillarin 27 34201 1 2.8 89 480.7869 26.92
869675 a1 F-actin-capping r t i  subunit alpha-1 27 2889 1 4 9 262 79 63 27.02
1528 Tsta3 GDP-L fucose synth se 26 35774 1 3 7 24 64 86 3 25 5
I I 198685 P k1 Serine/threonin -protein kinase PAK 1 26 60540 1.7 12 509.3 38 2 .47
IPI00767671 yh15 myosin, heavy chain 15 26 230036 2 0.9 133 517.7596 26.04
IPI00359317 Frmd4a Uncharacterized protein 26 113768 1 1 158 574.8184 26.01
IPI00210317 Mvd Diphosphomevalonate decarboxylase 25 43875 1 3.5 245 741.4694 25.14
IPI00566814 Cd200 OX-2 membrane glycoprotein 25 31068 1 3.2 104 506.3219 24.79
IPI00400615 Atp6v1e1 V-type proton ATPase subunit E 1 25 26112 1 5.3 167 679.4033 25.22
IPI00364925 Dhtkd1 Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial24 102576 2 1.4 31 668.4306 4.48
IPI00210964 Rps5 40S ribosomal protein S5 23 22864 1 3.9 98 450.7602 23.1
IPI00366920 Phf3 Uncharacterized protein 23 225176 1 0.4 97 496.2613 22.76
I I 65201 LOC100360757 Ctcfl protein-like isoform 1 2 73362 1 1.2 61 427.7452 23.42
65698 Chd4 chromodomai  helicase DNA binding protein 42 23194 1 5 21 544.328 23 27
I I 382233 Acat3 Ab2-076 23 103244 2 2. 19 702.4139 22.71
IPI00382220 Tifa Ab2-389 22 46849 1 3.8 317 893.0258 21.99
IPI00766819 RGD1563224 RGD1563224 protein 22 27884 2 8.8 195 577.3734 15.43
IPI00207973 Lgi4 Uncharacterized protein 22 59319 1 1.9 134 595.3392 21.53
IPI00553899 Glrx3 Isoform 1 of Glutaredoxin-3 22 37825 1 3.9 274 789.468 22.43
IPI00191571 Usp28 Uncharacterized protein 21 83608 1 1.6 208 655.9437 21.49
IPI00231714 Dlat Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial21 67123 1 2.4 244 745.4633 20.89
IPI00911297 Creb5 Uncharacterized protein 21 62804 2 2.9 20 489.3024 20.6
IPI00230939 Rpl24 60S ribosomal protein L24 20 17768 1 10.8 344 925.0833 19.95
I I 21038 Glra2 Isoform Alpha-2* of Glycine receptor subunit alpha-220 52020 1 2.7 229 675.809 19. 4
372006 Cdc73 Parafib omin 20 60565 1 2 3 801 96 5 20 01
0123 bcc9 Isoform SUR2A of ATP-binding cassette sub-family C member 920 174007 0 5 49 451 2668 19 72
I I00911298 RGD1566243 hypothetical protein LOC500992 19 56497 1 2.4 242 694.4314 19.19
IPI00213299 Mapre1 Microtubule-associated protein RP/EB family member 119 29985 1 6.7 315 612.3682 18.99
IPI00365340 Cpne7 Uncharacterized protein 19 62067 1 2.5 237 767.9626 19.48
IPI00231967 Arf6 ADP-ribosylation factor 6 18 20069 1 8 316 803.44 17.68
IPI00208240 Unc13c protein unc-13 homolog C 17 249310 1 0.8 323 1038.6261 17.03
IPI00454355 Slc2a3 Slc2a3 protein 17 35764 1 3.6 213 479.65 16.57
IPI00360057 Prkd3 Uncharacterized protein 17 33563 1 4.4 265 793.9805 16.87
IPI00781221 L-lactate dehydrogenase (Fragment) 16 37205 1 4.1 229 818.4702 15.56
I I 7812 4 RGD1562937 Uncharacterized protein 15 15 06 12 9 861.0014 15.08
358443 Fkbp4 Peptidyl-prolyl cis-trans isomerase FKBP415 51418 2.8 2 4 725 9031 13 79
896207 Ex l2 Uncharacterized protein 15 3726 1 6 235 843 4513 14 55
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Table 11. Proteomics round 1: Hits identified in the α2 ECDs- binding assay and absent 
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prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00960040 LOC680097 histone cluster 1, H2ae-like 169 51695 12 13.5 129 425.7731 0.09
IPI00231192 LOC689064;LOC100134871;Hbb Hemoglobin subunit beta-2154 15972 12 44.9 145 459.7599 7.98
IPI00213546 Hspa1l Heat shock 70 kDa protein 1-like 121 70505 5 8 316 614.8395 45.17
IPI00205163 Cnpy2 Uncharacterized protein 74 20696 3 12.1 170 524.7864 19.04
IPI00367633 RGD1560350 hypothetical protein LOC36555470 16841 1 8.4 347 643.3766 69.51
IPI00364262 Gars glycyl-tRNA synthetase 63 81741 2 3.3 350 657.8705 2.78
IPI00470317 Eef1g Elongation factor 1-gamma 60 50029 2 4.8 32 488.2887 2.4
IPI00358083 Ppp1r7 Protein phosphatase 1 regulatory subunit 759 41271 1 3.1 298 634.895 59.2
IPI00371003 Krt25 Keratin, type I cytoskeletal 25 58 48913 2 4 245 545.7838 57.5
IPI00382241 Bco2 Ab2-079 56 54389 2 3.7 122 487.7673 16.65
IPI00188666 Krt27 Keratin, type I cytoskeletal 27 45 49078 1 2 239 545.7855 44.81
IPI00189404 Hddc3 Uncharacterized protein 43 20242 2 9.5 523 881.4503 11.1
IPI00365487 Eif3g Eukaryotic translation initiation factor 3 subunit G43 35629 1 4.1 369 687.8865 42.65
IPI00195999 RGD1560831 Uncharacterized protein 42 26613 1 3.7 247 546.8006 41.88
IPI00565381 LOC100363177;LOC100365139 Ferritin 41 20748 3 22.4 341 695.3793 3.27
IPI00200539 RGD1563551 mCG49427-like 41 19206 1 5.4 131 494.7804 40.85
IPI00207014 Krt19 Keratin, type I cytoskeletal 19 41 44609 4 7.9 96 404.2112 29.97
IPI00201528 Tsta3 GDP-L-fucose synthase 41 35774 1 3.7 287 564.8538 40.91
IPI00325281 Eef1a2 Elongation factor 1-alpha 2 40 50422 2 4.1 159 488.294 10.72
IPI00357947 Tbc1d20 Uncharacterized protein 40 45855 1 2.5 257 587.3081 40.23
IPI00368131 LOC100364984;LOC100360253 Uncharacterized protein39 24644 2 11.2 386 658.8458 38.85
IPI00192216 Rab33b ras-related protein Rab-33B 39 25736 1 4.8 386 658.8458 38.85
IPI00196795 Rab15 Ras-related protein Rab-15 39 24268 1 5.2 386 658.8458 38.85
IPI00203760 Rab39 Uncharacterized protein 39 24905 1 5.1 386 658.8458 38.85
IPI00202238 Ndufb10 Uncharacterized protein 36 20845 1 6.8 461 735.4121 35.92
IPI00389636 Ppp2r1b Uncharacterized protein 36 76057 1 1.7 230 621.8909 36
IPI00231495 Map1lc3b Isoform 2 of Microtubule-associated proteins 1A/1B light chain 3B35 14590 2 16.8 127 420.2794 35.18
IPI00191288 Cox4nb Neighbor of COX4 35 23390 1 4.3 150 481.2766 35.04
IPI00763927 Tcp11l1 T-complex protein 11-like protein 1 35 56217 1 2.4 291 672.9058 34.69
IPI00358229 Abhd8 Uncharacterized protein 35 48337 2 2.3 121 571.8611 35.2
IPI00231650 Hist1h1d Histone H1.2 34 21974 1 5 257 554.2986 34.42
IPI00363763 RGD1311558 Isoform 1 of Shootin-1 34 71402 1 1.7 241 629.363 34.5
IPI00192612 Has1 Uncharacterized protein 33 65683 1 1.4 62 435.7863 32.55
IPI00205128 Ubl4 Ubiquitin-like protein 4A 32 17780 1 5.1 122 487.7673 32.26
IPI00358383 Pcdhb21 protocadherin beta-11 32 82822 1 1.6 310 650.3462 31.54
IPI00421802 Krt40 Keratin, type I cytoskeletal 40 30 48265 2 3.7 96 404.2112 29.97
IPI00421798 Krt32 Uncharacterized protein 30 51150 2 5.1 96 404.2112 29.97
IPI00948302 Atp5c1 ATP synthase gamma chain 29 32975 4 9.7 107 432.7598 14.22
IPI00201399 Alad Delta-aminolevulinic acid dehydratase 29 36008 2 6.4 217 524.8174 28.64
IPI00192234 Adrm1 Uncharacterized protein 29 32713 2 4.9 422 766.4308 28.73
IPI00210405 Met C-met/hepatocyte growth factor receptor (Fragment)29 15177 2 412 2 1478.8064 19
IPI00388143 LOC689656 Uncharacterized protein 28 38220 2 5.2 99 537.2172 28.12
IPI00949165 Copz1 Uncharacterized protein 27 20185 1 7.9 444 832.9532 26.61
IPI00212314 Msn Moesin 26 67697 2 3.3 251 552.8117 25.66
IPI00369635 Rdx Radixin 26 68501 3 4.6 238 538.3167 0.14
IPI00368617 Arhgef2 Rho guanine nucleotide exchange factor 225 111840 2 1.9 90 439.7678 25.05
IPI00371863 Kpna5 Importin subunit alpha-6 25 60261 1 1.3 14 421.2471 25
IPI00200486 Khdrbs2 KH domain-containing, RNA-binding, signal transduction-associated protein 223 38831 1 4 300 656.3455 23.4
IPI00454495 Rab31 ras-related protein Rab-31 23 21486 2 10.8 159 488.2841 5.52
IPI00205912 Nono Non-POU domain-containing octamer-binding protein23 54891 1 1.9 163 551.7986 22.93
IPI00476864 Rbm33 Uncharacterized protein 23 136361 2 1.7 145 545.3466 22.77
IPI00363828 Actr3 Uncharacterized protein 22 47164 3 6.7 324 705.4153 22.43
IPI00364414 Kpna3 Uncharacterized protein 22 57737 1 2.5 321 700.4139 21.74
IPI00212479 Hbe2 Uncharacterized protein 21 16378 1 6.8 347 644.8721 21.49
IPI00208197 Adprh [Protein ADP-ribosylarginine] hydrolase21 39935 1 2.8 271 551.812 20.54
IPI00362888 Arglu1 Arginine and glutamate-rich protein 1 21 32868 1 4.1 177 417.2262 21.47
IPI00193605 Pfdn1 Uncharacterized protein 20 14247 2 17.2 257 558.3308 18.76
IPI00563558 - Uncharacterized protein 20 91547 1 1.1 200 544.8039 20.18
IPI00365036 Prex1 Uncharacterized protein 19 184560 3 2.1 511 583.9097 6.48
IPI00212365 Akap4 A-kinase anchor protein 4 19 93434 5 2 62 461.7437 7.27
IPI00362386 RGD1560175 similar to hypothetical protein KIAA201818 246437 2 0.7 336 620.8569 18.11
IPI00368084 Bcas3 breast carcinoma amplified sequence 318 101001 2 1.8 484 911.9341 18.45
IPI00563107 - Uncharacterized protein (Fragment) 18 16740 1 9 302 710.8801 17.82
IPI00779103 LOC679154 family with sequence similarity 59, member A-like17 96613 3 1.1 328 609.3481 0.67
IPI00360078 Eml4 Uncharacterized protein (Fragment) 16 95649 2 1 250 568.8025 16.04
IPI00210005 Sycp3 Synaptonemal complex protein 3 16 29714 3 5.8 409 608.318 9
IPI00555187 Cap1 Adenylyl cyclase-associated protein 1 16 51556 1 4 526 1086.6337 16.29
IPI00679252 Gabra2 Uncharacterized protein 15 51089 1 2.7 429 713.3727 15.12
IPI00369982 Mrpl27 Uncharacterized protein 15 16014 1 7.3 183 633.2994 15.45
IPI00198781 Chrna3 Neuronal acetylcholine receptor subunit alpha-315 56960 1 1.4 102 738.426 14.97
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prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00205224 Fbxo30 F-box only protein 30 22 81958 1 2.3 327 903.9742 22.17
IPI00370418 Mettl23 Methyltransferase-like protein 23 22 25261 1 10.2 390 1294.309 22.11
IPI00361097 RGD1311993 Uncharacterized protein 22 112604 1 1.4 332 801.4492 22.34
IPI00369179 Wdr18 WD repeat-containing protein 18 22 47195 2 2.8 305 756.4391 21.65
IPI00870077 Neuroprotective protein 1 21 45987 1 3.4 257 777.8743 21.38
IPI00206949 Npr3 Homologue to natriuretic peptide clearance receptor21 53636 1 1.5 102 457.7729 21.28
IPI00206015 Tceb1 Transcription elongation factor B polypeptide 121 12465 2 17 132 505.2673 19.91
IPI00201969 Vat1 Vesicle amine transport protein 1 homolog (T californica), isoform CRA_a21 43091 2 3.5 280 740.4037 10.36
IPI00205644 LOC500974 Uncharacterized protein 20 60547 1 1.6 138 1021.7145 19.7
IPI00870584 Lrp6 Uncharacterized protein (Fragment) 20 178296 1 0.8 225 721.3372 19.8
IPI00213559 Rtn1 Isoform RTN1-B of Reticulon-1 19 82951 1 1.2 101 491.7809 19.26
IPI00213013 Stip1 Stress-induced-phosphoprotein 1 19 62530 1 1.8 162 569.2872 18.77
IPI00366977 Cpne3 Uncharacterized protein 18 59648 1 1.7 94 450.2577 18.02
IPI00199980 Psmb7 Proteasome subunit beta type-7 18 29908 2 6.9 376 1073.5724 18.9
IPI00366038 Atxn2l Atxn2l protein 17 112784 1 0.7 88 488.2571 16.55
IPI00188909 Col1a1 Collagen alpha-1(I) chain 17 137869 1 0.7 118 473.2913 17.23
IPI00389749 Dnm2 Isoform 2 of Dynamin-2 17 98098 3 2.5 90 440.2574 21.74
IPI00325049 Dnm3 Isoform 1 of Dynamin-3 17 97853 5 4.9 67 418.2159 19.33
IPI00211891 Nck2 Uncharacterized protein 17 42883 1 2.1 88 488.2571 16.55
IPI00199691 Nelf Isoform 1 of Nasal embryonic luteinizing hormone-releasing hormone factor17 60244 1 1.7 88 488.2571 16.55
IPI00382214 Psme3 Ab2-371 17 183415 1 0.5 88 488.2571 16.55
IPI00562727 RGD1565071 EG212225 protein-like 17 54929 1 1.8 88 488.2571 16.55
IPI00914757 Slc22a23 Solute carrier family 22 member 23 17 74159 1 1 88 488.2571 16.55
IPI00569284 Tet2 Uncharacterized protein 17 213736 1 0.7 217 838.9493 17.21
IPI00778588 Top3a Uncharacterized protein 17 9714 1 9.4 88 488.2571 16.55
IPI00362313 Ubtfl1 Uncharacterized protein 17 46403 1 2.3 88 488.2571 16.55
IPI00869671 Dock9 Uncharacterized protein (Fragment) 16 232884 2 1.1 125 532.2596 9.47
IPI00205419 Nf1 Neurofibromin 16 316880 3 1.7 229 651.8948 1.93
IPI00324590 Itgb7 integrin, beta 7 15 87572 1 2.1 300 912.4273 15.29
IPI00213554 Itpka Inositol-trisphosphate 3-kinase A 15 50839 1 5.4 357 1310.6636 15.28
IPI00400495 Neb Uncharacterized protein (Fragment) 14 40598 1 4.8 339 960.0231 14.43
IPI00958465 Uty (Fragment) 13 128187 1 1.3 311 854.5187 13.48
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00776619 Sptan1 Spectrin alpha chain, brain 429 284462 17 7 113 451.2685 35.78
IPI00360075 Lrpprc Leucine-rich PPR motif-containing protein, mitochondrial323 156554 13 9.8 73 426.7307 4.23
IPI00957899 LOC100360950 GF20391-like isoform 2 299 21227 9 37 96 451.2356 30.88
IPI00206171 Map2 Isoform MAP2x of Microtubule-associated protein 2258 02288 10 6.2 126 479.7794 1.31
IPI00205519 Uggt1 UDP-glucose:glycoprotein glucosyltransferase 1235 176320 12 7.7 77 429.2184 28.96
IPI00364046 Tuba1c Tubulin alpha-1C chain 233 49905 5 15.4 137 508.2849 45.06
IPI00199421 Tsnax Translin-associated protein X 212 32985 3 6.6 394 1038.5846 82.11
IPI00393508 Hist1h2bb Histone H2B 209 13914 5 27 86 477.2898 26.79
IPI00372557 Vars Valyl-tRNA synthetase 207 140280 4 4.7 114 482.2652 38.21
IPI00366405 Fam49b Uncharacterized protein 193 36753 5 17.3 167 569.2819 59.48
IPI00214889 Psmb3 Proteasome subunit beta type-3 193 22949 3 12.2 65 446.7494 25.84
IPI00190462 Ppp2cb Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform184 35552 5 11 115 480.7332 67.28
IPI00231966 Arf4 ADP-ribosylation factor 4 182 20384 4 15 40 420.7549 16.01
IPI00363440 Plxna2 plexin-A2 178 211469 8 5.1 89 421.2379 6.33
IPI00958044 Hist1h2ai histone cluster 1, H2ae-like 177 28038 8 29.2 76 425.7294 26.58
IPI00777130 Ncam1 Uncharacterized protein (Fragment) 177 118504 7 5.8 69 424.2314 26.37
IPI00324893 Ywhaz 14-3-3 protein zeta/delta 175 27754 5 15.5 178 573.7977 1.07
IPI00556932 LOC100359692;LOC100365976 Histone H2B 173 16342 5 27.9 96 451.2356 30.88
IPI00201407 Ppp3cb Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform168 59076 5 10.5 187 584.7758 33.55
IPI00203181 Bag6 Isoform 2 of Large proline-rich protein BAG6156 114576 3 3.6 159 557.3309 48.95
IPI00210975 Hyou1 Hypoxia up-regulated protein 1 154 111220 6 5.2 77 430.2513 29.24
IPI00389890 Dnm1l Isoform 5 of Dynamin-1-like protein 150 82488 5 8.7 73 420.2227 33.68
IPI00476899 Eef1b2 Uncharacterized protein 142 24660 4 16.4 117 473.2902 48.6
IPI00392583 Dynlrb1 Dynein light chain roadblock-type 1 123 10983 2 21.9 168 558.7708 74.39
IPI00763802 Cyfip2 Uncharacterized protein 121 145440 9 5.6 52 411.7494 16.44
IPI00212776 Rps3 40S ribosomal protein S3 118 26657 3 14.4 157 546.7822 46.01
IPI00194324 Pdhb Pyruvate dehydrogenase E1 component subunit beta, mitochondrial115 38957 2 4.5 342 874.451 76.21
IPI00201410 Ppp3ca Isoform 1 of Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform114 58606 4 8.4 187 584.7758 33.55
IPI00212186 RGD1562259 ribosomal protein S20-like 111 13368 3 19.3 203 624.3007 68.35
IPI00382182 Tsn Da2-35 111 31370 2 6.5 128 537.2587 56.93
IPI00204225 Glrx3 Isoform 2 of Glutaredoxin-3 110 31341 1 7.5 312 956.507 109.68
IPI00422001 Lsm2 LSM2 homolog, U6 small nuclear RNA associated isoform 1104 14770 1 14.5 288 1073.019 103.5
IPI00363423 Ckap5 cytoskeleton associated protein 5 100 196836 4 2.8 192 593.3586 55.5
IPI00197711 Ldha L-lactate dehydrogenase A chain 100 36427 2 7.5 164 565.7925 49.03
IPI00421855 Krt14 Keratin, type I cytoskeletal 14 99 52651 4 5.8 124 495.248 6.28
IPI00829443 Tubb5 Isoform 2 of Tubulin beta-5 chain 98 24256 4 13.7 140 505.2715 9.68
IPI00212523 Park7 Protein DJ-1 96 19961 1 10.1 352 947.5156 95.76
IPI00370090 Krt15 Keratin, type I cytoskeletal 15 93 48840 3 3.6 72 405.2054 32.27
IPI00360079 RGD1307235 Uncharacterized protein 93 134566 3 2.6 64 420.2241 40.96
IPI00369646 Pfas Uncharacterized protein 92 136808 3 3.5 176 582.3154 72.99
IPI00679252 Gabra2 Uncharacterized protein 91 51089 4 9.1 98 453.7376 47.32
IPI00367829 Cyfip1 Uncharacterized protein 86 145164 9 5.3 52 411.7494 16.44
IPI00869546 Xpo7 Uncharacterized protein 86 123947 2 2.4 185 591.3218 42.35
IPI00231134 Gnb2l1 Guanine nucleotide-binding protein subunit beta-2-like 185 35055 3 9.8 148 530.2976 48.25
IPI00206054 Cntn1 Contactin-1 84 113423 4 3.8 99 452.753 27.13
IPI00192246 Cox5a Cytochrome c oxidase subunit 5A, mitochondrial84 16119 2 16.4 126 496.7478 36.35
IPI00372857 Sar1a Uncharacterized protein 84 22384 3 15.7 64 446.7113 32.17
IPI00371266 Naca nascent polypeptide-associated complex subunit alpha isoform 183 23370 1 7 302 807.8847 83.32
IPI00886474 Rps5 Uncharacterized protein 83 22892 3 13.2 68 450.7067 54.6
IPI00205163 Cnpy2 Uncharacterized protein 82 20696 1 6.6 248 722.3796 81.75
IPI00950135 Pfn2 Profilin 82 15792 1 9.5 261 717.7923 82.34
IPI00209412 Cul3 Cullin-3 81 88875 5 7.2 127 493.2893 30.83
IPI00197900 Eef1d Translation elongation factor 1-delta subunit81 28748 2 9.3 213 643.3479 62.89
IPI00198978 Psmd12 Uncharacterized protein 80 52903 1 2.9 288 757.9491 79.63
IPI00231765 Rtn4 Isoform 1 of Reticulon-4 80 126310 3 2.7 105 472.7184 58.1
I I00210147 Sec31a Isoform 1 of Protein transport protein Sec31A80 135187 4 3.2 44 777.4368 4.19
I I 35844 dufa9 NADH d hydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial79 532 2 6.9 282 761.912 53.18
I I 35 278 Cnrip1 CB1 cannabinoid receptor-interacti  protein 176 186 7 9.8 319 856.9148 75.87
231783 Ldhb L-lactate dehydrogenase B chain 76 36589 2 4.5 311 815.4294 38.55
19 240 Npm3 Uncharacterized protein 76 18 05 9.2 279 801.919 76.02
2 3579 Tpp2 Tripeptidyl-pept dase 2 74 138206 2 1.8 197 413.558 34.97
205022 Nucb1 Nucleobindin-1 73 5 474 2.8 297 753.921 72.58
I I 369 17 Lrrc40 Leucine rich r peat co taining 40 72 67898 2.7 341 857.5006 71.89
I I 6652 Neo  c r ct riz  r t i  (Fragment) 72 15 047 2 2 189 625.3524 21.59
IPI00194524 Prpsap2 Phosphoribosyl pyrophosphate synthase-associated protein 272 40840 1 4.6 339 1041.5449 72.11
IPI00205910 Dcc Uncharacterized protein 70 157842 2 1.4 104 472.2451 4.83
IPI00471889 Anxa5 Annexin A5 69 35722 1 5 330 844.4576 68.85
IPI00193219 Cnot7 Uncharacterized protein 69 32697 1 6.7 389 1146.6182 69.27
IPI00191142 LOC100364787;LOC100363439;Rps10 40S ribosomal protein S1068 18904 2 5.5 141 555.3311 49.53
IPI00210635 Nsf Vesicle-fusing ATPase 68 82600 4 5.1 84 433.2095 7.03
IPI00372125 Psmd14 RCG26455, isoform CRA_b 68 34555 2 6.5 63 410.2397 53.44
IPI00200539 RGD1563551 mCG49427-like 66 19206 1 5.4 121 494.755 65.98
IPI00421782 Krt75 keratin, type II cytoskeletal 75 65 62130 2 4.7 217 651.7961 64.54
IPI00230866 Gna12 Guanine nucleotide-binding protein subunit alpha-1264 44037 1 2.9 141 529.3142 64.49
IPI00870631 Pnp Purine nucleoside phosphorylase 64 32281 1 3.8 177 584.7978 64.36
IPI00362998 Trip12 Uncharacterized protein 64 223788 1 0.6 217 669.3805 64.43
IPI00360418 Srgap1 SLIT-ROBO Rho GTPase-activating protein 163 123960 1 1.1 314 761.4164 62.69
IPI00563088 Eif4g1 eukaryotic translation initiation factor 4 gamma, 1 isoform 162 174979 2 1.3 190 589.3466 44.2
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Table 13: Hits identified in the α1 ECDs-binding assay and absent from the α2 ECDs-
binding assay analysed with Mascot found in Proteomics round 1 and 2 
  
Table 14: Hits identified in the α2 ECDs-binding assay and absent from the α1 ECDs-
binding assay analysed with Mascot found in Proteomics round 1 and 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
prot_descr prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
Tax_Id=10116 Gene_Symbol=Cap1 Adenylyl cyclase-associated protein 1110 51556 3 9.9 404 1086.6218 75.45
Tax_Id=10116 Gene_Symbol=Gabra2 Uncharacterized protein 91 51089 4 9.1 259 713.3469 53.09
Tax_Id=10116 Gene_Symbol=Cnpy2 Uncharacterized protein 82 20696 1 6.6 248 722.3796 81.75
Tax_Id=10116 Gene_Symbol=Actr3 Uncharacterized protein 80 47164 5 8.9 233 705.3752 50.13
Tax_Id=10116 Gene_Symbol=Cct5 T-complex protein 1 subunit epsilon 70 59499 2 5.4 402 1070.0732 48.06
Tax_Id=10116 Gene_Symbol=Eef1g Elongation factor 1-gamma 69 50029 3 6.4 185 621.3167 53.67
Tax_Id=10116 Gene_Symbol=RGD1563551 mCG49427-like 66 19206 1 5.4 121 494.755 65.98
Tax_Id=10116 Gene_Symbol=Gars glycyl-tRNA synthetase 58 81741 1 1.1 99 450.238 57.71
Tax_Id=10116 Gene_Symbol=Ppp1r7 Protein phosphatase 1 regulatory subunit 753 41271 1 5 384 996.0356 52.8
Tax_Id=10116 Gene_Symbol=Nono Non-POU domain-containing octamer-binding protein42 54891 1 1.9 164 551.7867 42.18
Tax_Id=10116 Gene_Symbol=Map1lc3b Isoform 2 of Microtubule-associated proteins 1A/1B light chain 3B37 14590 3 21.6 69 420.2321 38.17
Tax_Id=10116 Gene_Symbol=Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial36 79362 1 1.8 266 702.3893 36.48
Tax_Id=10116 Gene_Symbol=LOC100365478;LOC685091 high-mobility group box 1-like32 23327 1 6.9 293 531.5948 31.65
Tax_Id=10116 Gene_Symbol=Pcdhb21 protocadherin beta-11 32 82822 1 1.6 197 650.2932 32.31
Tax_Id=10116 Gene_Symbol=Kpna5 Importin subunit alpha-6 28 60261 1 1.3 66 421.2283 28.34
prot_descr prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
Tax_Id=10116 Gene_Symbol=Calm2;Calm3;Calm1 Calmodulin 158 16827 5 27.5 313 782.3983 82.45
Tax_Id=10116 Gene_Symbol=Vps35 maternal embryonic message 3 156 91669 6 9.3 178 622.3725 65.35
Tax_Id=10116 Gene_Symbol=Hspa9 Stress-70 protein, mitochondrial 107 73812 3 6 269 797.0264 49.39
Tax_Id=10116 Gene_Symbol=Gabra1 Gamma-aminobutyric acid receptor subunit alpha-1100 51721 5 10.1 101 509.7872 62.88
Tax_Id=10116 Gene_Symbol=Arg2 Arginase-related protein 86 37776 1 4.4 217 786.4623 86.04
Tax_Id=10116 Gene_Symbol=Arg2 Arginase-2, mitochondrial 86 38616 1 4.2 217 786.4623 86.04
Tax_Id=10116 Gene_Symbol=Ndufs8 Uncharacterized protein 71 23955 1 5.2 204 637.3755 70.82
Tax_Id=10116 Gene_Symbol=Sh3gl1 Endophilin-A2 61 41466 1 1.9 61 436.2566 61.05
Tax_Id=10116 Gene_Symbol=Farsa Phenylalanyl-tRNA synthetase alpha chain 57 57684 1 2.2 195 655.4112 56.94
Tax_Id=10116 Gene_Symbol=Ddx3x Uncharacterized protein 56 73100 1 1.8 156 646.4171 56.1
Tax_Id=10116 Gene_Symbol=Gga3 Uncharacterized protein 52 78710 1 1.7 211 679.4208 52.38
Tax_Id=10116 Gene_Symbol=Sod2 Superoxide dismutase [Mn], mitochondrial 51 24659 2 9.5 251 720.9343 51.47
Tax_Id=10116 Gene_Symbol=- Uncharacterized protein (Fragment) 50 34410 2 9.7 313 895.9964 49.95
Tax_Id=10116 Gene_Symbol=- Uncharacterized protein (Fragment) 47 225547 3 1.4 153 588.8526 46.88
Tax_Id=10116 Gene_Symbol=Calr Calreticulin 45 47966 2 3.8 94 488.2718 41.79
Tax_Id=10116 Gene_Symbol=Map1a Uncharacterized protein 38 324819 1 0.3 151 514.8324 38.14
Tax_Id=10116 Gene_Symbol=Atp6v1c1 V-type proton ATPase subunit C 1 37 43873 2 6.3 287 815.0042 36.83
Tax_Id=10116 Gene_Symbol=- Uncharacterized protein 36 14291 1 9 134 616.3315 36.35
Tax_Id=10116 Gene_Symbol=Atp6v0d1 Uncharacterized protein 36 40275 1 2.8 136 597.3638 35.67
Tax_Id=10116 Gene_Symbol=Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial35 79362 1 1.9 279 806.4742 34.61
Tax_Id=10116 Gene_Symbol=Ckap2l Uncharacterized protein 32 82658 1 1.6 242 697.3962 31.55
Tax_Id=10116 Gene_Symbol=RGD1565297 RAN binding protein 1-like 31 23722 1 4.4 106 517.7965 31.18
Tax_Id=10116 Gene_Symbol=Cct5 T-complex protein 1 subunit epsilon 29 59499 2 5 366 1070.105 29.46
Tax_Id=10116 Gene_Symbol=Lrrc16a Uncharacterized protein (Fragment) 27 143066 2 1.2 255 858.4806 27.48
Tax_Id=10116 Gene_Symbol=Acat3 Ab2-076 23 103244 2 2.9 191 702.4139 22.71
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Table 15. Proteomics round 1: Hits identified in the α1 ECDs- binding assay and present 
in the α2 ECDs- binding assay analysed with MASCOT. 
 
Table 16. Proteomics round 2: Hits identified in the α1 ECDs- binding assay and present 
in the α2 ECDs- binding assay analysed with MASCOT.  
 
  
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00231955 Calm2;Calm3;Calm1 Calmodulin 187 16827 6 26.2 204 547.2468 42
IPI00206624 Hspa5 78 kDa glucose-regulated protein 150 72302 7 9.5 155 493.7789 33.5
IPI00421389 Ndrg1 Protein NDRG1 138 42927 3 11.9 352 676.864 79.4
IPI00373591 Fubp1 Far upstream element-binding protein 1122 67155 7 9.5 234 534.3141 24.96
IPI00358033 Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial80 79362 3 5.8 229 532.7991 26.42
IPI00215184 Rps25 40S ribosomal protein S25 60 13734 1 8 237 542.8337 60.19
IPI00470301 Cct5 T-complex protein 1 subunit epsilon 57 59499 1 1.8 160 547.2847 57.12
IPI00388209 Prkcsh Uncharacterized protein 55 59181 1 1.9 297 595.3281 54.7
IPI00951116 Hbb 16 kDa protein 53 15955 5 38.1 202 545.8051 9.48
IPI00364376 Mapk1ip1l Uncharacterized protein 50 23640 1 7.1 563 918.954 50.44
IPI00198665 Ssbp3 Uncharacterized protein 48 40395 1 2.6 246 576.3296 48.22
IPI00197585 Myg1 UPF0160 protein MYG1, mitochondrial 44 42862 1 2.6 270 550.3248 44.21
IPI00958235 RGD1565403 nucleoside diphosphate kinase B-like42 17104 4 33.1 68 741.3911 2.78
IPI00204065 Rufy3 Isoform 1 of Protein RUFY3 42 52873 2 4.7 85 473.7768 3.39
IPI00211593 Sod2 Superoxide dismutase [Mn], mitochondrial42 24659 1 6.3 454 720.9189 42.24
IPI00192642 Gabra1 Gamma-aminobutyric acid receptor subunit alpha-141 51721 2 1.8 160 483.2477 7.76
IPI00198118 Map1a Uncharacterized protein 41 324819 1 0.3 197 514.816 40.84
IPI00958625 LOC100365478;LOC685091 high-mobility group box 1-like39 23327 1 6.9 518 531.6066 39.22
IPI00367660 RGD1562502 hypothetical protein LOC363485 39 22410 1 7.6 501 558.3021 38.73
IPI00213552 Dync1li1 Cytoplasmic dynein 1 light intermediate chain 138 56757 2 4.6 124 511.3047 0.85
IPI00362341 RGD1565297 RAN binding protein 1-like 38 23722 2 5.4 449 691.3418 38.39
IPI00214192 Sh3gl1 Endophilin-A2 36 41466 1 1.9 116 436.2462 35.86
IPI00366327 Lrrc16a Uncharacterized protein (Fragment) 35 143066 2 1.2 549 858.4612 35.23
IPI00205693 Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-234 112145 1 1.5 509 810.3995 34.42
IPI00421395 RGD1304704 Uncharacterized protein 31 33804 1 2.7 192 511.812 31.07
IPI00188330 Ndufs8 Uncharacterized protein 27 23955 2 9.4 324 612.8325 0.4
IPI00551558 Krt2 Uncharacterized protein 26 69248 1 2 361 627.8218 25.5
IPI00197529 Zfp423 Zinc finger protein 423 25 147131 1 1 404 468.9272 24.62
IPI00203773 Mrpl12 Uncharacterized protein 24 29423 1 5.1 416 677.3633 23.58
IPI00188112 Psph Phosphoserine phosphatase 21 24952 1 5.3 389 680.3787 21.41
IPI00363265 Hspa9 Stress-70 protein, mitochondrial 18 73812 1 1.8 358 667.3887 18.21
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00215291 Ddx39b Spliceosome RNA helicase Ddx39b 31 49004 3 6.8 60 431.7336 1.33
IPI00361415 Pdxp Pyridoxal phosphate phosphatase 31 33094 1 3.6 196 596.8138 30.53
IPI00208429 Gng3 guanine nucleotide binding protein, gamma 3 30 8299 1 9.3 86 419.2398 30.26
IPI00202616 Ndufs3 Uncharacterized protein 30 30208 1 5.3 287 768.9249 30.29
IPI00326085 Kif3a Uncharacterized protein (Fragment) 29 79822 2 4.9 377 926.0197 7.89
IPI00213571 Acot7 Isoform 1 of Cytosolic acyl coenzyme A thioester hydrolase28 37537 1 3.3 196 649.3885 28.34
IPI00366218 Cct2 T-complex protein 1 subunit beta 28 57422 2 4.3 175 638.3144 10.98
IPI00371863 Kpna5 Importin subunit alpha-6 28 60261 3 4.1 72 672.4127 2.02
IPI00200145 Rplp1;LOC100360522 60S acidic ribosomal protein P128 11491 1 14 302 851.9131 28.03
IPI00191335 Syn1 Isoform IA of Synapsin-1 28 73943 1 1.4 183 594.3553 27.64
IPI00230981 Vac14 Protein VAC14 homolog 28 88012 1 1.4 227 645.3824 28.23
IPI00231194 Ddah1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 127 31406 1 3.9 156 585.318 26.74
IPI00882480 Pcbp1 poly(rC) binding protein 1-like 27 55046 1 2.5 204 694.9137 26.51
IPI00560533 Hprt1 Hypoxanthine-guanine phosphoribosyltransferase26 24462 1 4.6 210 622.8365 26.17
IPI00362014 Tln1 talin-1 25 269504 1 1.3 392 1152.9946 25.03
IPI00200828 Cops3 COP9 signalosome complex subunit 3 24 47828 1 1.7 65 439.217 24.05
IPI00959479 Ckap2l Uncharacterized protein 23 82658 2 1.6 249 697.3508 23.2
IPI00193568 Dnm1l Isoform 4 of Dynamin-1-like protein 22 83168 2 3.3 145 523.7642 10.87
IPI00215574 Eci1 Enoyl-CoA delta isomerase 1, mitochondrial 21 32234 2 9.7 283 764.3859 23.27
IPI00769124 Usp42 Ubiquitin carboxyl-terminal hydrolase 42 19 146266 2 2 184 643.8314 7.08
IPI00190020 Atp2a2 Uncharacterized protein 18 114741 2 2.1 117 460.296 11.54
IPI00203214 Eef2 Elongation factor 2 18 95223 3 2.6 164 553.2857 5.47
prot_acc Hits prot_score prot_mass prot_matches prot_cover pep_query pep_exp_mz pep_score
IPI00370815 Cct8 Uncharacterized protein 449 59550 17 27.7 89 444.7452 29.92
IPI00554039 RGD1565368 glyceraldehyde-3-phosphate dehydrogenase-like436 35760 13 19.5 192 678.843 48.23
IPI00949013 Crmp1 Dihydropyrimidinase-related protein 1 415 62157 14 26.9 75 425.2151 34.77
IPI00767139 Gcn1l1 GCN1 general control of amino-acid synthesis 1-like 1350 292886 20 10.2 107 443.2816 20.1
IPI00368347 Uba1 Ubiquitin-like modifier-activating enzyme 1 296 117713 8 9.8 120 492.7536 40.1
IPI00194045 Idh1 Isocitrate dehydrogenase [NADP] cytoplasmic286 46705 12 30 38 404.2138 13.6
IPI00231929 Pkm2 Isoform M1 of Pyruvate kinase isozymes M1/M2283 57781 10 14.7 72 420.7689 16.92
IPI00370456 Psmd2 26S proteasome non-ATPase regulatory subunit 2265 100124 8 11.3 62 412.7318 21.09
IPI00326305 Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1262 112982 6 7.5 187 570.3099 4.38
IPI00337168 Cct4 T-complex protein 1 subunit delta 259 58063 12 19.5 61 409.2168 3.99
IPI00339129 Dclk1 Uncharacterized protein 240 46558 8 11.4 168 560.794 36.88
IPI00214665 Acly ATP-citrate synthase isoform 1 222 120704 9 9.1 55 410.7348 8.26
IPI00364311 Gpi Glucose-6-phosphate isomerase 219 62787 7 11.8 67 416.1979 35.9
IPI00372700 Npepps puromycin-sensitive aminopeptidase 216 103279 12 12.6 125 500.2893 4.74
IPI00324741 Pdia3 Protein disulfide-isomerase A3 201 56588 11 19.2 88 444.735 23.06
IPI00188111 Cct6a Uncharacterized protein 199 57981 7 12.1 56 404.221 20.68
IPI00364286 Cct7 Uncharacterized protein 193 59620 11 12.9 66 415.2232 21.81
IPI00339148 Hspd1 60 kDa heat shock protein, mitochondrial 190 60917 4 10.3 100 456.7932 35.5
IPI00339109 LOC100360573;LOC100363860 40S ribosomal protein S12186 15210 2 16.1 353 1129.0671 110.38
IPI00205372 Stxbp1 Isoform 1 of Syntaxin-binding protein 1 183 67526 5 10.1 121 479.2922 40.32
IPI00204843 Gnao1 Isoform Alpha-2 of Guanine nucleotide-binding protein G(o) subunit alpha176 40055 5 14.4 105 446.2444 14.25
IPI00231674 Arf3 ADP-ribosylation factor 3 164 20588 10 24.9 40 420.7549 16.01
IPI00365929 Pdia6 protein disulfide-isomerase A6 162 48730 3 6.1 221 693.8737 113.04
I I00195818 Ipo9 Uncharacterized protein 160 116575 4 .3 219 650.3499 83.95
I I00188686 LOC100364558;LOC100360846 roteasome subunit beta type 6-like160 25287 3 12 48 424 2 47 74.2
I I00231965 Arf5 ADP-ribosylation factor 5 158 20517 4 15 40 20 7549 16.01
I I00191749 Psmb1 Prote some subunit beta type-1 156 26462 3 17 5 158 573.786 76.96
I I00869818 Sec23a Unch racterized protein 154 86106 3 3.5 265 701.408 50.35
I I00869568 Vps35 maternal embry nic message 3 150 91669 9 10.2 55 39 .7559 12.92
IPI00358371 RGD1560871 Uncharacterized protein 148 210759 8 3.6 89 421.2379 6.33
IPI00202725 LOC100363012;Rps21 40S ribosomal protein S21 135 9122 2 31.3 173 569.7266 76.43
IPI00768246 Uba2 Uba2 protein 135 70726 6 9.2 100 450.2385 35.18
IPI00471835 Hsph1 Heat shock protein 105 kDa 133 96357 3 4.4 167 560.3088 47.89
IPI00372520 Eef1b2l Uncharacterized protein 129 27952 2 5.9 204 809.4351 79.51
IPI00563746 Glyceraldehyde-3-phosphate dehydrogenase 128 33981 4 12.1 282 890.4225 67.08
IPI00360356 Actbl2 Uncharacterized protein 126 41936 2 9 323 895.9135 125.97
IPI00212512 Psmd1 26S proteasome non-ATPase regulatory subunit 1121 105681 5 3.9 76 428.7498 17.84
IPI00287338 Xpo1 Exportin-1 121 122959 9 8.1 111 475.8008 27.85
IPI00365944 Myl6l Myosin light polypeptide 6 119 16964 6 25.2 127 498.2792 48.74
IPI00231358 Pfn1 Profilin-1 119 14948 4 35.7 91 445.7508 3.27
IPI00212622 Hadha Trifunctional enzyme subunit alpha, mitochondrial114 82613 4 4.6 129 499.7804 23.02
IPI00231757 Psma2 Proteasome subunit alpha type-2 109 25910 3 17.5 95 486.2625 22.91
IPI00231697 Stmn1 Stathmin 109 17278 4 25.5 72 456.7219 40.57
I I00373419 Sptbn1 Non-erythrocyte beta-spectrin 107 250863 7 3.2 115 456.8009 7.6
IPI00194404 Nme1 Nucleoside diphosphate kinase A 105 17182 3 25.7 178 582.2945 35.45
IPI00325189 Nme2 Nucleoside diphosphate kinase B 105 17272 3 25.7 180 588.3043 34.35
IPI00196794 Rab14 Ras-related protein Rab-14 105 23912 3 17.7 173 591.3084 30.94
IPI00372524 Aldh18a1 Uncharacterized protein 104 87275 3 4 96 446.2272 4
IPI00210257 Dynlt1 Dynein light chain Tctex-type 1 103 12444 2 35.4 341 1045.0347 74.28
IPI00215294 Ddah2 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2100 9669 1 8.1 295 1040.5607 99.72
IPI00371204 Eif3f Uncharacterized protein 100 37973 1 5.3 388 1025.5752 100.27
IPI00207707 Lamtor1;LOC100361543 Ragulator complex protein LAMTOR1100 17710 1 8.1 232 694.849 99.61
IPI00325517 Cul5 Cullin-5 96 90832 2 2.7 160 539.3037 38.66
IPI00198371 Ap2s1 AP-2 complex subunit sigma 95 17007 2 15.5 97 452.2494 41.18
IPI00230972 Mapt Isoform Tau-E of Microtubule-associated protein tau94 45095 3 6.9 58 431.2332 56.5
IPI00231539 Psma7 Proteasome subunit alpha type 94 28381 2 5.5 208 817.9429 58.46
IPI00202543 Hk1 Hexokinase-1 93 102342 2 2.9 256 700.9091 57.63
IPI00209908 Mt-co2 Cytochrome c oxidase subunit 2 91 25925 3 7.5 52 429.7268 45.61
IPI00869998 Psmb5 Proteasome subunit beta type-5 90 28567 4 14.1 194 621.8217 33.1
IPI00361151 Rrm1 Ribonucleoside-diphosphate reductase 90 90236 3 3.9 214 420.8839 80.02
IPI00359981 Ndufa13 rCG38845-like 89 16950 2 13.9 157 536.2913 71.97
IPI00365531 Fam49a Uncharacterized protein 88 37305 3 7.4 167 569.2819 59.48
IPI00191505 Psmb4 Proteasome subunit beta type-4 88 29209 2 9.1 111 511.7531 48.22
IPI00191502 Psma5 Proteasome subunit alpha type-5 87 26374 2 5.4 258 716.3603 61.65
IPI00191501 Psma6 Proteasome subunit alpha type-6 87 27382 1 5.3 219 643.3328 86.8
IPI00454479 Ka11 Uncharacterized protein 85 52564 3 6.5 137 534.3038 4.92
IPI00210920 Got2 Aspartate aminotransferase, mitochondrial 84 47284 2 4.7 110 439.2523 62.52
IPI00363828 Actr3 Uncharacterized protein 80 47164 5 8.9 85 474.2421 37.36
IPI00198418 Snrpe Uncharacterized protein 79 10754 3 29.3 206 673.3362 32.3
IPI00366014 LOC100364569;Rps13;LOC684988 40S ribosomal protein S1378 7212 3 13.2 95 484.7113 54.37
IPI00231920 Pfn2 profilin-2 78 16104 2 14.8 100 454.7488 20.05
IPI00198620 Atp5d ATP synthase subunit delta, mitochondrial 77 17584 2 13.7 120 493.7347 36.89
IPI00215532 Cuta Protein CutA 76 18647 2 7.9 274 774.3904 51.69
IPI00200920 Khsrp Far upstream element-binding protein 2 76 74180 2 2.8 87 436.7315 40.59
IPI00206234 Ipo7 Uncharacterized protein 75 119412 5 6.6 87 438.7226 35.89
IPI00959226 LOC100361067;Psma3l;Psma3;LOC100365943 Proteasome subunit alpha type75 28336 2 7.8 127 488.2459 1.36
IPI00389722 LOC100365156;LOC686066 Uncharacterized protein74 7884 1 19.1 245 525.9426 73.53
IPI00231643 Sod1 Superoxide dismutase [Cu-Zn] 73 15902 1 8.4 223 684.3555 73.18
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